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General introduction 
and outline of this thesis
 
Adapted from
Annals of Intensive Care, 2017
American Journal of Kidney Disease, 2014 
Journal of Pharmacology and Experimental Therapeutics, 2013 
General introduction
A 
cute kidney injury (AKI) is a frequently encountered clinical problem in 
critically ill patients and associated with significant morbidity and mortality.
    AKI is characterized by a rapid loss of kidney function, resulting in the 
organ’s inability to filter out waste products from the bloodstream and to maintain fluid 
and electrolyte homeostasis. One- to two-thirds of intensive care unit (ICU) patients 
develop AKI and its incidence is increasing.1-4 Approximately half of the ICU patients with 
AKI die and those patients surviving an episode of AKI have an increased risk of developing 
chronic kidney failure, resulting in a tremendous burden for both patient and society.5,6 
The severity of AKI can be defined using diverse classification systems, including the RIFLE 
criteria, which classifies AKI into three severity classes (Risk, Injury and Failure) and two clinical 
outcome categories (Loss and End-Stage Renal Disease) based on serum creatinine and urine 
output measurements.7 While AKI may occur after cardiovascular surgery, administration of 
nephrotoxic drugs, trauma and burns, sepsis represents the most important etiology in the 
critically ill.5
Sepsis
Sepsis represents an important syndrome in the intensive care unit (ICU) and presents as 
life-threatening organ dysfunction caused by a dysregulated host response to infection.8 This 
infectious-inflammatory syndrome has an incidence of approximately 3 cases per 1,000 indi-
viduals and more than 50% of the patients are admitted to the ICU, with a mortality of approx-
imately 1 out of 3 patients.9 Therapies aimed to modulate the immune response have led to 
disappointing results in septic patients.10 
Sepsis-associated AKI increases the mortality rate to two out of three patients.11 Currently, no 
pharmacological therapeutic interventions are approved to prevent or to treat AKI. As a conse-
quence, treatment is limited to mitigating secondary hemodynamic and toxic renal insults 
and provision of supportive measures such as diuretics and renal replacement therapy (RRT).12 
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Considering the high incidence and related morbidity and mortality of sepsis-associated AKI, 
there is clearly an urgent medical need to investigate novel pharmacological interventions to 
treat or prevent AKI. Unfortunately, the heterogeneity of the patient population as well as the 
complex pathogenesis of the syndrome complicate the discovery of new therapies.13
Pathogenesis of sepsis-associated acute kidney injury  
The pathogenesis of AKI in general, and of sepsis-associated AKI in particular, is still not 
completely understood. Sepsis-associated AKI is believed to be a multifactorial disease, 
caused by an interplay of inflammatory insults, altered microcirculation and unbalanced renal 
bioenergetics, resulting in rapid functional deterioration of the kidney.14
Inflammatory response
During sepsis, the body’s response to an infection is characterized by the release of several 
inflammatory mediators, including many pro-inflammatory cytokines and arachidonic acid 
metabolites, the up-regulation of inducible nitric oxide synthase (iNOS) and activation of 
the complement cascade.15 These mediators are necessary to fight the infection, but too 
pronounced or persistent release causes collateral damage to the host and may therefore be 
detrimental to the patient. Sepsis can be caused by different pathogens and certain motifs of 
these pathogens, so called ‘pathogen-associated molecular patterns’ (PAMPs), are recognized 
by the innate immune system. These PAMPs signal via Toll-like receptors or other pathogen 
recognition receptors, thereby triggering an inflammatory response.16 Lipopolysaccharide 
(LPS) is the most frequently studied endotoxin and is considered an important PAMP initiating 
the inflammatory cascade through Toll-like receptor 4 (TLR4) signaling.17 LPS, which is a part 
of the outer membrane of these Gram-negative bacteria, binds in complex with LPS-binding 
protein (LBP) to TLR4. Subsequently, the transcriptional nuclear factor-κB (NF-κB) is activated 
through myeloid differentiation primary response gene (88) (MyD88)-dependent and -inde-
pendent pathways, resulting in the activation of cytokine gene promoters.18 This results in the 
systemic release of pro- and anti-inflammatory cytokines, further enhancing hematopoiesis 
and phagocytosis, and recruitment of leukocytes towards the site of infection.19
Also in the kidney, LPS can interact directly with TLR4 resulting in an activation of the NF-κB 
signaling pathway. TLR4 is endogenously expressed in the cortex and medulla and appears 
to be up-regulated in the renal tubules, glomeruli and renal vasculature during polymicrobial 
sepsis.20 Within 10 minutes following LPS infusion in mice, the endotoxin is present in renal 
tissue where it interacts with TLR4 localized at the brush border membrane of the first part 
of the proximal tubule.21 This results in downstream oxidative stress in lower segments of 
these tubules.22 Next to oxidative stress, LPS activates the immune system resulting in a local 
inflammatory response.23,24 Tubular epithelium in the outer medullary region responds to LPS 
by producing pro-inflammatory and chemotactic cytokines, such as tumor necrosis factor 
(TNF)-α, monocyte chemoattractant protein-1, interleukin (IL)-6 and IL-8, which will result in 
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the activation of inflammatory cells.25 This is accompanied by complement and coagulation 
pathways activation, protease activation, production of reactive oxygen species (ROS) and 
nitrogen species (RNS), and up-regulation of TLR425, further accelerating the inflammatory 
cascade by activation of resident dendritic cells.26 Subsequently, these cells produce several 
pro-inflammatory cytokines and attract macrophages, neutrophils and other immune cells 
as well.26 This results in morphological and functional changes in epithelial and endothelial 
cells, causing the development of tubular apoptosis.27 28 29 Both cell death and renal leuko-
cyte infiltration are, together with acute tubular lesions, important events in the pathogenesis 
of sepsis-associated AKI (Figure 1).30 These findings illustrate that inflammation by itself may 
account for an important part of the AKI observed in sepsis patients.
Figure 1. 
 Renal inflammation and impaired microcirculation in the pathogenesis of sepsis-associated acute 
kidney injury. 
 Lipopolysaccharide (LPS) binds to Toll-like receptor 4 (TLR4) on immune cells (ICs), triggering the inflammatory 
response causing systemic inflammation. Alternatively, LPS binds to TLR4 expressed on proximal tubule epithe-
lial cells (PTEC), inducing renal inflammation. Endothelial cells exposed to LPS and circulating cytokines may 
result in impaired renal microcirculation causing hypoxia. The immune response is enhanced further by renal 
inflammation and hypoxia, eventually causing AKI characterized by leukocytes infiltration, acute tubular lesions 
and apopotosis. ATP, adenosine triphosphate; iNOS, inducible nitric oxide synthase; ROS, reactive oxygen species; 
RNS, reactive nitrogen species. Published previously in the American Journal of Kidney Diseases.14 
Inammatory mediators  
- Cytokines  
- Extracellular ATP  
Complement 
activation 
Intravascular 
iNOS  
Coagulation 
pathway 
Epithelial cells  
RENAL INFLAMMATION Endothelial cells  
Cytokines / chemokines  
Dendritic Cell activation  
Complement activation 
Coagulation activation  
Extracellular ATP  
release 
Renal inammation  
Leukocyte transmigration  
 Swelling  
Vasoconstriction  
Hypoxia  
Renal leukocyte inltration, Acute tubular lesions, Apoptosis 
Acute Kidney Injury  
Impaired microcirculation  
SYSTEMIC INFLAMMATION 
 Cytokine production  
Upregulation adhesion  
molecules  
Cytokines / chemokines
 
Coagulation activation  
Activation  
inammatory cells 
LPS  
ROS and RNS  
Gram-negative bacteria  
TLR4  
IC 
PTEC  
16  |  CHAPTER 1 |  Introduction & outline of this thesis
Renal microcirculation
The renal vascular endothelium is also exposed directly to pathogens and inflammatory medi-
ators (e.g. pro-inflammatory cytokines), triggering the up-regulation of endothelial adhesion 
molecules and production of cytokines and chemokines. This results in endothelial-leukocyte 
interactions causing leukocyte transmigration towards renal interstitium, further enhancing 
epithelial inflammation through the production of cytokines, ROS and RNS.23 Sepsis-induced 
endothelial leukocyte transmigration, together with excessive platelet activation, the acti-
vated coagulation system, endothelial swelling and enhanced vasoconstriction of the arteri-
oles, result in a compromised renal microcirculation.31-35 The impaired renal microcirculation, 
causes heterogeneity of blood flow, resulting in some parts of the kidney being well-per-
fused while other parts being hypoperfused and hypoxic.36,37 Renal hypoxia is harmful for 
the kidney, as it affects the balance of ROS, nitric oxide (NO) production and renal oxygen-
ation. Inflammation increases the activation of iNOS in the kidney resulting in the production 
of an excessive amount of NO. Subsequently, NO reacts with superoxide ions resulting in the 
production of RNS, such as peroxynitrite, and both nitrosative and oxidative stress further 
compromise the microcirculation (Figure 1).38 
Renal bioenergetics
Another pathophysiological process that is potentially relevant in the development of sepsis-as-
sociated AKI is represented by an imbalance in renal bioenergetics. Mitochondrial dysfunction 
plays a major role in the development of multi-organ failure during sepsis. In response to the 
inflammatory and hypoxic insults, tubular cells reprioritize and down-regulate cellular func-
tions in order to prevent further damage. This adaptive response is mainly orchestrated by 
the mitochondria, organelles that are primarily responsible for providing energy, in the form 
of ATP, through oxidative phorphorylation.39,40 When exposed to stress, mitochondria reduce 
the metabolic activity of cells by reducing energy requirements. To this end, mitochondria 
remove and digest dysfunctional organelles and initiate cell cycle arrest to prevent further 
damage.41 During this state, akin to hibernation, mitochondria do not function normally, but 
do produce enough ATP to prevent activation of cell death pathways.42 Exactly how mitochon-
drial dysfunction contributes to the development of AKI is poorly understood, but during over-
whelming cellular stress, the protective capacity of mitochondria might be exhausted.43
Pharmacological interventions
Although several clinical trials to treat patients suffering from AKI have been executed with 
diverse pharmacological interventions, mostly disappointing results were obtained. Exam-
ples of trials include the use of Vitamin E and N-acetylcysteine to treat contrast-induced 
nephropathy, and furosemide treatment for hemofiltration-dependent AKI.44-46 Interestingly, 
two small Phase II studies demonstrated that parenteral administration of the dephosphor-
ylating enzyme alkaline phosphatase (AP) to critically ill patients with sepsis and associated 
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AKI improved kidney function and biomarker read-outs of inflammation and kidney injury.47,48 
Through what mechanisms of action AP exerts renal protective effects is largely unknown.
Alkaline Phosphatase
AP is an endogenous membrane-bound homodimeric enzyme that contains two zink ions 
and one magnesium ion per active site, necessary for its activity.49 This dephosphorylating 
glycoprotein is the most stable in the pH range of 7.4–9.850 and catalyzes transphosphoryla-
tion reactions and the hydrolysis of monoesters, thiophosphate, phosphorothiates and phos-
phoramidates (e.g. ATP).49 Four different isoenzymes are known, namely placental (PLAP), 
germ cell (GCAP), intestinal (IAP), and tissue non-specific (TNAP, liver/bone/kidney) AP, which 
illustrates the expression of AP and emphasizes its broad array of functions during health 
and disease.51 AP measured in serum is mostly derived from liver and bone.52 The function 
of AP in the intestine has been extensively studied in animal studies; IAP has been shown 
to be involved in the regulation of pH and bicarbonate secretion, regulation of lipid absorp-
tion across the enterocyte apical membrane, and detoxification of bacterial endotoxins 
through dephosphorylation.53 Bone AP is involved in bone mineralization, but the exact role 
of the other iso-enzymes is still unknown.51 However, they can serve as markers of disease 
as elevated serum levels of PLAP, bone derived AP and liver-derived AP levels can be used 
as a marker for testicular cancer54, fracture prediction55 and cholestasis56, respectively. In the 
kidney, two different iso-enzymes are expressed at the brush border membrane of the prox-
imal tubule cell; TNAP is present in the entire proximal tubule and IAP is localized in the lower 
tubular segments.57-59 As with other organs, not much is known about the function of AP in 
the kidney, but during systemic inflammation in rats, a reduction in renal function and loss of 
brush border membranes were observed, accompanied by increased levels of AP in urine.27 
Additionally, during renal ischemia-reperfusion injury the AP brush border activity, measured 
in vesicles isolated from whole cortex, was shown to be attenuated while AP levels were 
increased in urine indicating injury to the proximal tubule brush border.60,61 
Clinical Trials
AP was originally considered as a novel treatment for sepsis and not intended specifically for 
AKI.62,63 A variety of animal experiments aimed at obtaining evidence for dephosphorylation 
and detoxification of the endotoxin LPS62-65, which is thought to play a pivotal role during 
sepsis.17 Initially, clinical development was conducted using purified bovine intestinal alka-
line phosphatase (biAP), a close homologue of human intestinal AP. Preceding the paren-
teral administration of exogenous biAP in patients, the clinical pharmacokinetics and safety 
were assessed. A loading dose of biAP followed by continuous infusion resulted in relatively 
stable serum enzyme activity in healthy volunteers, also when pre-exposed to LPS, as well 
as in sepsis patients, at a level that is approximately double that of endogenous enzyme for 
a period of 24-72 hours. Being a non-sialylated glycoprotein, biAP is primarily cleared by the 
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asialoglycoprotein receptor on liver cells, therefore, a loading dose is required to saturate the 
liver clearance before a steady state of 2-fold higher AP levels than endogenous circulating 
levels can be reached and maintained.64 Also, exogenous biAP was shown not to cause any 
relevant adverse effects in humans.66
From the first human Phase IIa clinical trial conducted in 36 severe sepsis or septic shock 
patients admitted to the ICU (with or without AKI), it became clear that BiAP displayed clin-
ical activity particularly in those patients who also suffered from AKI, a finding discovered 
by coincidence by scientists of the department of Intensive Care Medicine (Radboudumc, 
Nijmegen).47 In that trial, patients were randomized to receive either AP or matching placebo 
intravenously for 24 hours. BiAP significantly improved kidney function, as was determined 
by median plasma creatinine levels. Also, patients with AKI showed a reduced need for 
RRT during the 28-day follow-up period, whereas patients without AKI during enrollment 
appeared to be less prone to the development of AKI (Figure 2). However, because of the 
small number of patients and the heterogeneity within the study group, these clinically 
relevant effects did not reach statistical significance. In addition and in line with these clin-
ical end-points, bIAP treatment attenuated the up-regulation of renal inducible nitric oxide 
synthase (iNOS) expression resulting in a reduction of urinary NO metabolites, and this was 
correlated with the reduced urinary excretion of the proximal tubule injury marker glutathi-
one-S-transferase-A1 (GST1A-1).47
Based on these results, the company AM-Pharma decided to explore further the renal bene-
ficial effects of biAP, and a second prospective Phase IIa clinical trial was designed. This study 
focused on patients with severe sepsis or septic shock with evidence of early AKI. In this 
trial, 36 patients with sepsis-associated AKI were included, receiving either biAP or matching 
placebo intravenously for 48 hours.48 Treatment with bIAP improved overall renal function 
with respect to the combined endpoint consisting of endogenous creatinine clearance, need 
for renal replacement therapy (RRT) and duration of renal replacement therapy. Also, the 
decline in the inflammatory markers C-reactive protein, LBP and Interleukin (IL)-6 was more 
pronounced in the bIAP treatment group compared to placebo, as was the reduction in the 
urinary excretion of the renal damage markers Kidney Injury Molecule (KIM)-1 and IL-18.48 Of 
note, biAP treatment might have supported improvement of other organs in these critically 
ill patients as well, as exemplified by the significantly reduced duration of mechanical ventila-
tion (3.9 days vs 6.0 days, p<0.03). 
Combining the data from both trials (n=52 patients with evidence of AKI) demonstrates that 
administration of BiAP reduced plasma creatinine levels within 48 hours from a median [inter-
quartile range] of 181 [153 – 227] to 145 [106 – 212] µmol/L, compared to a further increase 
from 180 [152 – 267] to 216 [113 – 336] µmol/L in placebo-treated patients (p=0.05). Also 
the need for renal replacement therapy in the patients with evidence of AKI tended to be 
lower in AP-treated patients: 26% (n=27 AP patients) vs. 46% (n=24 placebo patients), (p=0.09, 
analyzed using Stouffer’s method).  Together, these two small Phase IIa clinical trials demon-
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strated potential promising effects of biAP on kidney function in critically ill patients with 
sepsis-associated AKI (Figure 3), suggesting that use of AP as a therapeutic intervention to 
ameliorate AKI related to sepsis may be favorable. 
As the protective effect of AP was demonstrated in a limited number of patients only, results 
needed to be reconfirmed in larger trials. However, administering bovine-sourced material to 
humans is less desirable due to the risk of immune reactions and challenges obtaining bovine 
spongiform encephalopathy (BSE)-free sources of AP. Therefore, a human recombinant AP 
(recAP) was developed. This human recAP combines two iso-enzymes of AP, the biologi-
cally most active intestinal AP and the placental AP with the longest half-life. By replacing 
the crown domain of a human intestinal AP with the crown domain of human placental AP, 
a highly stable, biologically active enzyme67 was created, of which safety, pharmacokinetics 
and efficacy have to be confirmed.
AP mode of action in sepsis-associated AKI 
Despite the described beneficial effects of bovine AP in the treatment of AKI in sepsis 
patients, the underlying molecular mechanism(s) of AP improving kidney function remain(s) 
to be unraveled. AP is a membrane-bound endogenously present enzyme that can detoxify 
molecules through dephosphorylation.49 There is, indeed, a limited number of candidate 
substrates potentially connected to inflammation and subsequent kidney damage that could 
be dephosphorylated by AP. One of these substrates is the endotoxin (LPS) itself, which elicits 
potent systemic as well renal immune activation (Figure 1).
Figure 2.
 Alkaline phosphatase exerts renal protective effects in sepsis patients. 
 Patients were administered an IV bolus injection of biAP or placebo, followed by continuous infusion up to 24 hours. 
Treatment appeared to reduce the need for renal replacement therapy (RRT) during the 28-day follow-up period in 
patients with signs of AKI at baseline and the occurrence of AKI in patients without signs of AKI at baseline.47 
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LPS as a therapeutic target
In view of the detrimental role of LPS in the development of sepsis, endotoxin might repre-
sent an interesting pharmacological target. Unfortunately, the direct targeting of LPS by an 
Immunoglobulin G-Anti-LPS antibody68, as well as inhibition of the LPS signaling pathway 
through TLR4 antagonism by Eritoran69 were found ineffective in clinical trials in critically ill 
severe sepsis patients. Another strategy could be detoxification of LPS. LPS is comprised of 
a polysaccharide chain, an oligosaccharide core component and the lipid A part, the latter 
causing the toxicity of this molecule. This toxic moiety is composed of two carbohydrate 
units and several fatty acid chains. Each carbohydrate usually contains one phosphate group 
and removal of one of these two phosphate groups by a dephosphorylating molecule 
results in a non-toxic lipid A moiety.70 Subsequently, dephosphorylated LPS is far less toxic, 
can still bind to TLR4, but will actually work as a TLR4 antagonist because the inflammatory 
cascade can no longer be triggered. According to several in vitro and in vivo experiments, 
LPS indeed can be dephosphorylated in the presence of AP. In rats, inhibition of endoge-
nous AP levels by administration of levamisole significantly decreased the survival rates 
after being exposed to a sublethal dose of gram-negative E. coli, while levamisole did not 
alter the survival rates after treatment with the Gram-positive bacteria S. aureus.62 In several 
animal models, exogenous PLAP and bIAP attenuated the inflammatory response induced 
by LPS and improved survival.64,70 In mice, PLAP and bIAP appeared protective during E. 
coli induced inflammation, as treatment reduced fever and attenuated the systemic cyto-
kine response, serum nitric oxide levels and liver and lung damage.63,71 Also, treatment with 
Figure 3.
 The beneficial clinical and molecular effects of AP administration to critically ill patients suffering 
from severe sepsis/septic shock, with or without AKI. 
 Published previously in the American Journal of Kidney Diseases.14
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bIAP preceding the administration of LPS resulted in an accelerated recovery according to 
physiological parameters (e.g. temperature and heart and breathing rate), a reduced TNF-α 
response and attenuated hematological changes in piglets.64 Furthermore, IAP reduced 
blood IL-6 concentration and improved gas exchange during septic shock induced by fecal 
peritonitis in sheep.65 These beneficial effects were accompanied by the AP-mediated reduc-
tion in serum LPS levels, as it was demonstrated that serum LPS levels significantly increased 
in the presence of the IAP inhibitor L-phenylalanine.72 AP seems to interact with the LPS-TLR4 
pathway, because the LPS-induced increase in NF-κB activity was attenuated in endothe-
lial cells pre-treated with exogenous bIAP.73 Also, up-regulation of endogenous IAP by the 
pro-inflammatory Resolvin-E1 reduced the LPS induced NF-κB activity.73 This reduction 
is probably mediated through dephosphorylation and thereby detoxification of LPS. The 
ability of AP to dephosphorylate LPS was demonstrated through the presence of free phos-
phate using enzymatic in vitro assays and in vivo histochemical analysis, revealing phospha-
tase activity present at the tubular brush borders.62,63,70 Together, these studies demonstrate 
several anti-inflammatory effects of AP on LPS-induced systemic inflammation (Table 1). 
Unfortunately, renal function was not assessed in these models and the effects of AP in this 
respect were not investigated. Since systemic inflammation directly affects the renal micro-
vascular blood flow, and improvement of renal microcirculation protects the tubular epithe-
lium and prolongs survival in sepsis-induced AKI mice model74, the effects of AP on LPS-in-
duced inflammation may also be protective to the kidneys. Attenuating circulating LPS and 
cytokine levels by AP could have the same beneficial effects, thereby preventing the devel-
opment of renal hypoxia and subsequent AKI. Furthermore, the detoxification of LPS by AP 
locally within the kidney may exert direct anti-inflammatory renal effects, and could poten-
tially prevent the development of AKI. 
ATP as a therapeutic target
Another protective compound during sepsis-associated AKI could be adenosine. Adenosine 
is an endogenous signaling molecule ubiquitously present, including in the kidney, where it is 
involved in the regulation of blood flow via tubuloglomerular feedback mechanisms, glomer-
ular filtration rate, renin release and vascular tone.75 Adenosine signals through binding to one 
of the four adenosine receptors A1, A2A, A2B and A3, all of which are expressed on immune cells76 
as well as in nephron segments, including the glomerular epithelium, renal vasculature, the 
proximal tubules and the collecting ducts.77 Adenosine is formed through phosphohydrolysis 
of adenosine triphosphate (ATP), adenosine diphosphate (ADP) and finally adenosine mono-
phosphate (AMP), or through conversion of cyclic AMP (cAMP).78,79 In the kidney, the most essen-
tial enzymes involved in these reactions are the ectonucleotidases CD39 (cluster of differentia-
tion 39), converting ATP into both ADP and AMP, and CD73, converting AMP into adenosine.79 
While ATP is associated with pro-inflammatory and tissue damaging properties80, adenosine 
may protect the body from injury provoked by these detrimental effects. Administering a 
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Table 1. Reported Beneficial Effects of AP Administration in Preclinical Studies of 
   Systemic Inflammation
 STUDY SPECIES MODEL TREATMENT SAMPLE SIZEa OUTCOME
Bentala et 
al (2002)70
Mice Intraperito-
neal D-galac-
tosamine and 
LPS injection
IV bolus injection 
of 0.1 U placental 
AP
7 Survival rate: 57% (untreated) 
vs 100% (treated), P = NR
Verweij et 
al (2004)63
Mice Intraperitoneal 
E coli 
injection
IV bolus injection 
of 1.5 U placental 
AP
14 Survival rate: 58% (untreated) 
vs 100% (treated), P < 0.01
Serum NO levelsb: 75 µmol/L 
(untreatedc) vs 16 µmol/L 
(control [no E coli]d), P < 0.01; 
39  µmol/L (treated) vs 16 
µmol/L (control [no E coli]d, 
P > 0.05
Beumer et 
al (2003)64
Mice Intraperitoneal 
E coli 
injection
IV bolus injection 
of 1.5 U bovine 
intestinal AP
5 Survival rate: 20% (untreated) 
vs 80% (treated), P < 0.01 
Body temperature: 34.2ºC ± 
0.8ºC  (untreated) vs 36.2ºC ± 
0.7ºC (treated), P < 0.05
Van Veen 
et al 
(2005)71
Mice Cecal ligation 
and puncture
IV bolus injection 
of 0.15 U/g body 
weight bovine 
intestinal AP 
8 Plasma TNF-α peak level: 170 
pg/mL (untreated) vs 57.5 pg/
mL (treated),  P < 0.05 Plasma 
IL-6 peak level: 19.3 pg/mL 
(untreated) vs 3.4 pg/mL 
(treated),  P < 0.05
Plasma MCP-1 peak level: 2.0 
pg/mL (untreated) vs 1.0 pg/
mL (treated), P < 0.05
Liver damage (AST levelb): 
1,300 IU/L (untreated) vs 800 
IU/L (treated), P < 0.05
Lung damage (MPO activityb): 
137.5 U/g (untreated) vs 90 
U/g (treated), P < 0.05
Koyama et 
al (2002)72
Rats Oral LPS 
administration
Oral administration 
of 40 mg/kg body 
weight  L-phenylal-
anine (inhibitor of 
intestinal AP)
3 Serum LPS levelb: 340 pg/
mL (untreated) vs 180 pg/mL 
(treated), P < 0.05
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synthetic adenosine analogue reduced circulating TNF-α levels and improved survival in mice 
receiving a normally lethal dose of LPS81, whereas increased mortality was observed in endo-
toxemic mice treated with an adenosine A2A receptor antagonist.82 Pretreatment of healthy 
volunteers with dipyridamole, which increases extracellular adenosine concentrations by 
blocking its cellular uptake, resulted in a more rapid decline of the pro-inflammatory cytokines 
IL-6 and TNF-α and enhanced the LPS-induced increase in the anti-inflammatory cytokine IL-10 
during experimental human endotoxemia.83 The immune-modulating effects of extracellular 
adenosine may also protect the kidney, as activation of the adenosine receptors A2A and A2B 
in the tubular lumen exerts anti-inflammatory effects.75 Mice lacking either adenosine receptor 
A1 or A3 showed increased renal expression of pro-inflammatory markers and the intracel-
lular adhesion molecule-1, and enhanced infiltration of leukocytes in septic peritonitis.84,85 
In addition, adenosine can reduce harmful effects of hypoxia, including hypoxia-induced 
inflammation, ischemia-associated organ dysfunction and hypoxia-induced vascular 
leakage.80 Hypoxia activates several protective genes such as hypoxia-inducible factor (HIF), 
which increases the extracellular levels of adenosine through transcriptional induction of 
ectonucleotidases and attenuation of adenosine breakdown enzymes and uptake trans-
porters, and increases signaling through enhancement of adenosine A2B receptor expres-
sion.80,86 Adenosine receptor binding on inflammatory cells increases intracellular second 
messenger cAMP levels, resulting in activation of several anti-inflammatory pathways causing 
leukocyte inhibition.75,87 In the kidney, HIF is widely expressed and detected in renal epithe-
lial cells, endothelial cells, and renal interstitial fibroblast-like cells.88-90 During hypoxic circum-
stances HIF appears to protect these cells by reducing oxidative stress and increasing cell 
survival.88-90 Intrarenal adenosine concentrations are increased during hypoxia91 and adenosine 
 STUDY SPECIES MODEL TREATMENT SAMPLE SIZEa OUTCOME
Su et al 
(2006)65
Sheep Intraperitoneal 
feces injection
Intestinal AP: IV 
bolus injection 
of 60 U/kg body 
weight, then contin-
uous infusion of 20 
U/kg/h for 15 h
NR Plasma IL-6 levelb: 0.20 
AU (untreated) vs 0.16 AU 
(treated), P < 0.05. Gas 
exchange (PaO2:FiO2 ratio)
b: 
50 mmHg (untreated) vs 320 
mmHg (treated), P < 0.05
Beumer et 
al (2003)64
Piglets IV LPS 
injection
IV injection of 
2,500 U bovine 
intestinal AP
NR Thrombocyte counts: 19 ± 1 
x 109/L (untreated) vs 41 ± 4 x 
109/L (treated), P < 0.05
 a Number of animals per group, unless otherwise noted.,  b Values are estimated from a graph. c Only 8 animals 
survived to have serum NO measured. d There were 6 animals in the control group.
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protects human proximal tubular epithelial cells from oxidant injury via adenosine receptors,92 
suggesting that these HIF-induced effects are mediated through extracellular adenosine as well. 
During circumstances of both inflammation and hypoxia (such as during sepsis), extracellular 
ATP is released by inflammatory and apoptotic cells which stimulates inflammation and tissue 
injury by attracting phagocytes and activating the NLR family pyrin domain-containing-3 
(NLRP3) inflammasome.93-98 Considering its detrimental effects, a rapid hydrolysis of ATP into 
adenosine is clearly warranted. Intriguingly, APs are the only ectonucleotidases known to be 
able to fully degrade extracellular ATP into adenosine. Since AP is depleted from the prox-
imal tubule during AKI, administration of exogenous AP could result in an increased turnover 
of ATP into adenosine within the kidney.79 Subsequently, adenosine can exert its anti-inflam-
matory and tissue-protective protective effects during hypoxia and inflammation, thereby 
preventing the development and/or attenuating ongoing sepsis-associated AKI (Figure 4).
Figure 4. 
 Detrimental extracellular ATP may be converted by AP into tissue-protective and anti-inflammatory 
adenosine. 
 During hypoxia and inflammation, ATP is released from inflammatory (ICs) and apoptotic cells (ACs), which can 
be converted by CD39 and CD73 expressed on renal endothelial (EnC) and epithelial cells (ECs) into ADP, AMP, 
and subsequently adenosine. Exogenously present AP may convert ATP into adenosine as well, which can then 
bind to adenosine receptors on EnCs, ECs, and ICs, resulting in renal-protective and anti-inflammatory effects. 
Published previously in the American Journal of Kidney Diseases.14
Tissue 
protective 
and anti-ATP ADP AMP Adenosine
AP
EnC
EC
ICICAC
EC EnC EC EnC
=  adenosine receptors= CD73= CD39
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Putative therapeutic use of AP
Both bacterially derived (e.g. LPS) and endogenous derived (e.g. ATP) substrates are thought 
to be pivotal targets for the therapeutic activity of AP in sepsis-induced AKI. Whether AP-me-
diated dephosphorylation of LPS, ATP and its derivatives, or other substrates are most critical 
for the beneficial effects of AP is currently unclear. It is known that circulating levels of endog-
enous AP become depleted during sepsis and that local expression of AP is lost in damaged 
kidneys.60,70 However, it appears unlikely that biAP infusion simply constitutes replacement 
therapy in the kidney. For instance, there is no evidence suggesting that therapeutic admin-
istration of biAP leads to its accumulation in the kidney, or that biAP even reaches the prox-
imal tubule apical membrane. The observation that other organs (e.g. the lungs) also appear 
to respond to biAP infusion could be interpreted as an indication of systemic anti-inflamma-
tory activity and might also support the hypothesis that the kidney is key in organ cross-talk 
mechanisms.99 Nevertheless, because in septic AKI patients renal injury biomarkers (KIM-1 and 
IL-18) and markers of systemic inflammation (LBP, CRP, IL-6) respond within hours after initi-
ating biAP treatment, it is likely that its mode of action is both systemic through detoxifying 
endotoxin and local by neutralizing the pro-inflammatory activity of extracellular purines and 
possibly the endotoxin itself. 
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Aim and outline of this thesis
The aim of this thesis is to conduct in vitro, animal and human studies to obtain insight into 
the molecular mechanism of action of AP, and to evaluate the potential of AP as a treatment 
for sepsis-associated AKI. 
Part one of this thesis assesses the global burden of sepsis-associated AKI and investigates 
the protective potential of endogenous AP in critically ill patients. Chapter 2 describes the inci-
dence and evolution of AKI and its effect on clinical outcomes in septic and non-septic criti-
cally ill patients worldwide. In chapter 3, we investigate the interplay between endogenously 
occurring AP levels, inflammation and clinical outcomes in critically ill sepsis patients. 
Part two discusses preclinical studies to assess the molecular mechanism of action of the 
protective effect of human recombinant AP (recAP), intended as treatment of sepsis-asso-
ciated AKI. Chapter 4 presents the renal protective effects of recAP during endotoxemia-in-
duced AKI in rats and investigates the mechanism of action behind these effects using a 
human proximal tubule cell model. Subsequently, this cell model is used in chapter 5 to 
investigate further the effects of recAP during impaired mitochondrial function. Chapter 6 
explores whether or not recAP modulates renal hemodynamics, oxygenation and inflamma-
tion in two rat models of ischemia-reperfusion and endotoxemia-induced AKI. In chapter 7, 
we characterize the platelet-inhibiting effects of recAP in healthy volunteers and septic shock 
patients by ex vivo blood stimulations.
Part three of this thesis focuses on the clinical development of recAP. In chapter 8, we investi-
gate the biodistribution of recAP during endotoxemia-induced AKI in rats and study pharma-
cokinetics (PK) of recAP in rats and minipigs to develop a translational population PK model. 
Chapter 9 describes a first-in-human study to investigate PK, safety and tolerability of recAP 
in healthy volunteers. Using these data, the population PK model is further refined to support 
the design and dose selection of a phase II clinical trial with recAP in critically ill patients 
suffering from sepsis-associated AKI. This multicenter trial, of which the study protocol is 
presented in chapter 10, is currently being conducted in approximately 50 sites in the Euro-
pean Union and North America.
Finally, the thesis concludes with a summary, general discussion, and future perspectives, 
presented in chapter 11.   
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Abstract
H ere, we provide an overview of the incidence and evolution of acute kidney injury (AKI) and its effects on clinical outcomes in septic and non-septic critically ill patients worldwide. Data was used from an inter-
national database of 10069 adult intensive care unit (ICU) patients. AKI was evaluated 
within the first two days after admission and before discharge or death up to day 7 according 
to the Risk, Injury, Failure, Loss and End-Stage (RIFLE) criteria. 7970 patients were included, 4727 
(59%) of whom had AKI within the first two days of their ICU stay. On admission to the ICU, 
1946 (24%) patients had sepsis of whom 1318 (68%) developed AKI, compared to 3409/6024 
(57%) in the non-septic population (p<0.001). More patients with sepsis than without had 
severe AKI (AKI-Failure 40% vs. 24%, p<0.001) and received renal replacement therapy (20% 
vs. 5%, p<0.0001). Patients with sepsis and AKI-F were less likely to recover to a lower RIFLE 
category during the first 7 days of their ICU stay compared to patients with AKI-F but without 
sepsis (21% vs. 32%, p<0.0001). In-hospital mortality rates were higher in patients with septic 
dis comparable among income classes and remains high even if there is full recovery. AKI-F 
was independently associated with in-hospital mortality in patients with and without sepsis 
(p<0.001). These findings emphasize the clinical importance of septic and non-septic AKI, 
even when there is full renal recovery. 
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Introduction
Acute kidney injury (AKI) is a serious complication in critically ill patients and is independently 
associated with poorer outcomes, creating a large burden on both patient and society.1,2 One- 
to two-thirds of intensive care unit (ICU) patients develop AKI and its incidence is increasing.3-8 
Approximately half of the ICU patients with AKI die and those patients surviving an episode of 
AKI have an increased risk of developing chronic kidney disease.9,10 Currently, there are no phar-
macological therapeutic options available to prevent or treat AKI and management is limited 
to mitigating secondary haemodynamic and toxic renal insults and providing supportive 
measures, such as diuretics and renal replacement therapy (RRT). AKI can be caused by a 
variety of factors,9 but sepsis is the most important aetiology in the critically ill.11 Sepsis-associ-
ated AKI is distinct from non-sepsis AKI, with differences in pathogenesis, patient characteris-
tics and clinical outcomes.11,12 Global epidemiological data comparing the clinical course and 
outcomes in septic and non-septic AKI are sparse. Further, while the impact of development 
of de novo AKI on short- and long-term outcomes is well recognized, the influence of deteri-
oration or improvement in renal function on clinical outcomes after established AKI remains 
unclear, although these aspects are of importance for clinical decision making and future 
research. The objective of this study was, therefore, to provide an overview of the incidence 
and evolution of AKI and its effect on clinical outcomes in critically ill adult patients world-
wide to provide greater insight into the global burden of this condition. Using a large global 
registry, the Intensive Care Over Nations (ICON) audit, we sought to compare and contrast 
progression and outcomes from septic and non-septic AKI. We hypothesized that septic AKI 
would be associated with worse outcomes than non-septic AKI.
Methods
Study population and data collection
This was a substudy of ICON, a multicentre, worldwide audit conducted between May 8th and 
May 18th, 2012. Full details of the methodology have been provided previously.13 ICUs were 
recruited by open invitation and participated on a voluntary basis with no financial incentive. 
In each institution, the study was approved by the institutional research ethics committee in 
accordance with local ethical regulations. Informed consent was not required due to the obser-
vational and anonymous nature of data collection. The participating centres prospectively 
collected data from all adult patients (>16 years) admitted to the ICU during the study period, 
except those admitted for less than 24 h for routine postoperative surveillance. Readmissions 
of previously included patients were not included. Data were collected daily during the ICU 
stay for up to 28 days and patients were followed up for outcome data until hospital discharge 
or death for a maximum of 60 days. Participating centres submitted data using a secured elec-
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tronic case report form.13 Data collected included demographic and comorbidity data, micro-
biological and clinical infections, use of antibiotics, and clinical and laboratory data. The acute 
physiology and chronic health evaluation (APACHE) II14 and non-renal APACHE II were calculated 
from the worst values taken during the first 24 h after admission (day 0). The sequential organ 
failure assessment (SOFA)15 and non-renal SOFA score were calculated daily. For the purposes of 
this substudy, only patients with full creatinine and urine output data were included. Patients 
who developed sepsis during the ICU stay (≥ 2 days after admission) were excluded. 
Definitions 
Sepsis was defined as the occurrence of at least one failing organ (SOFA score > 2 for respec-
tive organ system), combined with the presence of infection, as defined according to the 
International Sepsis Forum.16 The presence of AKI was evaluated within the first two days after 
admission using the Risk, Injury, Failure, Loss and End-Stage (RIFLE) criteria.17 As urine output 
was only recorded per 24 hour period in ICON, we adjusted the Risk and Injury urine output 
criteria accordingly (Supplemental Table 1). The criterion (urine output or serum creatinine) 
that led to the worst possible RIFLE classification was used in each case. An increase in serum 
creatinine was calculated using the highest value on day 1 after admission compared to the 
serum creatinine at admission (day 0); day 2 values were used when day 1 data were missing. 
Urine output data from the first 24 hrs after admission (day 0) were used. To assess AKI progres-
sion, the last serum creatinine or urine output data available before discharge or death up 
to day 7 were used to define the RIFLE category. This RIFLE category was compared to the 
RIFLE category at admission, and patients were identified as having deteriorated, improved, 
or remained in the same category. Complete recovery was defined as improvement from 
Risk, Injury or Failure categories towards the No AKI category. The inotropic score was calcu-
lated to express the use of vasoactive/vasopressor agents, as described elsewere.18  Patients 
with comorbid chronic renal failure (CRF), defined as the need for chronic renal support or as 
a history of chronic renal insufficiency with a serum creatinine greater than 3.6 mg/dL (300 
µmol/L), were analyzed as a separate subgroup. Definitions of other comorbid disorders and 
surgical admissions are described elsewhere.13 
Quality management  
All participating centres had access to a secured website throughout the study, on which 
detailed instructions about the aim of the study, data collection and definitions were 
provided. A coordinating centre (Erasme Hospital) answered any questions during data 
collection on a case-by-case basis. Validity of the data was checked upon data entry on the 
eCRF, including checks for plausibility within and between variables. The coordinating centre 
further reviewed all data for plausibility and availability of the outcome parameter (death 
or hospital discharge). Any uncertainties were clarified by consulting the centre in question. 
There was no on-site monitoring. 
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Statistical analysis 
All statistical analyses were conducted in the Department of Intensive Care of Erasme Hospital. 
For the purpose of this study, the world was divided into nine geographical regions, and 
individual countries were classified into three income groups in accordance with the gross 
national income (GNI) per person.13 Data are expressed as mean and standard deviation (SD), 
median with interquartile range [IQR, first and third] or numbers and percentages. For contin-
uous variables, normality assumption checking was performed by inspection of residual and 
normal plots and by using the Kolmogorov-Smirnov test. Difference testing between groups 
was performed using the Generalized Linear Models procedure, Kruskal-Wallis test, Student’s 
T test, Mann-Whitney test, χ² test, or Fisher’s exact test, as appropriate. To describe the inci-
dence of patients receiving RRT up to day 7, data were imputed by the last observation carried 
forward in case of discharge or death. If a patient died before day 60, ICU and hospital lengths 
of stay (LOS) were set to 60 days. A Cox regression model was used to estimate crude and 
adjusted hazard ratios (HRs) and their 95% CIs for ICU and hospital mortality according to AKI 
stage or CRF group. To determine the adjusted relative risk of in-ICU or in-hospital death, we 
developed a multivariable Cox proportional hazard model in patients, stratified according 
to the presence or not of sepsis. Other confounding variables considered included age, sex, 
non-renal APACHE II score, type of admission, source of admission, reason for admission, 
the need for mechanical ventilation or RRT on admission to the ICU, comorbidities, and the 
inotropic score. We also adjusted for ICU and hospital-related organizational factors including 
type of hospital, ICU specialty, total number of ICU patients in 2011, and number of staffed ICU 
beds. Geographic region and GNI were also considered. Collinearity between variables was 
excluded before modelling and the time-dependent covariate method was used to check 
the proportional hazard assumption of the model. The Kaplan-Meier method was used to 
estimate 60-day survival curves and the statistical significance of observed differences was 
tested using the log-rank test. A two-sided p value less than 0.05 was considered statistically 
significant. Data were analyzed using IBM® SPSS® Statistics software, version 23 for Windows 
(IBM, Armonk, NY). 
 
Results
A total of 10 069 patients were included in the ICON audit13; most patients were from ICUs in 
Europe (54%), Asia (19%), and the Americas (17%). Because of missing serum creatinine and 
urine output data, 9 579 patients (95%) were eligible for the present analyses; 764 patients 
developed sepsis during the ICU stay (≥ 2 days after admission) and were excluded. The 845 
patients with pre-existing CRF were analyzed as a separate subgroup. Of the remaining 7 970 
patients, 1 946 [24%] had sepsis on admission. A total of 4 727 patients had AKI within 2 days 
after ICU admission. AKI was more frequent (n=1 318 [68%] vs. n=3 409 [57%], p<0.001) and 
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more severe in patients with sepsis than in those without (Figure 1). The demographic and 
clinical characteristics of these patients are shown in Supplemental Tables 2 and 3.   
AKI follow-up
During follow-up, sepsis patients without AKI at ICU admission were less likely to develop AKI 
compared to the non-septic population (n=325 [52%] vs. n=1 582 [60%], p<0.0001). Sepsis 
patients admitted with AKI-R or AKI-I were more likely to show complete recovery of AKI, 
compared to patients without sepsis for the same AKI category (n=206 [36%] vs. n=522 [26%] 
for AKI-R, p<0.0001; n=65 [30%] vs. n=130 [21%] for AKI-I, p=0.005, respectively). However, 
sepsis patients with AKI-F were less likely to recover to a lower RIFLE category compared to 
non-septic patients with AKI-F upon follow-up (n=108 [21%] vs. n=258 [32%], p<0.0001). 
 
Renal replacement therapy and length of stay
The use of RRT was greater in the septic cohort than in the non-septic population (n=380 
[20%] vs. n=326 [5%], p<0.0001, Supplemental Figure 1A). During the first four days, haemofil-
tration was the most frequent form of RRT in sepsis patients and haemodialysis in non-septic 
Figure 1.
 Evolution of acute kidney injury (AKI) in septic and non-septic critically ill patients.
 The vertical bargraphs represent AKI diagnosed at admission (first 2 days in ICU) in septic patients (left) and 
non-septic patients (right), according to RIFLE categories No AKI, Risk, Injury and Failure. The horizontal bargraphs 
in the middle represent the evolution of AKI until day 7 within each RIFLE admission category. For example, of the 
30% of septic patients with AKI-R, 27% remained in the AKI-R group and 36% improved to No AKI. 
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patients (Supplemental Table 4). RRT use was greatest in patients admitted with AKI-F (Table 1) 
who had not improved by day 7 or who deteriorated to AKI-F during this period (Supple-
mental Figure 1B). In patients with AKI-F, RRT was more often initiated in upper-middle and 
high income class counties compared to low and lower-middle income class countries 
(Supplemental Table 5). RRT treatment modality for each region and income class is presented 
in Supplemental Table 6.  ICU and hospital LOS were longer for patients admitted with sepsis 
compared to patients without sepsis (8 [4-60] vs. 3 [2-6], p<0.001; 38 [14-60] vs. 11 [6-32], 
p<0.001, respectively) and increased with increasing AKI severity (Table 1). ICU and hospital 
LOS for each region and income class are shown in Supplemental Table 7.
Mortality 
Crude ICU (n=491 [25%] vs. n=655 [11%], p<0.0001) and in-hospital (n=651 [33%] vs. n=869 
[14%], p<0.0001) mortality rates were significantly higher in patients with sepsis compared 
to patients without sepsis, and were lower in high-income than in lower income countries 
(Supplemental Table 5). Crude mortality rates were higher in patients receiving RRT compared 
to those without RRT (ICU mortality sepsis: n=150 [40%] vs. n=341 [22%], no sepsis: n=91 [29%] 
vs. n=564 [10%]; in-hospital mortality sepsis: n=180 [49%] vs. n=71 [32%], no sepsis: n=105 
[34%] vs. n=764 [14%], all p<0.001). Of those receiving RRT, in-hospital mortality was higher 
in non-septic patients receiving haemofiltration compared to haemodialysis, whereas in the 
septic group, there were no differences between the modalities (Supplemental Table 8). 
Crude in-hospital mortality rates were 2 to 3-fold higher in patients with AKI-F compared to 
patients without AKI (Table 1). In patients with AKI-F, in-hospital mortality was comparable for 
each income class (Supplemental Table 5).
In patients with sepsis, crude in-hospital mortality was greatest in those admitted with AKI-F 
and AKI-I who had not recovered by day 7 (Figure 2); in patients without sepsis, this relation-
ship was only present in patients with AKI-F. In contrast to the non-septic population, mortality 
was higher in sepsis patients who developed AKI-I than in patients without AKI or with AKI-R. 
AKI-F patients who recovered renal function had a 13% (septic patients) and 20% (non-septic 
patients) lower in-hospital mortality compared to those who remained in AKI-F. However, 
in-hospital mortality in these patients was twice as high compared to patients recovering 
from AKI-R or AKI-I (Figure 2). Cumulative survival curves are shown in Figure 3. AKI-I and AKI-F 
were associated with significantly higher hazard ratios of crude ICU and hospital mortality in 
septic and non-septic patients (Table 2). When adjusted for covariates, AKI-F was still associ-
ated with ICU and in-hospital mortality in both patient groups and AKI-I was associated with 
in-hospital mortality in non-septic patients (Table 2). 
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Figure 2.
 Hospital mortality in septic and non-septic critically ill patients during follow-up. 
 At admission (first 2 days in ICU), patients were categorized as No AKI, Risk (R), Injury (I) or Failure (F), presented on 
the x-axis. Patients were followed-up until day 7 to determine whether they improved to a lower RIFLE class or 
deteriorated further to a more severe RIFLE class, as presented on the z-axis. Hospital mortality was determined 
for the groups in which patients improved or deteriorated during follow-up.  
Table 1. Clinical outcomes
SEPSIS
n=1946
NO SEPSIS
n=6024
No AKI
n=628
Risk
n=575
Injury 
n=219
Failure
n=524
No AKI
n=2615
Risk
n=1976
Injury
 n=627
Failure
n=806
ICU LOS, 
days
7 
[2-22]*
7
[3-29]*
8
[4-54]#*
19
[6-60]#*
3
[1-5]
3
[2-5]
2
[1-6]#
4
[2-60]#
Hospital LOS, 
days
25
[12-60]*
28
[13-60]*
49
[14-60]#*
60
[22-60]#*
10
[6-22]
10
[6-24]
11
[6-35]#
20
[7-60]#
RRT, 
n (%)
25
(4.0)*
33
(5.7)*
15
(6.8)*
307
(58.6)#*
27
(1.0)
22
(1.1)
10
(1.6)
267
(33.1)#
ICU mortality,
n (%) 
108
(17.6)*
117
(20.6)#*
50
(23.5)#*
216
(41.5)#*
213
(8.4)
138
(7.2)#
76
(12.4)#
228
(29.2)#
Hospital mortality, 
n (%)
154
(25.9)*
162
(29.3)#*
74
(35.6)#*
261
(51.7)#*
286
(11.8)
219
(11.9)#
102
(17.4)#
262
(34.6)#
 Significant at 5% level: # vs. No AKI in the same group (sepsis or no sepsis), * vs. No sepsis patients with the same 
RIFLE classification. LOS, length of stay; RRT, renal replacement therapy.
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Table 2. Hazard ratio for mortality
SEPSIS NO SEPSIS
Crude HR  [95% CI] Covariate-adjusted 
HR [95% CI]
Crude HR [95% CI] Covariate-adjusted 
HR [95% CI]
ICU mortality
     Risk 1.15 [0.89-1.50]*‡ 1.03 [0.78-1.35]‡ 0.83 [0.67-1.03]‡ 0.90 [0.72-1.13]‡
     Injury 1.36 [0.98-1.91]# 1.18 [0.83-1.68]* 1.54 [1.18-2.00]# 1.29 [0.98-1.69]
     Failure 2.48 [1.95-3.16]#*‡ 1.88 [1.45-2.44]#* 3.56 [2.93-4.33]#‡ 2.18 [1.74-2.72]#‡
     CRF 1.85 [1.37-2.51]# 1.59 [1.15-2.20]# 1.96 [1.54-2.51]# 1.38 [1.06-1.81]#
Hospital mortality
     Risk 1.15 [0.92-1.44]*‡ 0.98 [0.78-1.23]‡ 0.98 [0.82-1.17]‡ 0.99 [0.82-1.19]‡
     Injury 1.39 [1.05-1.83]#*‡ 1.19 [0.89-1.59] 1.52 [1.22-1.91]#‡ 1.35 [1.06-1.70]#
     Failure 2.54 [2.06-3.13]#*‡ 1.92 [1.53-2.40]#* 3.47 [2.91-4.14]#‡ 2.14 [1.76-2.61]#‡
     CRF 1.94 [1.51-2.51]# 1.62 [1.24-2.12]# 2.06 [1.67-2.54]# 1.45 [1.15-1.82]#
 Significant at 5% level: # vs. No AKI in the same group (sepsis or no sepsis). * vs. No sepsis patients with the same 
RIFLE classification. ‡ vs. CRF in the same group (sepsis or no sepsis). No AKI is the reference category. Hazard 
ratios (HR) were estimated by stratified Cox model regression. CRF, chronic renal failure.
Figure 3. 
 Kaplan-Meier 60-day survival curves in critically ill patients with (left panel) and without (right panel) 
sepsis.
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Chronic renal failure patients
Of the 845 patients with a medical history of CRF at ICU admission, 263 (31%) had sepsis. Base-
line demographic and clinical characteristics are presented in Supplemental Tables 9 and 10. 
RRT incidence, ICU and in-hospital LOS and mortality are shown in Supplemental Table 11. CRF 
patients had a lower mortality rate than AKI-F patients (sepsis: p=0.017; non-sepsis: p<0.001) 
(Figure 3). When adjusted for covariates, this difference disappeared in sepsis patients, but 
remained in non-septic patients (Table 2). 
Discussion
The data obtained from this large international multicentre audit confirm previously reported 
incidences of AKI and that the condition is more common in patients with sepsis than in those 
without.3,6-8,19 Sepsis patients with less severe AKI were more likely to recover renal function 
within the first week after admission than non-septic patients, whereas sepsis patients with 
more severe AKI (AKI-F) were less likely to recover renal function than non-sepsis patients with 
AKI-F. These data on the kinetics of AKI mirror those of the FINAKKI study, in which 86% of criti-
cally ill patients admitted with AKIN stage 3 (an equivalent to AKI-Failure) remained in this most 
severe category.3 Our results also corroborate those from a study by Hoste et al., in which more 
than half of the AKI-R patients and one-third of the AKI-I patients deteriorated further.6 However, 
neither of these studies differentiated between patients with and without sepsis and large multi-
centre studies describing the characteristics and clinical outcomes of patients with septic and 
non-septic AKI have not been published recently.20,21 Although it is well known that increasing 
severity of AKI is associated with a higher mortality,6 as confirmed in this study, we now show 
that transition to a lower RIFLE category is associated with an improvement in survival. Never-
theless, once AKI-F is reached, mortality remains high even if there is full renal recovery.  
AKI in patients with and without sepsis
Septic patients suffering from less severe AKI were more likely to recover renal function during 
the first week after admission than non-septic patients with the same initial degree of AKI, 
whereas septic patients admitted with AKI-F were less likely to recover to a lower RIFLE cate-
gory. This observation may be explained by the different timing of AKI occurrence, or by 
differences in the distinct pathogenesis of septic versus non-septic AKI. Although a variety 
of mechanisms are involved in the development of AKI, including endothelial injury from 
vascular perturbations, the effect of nephrotoxic factors, disturbed renal autoregulation, and 
the release of inflammatory mediators,22 AKI in patients with sepsis may predominantly be 
the consequence of the dysregulated inflammatory response to an infection, resulting in 
renal inflammation, microcirculatory dysfunction and cell bioenergetic adaptive responses.12 
Clearing underlying infection may be more likely to help AKI resolution in milder cases than 
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in more severe stages. This observation may also be related to the general severity of illness 
in septic patients, as underlined by the high SOFA score and the greater need for vasoac-
tive agents.23,24 Conversely, non-septic AKI, such as occurs from adverse drug reactions, may 
be related more to extensive damage to the micro-architecture of the kidney, requiring 
prolonged periods for repair and renal recovery. In support of this suggestion, recent autopsy 
investigations failed to reveal widespread tubular damage and cell death in septic AKI.25
Influence of RRT and transition to another RIFLE category  
In this study, RRT was mostly started within the first two days after ICU admission and primarily 
in patients admitted with AKI-F who did not recover during the first week after admission. RRT is 
not only initiated to replace the failing kidney, but also has non-renal indications, such as immu-
nomodulation in sepsis and fluid overload. It is currently unclear whether or not early initiation 
of RRT may improve patient outcome,26,27 despite two large clinical trials28,29 and further study, 
such as the ongoing STARRT-AKI trial (ClinicalTrials.gov Identifier: NCT02568722), is necessary to 
elucidate the effects of RRT timing on outcome and guide clinical decisions related to the initia-
tion of RRT. Although in-hospital mortality was lower in patients with renal recovery, septic and 
non-septic AKI-F patients who recovered full renal function still had a two-fold higher in-hos-
pital mortality rate than patients recovering from AKI-I or AKI-R or patients without AKI. In addi-
tion, our data confirm that mortality is higher in patients receiving RRT compared to those who 
are not.30 Our hypothesis-generating data could help establish a novel approach to risk strati-
fication in AKI for current therapy, future investigations and clinical therapeutic trials. Firstly, in 
the absence of life threatening complications, it may be prudent to delay RRT, as a large number 
of patients, especially in the lower RIFLE categories, recovered full renal function. Indeed, RRT 
has been shown to delay recovery of renal function.31 Secondly, the finding that renal func-
tion can recover in AKI-F patients suggests that these patients, although having a high risk of 
death can still improve. Almost 40% of patients admitted with AKI-R and AKI-I at admission 
improved during the first week after admission. Secondary prevention, by mitigating further 
toxic and haemodynamic renal insults, is therefore likely an important therapeutic opportunity 
in this population. Thirdly, models of ICU mortality and prognostic scores can likely be refined 
by considering the dynamic changes in renal function over time.
Chronic renal failure patients
The incidence of CRF is increasing, especially among elderly patients, and is associated with 
substantial mortality.32,33 We confirmed that pre-existing CRF was independently associated 
with ICU and in-hospital mortality. Of interest, CRF impaired survival to a similar extent to 
AKI-F in septic patients and to a lesser extent in non-septic patients. Although the assessment 
of acute-on-chronic kidney disease in this population was beyond the scope of this study, it is 
known that patients with CRF have a higher propensity to develop in-hospital AKI.34 In addi-
tion, CRF is strongly associated with the occurrence of maximum RIFLE class F in the critically ill.6 
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Strengths and limitations of this study
Our study has some limitations. Firstly, we lack information about secondary renal insults that 
may have occurred as a result of hypotension, adverse drug reactions or inappropriate blood 
pressure targets. These factors can play an important role in the progression of or recovery 
from AKI. Secondly, renal function was assessed using the RIFLE criteria, a widely accepted 
and validated classification system for AKI in the critically ill,17 which we had to adjust due to 
the absence of a pre-ICU baseline creatinine value and because urine output was only avail-
able per 24-hour period. Importantly, applying this modified version of the RIFLE criteria may 
have led to an underestimation of renal failure. Moreover, serum creatinine35 and urine output36 
have known limitations for the diagnosis of AKI. Urinary and systemic biomarkers are a prom-
ising alternative,37-39 but have not yet been demonstrated to be of use in daily clinical prac-
tice. Thirdly, we were unable to discern longer term consequences of AKI and progression 
to chronic kidney disease. In light of our findings, these long term consequences, stratified 
by evolution of AKI across RIFLE categories, represent an important area for future investiga-
tions. Fourthly, although the worldwide inclusion of patients provides a valuable insight into 
the global burden of AKI, the causes of AKI vary by country and economic status, as recently 
published.40 Also, resources may differ among various regions around the world, which could 
influence the clinical outcome of AKI patients. However, we showed that although the inci-
dence of dialysis in AKI-F patients was higher in upper-middle and high income countries 
compared to low and lower-middle income countries, in-hospital mortality rates were compa-
rable across income classes in these patients. Finally, some centres included a limited number 
of patients, possibly leading to sampling bias, and the voluntary participation of ICUs may have 
resulted in compliance bias. Nevertheless, this is a prospective study in which a large number 
of patients was included from all over the world with daily assessment of changes in renal 
function and an extensive follow-up period, allowing a useful comparison of the incidence and 
evolution of AKI and its consequences between patients with septic and non-septic patients.
Conclusion
AKI is more frequent, more severe, less likely to recover once AKI-F is reached, and associated 
with higher mortality rates in patients with sepsis than in those without. Deterioration to a 
more severe category of AKI negatively influences clinical outcome, while improvement is 
associated with increased survival. These results emphasize the severity of the disease, which 
represents a tremendous burden for both patient and society. 
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Supplemental Figure
Supplemental Figure 1.
 Renal replacement therapy (RRT) in critically ill patients with and without sepsis. 
 A) Percentage of patients receiving RRT per day per RIFLE category at admission. B) RRT incidence per RIFLE cate-
gory during follow up. The admission category is presented on the x-axis. Patients were followed-up until day 7 
to determine whether they improved to a lower RIFLE class or deteriorated further to a more severe RIFLE class, as 
presented on the z-axis. In case of discharge or death, data were imputed by last observation carried forward.
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 Supplemental Tables
Supplemental Table 1.  Adjusted RIFLE criteria for diagnosis of acute kidney injury
SERUM CREATININE ORIGINAL URINE 
OUTPUT CRITERIA
ADJUSTED URINE 
OUTPUT CRITERIA
Risk Increased creatinine x 1.5 <0.5 ml/kg/h x 6h <1.0 ml/kg/h x 24h
Injury Increased creatinine x 2 <0.5 ml/kg/h x 12h <0.5 ml/kg/h x 24h
Failure Increased creatinine x 3 or creati-
nine ≥ 4 mg per 100 ml 
(acute rise of  ≥ 0.5 mg per 100 ml)
<0.3 ml/kg/h x 24h 
   or anuria x 12h
<0.3 ml/kg/h x 24h 
   or anuria x 24h
Loss Persistent acute renal failure = complete loss of renal function > 4 weeks
ESRD End-stage renal disease (> 3 months)
  Adapted from Bellomo et al.17 RIFLE, Risk, Injury, Failure, Loss and End-stage renal disease (ESRD).
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Supplemental Table 2.  Baseline demographic characteristics of patients with and 
      without sepsis, stratified by RIFLE criteria
SEPSIS NO SEPSIS
No AKI Risk Injury Failure No AKI Risk Injury Failure
Number of patients, (%) 628 (32.3) 575 (29.5) 219 (11.3) 524 (26.9) 2615 (43.4) 1976 (32.8) 627 (10.4) 806 (13.4)
Age, mean (SD) years 58.5 (17.6) 61.7 (17.3)#* 64.8 (17.8)#* 63.3 (15.9)# 56.0 (19.1) 59.4 (17.9) 61.1 (17.9)# 61.7 (17.8)#
Male, n (%) 383 (61.8) 352 (62.0) 118 (54.9) 312 (59.8) 1477 (57.4) 1226 (62.6)# 376 (60.6) 450 (56.4)
Weight, mean (SD) kg 70.1 (19.2) 75.3 (21.0) 77.6 (21.4) 76.6 (22.3) 70.5 (16.4) 76.4 (17.7)# 80.6 (24.1)# 77.9 (23.6)#
Height, mean (SD) cm 167.2 (9.7) 168.0 (10.4) 167.9 (10.2) 167.6 (10.6) 167.1 (10.0) 168.6 (9.5)# 168.2 (10.0)# 167.5 (10.4)
Severity scores, mean (SD)
     APACHE II 20.6 (7.7)* 22.0 (7.8)#* 22.3 (7.9)#* 26.7 (9.2)#* 14.8 (7.5) 15.1 (7.2) 16.1 (8.5)# 20.7 (10.9)#
     Non-renal APACHE II     19.6 (7.5)* 20.9 (7.5)#* 21.1 (7.6)#* 23.6 (8.4)#* 14.1 (7.3) 14.4 (6.9) 15.3 (8.1)# 18.6 (10.0)#
     SOFA 8.1 (3.3)* 8.2 (3.4)#* 8.7 (3.7)#* 11.4 (4.2)#* 4.7 (3.4) 4.7 (3.5) 4.8 (3.8) 7.6 (4.9)#
     Non-renal SOFA 7.4 (3.1)* 7.3 (3.1)#* 7.6 (3.5)* 8.8 (3.7)#* 4.0 (3.2) 4.1 (3.2) 4.1 (3.5) 5.5 (4.1)#
Type of admission, n (%)
     Surgical (non-trauma) 199 (33.8) 171 (31.5)* 68 (31.9) 146 (28.9)# 953 (38.3) 799 (42.3)# 216 (35.9) 209 (28.4)#
     Medical 355 (60.4)* 355 (65.4)* 137 (64.3) 348 (68.9)# 1277 (51.3) 923 (48.9) 346 (57.6)# 482 (65.5)#
     Trauma 28 (4.8)* 16 (2.9)* 8 (3.8) 8 (1.6)#* 231 (9.3) 159 (8.4) 38 (6.3)# 39 (5.3)#
     Other 6 (1.0) 1 (0.2)# 0 (0.0)# 3 (0.6) 26 (1.0) 7 (0.4)# 1 (0.2)# 6 (0.8)
Source of admission, n (%)
     Other hospital 62 (9.9) 65 (11.3) 22 (10.0) 59 (11.3) 231 (8.8) 198 (10.0) 55 (8.8) 81 (10.0)
     ER/ambulance 229 (36.5) 208 (36.2) 74 (33.8) 156 (29.8)* 1047 (40.0) 733 (37.1) 262 (41.8) 335 (41.6)
     OR/Recovery 88 (14.0)* 80 (13.9)* 34 (15.5) 65 (12.4) 516 (19.7) 476 (24.1)# 107 (17.1) 100 (12.4)#
     Hospital floor 206 (32.8)* 179 (31.1)* 63 (28.8) 200 (38.2)#* 584 (22.3) 414 (21.0) 148 (23.6) 222 (27.5)#
     Other 43 (6.8) 43 (7.5) 26 (11.9) 44 (8.4) 237 (9.1) 155 (7.8) 55 (8.8) 68 (8.4)
Reason for admission, n (%)
     Neurological 102 (16.2) 66 (11.5)# 16 (7.3)# 26 (5.0)# 438 (16.7) 261 (13.2)# 74 (11.8)# 59 (7.3)#
     Respiratory 174 (27.7)* 163 (28.3)* 54 (24.7)* 91 (17.4)#* 299 (11.4) 237 (12.0) 100 (15.9)# 101 (12.5)
     Cardiovascular 143 (22.8)* 146 (25.4)* 71 (32.4)# 200 (38.2)# 707 (27.0) 651 (32.9)# 203 (32.4)# 308 (38.2)#
     Renal/Ob-gyn 11 (1.8)* 15 (2.6)* 4 (1.8) 42 (8.0)# 99 (3.8) 74 (3.7) 25 (4.0) 73 (9.1)#
     Haematological 10 (1.6) 17 (3.0)* 8 (3.7) 14 (2.7) 37 (1.4) 18 (0.9) 11 (1.8) 17 (2.1)
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SEPSIS NO SEPSIS
No AKI Risk Injury Failure No AKI Risk Injury Failure
Number of patients, (%) 628 (32.3) 575 (29.5) 219 (11.3) 524 (26.9) 2615 (43.4) 1976 (32.8) 627 (10.4) 806 (13.4)
Age, mean (SD) years 58.5 (17.6) 61.7 (17.3)#* 64.8 (17.8)#* 63.3 (15.9)# 56.0 (19.1) 59.4 (17.9) 61.1 (17.9)# 61.7 (17.8)#
Male, n (%) 383 (61.8) 352 (62.0) 118 (54.9) 312 (59.8) 1477 (57.4) 1226 (62.6)# 376 (60.6) 450 (56.4)
Weight, mean (SD) kg 70.1 (19.2) 75.3 (21.0) 77.6 (21.4) 76.6 (22.3) 70.5 (16.4) 76.4 (17.7)# 80.6 (24.1)# 77.9 (23.6)#
Height, mean (SD) cm 167.2 (9.7) 168.0 (10.4) 167.9 (10.2) 167.6 (10.6) 167.1 (10.0) 168.6 (9.5)# 168.2 (10.0)# 167.5 (10.4)
Severity scores, mean (SD)
     APACHE II 20.6 (7.7)* 22.0 (7.8)#* 22.3 (7.9)#* 26.7 (9.2)#* 14.8 (7.5) 15.1 (7.2) 16.1 (8.5)# 20.7 (10.9)#
     Non-renal APACHE II     19.6 (7.5)* 20.9 (7.5)#* 21.1 (7.6)#* 23.6 (8.4)#* 14.1 (7.3) 14.4 (6.9) 15.3 (8.1)# 18.6 (10.0)#
     SOFA 8.1 (3.3)* 8.2 (3.4)#* 8.7 (3.7)#* 11.4 (4.2)#* 4.7 (3.4) 4.7 (3.5) 4.8 (3.8) 7.6 (4.9)#
     Non-renal SOFA 7.4 (3.1)* 7.3 (3.1)#* 7.6 (3.5)* 8.8 (3.7)#* 4.0 (3.2) 4.1 (3.2) 4.1 (3.5) 5.5 (4.1)#
Type of admission, n (%)
     Surgical (non-trauma) 199 (33.8) 171 (31.5)* 68 (31.9) 146 (28.9)# 953 (38.3) 799 (42.3)# 216 (35.9) 209 (28.4)#
     Medical 355 (60.4)* 355 (65.4)* 137 (64.3) 348 (68.9)# 1277 (51.3) 923 (48.9) 346 (57.6)# 482 (65.5)#
     Trauma 28 (4.8)* 16 (2.9)* 8 (3.8) 8 (1.6)#* 231 (9.3) 159 (8.4) 38 (6.3)# 39 (5.3)#
     Other 6 (1.0) 1 (0.2)# 0 (0.0)# 3 (0.6) 26 (1.0) 7 (0.4)# 1 (0.2)# 6 (0.8)
Source of admission, n (%)
     Other hospital 62 (9.9) 65 (11.3) 22 (10.0) 59 (11.3) 231 (8.8) 198 (10.0) 55 (8.8) 81 (10.0)
     ER/ambulance 229 (36.5) 208 (36.2) 74 (33.8) 156 (29.8)* 1047 (40.0) 733 (37.1) 262 (41.8) 335 (41.6)
     OR/Recovery 88 (14.0)* 80 (13.9)* 34 (15.5) 65 (12.4) 516 (19.7) 476 (24.1)# 107 (17.1) 100 (12.4)#
     Hospital floor 206 (32.8)* 179 (31.1)* 63 (28.8) 200 (38.2)#* 584 (22.3) 414 (21.0) 148 (23.6) 222 (27.5)#
     Other 43 (6.8) 43 (7.5) 26 (11.9) 44 (8.4) 237 (9.1) 155 (7.8) 55 (8.8) 68 (8.4)
Reason for admission, n (%)
     Neurological 102 (16.2) 66 (11.5)# 16 (7.3)# 26 (5.0)# 438 (16.7) 261 (13.2)# 74 (11.8)# 59 (7.3)#
     Respiratory 174 (27.7)* 163 (28.3)* 54 (24.7)* 91 (17.4)#* 299 (11.4) 237 (12.0) 100 (15.9)# 101 (12.5)
     Cardiovascular 143 (22.8)* 146 (25.4)* 71 (32.4)# 200 (38.2)# 707 (27.0) 651 (32.9)# 203 (32.4)# 308 (38.2)#
     Renal/Ob-gyn 11 (1.8)* 15 (2.6)* 4 (1.8) 42 (8.0)# 99 (3.8) 74 (3.7) 25 (4.0) 73 (9.1)#
     Haematological 10 (1.6) 17 (3.0)* 8 (3.7) 14 (2.7) 37 (1.4) 18 (0.9) 11 (1.8) 17 (2.1)
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SEPSIS NO SEPSIS
No AKI Risk Injury Failure No AKI Risk Injury Failure
Reason for admission, n (%)
     Digestive/Liver 96 (15.3) 106 (18.4) 46 (21.0)# 104 (19.8)#* 298 (11.4) 287 (14.5)# 94 (15.0)# 121 (15.0)#
     Metabolic 21 (3.3)* 20 (3.5)* 6 (2.7)* 19 (3.6)* 229 (8.8) 91 (4.6)# 37 (5.9)# 49 (6.1)#
     Trauma 49 (7.8) 25 (4.3)* 10 (4.6) 8 (1.5)#* 337 (12.9) 221 (11.2) 49 (7.8)# 48 (6.0)#
     Other diseases 22 (3.5)* 17 (3.0)* 4 (1.8)* 20 (3.8) 145 (5.5)* 98 (5.0) 32 (5.1) 24 (3.0)
Comorbidities, n (%)
     COPD 113 (18.0)* 91 (15.8)* 40 (18.3) 73 (13.9)* 256 (9.8) 224 (11.3) 79 (12.6) 86 (10.7)
     Cancer 79 (12.6) 67 (11.7) 32 (14.6) 54 (10.3) 273 (10.4) 199 (10.1) 71 (11.3) 69 (8.6)
     Metastatic cancer 24 (3.8) 28 (4.9) 9 (4.1) 24 (4.6) 73 (2.8) 68 (3.4) 27 (4.3) 29 (3.6)
     Haematologic cancer 33 (5.3)* 19 (3.3)* 8 (3.7) 26 (5.0) 30 (1.1) 19 (1.0) 11 (1.8) 23 (2.9)#
     Insulin-DM 44 (7.0) 53 (9.2) 21 (9.6) 60 (11.5) 209 (8.0) 162 (8.2) 46 (7.3) 73 (9.1)
     Heart failure, NYHA III-IV 51 (8.1) 57 (9.9)#* 22 (10.0)#* 69 (13.2)# 160 (6.1) 138 (7.0) 41 (6.5) 79 (9.8)#
     HIV infection 4 (0.6) 4 (0.7) 4 (1.8) 11 (2.1)#* 17 (0.7) 5 (0.3) 4 (0.6) 5 (0.6)
     Cirrhosis 28 (4.5)* 29 (5.0) 9 (4.1) 34 (6.5) 60 (2.3) 63 (3.2) 16 (2.6) 41 (5.1)#
     Immunosuppression 46 (7.3)* 37 (6.4)* 16 (7.3)* 32 (6.1)* 50 (1.9) 36 (1.8) 15 (2.4) 23 (2.9)
     Steroid therapy 39 (6.2)* 33 (5.7)* 13 (5.9)* 26 (5.0)* 70 (2.7) 50 (2.5) 11 (1.8) 20 (2.5)
     Chemotherapy 27 (4.3)* 21 (3.7) 7 (3.2) 24 (4.6) 65 (2.5) 45 (2.3) 18 (2.9) 20 (2.5)
 Significant at 5% level: # vs. No AKI in the same group (sepsis or no sepsis), * vs. No sepsis patients with the same 
RIFLE classification. SD – standard deviation; n- number of patients; SOFA – Sequential Organ Failure Assess-
ment; ER – emergency room; OR – operating room; Ob-gyn – Obstetric-gynaecology; COPD – Chronic Obstruc-
tive Pulmonary Disease; DM – Diabetes mellitus; NYHA – New York Heart Association; HIV – human immunode-
ficiency virus; AKI – acute kidney injury
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SEPSIS NO SEPSIS
No AKI Risk Injury Failure No AKI Risk Injury Failure
Reason for admission, n (%)
     Digestive/Liver 96 (15.3) 106 (18.4) 46 (21.0)# 104 (19.8)#* 298 (11.4) 287 (14.5)# 94 (15.0)# 121 (15.0)#
     Metabolic 21 (3.3)* 20 (3.5)* 6 (2.7)* 19 (3.6)* 229 (8.8) 91 (4.6)# 37 (5.9)# 49 (6.1)#
     Trauma 49 (7.8) 25 (4.3)* 10 (4.6) 8 (1.5)#* 337 (12.9) 221 (11.2) 49 (7.8)# 48 (6.0)#
     Other diseases 22 (3.5)* 17 (3.0)* 4 (1.8)* 20 (3.8) 145 (5.5)* 98 (5.0) 32 (5.1) 24 (3.0)
Comorbidities, n (%)
     COPD 113 (18.0)* 91 (15.8)* 40 (18.3) 73 (13.9)* 256 (9.8) 224 (11.3) 79 (12.6) 86 (10.7)
     Cancer 79 (12.6) 67 (11.7) 32 (14.6) 54 (10.3) 273 (10.4) 199 (10.1) 71 (11.3) 69 (8.6)
     Metastatic cancer 24 (3.8) 28 (4.9) 9 (4.1) 24 (4.6) 73 (2.8) 68 (3.4) 27 (4.3) 29 (3.6)
     Haematologic cancer 33 (5.3)* 19 (3.3)* 8 (3.7) 26 (5.0) 30 (1.1) 19 (1.0) 11 (1.8) 23 (2.9)#
     Insulin-DM 44 (7.0) 53 (9.2) 21 (9.6) 60 (11.5) 209 (8.0) 162 (8.2) 46 (7.3) 73 (9.1)
     Heart failure, NYHA III-IV 51 (8.1) 57 (9.9)#* 22 (10.0)#* 69 (13.2)# 160 (6.1) 138 (7.0) 41 (6.5) 79 (9.8)#
     HIV infection 4 (0.6) 4 (0.7) 4 (1.8) 11 (2.1)#* 17 (0.7) 5 (0.3) 4 (0.6) 5 (0.6)
     Cirrhosis 28 (4.5)* 29 (5.0) 9 (4.1) 34 (6.5) 60 (2.3) 63 (3.2) 16 (2.6) 41 (5.1)#
     Immunosuppression 46 (7.3)* 37 (6.4)* 16 (7.3)* 32 (6.1)* 50 (1.9) 36 (1.8) 15 (2.4) 23 (2.9)
     Steroid therapy 39 (6.2)* 33 (5.7)* 13 (5.9)* 26 (5.0)* 70 (2.7) 50 (2.5) 11 (1.8) 20 (2.5)
     Chemotherapy 27 (4.3)* 21 (3.7) 7 (3.2) 24 (4.6) 65 (2.5) 45 (2.3) 18 (2.9) 20 (2.5)
 Significant at 5% level: # vs. No AKI in the same group (sepsis or no sepsis), * vs. No sepsis patients with the same 
RIFLE classification. SD – standard deviation; n- number of patients; SOFA – Sequential Organ Failure Assess-
ment; ER – emergency room; OR – operating room; Ob-gyn – Obstetric-gynaecology; COPD – Chronic Obstruc-
tive Pulmonary Disease; DM – Diabetes mellitus; NYHA – New York Heart Association; HIV – human immunode-
ficiency virus; AKI – acute kidney injury
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Supplemental Table 3.  Baseline clinical characteristics of patients with and without 
      sepsis, stratified by RIFLE criteria 
SEPSIS NO SEPSIS
No AKI Risk Injury Failure No AKI Risk Injury Failure
Systemic 
inflam-
matory 
response 
syndrome
Temperature, n (%)
<36 14 (2.3) 19 (3.4) 7 (3.3) 38 (7.4)# 59 (2.3) 51 (2.6) 21 (3.4) 69 (8.8)#
36-38 415 (67.4)* 365 (64.7)* 167 (77.7)* 341 (66.0)* 2033 (80.5) 1654 (84.9)# 522 (84.2)# 600 (76.4)#
>38 187 (30.4)* 180 (31.9)* 41 (19.1)#* 138 (26.7)* 432 (17.1) 243 (12.5)# 77 (12.4)# 116 (14.8)
Leucocytes (x109/L),  n (%)
<4 28 (4.6) 22 (3.9)* 14 (6.4)* 26 (5.0)* 79 (3.3) 37 (2.0) 12 (2.0) 18 (2.3)
4-12 247 (40.7)* 203 (35.7)* 73 (33.5)* 157 (30.5)#* 1122 (46.4) 925 (49.6)# 288 (49.0) 323 (41.8)#
>12 332 (54.7)* 343 (60.4)* 131 (60.1)* 332 (64.5)#* 1215 (50.3) 904 (48.4) 288 (49.0) 432 (55.9)#
Heart rate, mean (SD) bpm 112.5 (24.0)* 116.1 (26.2)#* 111.9 (25.7)* 118.5 (26.6)#* 104.1 (23.0) 102.3 (23.2) 102.6 (24.5) 106.4 (26.9)#
Mean arterial pressure, 
mean (SD) mmHg
98.4 (18.6) 97.5 (17.8) 92.1 (17.7)#* 91.2 (19.8)# 100.3 (19.4) 98.4 (19.0)# 98.1 (21.0)# 94.1 (21.7)#
Respiratory rate, mean (SD) 
bpm
25.9 (8.7)* 26.6 (9.3)* 25.4 (8.8) 26.7 (9.0)* 24.2 (7.9) 23.9 (7.6) 24.9 (8.2) 24.7 (8.3)
Patients on ventilator, n (%) 434 (69.1)* 396 (68.9)* 150 (68.5)* 378 (72.1)* 1089 (41.6) 818 (41.4) 249 (39.7) 364 (45.2)#
Blood 
parameters
FiO2, mean (SD) 59.2 (24.9)* 63.9 (25.9)#* 63.4 (27.6)#* 68.1 (26.9)#* 48.2 (24.4) 48.6 (24.2) 49.2 (25.7) 56.4 (28.7)
PaO2, mean (SD) mmHg 141.2 (72.6) 141.2 (77.8) 138.3 (75.0) 142.2 (81.6) 147.4 (77.5) 143.4 (77.6) 134.3 (75.2)# 138.1 (86.3)#
PaCO2, mean (SD) mmHg 45.5 (18.4)* 44.8 (19.4)* 44.5 (18.2) 44.5 (18.8)* 42.0 (15.0) 42.3 (15.6) 43.3 (17.2) 41.3 (17.9)
Bicarbonate, mean (SD)  
mmol/L   
25.3 (6.2) 24.2 (5.5) 23.6 (6.4)# 21.6 (6.3)# 24.5 (5.2) 24.1 (4.8)# 23.6 (5.4)# 21.9 (6.3)#
Arterial pH, mean (SD)  7.4 (0.1) 7.4 (0.1) 7.4 (0.1) 7.3 (0.1) 7.4 (0.1) 7.4 (0.1) 7.4 (0.1) 7.3 (0.1)
Creatinine, mean (SD)  
mg/dL
1.4 (1.6)* 1.5 (1.6)* 1.6 (1.5) 3.2 (3.5)#* 1.1 (1.4) 1.3 (1.5) 1.4 (1.8)# 2.6 (3.3)#
Potassium, mean (SD) 
mmol/L
4.2 (0.7) 4.3 (0.7)# 4.4 (0.8)# 4.8 (1.1)#* 4.2 (0.7) 4.3 (0.7)# 4.3 (0.7)# 4.6 (1.0)#
Sodium, mean (SD) mmol/L 140.1 (7.2) 140.6 (6.8)* 140.3 (5.9)* 139.8 (6.8) 139.7 (5.9) 139.6 (5.7) 139.2 (5.9) 139.4 (6.8)
Urea, median [IQR] mmol/L 0.6 [0.1-35.0] 5.0 [0.1-39.0] 4.6 [0.1-35.0] 21.0 [0.2-73.0]#* 13.0 [0.1-31.0] 16.0 [0.1-37.0] 17.0 [0.1-36.0] 15.0 [0.2-44.0]
Haematocrit, median  
[IQR] L/L
33.2 [28.9-38.4] 33.7 [28.5-38.8] 33.0 [28.0-38.0] 32.5 [27.1-37.7] 35.2 [30.0-40.0] 35.6 [30.2-40.6] 36.0 [30.0-41.0] 34.5 [29.0-40.0]
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Supplemental Table 3.  Baseline clinical characteristics of patients with and without 
      sepsis, stratified by RIFLE criteria 
SEPSIS NO SEPSIS
No AKI Risk Injury Failure No AKI Risk Injury Failure
Systemic 
inflam-
matory 
response 
syndrome
Temperature, n (%)
<36 14 (2.3) 19 (3.4) 7 (3.3) 38 (7.4)# 59 (2.3) 51 (2.6) 21 (3.4) 69 (8.8)#
36-38 415 (67.4)* 365 (64.7)* 167 (77.7)* 341 (66.0)* 2033 (80.5) 1654 (84.9)# 522 (84.2)# 600 (76.4)#
>38 187 (30.4)* 180 (31.9)* 41 (19.1)#* 138 (26.7)* 432 (17.1) 243 (12.5)# 77 (12.4)# 116 (14.8)
Leucocytes (x109/L),  n (%)
<4 28 (4.6) 22 (3.9)* 14 (6.4)* 26 (5.0)* 79 (3.3) 37 (2.0) 12 (2.0) 18 (2.3)
4-12 247 (40.7)* 203 (35.7)* 73 (33.5)* 157 (30.5)#* 1122 (46.4) 925 (49.6)# 288 (49.0) 323 (41.8)#
>12 332 (54.7)* 343 (60.4)* 131 (60.1)* 332 (64.5)#* 1215 (50.3) 904 (48.4) 288 (49.0) 432 (55.9)#
Heart rate, mean (SD) bpm 112.5 (24.0)* 116.1 (26.2)#* 111.9 (25.7)* 118.5 (26.6)#* 104.1 (23.0) 102.3 (23.2) 102.6 (24.5) 106.4 (26.9)#
Mean arterial pressure, 
mean (SD) mmHg
98.4 (18.6) 97.5 (17.8) 92.1 (17.7)#* 91.2 (19.8)# 100.3 (19.4) 98.4 (19.0)# 98.1 (21.0)# 94.1 (21.7)#
Respiratory rate, mean (SD) 
bpm
25.9 (8.7)* 26.6 (9.3)* 25.4 (8.8) 26.7 (9.0)* 24.2 (7.9) 23.9 (7.6) 24.9 (8.2) 24.7 (8.3)
Patients on ventilator, n (%) 434 (69.1)* 396 (68.9)* 150 (68.5)* 378 (72.1)* 1089 (41.6) 818 (41.4) 249 (39.7) 364 (45.2)#
Blood 
parameters
FiO2, mean (SD) 59.2 (24.9)* 63.9 (25.9)#* 63.4 (27.6)#* 68.1 (26.9)#* 48.2 (24.4) 48.6 (24.2) 49.2 (25.7) 56.4 (28.7)
PaO2, mean (SD) mmHg 141.2 (72.6) 141.2 (77.8) 138.3 (75.0) 142.2 (81.6) 147.4 (77.5) 143.4 (77.6) 134.3 (75.2)# 138.1 (86.3)#
PaCO2, mean (SD) mmHg 45.5 (18.4)* 44.8 (19.4)* 44.5 (18.2) 44.5 (18.8)* 42.0 (15.0) 42.3 (15.6) 43.3 (17.2) 41.3 (17.9)
Bicarbonate, mean (SD)  
mmol/L   
25.3 (6.2) 24.2 (5.5) 23.6 (6.4)# 21.6 (6.3)# 24.5 (5.2) 24.1 (4.8)# 23.6 (5.4)# 21.9 (6.3)#
Arterial pH, mean (SD)  7.4 (0.1) 7.4 (0.1) 7.4 (0.1) 7.3 (0.1) 7.4 (0.1) 7.4 (0.1) 7.4 (0.1) 7.3 (0.1)
Creatinine, mean (SD)  
mg/dL
1.4 (1.6)* 1.5 (1.6)* 1.6 (1.5) 3.2 (3.5)#* 1.1 (1.4) 1.3 (1.5) 1.4 (1.8)# 2.6 (3.3)#
Potassium, mean (SD) 
mmol/L
4.2 (0.7) 4.3 (0.7)# 4.4 (0.8)# 4.8 (1.1)#* 4.2 (0.7) 4.3 (0.7)# 4.3 (0.7)# 4.6 (1.0)#
Sodium, mean (SD) mmol/L 140.1 (7.2) 140.6 (6.8)* 140.3 (5.9)* 139.8 (6.8) 139.7 (5.9) 139.6 (5.7) 139.2 (5.9) 139.4 (6.8)
Urea, median [IQR] mmol/L 0.6 [0.1-35.0] 5.0 [0.1-39.0] 4.6 [0.1-35.0] 21.0 [0.2-73.0]#* 13.0 [0.1-31.0] 16.0 [0.1-37.0] 17.0 [0.1-36.0] 15.0 [0.2-44.0]
Haematocrit, median  
[IQR] L/L
33.2 [28.9-38.4] 33.7 [28.5-38.8] 33.0 [28.0-38.0] 32.5 [27.1-37.7] 35.2 [30.0-40.0] 35.6 [30.2-40.6] 36.0 [30.0-41.0] 34.5 [29.0-40.0]
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SEPSIS NO SEPSIS
No AKI Risk Injury Failure No AKI Risk Injury Failure
Blood 
parameters
Bilirubin, median [IQR] 
mg/dL
0.9 [0.5-2.0] 0.9 [0.5-2.0] 1.1 [0.5-3.0] 1.3 [0.6-3.6] 0.8 [0.5-1.3] 0.8 [0.5-1.4] 0.8 [0.5-1.5] 0.9 [0.5-2.3]
Noradrenaline infusion
rate, median [IQR] µg/kg/
min
0.0 [0.0-0.2] 0.0 [0.0-0.2] 0.1 [0.0-0.3]#* 0.1 [0.0-0.5]#* 0.0 [0.0-0.0] 0.0 [0.0-0.0] 0.0 [0.0-0.0] 0.0 [0.0-0.0]
Inotropic score, median 
[IQR]
0 [0-19]* 0 [0-20]* 9 [0-37]#* 13 [0-60]#* 0 [0-0] 0 [0-0] 0 [0-0] 0.0 [0-10]
Urine output, median [IQR] 
mL/24 h
2,500 
[2,000-3,280]
1,376 
[1,100-1,700]#
750 
[600-1,000] #
355 
[120-906]#
2,500
[2,000-3,250]
1,350
[1,100-1,666]#
750
[600-953]#
350
[138-648]#
 Significant at 5% level: # vs. No AKI in the same group (sepsis or no sepsis), * vs. No sepsis patients with 
the same RIFLE classification. SD – standard deviation; n- number of patients; IQR – interquartile 
range; AKI – acute kidney injury
Supplemental Table 3.  Continued
Supplemental Table 4.  Renal replacement therapy modality per day 
TOTAL POPULATION SEPSIS NO SEPSIS
Haemo-
dialysis
Haemo-
filtration
Haemo-
dialysis
Haemo-
filtration
Haemo-
dialysis
Haemo-
filtration
0 325 (66) 278 (56) 143 (61) 152 (65)* 182 (70) 126 (48)
1 352 (61) 371 (64) 178 (56)* 224 (71)* 174 (66) 147 (56)
2 265 (58) 302 (66) 143 (54)* 192 (72)* 122 (65) 110 (58)
3 229 (61) 248 (66) 130 (57)* 159 (69) 99 (68) 89 (61)
4 175 (61) 184 (65) 112 (57)* 134 (69)* 63 (70) 50 (56)
5 142 (62) 142 (62) 94 (59) 100 (63) 48 (68) 42 (59)
6 119 (60) 127 (64) 81 (58) 91 (65) 38 (66) 36 (62)
7 91 (57) 104 (65) 69 (58) 74 (62) 22 (56) 30 (77)
 Data presented as number (%). Day 0 is first day of admission. Significant at 5% level: * vs. No sepsis patients with 
the same treatment modality.
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SEPSIS NO SEPSIS
No AKI Risk Injury Failure No AKI Risk Injury Failure
Blood 
parameters
Bilirubin, median [IQR] 
mg/dL
0.9 [0.5-2.0] 0.9 [0.5-2.0] 1.1 [0.5-3.0] 1.3 [0.6-3.6] 0.8 [0.5-1.3] 0.8 [0.5-1.4] 0.8 [0.5-1.5] 0.9 [0.5-2.3]
Noradrenaline infusion
rate, median [IQR] µg/kg/
min
0.0 [0.0-0.2] 0.0 [0.0-0.2] 0.1 [0.0-0.3]#* 0.1 [0.0-0.5]#* 0.0 [0.0-0.0] 0.0 [0.0-0.0] 0.0 [0.0-0.0] 0.0 [0.0-0.0]
Inotropic score, median 
[IQR]
0 [0-19]* 0 [0-20]* 9 [0-37]#* 13 [0-60]#* 0 [0-0] 0 [0-0] 0 [0-0] 0.0 [0-10]
Urine output, median [IQR] 
mL/24 h
2,500 
[2,000-3,280]
1,376 
[1,100-1,700]#
750 
[600-1,000] #
355 
[120-906]#
2,500
[2,000-3,250]
1,350
[1,100-1,666]#
750
[600-953]#
350
[138-648]#
 Significant at 5% level: # vs. No AKI in the same group (sepsis or no sepsis), * vs. No sepsis patients with 
the same RIFLE classification. SD – standard deviation; n- number of patients; IQR – interquartile 
range; AKI – acute kidney injury
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Supplemental Table 5. Renal replacement therapy (RRT) and mortality per region 
      and gross national income (GNI)
SEPSIS NO SEPSIS
All No AKI Risk Injury Failure All No AKI Risk Injury Failure
RRT, 
n (%)
Region Africa 4 (20.0) 1 (25) 0 (0)‡ (0)‡ 3 (33.3) 16 (19.0)‡ 2 (7.4) 2 (7.1) 1 (11.1) 11 (55)#
Middle East 23 (22.8)$ 2 (5.4) 6 (19.4)‡ 0 (0)‡ 15 (55.6)# 19 (9.8)‡ 2 (2.1) 4 (6.9) 1 (5.6) 12 (52.2)#
South America 46 (23.1)$ 1 (2.6) 5 (8.6)* 3 (9.4) 37 (52.1)#* 31 (5.6) 3 (1.3) 1 (0.5) 1 (1.7) 26 (31.0)#
North America 10 (11.2)$‡ 2 (6.5) 0 (0)‡ 0 (0)‡ 8 (33.3)#‡ 13 (2.6) 0 (0)‡ 1 (0.7) 1 (1.8) 11 (15.9)#‡
West Europe 176 (20.1)$ 7 (2.6) 13 (5.0)* 11 (10.1)#* 145 (61.2)#* 134 (5.4) 17 (1.6) 7 (0.8) 3 (1.2) 107 (35.3)#
East Europe 38 (18.2)$ 5 (6.0)* 1 (2.1) 0 (0)#‡ 32 (54.2)#* 28 (4.0) 1 (0.3)‡ 3 (1.2) 0 (0) 24 (27.9)#
Oceania 15 (15.6)$ 1 (2.9) 1 (2.9) 0 (0)‡ 13 (86.7)#*‡ 9 (3.3) 0 (0)‡ 1 (1.2) 1 (2.3) 7 (20.6)#‡
South Asia 17 (19.5)$ 0 (0)‡ 1 (3.7) 0 (0)‡ 16 (66.7)#* 26 (3.4) 2 (0.7) 2 (0.8) 2 (1.9) 20 (21.1)#‡
East and southeast Asia 51 (18.9)$ 6 (6.1)* 6 (7.0)* 1 (3.7) 38 (65.5)# 50 (10.3)‡ 0 (0)‡ 1 (0.8) 0 (0) 49 (53.3)#‡
GNI Low and lower-middle income 19 (14.6)$ 1 (2.2) 1 (2.6) 0 (0)‡ 17 (43.6)#*‡ 30 (3.3) 3 (0.8) 2 (0.7) 2 (1.6) 23 (19.7)#‡
Upper-middle income 110 (20.6)$ 9 (5.3)* 14 (8.8)* 4 (6.7) 83 (57.2)#* 112 (7.7) 6 (1.0) 7 (1.5) 2 (1.5) 97 (43.5)#‡
High income 251 (19.6)$ 15 (3.6)* 18 (4.8)* 11 (7.2)* 207 (60.9)#* 184 (5.0) 18 (1.1) 13 (1.1) 6 (1.6) 147 (31.5)#
ICU 
mortality, 
n (%)
Region Africa 6 (30.0)$ 0 (0)‡ 0 (0)‡ 0 (0)‡ 6 (66.7)#* 6 (7.4) 2 (8.0) 1 (3.7) 0 (0)‡ 3 (15)‡
Middle East 35 (35.4)$ 7 (18.9) 10 (33.3) 0 (0)*‡ 18 (66.7)#‡ 35 (18.6)‡ 10 (11.0) 11 (19.3)‡ 4 (22.2) 10 (45.5)#
South America 78 (41.9)$‡ 8 (24.2) 18 (32.7)*‡ 12 (42.9)‡ 40 (57.1)#*‡ 73 (14.0) 27 (12.6) 14 (8.1) 13 (22.4) 19 (24.4)#‡ 
North America 17 (19.1)$ 4 (12.9) 5 (20.0)* 1 (11.1) 7 (29.2) 33 (6.6)‡ 14 (6.0) 5 (3.4)‡ 5 (9.1) 9 (13.2)‡
West Europe 179 (20.6)$ 35 (14.2)* 43 (16.5)* 16 (14.7) 85 (36.2)# 279 (11.5) 89 (8.4) 57 (6.9) 27 (11.2) 106 (35.6)#
East Europe 76 (36.4)$‡ 27 (32.5)*‡ 11 (23.4)* 11 (55.0)*‡ 27 (45.8) 101 (14.5) 38 (12.1) 24 (10.0) 9 (16.1) 30 (34.9)#
Oceania 11 (11.5) 2 (5.7) 4 (11.4) 1 (9.1) 4 (26.7) 23 (8.4) 5 (4.4) 7 (8.3) 4 (9.3) 7 (20.6)#‡
South Asia 28 (33.3)$ 7 (21.9)* 7 (28.0)* 3 (100)*‡ 11 (45.8)* 47 (6.8)‡ 11 (4.0)‡ 11 (4.5) 7 (7.5) 18 (20.7)#‡
East and southeast Asia 61 (23.3)$ 18 (19.1)* 19 (22.6)* 6 (22.2) 18 (31.6) 58 (12.3) 17 (7.9) 8 (6.2) 7 (17.9) 26 (29.2)#
GNI Low and lower-middle income 46 (36.5)$‡ 13 (28.9)*‡ 10 (27.8)* 5 (83.3)*‡ 18 (46.2)* 82 (9.8) 21 (6.3) 19 (6.7) 14 (12.3) 28 (25.7)#
Upper-middle income 179 (34.9)$‡ 42 (26.1)*‡ 47 (30.5)*‡ 21 (38.2)*‡ 69 (48.3)#*‡ 189 (13.4)‡ 65 (10.8)‡ 43 (9.3) 22 (16.9) 59 (27.7)#
High income 266 (20.9)$ 53 (13.0)* 60 (15.9)* 24 (15.8) 129 (38.2)#* 239 (18.1) 127 (8.0) 76 (6.4) 40 (10.9) 141 (30.7)#
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Supplemental Table 5. Renal replacement therapy (RRT) and mortality per region 
      and gross national income (GNI)
SEPSIS NO SEPSIS
All No AKI Risk Injury Failure All No AKI Risk Injury Failure
RRT, 
n (%)
Region Africa 4 (20.0) 1 (25) 0 (0)‡ (0)‡ 3 (33.3) 16 (19.0)‡ 2 (7.4) 2 (7.1) 1 (11.1) 11 (55)#
Middle East 23 (22.8)$ 2 (5.4) 6 (19.4)‡ 0 (0)‡ 15 (55.6)# 19 (9.8)‡ 2 (2.1) 4 (6.9) 1 (5.6) 12 (52.2)#
South America 46 (23.1)$ 1 (2.6) 5 (8.6)* 3 (9.4) 37 (52.1)#* 31 (5.6) 3 (1.3) 1 (0.5) 1 (1.7) 26 (31.0)#
North America 10 (11.2)$‡ 2 (6.5) 0 (0)‡ 0 (0)‡ 8 (33.3)#‡ 13 (2.6) 0 (0)‡ 1 (0.7) 1 (1.8) 11 (15.9)#‡
West Europe 176 (20.1)$ 7 (2.6) 13 (5.0)* 11 (10.1)#* 145 (61.2)#* 134 (5.4) 17 (1.6) 7 (0.8) 3 (1.2) 107 (35.3)#
East Europe 38 (18.2)$ 5 (6.0)* 1 (2.1) 0 (0)#‡ 32 (54.2)#* 28 (4.0) 1 (0.3)‡ 3 (1.2) 0 (0) 24 (27.9)#
Oceania 15 (15.6)$ 1 (2.9) 1 (2.9) 0 (0)‡ 13 (86.7)#*‡ 9 (3.3) 0 (0)‡ 1 (1.2) 1 (2.3) 7 (20.6)#‡
South Asia 17 (19.5)$ 0 (0)‡ 1 (3.7) 0 (0)‡ 16 (66.7)#* 26 (3.4) 2 (0.7) 2 (0.8) 2 (1.9) 20 (21.1)#‡
East and southeast Asia 51 (18.9)$ 6 (6.1)* 6 (7.0)* 1 (3.7) 38 (65.5)# 50 (10.3)‡ 0 (0)‡ 1 (0.8) 0 (0) 49 (53.3)#‡
GNI Low and lower-middle income 19 (14.6)$ 1 (2.2) 1 (2.6) 0 (0)‡ 17 (43.6)#*‡ 30 (3.3) 3 (0.8) 2 (0.7) 2 (1.6) 23 (19.7)#‡
Upper-middle income 110 (20.6)$ 9 (5.3)* 14 (8.8)* 4 (6.7) 83 (57.2)#* 112 (7.7) 6 (1.0) 7 (1.5) 2 (1.5) 97 (43.5)#‡
High income 251 (19.6)$ 15 (3.6)* 18 (4.8)* 11 (7.2)* 207 (60.9)#* 184 (5.0) 18 (1.1) 13 (1.1) 6 (1.6) 147 (31.5)#
ICU 
mortality, 
n (%)
Region Africa 6 (30.0)$ 0 (0)‡ 0 (0)‡ 0 (0)‡ 6 (66.7)#* 6 (7.4) 2 (8.0) 1 (3.7) 0 (0)‡ 3 (15)‡
Middle East 35 (35.4)$ 7 (18.9) 10 (33.3) 0 (0)*‡ 18 (66.7)#‡ 35 (18.6)‡ 10 (11.0) 11 (19.3)‡ 4 (22.2) 10 (45.5)#
South America 78 (41.9)$‡ 8 (24.2) 18 (32.7)*‡ 12 (42.9)‡ 40 (57.1)#*‡ 73 (14.0) 27 (12.6) 14 (8.1) 13 (22.4) 19 (24.4)#‡ 
North America 17 (19.1)$ 4 (12.9) 5 (20.0)* 1 (11.1) 7 (29.2) 33 (6.6)‡ 14 (6.0) 5 (3.4)‡ 5 (9.1) 9 (13.2)‡
West Europe 179 (20.6)$ 35 (14.2)* 43 (16.5)* 16 (14.7) 85 (36.2)# 279 (11.5) 89 (8.4) 57 (6.9) 27 (11.2) 106 (35.6)#
East Europe 76 (36.4)$‡ 27 (32.5)*‡ 11 (23.4)* 11 (55.0)*‡ 27 (45.8) 101 (14.5) 38 (12.1) 24 (10.0) 9 (16.1) 30 (34.9)#
Oceania 11 (11.5) 2 (5.7) 4 (11.4) 1 (9.1) 4 (26.7) 23 (8.4) 5 (4.4) 7 (8.3) 4 (9.3) 7 (20.6)#‡
South Asia 28 (33.3)$ 7 (21.9)* 7 (28.0)* 3 (100)*‡ 11 (45.8)* 47 (6.8)‡ 11 (4.0)‡ 11 (4.5) 7 (7.5) 18 (20.7)#‡
East and southeast Asia 61 (23.3)$ 18 (19.1)* 19 (22.6)* 6 (22.2) 18 (31.6) 58 (12.3) 17 (7.9) 8 (6.2) 7 (17.9) 26 (29.2)#
GNI Low and lower-middle income 46 (36.5)$‡ 13 (28.9)*‡ 10 (27.8)* 5 (83.3)*‡ 18 (46.2)* 82 (9.8) 21 (6.3) 19 (6.7) 14 (12.3) 28 (25.7)#
Upper-middle income 179 (34.9)$‡ 42 (26.1)*‡ 47 (30.5)*‡ 21 (38.2)*‡ 69 (48.3)#*‡ 189 (13.4)‡ 65 (10.8)‡ 43 (9.3) 22 (16.9) 59 (27.7)#
High income 266 (20.9)$ 53 (13.0)* 60 (15.9)* 24 (15.8) 129 (38.2)#* 239 (18.1) 127 (8.0) 76 (6.4) 40 (10.9) 141 (30.7)#
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SEPSIS NO SEPSIS
All No AKI Risk Injury Failure All No AKI Risk Injury Failure
Hospital 
mortality, 
n (%)
Region Africa 7 (38.9)$ 1 (33.3) 0 (0)‡ 0 (0)‡ 6 (66.7)* 6 (8.3) 2 (9.5) 1 (4.2)‡ 0 (0)‡ 3 (15)‡
Middle East 45 (45.9)$ 11 (30.6)* 13 (43.3) 1 (20.0) 20 (74.1)#‡ 42 (23.5)‡ 11 (12.8) 15 (27.3)#‡ 5 (29.4) 11 (52.4)#
South America 88 (50.6)$‡ 9 (30.0) 21 (40.4)*‡ 13 (50.0) 45 (68.2)#*‡ 98 (20.4) 33 (16.9) 24 (15.5) 16 (28.6) 25 (33.8)#
North America 22 (24.7)$ 5 (16.1) 7 (28.0) 2 (22.2) 8 (33.3) 48 (9.6)‡ 17 (7.3)‡ 11 (7.5)‡ 7 (12.7) 13 (19.4)#‡
West Europe 267 (31.5)$ 59 (22.8)* 64 (25.4)* 34 (31.8)* 110 (48.0)# 394 (16.7) 130 (12.6) 102 (12.8) 43 (18)# 119 (40.6)#
East Europe 90 (44.3)$‡ 32 (40.0)*‡ 16 (34.0)* 11 (57.9)*‡ 31 (54.4) 119 (17.6) 46 (15.0) 29 (12.4) 10 (18.5) 34 (41.0)#
Oceania 18 (18.8)$‡ 4 (11.4) 6 (17.1) 3 (27.3) 5 (33.3) 28 (10.3)‡ 5 (4.4)‡ 10 (12.2) 4 (9.3) 9 (26.5)#
South Asia 33 (39.8)$ 10 (32.3)* 7 (28.0)* 3 (100)#*‡ 13 (54.2)* 59 (9.3)‡ 18 (7.3)‡ 16 (7.0)‡ 7 (9.0)‡ 18 (22.2) #‡
East and southeast Asia 81 (32.0)$ 23 (25.6)* 28 (34.1)* 7 (25.9) 23 (42.6)# 75 (16.9) 24 (11.7) 11 (9.4) 10 (26.3) 30 (35.7)#
GNI Low and lower-middle income 53 (42.7)$‡ 16 (36.4)* 10 (27.8)* 5 (83.3)#*‡ 22 (57.9)#* 98 (12.7) 31 (10.2) 25 (9.4) 14 (14.4) 28 (27.2)#
Upper-middle income 207 (42.4)$‡ 49 (32.5)*‡ 58 (39.2)*‡ 23 (43.4)* 77 (56.6)#* 239 (18.1)‡ 81 (14.3) 60 (14.1) 29 (23.0)# 69 (34.0)#
High income 391 (31.3)$ 89 (22.3)* 94 (25.5)* 46 (30.9)#* 162 (48.9)#* 532 (15.1) 174 (11.1) 134 (11.7) 59 (16.2)# 165 (36.6)#
 AKI: acute kidney injury; Significant at 5% level: # vs. No AKI in the same group (sepsis or no sepsis), * vs. 
No sepsis patients with the same RIFLE classification, ‡ vs. West Europe or High income with the same 
RIFLE classification or the total population, in the same group (sepsis or no sepsis), $ vs. all patients 
without sepsis.
Supplemental Table 5.  Continued
61
SEPSIS NO SEPSIS
All No AKI Risk Injury Failure All No AKI Risk Injury Failure
Hospital 
mortality, 
n (%)
Region Africa 7 (38.9)$ 1 (33.3) 0 (0)‡ 0 (0)‡ 6 (66.7)* 6 (8.3) 2 (9.5) 1 (4.2)‡ 0 (0)‡ 3 (15)‡
Middle East 45 (45.9)$ 11 (30.6)* 13 (43.3) 1 (20.0) 20 (74.1)#‡ 42 (23.5)‡ 11 (12.8) 15 (27.3)#‡ 5 (29.4) 11 (52.4)#
South America 88 (50.6)$‡ 9 (30.0) 21 (40.4)*‡ 13 (50.0) 45 (68.2)#*‡ 98 (20.4) 33 (16.9) 24 (15.5) 16 (28.6) 25 (33.8)#
North America 22 (24.7)$ 5 (16.1) 7 (28.0) 2 (22.2) 8 (33.3) 48 (9.6)‡ 17 (7.3)‡ 11 (7.5)‡ 7 (12.7) 13 (19.4)#‡
West Europe 267 (31.5)$ 59 (22.8)* 64 (25.4)* 34 (31.8)* 110 (48.0)# 394 (16.7) 130 (12.6) 102 (12.8) 43 (18)# 119 (40.6)#
East Europe 90 (44.3)$‡ 32 (40.0)*‡ 16 (34.0)* 11 (57.9)*‡ 31 (54.4) 119 (17.6) 46 (15.0) 29 (12.4) 10 (18.5) 34 (41.0)#
Oceania 18 (18.8)$‡ 4 (11.4) 6 (17.1) 3 (27.3) 5 (33.3) 28 (10.3)‡ 5 (4.4)‡ 10 (12.2) 4 (9.3) 9 (26.5)#
South Asia 33 (39.8)$ 10 (32.3)* 7 (28.0)* 3 (100)#*‡ 13 (54.2)* 59 (9.3)‡ 18 (7.3)‡ 16 (7.0)‡ 7 (9.0)‡ 18 (22.2) #‡
East and southeast Asia 81 (32.0)$ 23 (25.6)* 28 (34.1)* 7 (25.9) 23 (42.6)# 75 (16.9) 24 (11.7) 11 (9.4) 10 (26.3) 30 (35.7)#
GNI Low and lower-middle income 53 (42.7)$‡ 16 (36.4)* 10 (27.8)* 5 (83.3)#*‡ 22 (57.9)#* 98 (12.7) 31 (10.2) 25 (9.4) 14 (14.4) 28 (27.2)#
Upper-middle income 207 (42.4)$‡ 49 (32.5)*‡ 58 (39.2)*‡ 23 (43.4)* 77 (56.6)#* 239 (18.1)‡ 81 (14.3) 60 (14.1) 29 (23.0)# 69 (34.0)#
High income 391 (31.3)$ 89 (22.3)* 94 (25.5)* 46 (30.9)#* 162 (48.9)#* 532 (15.1) 174 (11.1) 134 (11.7) 59 (16.2)# 165 (36.6)#
 AKI: acute kidney injury; Significant at 5% level: # vs. No AKI in the same group (sepsis or no sepsis), * vs. 
No sepsis patients with the same RIFLE classification, ‡ vs. West Europe or High income with the same 
RIFLE classification or the total population, in the same group (sepsis or no sepsis), $ vs. all patients 
without sepsis.
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Supplemental Table 6.  Renal replacement therapy modality per region and gross 
      national income
TOTAL POPULATION SEPSIS NO SEPSIS
Haemo-
dialysis
Haemo-
dialysis
Haemo-
dialysis
Haemo-
filtration
Haemo-
dialysis
Haemo-
filtration
Region Africa 14 (19.2) 5 (6.8) 2 (12.5) 2 (12.5) 12 (21.1) 3 (5.3)
Middle East 27 (16.6) 25 (15.3) 14 (21.9) 17 (26.6)* 13 (13.1) 8 (8.1)
South America 66 (13.5) 45 (9.2) 42 (26.1)* 28 (17.4)* 24 (7.3) 17 (5.2)
North America 17 (5.2) 10 (3.0) 6 (10.3) 5 (8.6)* 11 (4.1) 5 (1.9)
West Europe 155 (7.8) 221 (11.1) 90 (14.9)* 141 (23.3)* 65 (4.7) 80 (5.8)
East Europe 41 (8.0) 34 (6.7) 22 (17.5)* 22 (17.5)* 19 (4.9) 12 (3.1)
Oceania 11 (5.0) 21 (9.5) 8 (13.1)* 13 (21.3)* 3 (1.9) 8 (5.0)
South Asia 34 (6.6) 18 (3.5) 14 (25.5)* 7 (12.7)* 20 (4.4) 11 (2.4)
East and 
southeast Asia
50 (11.5) 71 (16.3) 25 (14.6) 38 (22.2)* 25 (9.5) 33 (12.5)
GNI Low and lower-
middle income
38 (6.1) 21 (3.4) 15 (17.9)* 8 (9.5)* 23 (4.2) 13 (2.4)
Upper-
middle income
148 (12.4) 126 (10.5) 78 (21.4)* 68 (18.6)* 70 (8.4) 58 (7.0)
High income 229 (7.9) 303 (10.4) 130 (15.0)* 197 (22.7)* 99 (4.9) 106 (5.2)
 Data presented as number (%). Significant at 5% level: * vs. No sepsis patients with the same treatment modality. 
GNI, gross national income. 
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Supplemental Table 7.  Length of stay per region and gross national income
SEPSIS NO SEPSIS
ALL NO AKI RISK INJURY FAILURE ALL NO AKI RISK INJURY FAILURE
ICU LOS, Region Africa 13 [6-60]$‡ 13 [8-24]* 6 [4-6]#*‡ 15 [15-15]* 60 [10-60]#*‡ 2 [1-4]‡ 2 [1-4] 2 [1-3]#‡ 3 [3-5]#‡ 2 [2-7]#‡
days Middle East 13 [6-60]$‡ 9 [6-27]*‡ 15 [8-60]#*‡ 5 [4-5]#*‡ 60 [11-60]#*‡ 3 [2-14]‡ 3 [2-6]‡ 3 [2-8]#‡ 7 [2-32]#‡ 6 [3-60]#‡
South America 21 [7-60]$‡ 11 [5-60]*‡ 18 [6-60]#*‡ 14 [5-60]#*‡ 60 [14-60]#*‡ 4 [2-7]‡ 4 [2-7]‡ 4 [2-7]#‡ 3 [2-14]#‡ 5 [3-46]#‡
North America 3 [2-16]$‡ 2 [1-14]*‡ 3 [2-16]#* 2 [2-4]#‡ 6 [2-60]#*‡ 2 [1-4]‡ 2 [1-4]‡ 2 [1-3]#‡ 2 [1-4]#‡ 2 [1-7]#‡
West Europe 7 [3-29]$ 6 [2-15]* 6 [3-18]#* 8 [3-21]#* 15 [5-60]#* 3 [1-6] 2 [1-5] 2 [1-5]# 2 [1-6]# 5 [2-60]#
East Europe 13 [4-60]$‡ 13 [5-60]*‡ 7 [3-60]#*‡ 60 [5-60]#*‡ 15 [5-60]#*‡ 3 [2-7]‡ 3 [2-6]‡ 3 [2-5]#‡ 3 [1-7]#‡ 6 [2-60]#
Oceania 4 [2-10]$‡ 3 [2-6]*‡ 4 [2-9]#*‡ 4 [2-9]#* 11 [4-60]#*‡ 2 [1-4]‡ 2 [1-3]‡ 2 [1-5]# 2 [1-6]#‡ 3 [2-12]#‡
East and southeast Asia 9 [5-41]$‡ 8 [4-26]*‡ 8 [5-35]*‡ 8 [4-16]* 12 [6-60]#*‡ 3 [2-7]‡ 3 [2-6] 3 [2-7]# 3 [2-8]#‡ 6 [3-60]#‡
South Asia 7 [3-60]$‡ 6 [3-29]*‡ 5 [3-60]*‡ 60 [60-60]#*‡ 20 [5-60]#* 2 [1-4]‡ 2 [1-4]‡ 3 [1-4]#‡ 2 [1-4]#‡ 2 [1-6]#‡
GNI Low and lower-middle income 10 [4-60]$‡ 8 [4-60]*‡ 6 [3-60]*‡ 60 [60-60]#*‡ 21 [6-60]#*‡ 3 [1-5]‡ 3 [1-4]‡ 3 [2-5]# 2 [1-5]# 3 [1-60]#‡
Upper-middle income 12 [5-60]$‡ 9 [5-60]*‡ 10 [5-60]#*‡ 10 [5-60]#*‡ 29 [7-60]#*‡ 3 [2-7]‡ 3 [2-6]‡ 3 [2-7]#‡ 3 [2-8]#‡ 5 [2-60]#‡
High income 7 [3-30]$ 6 [2-15]* 6 [3-18]# 7 [3-21]#* 16 [5-60]#* 2 [1-5] 2 [1-5] 2 [1-5]# 2 [1-6]# 4 [2-60]#
Hospital 
LOS, 
days
Region Africa 38 [21-60]$ 60 [44-60]*‡ 19 [9-24]#*‡ 32 [32-32]#*‡ 60 [23-60]* 9 [4-14]‡ 10 [5-13]‡ 5 [3-15]#‡ 7 [4-25]‡ 9 [3-15]‡
Middle East 60 [22-60]$ 46 [19-60]*‡ 60 [24-60]#*‡ 11 [10-19]#*‡ 60 [60-60]#*‡ 14 [7-60]‡ 14 [7-29]‡ 13 [7-60]#‡ 39 [11-60]#‡ 60 [7-60]#‡
South America 60 [24-60]$‡ 55 [20-60]*‡ 51 [21-60]*‡ 60 [25-60]#*‡ 60 [60-60]#*‡ 12 [6-60]‡ 12 [6-36]‡ 11 [6-36]‡ 12 [6-60]‡ 20 [6-60]#‡
North America 20 [7-60]$‡ 19 [7-50]*‡ 15 [6-60]*‡ 7 [5-12]#*‡ 27 [11-60]#*‡ 7 [4-15]‡ 7 [4-14]‡ 6 [4-14]‡ 8 [4-16]#‡ 9 [4-52]#‡
West Europe 36 [15-60]$ 24 [14-60]* 29 [15-60]#* 50 [17-60]#* 60 [22-60]#* 13 [7-34] 11 [7-25] 13 [7-29]# 13 [7-34]# 30 [11-60]#
East Europe 59 [14-60]$‡ 33 [13-60]*‡ 31 [10-60]* 60 [16-60]#*‡ 60 [19-60]#* 13 [8-41]‡ 12 [7-25]‡ 13 [8-22] 14 [9-60]#‡ 43 [8-60]#
Oceania 19 [8-60]$‡ 14 [7-32]*‡ 21 [8-59]#*‡ 24 [5-60]#*‡ 51 [12-60]#* 9 [5-18]‡ 7 [4-15]‡ 8 [5-16]#‡ 11 [6-22]#‡ 15 [6-60]#‡
East and southeast Asia 32 [12-60]$‡ 22 [11-60]* 30 [10-60]#* 25 [14-60]‡ 60 [19-60]#*‡ 15 [7-52]‡ 14 [7-35]‡ 12 [6-30]# 20 [6-60]#‡ 38 [8-60]#
South Asia 19 [7-60]$‡ 16 [9-60]*‡ 10 [5-60]#*‡ 60 [60-60]#*‡ 60 [14-60]#*‡ 6 [2-11]‡ 7 [3-11]‡ 7 [3-10]#‡ 5 [2-9]‡ 6 [2-28]#‡
GNI Low and lower-middle income 29 [10-60]$ 20 [9-60]*‡ 13 [7-60]#*‡ 60 [60-60]#*‡ 60 [20-60]#* 7 [3-13]‡ 7 [3-14]‡ 7 [3-11]#‡ 5 [2-14]#‡ 9 [2-60]#‡
Upper-middle income 46 [14-60]$‡ 37 [12-60]*‡ 33 [11-60]*‡ 60 [16-60]#* 60 [21-60]#* 13 [7-44]‡ 12 [7-26]‡ 12 [7-30]‡ 14 [7-60]#‡ 17 [7-60]#‡
High income 36 [14-60]$ 24 [12-60]* 29 [14-60]# 45 [14-60]#* 60 [22-60]#* 12 [6-30] 10 [6-23] 11 [6-27]# 12 [7-30]# 27 [8-60]#
 Significant at 5% level: # vs. No AKI in the same group (sepsis or no sepsis), * vs. No sepsis patients with 
the same RIFLE classification, ‡ vs. West Europe or High income with the same RIFLE classification or 
the total population, in the same group (sepsis or no sepsis), $ vs. all patients without sepsis.
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Supplemental Table 7.  Length of stay per region and gross national income
SEPSIS NO SEPSIS
ALL NO AKI RISK INJURY FAILURE ALL NO AKI RISK INJURY FAILURE
ICU LOS, Region Africa 13 [6-60]$‡ 13 [8-24]* 6 [4-6]#*‡ 15 [15-15]* 60 [10-60]#*‡ 2 [1-4]‡ 2 [1-4] 2 [1-3]#‡ 3 [3-5]#‡ 2 [2-7]#‡
days Middle East 13 [6-60]$‡ 9 [6-27]*‡ 15 [8-60]#*‡ 5 [4-5]#*‡ 60 [11-60]#*‡ 3 [2-14]‡ 3 [2-6]‡ 3 [2-8]#‡ 7 [2-32]#‡ 6 [3-60]#‡
South America 21 [7-60]$‡ 11 [5-60]*‡ 18 [6-60]#*‡ 14 [5-60]#*‡ 60 [14-60]#*‡ 4 [2-7]‡ 4 [2-7]‡ 4 [2-7]#‡ 3 [2-14]#‡ 5 [3-46]#‡
North America 3 [2-16]$‡ 2 [1-14]*‡ 3 [2-16]#* 2 [2-4]#‡ 6 [2-60]#*‡ 2 [1-4]‡ 2 [1-4]‡ 2 [1-3]#‡ 2 [1-4]#‡ 2 [1-7]#‡
West Europe 7 [3-29]$ 6 [2-15]* 6 [3-18]#* 8 [3-21]#* 15 [5-60]#* 3 [1-6] 2 [1-5] 2 [1-5]# 2 [1-6]# 5 [2-60]#
East Europe 13 [4-60]$‡ 13 [5-60]*‡ 7 [3-60]#*‡ 60 [5-60]#*‡ 15 [5-60]#*‡ 3 [2-7]‡ 3 [2-6]‡ 3 [2-5]#‡ 3 [1-7]#‡ 6 [2-60]#
Oceania 4 [2-10]$‡ 3 [2-6]*‡ 4 [2-9]#*‡ 4 [2-9]#* 11 [4-60]#*‡ 2 [1-4]‡ 2 [1-3]‡ 2 [1-5]# 2 [1-6]#‡ 3 [2-12]#‡
East and southeast Asia 9 [5-41]$‡ 8 [4-26]*‡ 8 [5-35]*‡ 8 [4-16]* 12 [6-60]#*‡ 3 [2-7]‡ 3 [2-6] 3 [2-7]# 3 [2-8]#‡ 6 [3-60]#‡
South Asia 7 [3-60]$‡ 6 [3-29]*‡ 5 [3-60]*‡ 60 [60-60]#*‡ 20 [5-60]#* 2 [1-4]‡ 2 [1-4]‡ 3 [1-4]#‡ 2 [1-4]#‡ 2 [1-6]#‡
GNI Low and lower-middle income 10 [4-60]$‡ 8 [4-60]*‡ 6 [3-60]*‡ 60 [60-60]#*‡ 21 [6-60]#*‡ 3 [1-5]‡ 3 [1-4]‡ 3 [2-5]# 2 [1-5]# 3 [1-60]#‡
Upper-middle income 12 [5-60]$‡ 9 [5-60]*‡ 10 [5-60]#*‡ 10 [5-60]#*‡ 29 [7-60]#*‡ 3 [2-7]‡ 3 [2-6]‡ 3 [2-7]#‡ 3 [2-8]#‡ 5 [2-60]#‡
High income 7 [3-30]$ 6 [2-15]* 6 [3-18]# 7 [3-21]#* 16 [5-60]#* 2 [1-5] 2 [1-5] 2 [1-5]# 2 [1-6]# 4 [2-60]#
Hospital 
LOS, 
days
Region Africa 38 [21-60]$ 60 [44-60]*‡ 19 [9-24]#*‡ 32 [32-32]#*‡ 60 [23-60]* 9 [4-14]‡ 10 [5-13]‡ 5 [3-15]#‡ 7 [4-25]‡ 9 [3-15]‡
Middle East 60 [22-60]$ 46 [19-60]*‡ 60 [24-60]#*‡ 11 [10-19]#*‡ 60 [60-60]#*‡ 14 [7-60]‡ 14 [7-29]‡ 13 [7-60]#‡ 39 [11-60]#‡ 60 [7-60]#‡
South America 60 [24-60]$‡ 55 [20-60]*‡ 51 [21-60]*‡ 60 [25-60]#*‡ 60 [60-60]#*‡ 12 [6-60]‡ 12 [6-36]‡ 11 [6-36]‡ 12 [6-60]‡ 20 [6-60]#‡
North America 20 [7-60]$‡ 19 [7-50]*‡ 15 [6-60]*‡ 7 [5-12]#*‡ 27 [11-60]#*‡ 7 [4-15]‡ 7 [4-14]‡ 6 [4-14]‡ 8 [4-16]#‡ 9 [4-52]#‡
West Europe 36 [15-60]$ 24 [14-60]* 29 [15-60]#* 50 [17-60]#* 60 [22-60]#* 13 [7-34] 11 [7-25] 13 [7-29]# 13 [7-34]# 30 [11-60]#
East Europe 59 [14-60]$‡ 33 [13-60]*‡ 31 [10-60]* 60 [16-60]#*‡ 60 [19-60]#* 13 [8-41]‡ 12 [7-25]‡ 13 [8-22] 14 [9-60]#‡ 43 [8-60]#
Oceania 19 [8-60]$‡ 14 [7-32]*‡ 21 [8-59]#*‡ 24 [5-60]#*‡ 51 [12-60]#* 9 [5-18]‡ 7 [4-15]‡ 8 [5-16]#‡ 11 [6-22]#‡ 15 [6-60]#‡
East and southeast Asia 32 [12-60]$‡ 22 [11-60]* 30 [10-60]#* 25 [14-60]‡ 60 [19-60]#*‡ 15 [7-52]‡ 14 [7-35]‡ 12 [6-30]# 20 [6-60]#‡ 38 [8-60]#
South Asia 19 [7-60]$‡ 16 [9-60]*‡ 10 [5-60]#*‡ 60 [60-60]#*‡ 60 [14-60]#*‡ 6 [2-11]‡ 7 [3-11]‡ 7 [3-10]#‡ 5 [2-9]‡ 6 [2-28]#‡
GNI Low and lower-middle income 29 [10-60]$ 20 [9-60]*‡ 13 [7-60]#*‡ 60 [60-60]#*‡ 60 [20-60]#* 7 [3-13]‡ 7 [3-14]‡ 7 [3-11]#‡ 5 [2-14]#‡ 9 [2-60]#‡
Upper-middle income 46 [14-60]$‡ 37 [12-60]*‡ 33 [11-60]*‡ 60 [16-60]#* 60 [21-60]#* 13 [7-44]‡ 12 [7-26]‡ 12 [7-30]‡ 14 [7-60]#‡ 17 [7-60]#‡
High income 36 [14-60]$ 24 [12-60]* 29 [14-60]# 45 [14-60]#* 60 [22-60]#* 12 [6-30] 10 [6-23] 11 [6-27]# 12 [7-30]# 27 [8-60]#
 Significant at 5% level: # vs. No AKI in the same group (sepsis or no sepsis), * vs. No sepsis patients with 
the same RIFLE classification, ‡ vs. West Europe or High income with the same RIFLE classification or 
the total population, in the same group (sepsis or no sepsis), $ vs. all patients without sepsis.
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Supplemental Table 8.  Mortality per renal replacement therapy modality 
TOTAL 
POPULATION
SEPSIS NO SEPSIS
ICU mortality, n (%)
     Haemodialysis 95 (25.6) 49 (34.5)*‡ 46 (20.1)#‡
     Haemofiltration 124 (38.9) 78 (45.6)* 46 (31.1)
     Mixed 105 (33.4) 66 (34.0) 39 (32.5)
Hospital mortality, n (%)
     Haemodialysis 114 (32.0) 58 (42.6)* 56 (25.5)‡
     Haemofiltration 143 (46.1) 90 (52.9)* 53 (37.9)
     Mixed 129 (42.2) 88 (47.1)* 41 (34.5)
 Significant at 5% level: * vs. No sepsis patients, # vs. Mixed, ‡ vs . Haemofiltration in the same group. ICU – inten-
sive care unit; n – number of patients.
 
Supplemental Table 9.  Baseline demographic characteristics of patients with chronic  
      renal failure, with and without sepsis  
ALL PATIENTS SEPSIS NO SEPSIS P-VALUE
Number of patients, (%) 845 (100) 263 (31.3) 582 (63.8) < 0.001
Age, mean (SD) years 67.7 (14.3) 67.9 (13.0) 67.6 (14.9 0.76
Male, n (%) 518 (61.8) 152 (58.7) 366 (63.2) 0.21
Weight, mean (SD) kg 76.1 (23.0) 76.0 (19.8) 76.1 (24.3) 0.94
Height, mean (SD) cm 167.4 (9.9) 167.2 (10.3) 167.5 (9.7) 0.72
Severity scores, mean (SD)
     APACHE II 25.6 (8.8) 28.9 (8.0) 24.1 (8.7) < 0.001
     Non-renal APACHE II     19.6 (8.2) 22.1 (7.7) 18.5 (8.2) < 0.001
     SOFA 8.0 (4.4) 9.9 (3.8) 7.1 (4.4) < 0.001
     Non-renal SOFA 5.4 (3.9) 7.0 (3.7) 4.7 (3.8) < 0.001
Type of admission, n (%) 0.19
     Surgical (non-trauma) 261 (32.6) 74 (28.8) 187 (34.4)
     Medical 523 (65.4) 180 (70.0) 343 (63.2)
     Trauma 9 (1.1) 1 (0.4) 8 (1.5)
     Other 7 (0.9) 2 (0.8) 5 (0.9)
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Supplemental Table 9.  Continued
ALL PATIENTS SEPSIS NO SEPSIS P-VALUE
Reason for admission, n (%) 0.001
Source of admission, n (%) 0.002
     Other hospital 73 (8.6) 29 (11.0) 44 (7.6)
     ER/ambulance 268 (31.7) 83 (31.6) 185 (31.8)
     OR/Recovery 138 (16.3) 33 (12.5) 105 (18.0)
     Hospital floor 307 (36.3) 110 (41.8) 197 (33.8)
     Other 59 (7.0) 8 (3.0) 51 (8.8)
Reason for admission, n (%) 0.001
     Neurological 50 (5.9) 8 (3.0) 42 (7.2)
     Respiratory 148 (17.5) 63 (24.0) 85 (14.6)
     Cardiovascular 346 (40.9) 117 (44.5) 229 (39.3)
     Renal/Ob-gyn 97 (11.5) 24 (9.1) 73 (12.5)
     Haematological 7 (0.8) 1 (0.4) 6 (1.0)
     Digestive/Liver 107 (12.7) 33 (12.5) 74 (12.7)
     Metabolic 30 (3.6) 6 (2.3) 24 (4.1)
     Trauma 19 (2.2) 2 (0.8) 17 (2.9)
     Other diseases 41 (4.9) 9 (3.4) 30 (5.2)
Comorbidities, n (%)
     COPD 127 (15.0) 40 (15.2) 87 (14.9) 0.92
     Cancer 88 (10.4) 25 (9.5) 63 (10.8) 0.56
     Metastatic cancer 18 (2.1) 6 (2.3) 12 (2.1) 0.84
     Haematologic cancer 20 (2.4) 9 (3.4) 11 (1.9) 0.18
     Insulin-DM 210 (24.9) 74 (28.1) 136 (23.4) 0.14
     Heart failure, NYHA III-IV 201 (23.8) 65 (24.7) 136 (23.4) 0.67
     HIV infection 8 (0.9) 4 (1.5) 4 (0.7) 0.25
     Cirrhosis 37 (4.4) 11 (4.2) 26 (4.5) 0.85
     Immunosuppression 66 (7.8) 21 (8.0) 45 (7.7) 0.9
     Steroid therapy 58 (6.9) 15 (5.7) 43 (7.4) 0.37
     Chemotherapy 18 (2.1) 4 (1.5) 14 (2.4) 0.41
 Significant at 5% level. SD – standard deviation; n- number of patients; SOFA – Sequential Organ Failure Assess-
ment; ER – emergency room; OR – operating room; Ob-gyn – Obstetric-gynaecology; COPD – Chronic Obstruc-
tive Pulmonary Disease; DM – Diabetes mellitus; NYHA – New York Heart Association; HIV - human immunode-
ficiency virus 
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Supplemental Table 10. Baseline clinical characteristics of patients with chronic renal 
      failure, with and without sepsis  
ALL PATIENTS SEPSIS NO SEPSIS P-VALUE
Systemic inflammatory response syndrome 
     Temperature, n (%) 0.03
          <36 52 (6.5) 17 (6.6) 35 (6.5)
          36-38 643 (80.8) 195 (76.2) 448 (83.0)
          >38 101 (12.7) 44 (17.2) 57 (10.6)
     Leucocytes (x109/L), n (%) 0.002
          <4 19 (2.4) 8 (3.1) 11 (2.1)
          4-12 319 (40.7) 82 (32.0) 237 (44.9)
          >12 446 (56.9) 166 (64.8) 280 (53.0)
     Heart rate, mean (SD)  
     bpm
104.6 (23.9) 109.1 (23.6) 102.4 (23.8) < 0.001
     Mean arterial pressure,  
     mean (SD) mmHg
97.1 (21.3) 95.9 (21.2 97.7 (21.3) 0.26
     Respiratory rate, mean  
     (SD) bpm
25.2 (8.0) 26.3 (8.0) 24.6 (8.0) < 0.01
     Patients on ventilator,  
     n (%)
388 (45.9) 153 (58.2) 235 (40.4) < 0.001
Blood parameters
     FiO2, mean (SD) 55.3 (26.4) 58.9 (26.6) 53.5 (26.2) < 0.01
     PaO2, mean (SD) mmHg 139.6 (77.3) 133.7 (72.7) 142.7 (79.4) 0.14
     PaCO2, mean (SD) mmHg 41.2 (15.3) 41.0 (16.8) 41.3 (14.5) 0.84
     Bicarbonate, mean (SD)  
     mmol/L        
22.2 (5.7) 21.9 (6.1) 22.4 (5.5) 0.31
     Arterial pH, mean (SD)  7.4 (0.1) 7.4 (0.1) 7.4 (0.1) 0.15
     Creatinine, mean (SD)  
     mg/dL
4.2 (3.6) 4.3 (3.2) 4.2 (3.8) 0.79
     Potassium, mean (SD)  
     mmol/L
4.8 (1.0) 4.7 (0.9) 4.8 (1.0) 0.08
     Sodium, mean (SD)  
     mmol/L
139.3 (6.2) 139.6 (6.7) 139.2 (5.9) 0.5
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ALL PATIENTS SEPSIS NO SEPSIS P-VALUE
Blood parameters
     Urea, median       
     [IQR] mmol/L
37.0 [0.3-90.0] 41 [0.3-94.5] 36.0 [0.3 - 87.0] 0.27
     Haematocrit, median  
     [IQR] L/L
30.9 [26.9-35.9] 30.0 [26.1-34.7] 31.0 [27.0 - 36.0] 0.09
     Bilirubin, median [IQR]            
     mg/dL
0.8 [0.5-1.7] 0.8 [0.5-1.9] 0.8 [0.5 - 1.6] 0.11
Noradrenaline infusation 
rate, median [IQR]  
µg/kg/min
0.0 [0.0-0.1] 0.0 [0.0-0.2] 0.0 [0.0 - 0.0] <0.001
Inotropic score, median 
[IQR]
0.0 [0.0-13.0] 4.0 [0.0-23.0] 0 [0 - 10] <0.001
Urine output, median  
[IQR] mL/24 h
848 [123-1,718] 600 [65-1405] 1000 [150 - 1844] <0.01
 Significant at 5% level. Legend: n – number of patients; SD – standard deviation; IQR – interquartile range. 
Supplemental Table 11. Outcome of patients with chronic renal failure at admission
 
SEPSIS  (N=263) NO SEPSIS (N=582)
ICU LOS, days 7 [3-60]* 3 [2-8]
Hospital LOS, days 43 [14-60]* 16 [7-60]
RRT, n (%) 133 (50.6)* 185 (31.8)
ICU mortality, n (%) 75 (28.7)* 103 (18.5)
Hospital mortality, n (%) 107 (42.0)* 137 (25.8)
 Significant at 5% level: * vs. No sepsis patients. ICU – intensive care unit; LOS – length of stay; RRT – 
renal replacement therapy; n – number of patients.
Supplemental Table 10.  Continued
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Abstract
W 
hile alkaline phosphatase (AP) is used as a marker to screen for liver and 
bone disease, AP also exerts immune-modulating and renal protective 
effects. We investigated the interplay between endogenous AP levels, the 
inflammatory response and clinical outcomes in critically ill sepsis patients. In two cohorts 
of septic shock (n=147) and septic Intensive Care Unit (ICU) patients (n=3276) we demon-
strated that inflammatory plasma cytokines TNF-α, IL-6, IL-8, IL-1ra and IL-10 on the first day 
of septic shock correlated with predominantly liver, but also bone-derived AP levels during 
follow-up (p<0.01). Moreover, in sepsis patients, the highest AP level during the ICU stay was 
independently associated with length of stay (r=0.67, p<0.001), with severe acute kidney injury 
(AKI-Failure) and the need for renal replacement therapy (RRT), which was most pronounced 
in the two highest AP quintiles (odds ratio [confidence interval]; quintile 4: AKI-Failure 1.5 [1.0-
2.1], RRT 1.9 [1.3-2.8]; quintile 5: AKI-Failure 1.7 [1.2-2.4], RRT 2.6 [1.8-3.9], all p<0.05). Endogenous 
AP levels were not associated with anti-inflammatory or beneficial clinical effects. These find-
ings indicate that endogenous AP levels reflect inflammation-induced organ dysfunction and 
do not represent an endogenous negative feedback response that limits inflammation and 
organ dysfunction in sepsis patients.
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Introduction
Alkaline phosphatases (APs) are membrane-bound metalloenzymes, endogenously 
expressed in the human body.  APs consist of a group of true isoenzymes, all glycoproteins, 
encoded for by four different gene loci and named after the tissue in which the enzymes 
were originally found, namely placental, germ cell, intestinal and tissue nonspecific (liver/
bone/kidney) AP.1,2 Bone and liver type AP are the predominant APs in human blood.3 APs 
are involved in a broad array of functions during health and disease, including bone mineral-
ization, regulating of intestinal barrier function and disease prediction.1,4-7 In clinical practice, 
endogenous AP is part of a panel of markers mainly used to screen for liver injury, as it may 
be increased in patients with e.g. obstructed bile ducts, liver cancer and cirrhosis. In addi-
tion, bone-derived AP is used to screen for increased osteoblastic activity in bone disease. 
Also in patients suffering from sepsis, increased AP levels are observed.8 In addition, AP plays 
a role in host defense as it modulates innate immunity. Inhibition of plasma AP resulted in 
significantly higher mortality rates in rats exposed to a sublethal dose of gram-negative Esch-
erichia coli9, whereas administration of placental and intestinal AP improved survival in rats, 
prevented organ damage and attenuated the inflammatory response in murine models of 
systemic inflammation.10,11 In sheep and piglets, exogenous intestinal AP reduced plasma 
cytokine levels, improved gas exchange and enhanced thrombocyte counts during inflam-
matory insults.12,13 Dephosphorylation, and thereby detoxification, of lipopolysaccharide (LPS), 
part of the outer membrane of gram-negative bacteria, appears to account for these benefi-
cial effects.9 LPS is a key player in the pathogenesis of sepsis, an important clinical syndrome 
in the intensive care unit (ICU), which represents the bodies systemic inflammatory response 
to a suspected or confirmed infection and is a major cause of multiple organ dysfunction and 
death in the ICU.14 Considering the immune-modulating effects of AP, the effects of intrave-
nous administration of bovine AP were investigated in critically ill patients with sepsis, with 
or without acute kidney injury (AKI). AP treatment resulted in more swift normalization of the 
inflammatory response and significantly improved renal function and prevented sepsis-in-
duced acute kidney injury.15,16  
Thus, on the one hand sepsis may lead to increases in circulating AP levels, which is viewed 
as a marker of liver injury. However, on the other hand, considering the protective effects 
of exogenous AP, sepsis patients with elevated endogenous levels may encounter benefi-
cial effects of AP, which could possibly represent a negative feedback mechanism limiting 
sepsis-induced inflammation and organ dysfunction. Therefore, the aim in this explorative 
study was to investigate the interplay between inflammation, endogenous AP levels and clin-
ical outcomes in critically ill sepsis patients. 
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Methods
Study population
Two sepsis patient cohorts were investigated. First, a prospective cohort study was conducted 
in septic shock patients (≥18 years) admitted to the ICU of the Radboud university medical 
center (Radboudumc, Nijmegen, The Netherlands; ‘Nijmegen cohort’). Septic shock was 
defined according to the definitions stated by ACCP and SCCM consensus conference17: A 
suspected or proven infection, two or more systemic inflammatory response syndrome 
(SIRS) criteria and the need for vasopressor therapy.  Patients (n=147) were enrolled between 
March 2012 and June 2015. The study was carried out in accordance with the applicable rules 
concerning the review of the ethical committee of Radboudumc, which state that in this case 
it is allowed to withdraw a very small amount of additional blood (<3ml) without the need to 
obtain informed consent, considering the severity of the illness of the patients, the presence 
of an arterial catheter, the research does not influence clinical policy and the research is not 
controversial (2016-2923). A second cohort of sepsis patients (n=3,276), admitted to the ICU 
of the Antwerp University Hospital (UZA, Edegem, Belgium; ‘Antwerp cohort’), was included 
between 2007 and 2014 and analyzed in retrospect. All 17,266 adults (≥18 years) admitted 
in this period were eligible for inclusion in the retrospective evaluation and screened for 
sepsis, defined as a suspected or proven infection and two or more SIRS criteria.17 A senior ICU 
staff member blinded to the patient’s status carried out a search query to extract data and 
confirmed the sepsis diagnosis according to the mentioned criteria. The study was approved 
by the ethical committee of UZA (11/2/19) who waived the need to obtain informed consent.
Sample and data collection 
In the Nijmegen cohort, ethylenediaminetetraacetic acid (EDTA) and lithium heparin (LH)-an-
ticoagulated blood was collected from the arterial catheter within 24 h after diagnosis of 
septic shock (day 1), and on days 3, 5 and 7 in case patients were still in the ICU. Blood was 
centrifuged (1600g, 4°C, 10 min), whereafter plasma was stored at -80°C until further anal-
ysis. Demographic, clinical and laboratory data were collected on days of blood sampling. 
In the Antwerp cohort, arterial blood was obtained in all patients on admission and at least 
once daily unless the patient was discharged from the ICU or deceased. Data was collected 
in retrospect for all ICU admission days. The simplified acute physiology score (SAPS; II18, 
Radboud cohort; III19, Antwerp cohort) was calculated from the worst values taken during the 
first 24 h following ICU admission. A daily RIFLE score, a validated score to categorise acute 
kidney injury20, was obtained from the patient data management system for all patients of 
the Antwerp cohort.
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Plasma cytokines and alkaline phosphatase
Tumor necrosis factor (TNF)-α, Interleukin (IL)-1 receptor antagonist (IL-1ra), IL-6, IL-8 and IL-10 
were analyzed batch-wise in EDTA plasma by a simultaneous Luminex assay according to the 
manufacturer’s instructions (Milliplex; Millipore, Billerica, MA). AP levels were determined by 
routine laboratory analysis in LH plasma (Radboud cohort) or serum (Antwerp cohort).
AP iso-enzymes 
To separate the different AP isoenzymes and isoforms present in LH plasma of the Nijmegen 
cohort (n = 46), agarose gel electrophoresis was performed with the Isopal Plus® kit (Beckman 
Europe, Analis S.A., Suarlé, Belgium) as described previously.21 Samples were subjected to a 
set of treatments for AP isoenzyme differentiation. All samples were treated with neuramini-
dase (2 U/ml, purified from Clostridium perfringens, Analis S.A., Suarlée, Belgium) for 30 min at 
37°C, which enhanced the separation of bone and liver AP on the agarose gel, due a different 
degree of sialylation 22. Bone AP was specifically inhibited by incubating the samples at 56°C 
for 10 min, while liver AP is less sensitive to this heat treatment. Overnight incubation with 
Phosphatidylinositol (PI)-specific phospholipase C (PLC) (≥200 U/mg, purified from Bacillus 
cereus, Sigma-Aldrich) caused in vitro dissociation of high molecular mass AP (HMW AP) into 
dimeric liver AP.2 Ultra-fast AP was identified based on its electrophoretic mobility (well in 
advance of HMW-AP), on its appearance (lipoprotein-bound fraction) and on its extractability 
in a cetavlon/ether mixture. For the detection of intestinal type AP, samples were treated with 
neuraminidase 2 U/mL at 37°C overnight (intestinal type AP is not sialylated and therefore, its 
migration was not influenced by neuraminidase). An atypically migrating AP fraction, identi-
fied as liver type AP based on its resistance to heating at 56°C and its sensitivity to treatment 
with neuraminidase, was found in 4 patients and was added to typical liver AP for statis-
tical analysis. To quantify the activity of the different AP isoenzymes and isoforms, gels were 
scanned at 600nm in a densitometer (Appraise, Beckman Instruments Inc.). AP isoenzyme 
activity was expressed in U/L and as a percentage of total AP activity.
Statistical analysis 
Data are expressed as median [25th percentile, 75th percentile] or numbers and percentages. 
Normality assumption checking was performed by inspecting residual and normal plots 
and using the Kolmogorov-Smirnov test. Differences within and between groups were esti-
mated using the Friedman test or Mann-Whitney U test. Correlation coefficients were calcu-
lated using Spearman correlation. Univariate regression analysis was performed to identify 
possible confounders for the maximum AP level, in addition to known confounders (age and 
gender). Odds ratios (ORs) with 95% Confidence Intervals (CIs) were estimated by univariate 
or multiple logistic regression, corrected for age, gender, BMI, SAPS3 score and maximum 
(non-renal) SOFA score, C-reactive protein level, white blood cell count, and lactate level. 
Multiple linear regression analysis also included these confounders. Linear regression analysis 
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was conducted with log-transformed data when data was not normally distributed. P < 0.05 
(two-sided) was considered statistically significant. Data were analyzed using IBM SPSS Statis-
tics software, version 22 (IBM, Armonk, NY). 
Results
Study populations 
Two cohorts were studied. First, septic shock patients (n=147) were prospectively included 
between March 2012 and June 2015 (‘Nijmegen cohort’). Baseline characteristics are presented in 
Table 1. In 78% of the patients, septic shock developed within 24h after ICU admission. The median 
ICU length of stay was 8 [4-19] days, with an ICU mortality of 26% and a hospital mortality of 30%. 
A second ICU cohort of 3276 patients with sepsis at admission was included between 2007 
and 2014 (‘Antwerp cohort’) and analyzed in retrospect (Table 1). The median ICU length of 
stay was 4 [1-11] days and the ICU and hospital mortality were 19% and 39%, respectively.
Table 1. Patient characteristics 
NIJMEGEN COHORT  (n=147) ANTWERP COHORT (n=3276)
Male, n (%) 82 (56) 1916 (59)
Age (years) 67 [56-73] 64 [53-73]
BMI (kg/m2) 25.1 [22.9-28.4] 25.1 [22.5-29.1]
SAPS scorea 55 [44-66] 59 [48-70]
 a Nijmegen cohort: SAPS II, Antwerp cohort: SAPS III. BMI, body mass index; SAPS, simplified acute physiology 
score. Data are presented as median [25th percentile, 75th percentile].
Alkaline phosphatase baseline levels not associated with beneficial 
clinical effects 
First, we aimed to identify whether elevated endogenous levels of AP on the first day of septic 
shock (baseline, day 1) is associated with beneficial effects on outcome. In the Nijmegen cohort, 
baseline plasma AP activity levels ranged from 29 U/L to 428 U/L, with a median value of 89 
U/L. AP levels correlated with bilirubin (r = 0.32, p = 0.006, n = 76), ALAT (r = 0.36, p = 0.001, n = 
81), ASAT (r = 0.29, p = 0.012, n = 72) and GGT (r = 0.69, p < 0.001, n = 60) at day 1, all markers of 
liver function. To determine the relationship of baseline AP levels with inflammation, circulating 
cytokines were measured serially during the ICU stay. Plasma TNF-α, IL-6, IL-8, IL-1ra and IL-10 
levels were profoundly increased during the first day of septic shock and declined rapidly during 
follow-up until day 7 (Figure 1; all p < 0.001). AP activity levels at day 1 positively correlated with 
TNF-α at day 3 (r = 0.26, p = 0.006, n = 115), but not at day 5 or 7, nor with IL-6, IL-8, IL-10 or IL-1ra 
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at follow-up (not shown). Furthermore, there was no correlation between AP levels and disease 
severity (SAPS II score; r = 0.04, p = 0.6, n = 138) or ICU length of stay (r = -0.11, p = 0.2, n = 147), 
and AP levels were comparable in ICU survivors (87 [59-126] U/L) and non-survivors (93 [61-146] 
U/L; P = 0.5). The effects of increased AP levels on clinical endpoints were explored further in the 
larger Antwerp cohort. The median plasma AP activity level at admission in sepsis patients was 
91 U/L and ranged from 11 U/L to 3190 U/L. AP admission levels showed a modest correlation 
with the SAPS III score (r = 0.13, p < 0.01, n = 3276), but not significantly with ICU length of stay (r 
= 0.03, p = 0.06 n = 3276). AP levels were slightly elevated in non-survivors compared to survivors 
(98 [70-163] U/L vs. 89 [64-138] U/L; p < 0.001). Finally, considering the beneficial effects of exog-
enous AP in patients with sepsis-associated AKI15,16, we studied the relation between endog-
enous AP and kidney function during follow-up. In total, 1739 patients (53%) developed AKI 
during their ICU stay (RIFLE-category 20 Risk: 12%, Injury: 58%, Failure: 30%). AP admission levels 
were not associated with the occurrence of AKI, nor with the most severe form of AKI, AKI-Failure 
(both OR: 1.0[1.0-1.0]; p > 0.1).  Overall, these results indicate that endogenous AP levels at ICU 
admission do not reflect overall disease severity and are not associated with anti-inflammatory 
or beneficial clinical effects in sepsis patients.
Inflammatory response at baseline associated with alkaline 
phosphatase levels at follow-up
Subsequently, we investigated in the Nijmegen cohort whether the inflammatory response on 
the first day of septic shock was associated with AP levels during follow-up. Baseline plasma 
cytokines correlated with the SAPS II score (TNF-α: r = 0.32, IL-6: r = 0.26, IL-8: 0.34, IL-1ra: r = 0.28, 
IL-10: r = 0.32, all p < 0.002, n = 135), norepinephrine infusion rate (TNF-α: r =0.32, IL-6: r = 0.40, 
IL-8: 0.43, IL-1ra: r = 0.52, IL-10: r = 0.48, all p < 0.001, n = 144), and were, except for TNF-α, higher 
in non-survivors compared to survivors (p < 0.05). Plasma AP activity levels increased during 
the first week in the ICU from 89 [60-130] to 154 [94-242]; p < 0.001) (Figure 2A). Similar results 
were obtained when only patients were included with a minimal follow-up until day 7, which 
was explored to correct for possible changes in the case mix (not shown). Although SAPS II and 
norepinephrine infusion rate did not correlate with AP levels at follow-up, cytokines at day 1 
correlated positively with AP at days 5 and 7 (Table 2; Supplemental Figure 1). This correlation 
remained statistically significant following adjustments for potential confounding factors (age, 
gender, disease severity and norepinephrine infusion rate; not shown). These results indicate that 
the inflammatory response is related to disease severity, and to an increase in AP levels during 
follow-up. To identify the source of the inflammation-induced AP release, iso-enzyme analysis 
was performed which indicated that the total AP fraction at day 1 predominantly consisted of 
liver-derived AP (81.7 [75.5-85.8]%), followed by bone- (14.9 [10.2-19.4]%) and intestinal-derived 
AP (2.2 [0-6.1]%). Kidney-derived AP was not detectable in the circulation. All fractions signif-
icantly increased to a similar extent during follow-up (Figure 2B). The intestinal-derived frac-
tion did not correlate with cytokine levels, but liver- and bone-derived AP did (Supplemental 
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Table 1). Liver-derived AP can be subdivided into unbound liver AP (day 5: 78 [63-87]%, day 7: 
73 [66-88]%) and liver-AP enriched microvesicles (high molecular weight [HMW]-AP; day 5: 
22 [13-34]%, day 7: 19 [11-32]%), which correlated both with cytokine levels (Supplemental 
Table 2). A third fraction, liver-AP bound to lipoproteins (ultra-fast AP), was not detectable 
in the majority of patients (not shown). Together, these data show that primarily liver and 
bone-derived AP account for the inflammation-induced increase in plasma AP.
Figure 1.
 Plasma concentrations of inflammatory cytokines in septic shock patients. 
 Plasma levels were determined upon diagnosis of septic shock (day 1) and on days 3, 5 and 7 in case patients 
were still admitted to the Intensive Care Unit. Presented are pro-inflammatory cytokines (A) tumor necrosis factor 
(TNF)-α, (B) interleukin (IL)-6, (C) IL-8, anti-inflammatory cytokines (D) IL-1 receptor antagonist (IL-1ra) and (E) 
IL-10. Data is expressed as median [25th percentile, 75th percentile]. Day 1, n = 144; day 3, n = 115; day 5, n = 83; day 
7, n = 64. Significant differences over time estimated using Friedman test (*p<0.001). 
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Table 2.  Correlations between inflammatory cytokines and alkaline phosphatase during 
   septic shock 
TNF-α IL-6 IL-8 IL-1Ra IL-10
AP Day 1 r = 0.21
p = 0.010
r = 0.01
p = 0.955
r  = -0.02
p = 0.828
r = -0.03
p = 0.760
r = -0.05
p = 0.527
AP Day 3 r = 0.35
p < 0.001
r = 0.16
p = 0.094
r = 0.21
p = 0.024
r = 0.08
p = 0.421
r = 0.04
p = 0.663
AP Day 5 r = 0.46
p < 0.001
r = 0.39
p < 0.001
r = 0.38
p < 0.001
r = 0.31
p = 0.004
r = 0.34
p = 0.002
AP Day 7 r = 0.41
p = 0.001
r = 0.42
p = 0.001
r = 0.46
p < 0.001
r = 0.43
p < 0.001
r = 0.39
p = 0.002
 Plasma levels of pro-inflammatory cytokines tumor necrosis factor (TNF)-α, interleukin (IL)-6, IL-8 and anti-in-
flammatory cytokines IL-1 receptor antagonist (IL-1ra) and IL-10 were determined upon diagnosis of septic shock 
(day 1) and were correlated with alkaline phosphatase (AP) enzyme activity levels, determined on day 1 and on 
days 3, 5 and 7 in case patients were still admitted to the Intensive Care Unit. Correlation coefficients were calcu-
lated using Spearman correlation. Day 1, n = 144; Day 3, n = 113; Day 5, n = 83; Day 7, n = 63.
Figure 2. 
 Plasma concentrations of alkaline phosphatase isoenzymes in septic shock patients. 
 Plasma levels were determined upon diagnosis of septic shock (day 1) and on days 3, 5 and 7 in case patients 
were still admitted to the Intensive Care Unit. Presented are (A) total alkaline phosphatase (AP) plasma concen-
trations and (B) AP isoenzyme plasma concentrations, determined in a subcohort of patients admitted until day 
7 (n = 46). Data is expressed as median [25th percentile, 75th percentile]. Panel A: Day 1, n = 147; day 3, n = 115; day 
5, n = 83; day 7, n = 64. Significant differences over time estimated using Friedman test (*p<0.001).
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Associations between maximum alkaline phosphatase levels 
and clinical outcomes 
Considering the association between inflammation and AP levels at follow-up, we investi-
gated in the Antwerp cohort whether the highest AP level during the entire ICU stay (APmax) 
related to clinical outcomes, aside from reflecting liver damage. APmax correlated with 
disease severity and organ dysfunction at admission (SAPS3: r = 0.26, p < 0.001, n = 3262; 
SOFA: r = 0.32, p < 0.001, n = 3219). In univariate analysis, APmax was not associated with the 
occurrence of AKI. However, APmax was associated with the occurrence of AKI-Failure, the 
need for renal replacement therapy during the ICU admission (n= 576) and the ICU length 
of stay (all p < 0.001). Furthermore, AP max was elevated in ICU non-survivors compared to 
survivors (179 [114-328] U/L vs. 122 [81-207] U/L; p < 0.001). To further explore these associ-
ations, APmax was divided into quintiles (very low: < 77 U/L, low: 78-108 U/L, moderately 
elevated: 109-159 U/L, high: 160-265 U/L, very high: 266-3190 U/L), and possible confounders 
were assessed by univariate regression analysis (Supplemental Table 3). With respect to renal 
function, APmax was independently associated with the occurrence of AKI-Failure and the 
need for RRT during the ICU stay, which reached statistical significance in the two highest 
quintiles (Figure 3). APmax was still independently associated with ICU length of stay (r = 0.67, 
β = 0.29, p < 0.001; n = 3142), irrespective whether the patient survived the ICU stay or not (not 
shown), but not with ICU survival (OR: 1.0 [1.0-1.0]; p=0.7, n = 3276). These results indicate that 
APmax is associated with a prolonged ICU stay, the occurrence of severe AKI, and the need 
for renal replacement therapy.
Figure 3.
 Adjusted odds ratios for acute kidney injury-failure (left) and renal replacement therapy (right) in 
patients with sepsis. 
 The maximum alkaline phosphatase level (APmax) during ICU admission was divided into quintiles (very low: < 
77 U/L, low: 78-108 U/L, moderate: 109-159 U/L, high: 160-265 U/L, very high: 266-3190 U/L). Quintile 1 is the refer-
ence category. Odds ratios, estimated by logistic regression analysis, were corrected for age, gender, BMI at admis-
sion, maximum non-renal SOFA score, SAPS3 score, maximum C-reactive protein level, maximum white blood cell 
count, and maximum lactate level. AKI Failure, n = 3141; renal replacement therapy, n = 3150. 
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Discussion
In the present study, we investigated the interplay between endogenous AP levels, the inflam-
matory response and clinical outcomes in critically ill patients with sepsis. While AP is an estab-
lished marker used for the evaluation of liver or bone disease, intravenous administration of 
AP exerts immune-modulating and renal protective effects in animal models9-11,23 and sepsis 
patients.15,16 As such, sepsis patients with elevated AP levels could potentially encounter bene-
ficial effects of AP during their critical illness, implying that the sepsis-induced increase in 
AP might represent a negative feedback mechanism. In this study, we demonstrate that the 
extent of inflammation indeed is associated with increased AP levels. However, as the patients’ 
highest level of AP during admission is independently associated with a prolonged ICU stay 
and more pronounced kidney dysfunction, we found no signal that elevated endogenous AP 
levels are associated with an anti-inflammatory phenotype or a beneficial clinical course.
Although we are not aware of other studies assessing the role of endogenous AP activity 
levels during sepsis, associations between endogenous AP and renal function have been 
reported previously in other, non-infectious, patient populations. Increased serum AP levels 
were observed in patients with urological conditions, which returned to normal upon treat-
ment of the underlying kidney-related lesion.24 In patients with heart failure, elevated levels 
of AP at admission were associated with worsening renal function.25 In addition, in peritoneal 
dialysis patients, increased endogenous AP levels are associated with a higher risk of infec-
tion-related hospitalization and mortality.26 In an attempt to clarify the mechanism under-
lying this relation, the authors cautiously postulated that the increased AP levels could be 
a response of infection.26 To continue on this finding, we here show that plasma cytokine 
levels on the first day of septic shock are associated with AP levels during follow-up. Subse-
quently, although it would be of interest the identify the relation of AP and the develop-
ment of secondary infections, this was beyond the scope of this study and further studies are 
warranted to further clarify this potential association.
Sepsis is often complicated by direct organ failure caused by e.g. hemodynamic insta-
bility leading to perfusion deficits, endothelial activation, tissue hypoxia and mitochondrial 
dysfunction.27,28 In addition, there is also organ crosstalk between the kidneys and e.g. the 
heart, lungs, and intestine, which may deteriorate further organ function.29,30 Also interplay 
between kidney dysfunction and liver dysfunction is observed. AKI may promote hepatic 
leukocyte influx, cytokine concentrations, apoptosis and oxidative stress31, whereas renal 
failure is commonly observed in patients with advanced chronic liver diseases.32 Also, another 
feature of critical illness is hyperresorptive bone failure, an often unrecognized component 
of the systemic inflammatory response syndrome.33 As bone resorption and bone forma-
tion are closely coupled34,35, hyperresorptive bone failure is expected to be accompanied by 
an increase in osteoblastic activity. As of yet, little is known about the source of AP during 
systemic inflammation. For the first time, we have demonstrated that circulating AP in septic 
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shock patients is primarily derived from the liver, followed by bone. The presence of these 
iso-enzymes, which both increased to a similar extent over time, and the fact that we do not 
have an indication that increased AP levels present a protective negative feedback mecha-
nism, suggest that the association between elevated AP levels and kidney dysfunction most 
likely reflects an epiphenomenon of inflammation-induced organ dysfunction.
One may argue that elevated AP levels upon diagnosis of septic shock patients, as found in 
our study, are not associated with any beneficial clinical effects. This is contradictory with 
previous studies, which demonstrated that intravenous administration of AP was associated 
with renal protective effects in rats23 and critically ill sepsis patients.15,16 The protective effects 
are ascribed to the dephosphorylating nature of AP, as it can hydrolyze LPS, part of the outer 
membrane of gram-negative bacteria involved in sepsis pathogenesis, as well as the detri-
mental purines adenosine triphosphate (ATP) and adenosine diphosphate (ADP), released 
during inflammation and hypoxia.23 Following these studies, a human recombinant AP 
(recAP) was developed as a pharmaceutically attractive replacement by replacing the crown 
domain of a human intestinal AP with the crown domain of human placental AP, resulting in 
a highly stable and highly active enzyme.36 Pharmacokinetic modelling demonstrated that 
clinical benefit in patients with sepsis-associated AKI may occur above serum recAP concen-
trations of at least 290 U/L, and maintained for at least 48 h and preferably for 5-7 days.37 
Moreover, serum AP activity levels following intravenous recAP infusion in patients may reach 
levels up to 10 000 U/L.37 Possibly, the threshold level and/or duration above this threshold 
associated with clinical benefit is not reached in our patients, which demonstrate median AP 
baseline levels of 89 [60-130] U/L in the septic shock Nijmegen cohort and 91 [65-141] U/L in 
the sepsis Antwerp cohort. In addition, the clinical trials were conducted with strict in- and 
exclusion criteria, and patients with e.g. confirmed gram-positive sepsis, history of chronic 
renal failure, renal replacement therapy at inclusion, acute pancreatitis with no established 
source of infection, immunosuppressant therapy, and expected death within 24 hours were 
not enrolled. We did not apply any of these exclusion criteria in the present observational 
study, resulting in a much more heterogeneous study population.
Elevated levels of AP can be the consequence of a wide range of other clinical conditions than 
sepsis8, before as well as during the ICU admission, which were not taken into account in this 
study and could have confounded the results. Moreover, even though we depict associations 
between the inflammatory response and AP, as well as AP and renal dysfunction, as this is an 
association study, we cannot draw any conclusions on the causality of these findings. 
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Conclusion
This observational study demonstrates that the inflammatory response observed in criti-
cally ill sepsis patients is associated with increased AP plasma concentrations, and that the 
maximum AP level during the ICU stay is independently and positively associated with ICU 
LOS, the occurrence of severe AKI, and the need for RRT. We did not find a relation between 
elevated endogenous AP levels and an anti-inflammatory phenotype or a beneficial clinical 
course in these patients, indicating that endogenous AP levels reflect inflammation-induced 
organ dysfunction and do not represent a putative endogenous negative feedback response 
limiting further inflammation and organ dysfunction.
Acknowledgments
We are grateful to the (research) nurses of the department of Intensive Care Medicine 
(Radboudumc, the Netherlands) and the department of Critical Care Medicine (Antwerp 
University Hospital, Belgium) for blood sampling. Also, we thank Pleun Hemelaar and Myriam 
Löffler for data extraction and data management of the septic shock patients. We thank Niels 
Van Regenmortel for critically and independently reviewing the diagnosis of sepsis in the 
Antwerp  patients in a blinded fashion. We are also greatly indebted to Wilfried Leyssens, 
Veerle Van Kelst and Marina Van Mullem for skilfully performing AP isoenzyme electropho-
resis and sample treatments. 
87
Supplemental Figure
A B
Supplemental Figure 1. 
 Correlations between inflammatory cytokines and alkaline phosphatase in patients with septic shock.
 Scatter graphs are presented of the correlations between the pro-inflammatory cytokine tumor necrosis factor 
(TNF)-α (panel a) or anti-inflammatory cytokine Interleukin (IL)-1 receptor antagonist (IL-1ra) (panel b) upon 
diagnosis of septic shock (day 1), and alkaline phosphatase (AP) enzyme activity levels on days 3, 5 and 7. Day 1, 
n = 144; Day 3, n = 113; Day 5, n = 83; Day 7, n = 63.
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Supplemental Tables
Supplemental Table 1.  Correlations between inflammatory cytokines and alkaline 
    phosphatase isoenzymes during septic shock
TNF-α IL-6 IL-8 IL-1Ra IL-10
Intestinal AP Day 5 r = 0.09
p = 0.562
r = -0.10
p = 0.492
r = -0.04
p = 0.777
r = -0.01
p = 0.952
r = -0.05
p = 0.720
Day 7 r = 0.16
p = 0.310
r = -0.06
p = 0.699
r = 0.13
p = 0.415
r = 0.18
p = 0.228
r = 0.09
p = 0.542
Liver AP Day 5 r =  0.41
p = 0.005
r = 0.48
p = 0.001
r = 0.48
p = 0.001
r = 0.29
p = 0.055
r = 0.30
p = 0.045
Day 7 r = 0.48
p = 0.001
r = 0.54
p < 0.001
r = 0.59
p < 0.001
r = 0.33
p = 0.024
r = 0.43
p = 0.003
Bone AP Day 5 r = 0.36
p = 0.015
r = 0.23
p = 0.128
r = 0.28
p = 0.060
r = 0.27
p = 0.074
r = 0.12
p = 0.459
Day 7 r = 0.46
p = 0.002
r =  0.43
p = 0.004
r = 0.53
p < 0.001
r =  0.31
p = 0.038
r = 0.36
p = 0.015
 Plasma levels of pro-inflammatory cytokines tumor necrosis factor (TNF)-α, interleukin (IL)-6, IL-8 and anti-in-
flammatory cytokines IL-1 receptor antagonist (IL-1ra) and IL-10 were determined upon diagnosis of septic shock 
(day 1) and were correlated with intestinal, bone and liver-specific isoenzymes of alkaline phosphatase (AP) 
enzyme activity levels, determined on days 5 and 7. Correlation coefficients were calculated using Spearman 
correlation. Day 5, n = 46; Day 7, n = 45.
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Supplemental Table 2.  Correlations between inflammatory cytokines and liver-
      specific alkaline phosphatase isoenzymes during septic shock
 
TNF-α IL-6 IL-8 IL-1Ra IL-10
Free fraction Day 5 r = 0.37
p = 0.012
r = 0.39
p = 0.007
r = 0.38
p = 0.010
r = 0.22
p = 0.151
r = 0.18 
p = 0.243
Day 7 r = 0.43
p = 0.004
r = 0.43
p = 0.003
r = 0.49
p = 0.001
r = 0.32
p = 0.030
r = 0.31
p = 0.037
Microvesicles Day 5 r = 0.42
p = 0.004
r = 0.45
p = 0.002
r = 0.53
p < 0.001
r = 0.32
p = 0.030
r = 0.39
p = 0.008
Day 7 r = 0.45
p = 0.002
r = 0.53
p < 0.001
r = 0.57
p < 0.001
r = 0.31
p = 0.039
r = 0.47
p = 0.001
 Plasma levels of pro-inflammatory cytokines tumor necrosis factor (TNF)-α, interleukin (IL)-6, IL-8 and anti-in-
flammatory cytokines IL-1 receptor antagonist (IL-1ra) and IL-10 were determined upon diagnosis of septic shock 
(day 1) and were correlated with the unbound liver-specific fraction (day 5: 78 [63-87]%, day 7: 73 [66-88]%) 
and liver-specific enriched microvesicles (high molecular weight [HMW]-alkaline phosphatase (AP); day 5: 22 
[13-34]%, day 7: 19 [11-32]%) of AP enzyme activity levels, determined on days 5 and 7. Correlation coefficients 
were calculated using Spearman correlation. Day 5, n = 46; Day 7, n = 45.
Supplemental Table 3.  Univariate regression analysis in patients with sepsis 
APMAX 
BMI r = 0.04 p = 0.015
SAPS3 r =  0.24 p < 0.001
Maximum SOFA score r = 0.34 p < 0.001
Maximum non-renal SOFA score r = 0.32 p < 0.001
Maximum C-reactive protein level r = 0.32 p < 0.001
Maximum white blood cell count r = 0.28 p < 0.001
Maximum lactate level r = 0.20 p < 0.001
Chronic kidney disease at admission r = 0.02 p = 0.257
 Univariate linear or logistic regression analysis was performed to identify possible confounders for the maximum 
level of alkaline phosphatase (APmax) during ICU admission. Data was log-transformed when not normally 
distributed (linear regression). Maximum values indicate the highest level during ICU admission. Maximum SOFA 
score: 6 [6-13]; maximum non-renal SOFA score: 8 [5-11]; maximum C-reactive protein level: 180 [100-277] mg/L; 
maximum white blood cell count: 17 [12-24] x 109/L; maximum lactate level: 2.8 [1.8-4.7] mmol/L. Parameters 
with a p value below 0.1 were subsequently used for multiple regression analysis.
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Abstract
R ecently, two phase-II trials demonstrated improved renal function in criti-cally ill patients with sepsis-associated acute kidney injury treated with the enzyme alkaline phosphatase. Here, we elucidated the dual active effect 
on renal protection of alkaline phosphatase.
Experimental approach 
The effect of human recombinant alkaline phosphatase (recAP) on LPS-induced renal injury 
was studied in Sprague–Dawley rats. Renal function was assessed by transcutaneous meas-
urement of FITC-sinistrin elimination in freely moving, awake rats. The mechanism of action 
of recAP was further investigated in vitro using conditionally immortalized human proximal 
tubular epithelial cells (ciPTEC).
Key results 
In vivo, LPS administration significantly prolonged FITC-sinistrin half-life and increased fractional 
urea excretion, which was prevented by recAP co-administration. Moreover, recAP prevented 
LPS-induced increase in proximal tubule injury marker, kidney injury molecule-1 expression and 
excretion. In vitro, LPS-induced production of TNF-α, IL-6 and IL-8 was significantly attenuated 
by recAP. This effect was linked to dephosphorylation, as enzymatically inactive recAP had no 
effect on LPS-induced cytokine production. RecAP-mediated protection resulted in increased 
adenosine levels through dephosphorylation of LPS-induced extracellular ADP and ATP. Also, 
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recAP attenuated LPS-induced increased expression of adenosine A2A receptor. However, the 
A2A receptor antagonist ZM-241385 did not diminish the effects of recAP.
Conclusions and implications 
These results indicate that the ability of recAP to reduce renal inflammation may account for 
the beneficial effect observed in septic acute kidney injury patients, and that dephosphoryl-
ation of ATP and LPS are responsible for this protective effect.
Introduction
Acute kidney injury (AKI) in critically ill patients admitted to the intensive care unit is frequently 
observed and is associated with a high mortality rate and an increased risk of endstage renal 
disease amongst survivors.1,2 The most common cause of AKI in the critically ill is sepsis. Its 
pathophysiology is complex, and suggested to be mediated by both inflammation and alter-
ations in the renal microcirculation3, for which a specific treatment is currently unavailable. 
LPS, a part of the outer membrane of Gram-negative bacteria, plays a major role in the inflam-
matory cascade observed during sepsis. LPS induces both systemic and renal inflammation 
through signalling via its pattern recognition receptor Toll-like receptor 4 (TLR4), localized on 
immune cells and on proximal tubule epithelial cells (PTEC), resulting in epithelial inflamma-
tion, endothelial inflammation and hypoxia.4-6 Due to the complex pathophysiology of sepsis, 
which involves systemic and renal inflammation combined with renal hypoxia, to be effective 
a treatment should aim to target all or a combination of these processes (reviewed by Peters 
et al.7). Alkaline phosphatase (AP), a dephosphorylating enzyme, is a molecule that might exert 
such a dual mechanism of action. Bovine intestinal AP (IAP), originally developed as an anti-
sepsis treatment as it dephosphorylates, and thereby thought to detoxify LPS, appeared to 
be renal protective in a subpopulation of critically ill patients with sepsis-associated AKI.8,9 
Currently, human recombinant AP (recAP) has been developed and is now being tested in a 
large multicentre phase II clinical trial. However, importantly, the specific renal protective mech-
anism of action of AP is still unknown. Possibly, AP can detoxify LPS, which is composed of an 
oligosaccharide core component, a polysaccharide chain and the toxic lipid A part with two 
phosphate groups. Removal of one of these two phosphate groups by AP results in a non-toxic 
LPS molecule, which can still bind to TLR4 but then acts as an antagonist.10 Another potentially 
protective mechanism of AP is dephosphorylation of ATP, an endogenous signalling molecule 
released during cell stress, induced by for example inflammation and hypoxia. Excreted ATP 
attracts phagocytes and activates platelets and the NLRP3 inflammasome, further enhancing 
inflammation and tissue injury.11,12 Upon dephosphorylation, possibly by exogenous AP, ATP 
yields ADP, AMP and adenosine, of which the latter exerts renal protective and anti-inflamma-
tory effects via binding to one of the four adenosine receptors A1, A2A, A2B and A3.13 Poten-
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tially, AP enhances the conversion of ATP into adenosine, thereby increasing adenosine levels 
and exerting its anti-inflammatory and tissue-protective effects.13 This study was designed to 
investigate whether recAP provides protection during LPS-induced AKI in rats, in vivo, and to 
unravel the molecular mechanisms of action behind these effects in a unique human condi-
tionally immortalized PTEC model, ciPTEC.14 It is presumed that these molecular mechanisms 
are related to dephosphorylation of the harmful molecule(s) LPS and/or ATP.
Methods
Animals
Animal experiments were performed according to the National Animal Protection Law (Tier-
schutzgesetz 13.7.2013) and Animal Welfare Ordinance (TierSchVersV 13.8.2013), and the Euro-
pean Union Guidelines for the Care and the Use of Laboratory Animals (Directive 2010/63/EU). 
Protocols were approved by the institutional review board for animal experiments (13/145). 
Male specific-pathogen free Sprague–Dawley rats (RjHan:SD, n = 18), weighing 150–200 g, 
were purchased at Janvier (Le Genest-Saint-Isle, France). Animals were housed (three rats 
per cage) in a specific-pathogen-free facility in open cages with aspen chip bedding, on a 
12/12 h light/dark cycle at 20–24°C with a relative humidity of 50 ± 5%. Standard laboratory 
chow (Ssniff, type R/M; ssniff Spezialdiäten GmbH, Soest, Germany) and water were avail-
able ad libitum. All procedures used were as humane as possible. Studies involving animals 
were reported in accordance with the ARRIVE guidelines for reporting experiments involving 
animals.15,16 The drug and molecular target nomenclature confirms to IUPHAR/BPS Guide to 
Pharmacology17 and the Concise Guide to Pharmacology.18-21
Experimental protocol
Rats were randomly divided into three groups: placebo (n = 6), LPS (n = 6) or LPS + recAP (n = 
6). A baseline plasma sample (lithium-heparin blood) was collected 7 days preceding the exper-
iment through a tail vein puncture using a Multivette (Sarstedt, Etten-Leur, the Netherlands). 
Three days preceding the experiment, the baseline renal function was assed as FITC-sinistrin 
half-life (t1/2).
22 At t = 0 h, placebo (0.9% NaCl, saline) or 0.3 mg/kg body weight (BW) LPS (E. coli 
0127:B8; Sigma-Aldrich, Zwijndrecht, the Netherlands; dissolved in saline) was administered to 
rats, weighing 298 ± 5 g, as an i.v. bolus into the tail vein to induce LPS-induced renal failure. 
Dose–response experiments demonstrated this dose to be optimal to induce renal failure (not 
shown). At t = 1.5 h plasma was obtained as described earlier. At t = 2 h, rats received an i.v. bolus 
into the tail vein of placebo or recAP (1000 U/kg BW, diluted in saline; kind gift from AM-Pharma, 
Bunnik, the Netherlands) followed by a second measurement of renal function. Previous dose–
response experiments indicated this dose to be optimal to prevent AKI in several animal species 
(unpublished data). At t = 5 h, all animals received 5 mL saline (s.c.) to prevent dehydration, 
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followed by a 16 h urine collection period. At t = 21.5 h the third transcutaneous measurement 
was performed. At t = 24 h, rats were anaesthetized (i.p., 3 mg/kg BW xylazine and 80 mg/kg BW 
ketamine 10%), a retrobulbar lithium-heparin blood sample was withdrawn to obtain plasma, 
and whole body perfusion was started [6 min, saline + 50 IU/mL heparin, 210 mbar; 3 min, 4% 
paraformaldehyde (PFA; 210 mbar)], which killed the animals. After saline perfusion, the right 
kidney was carefully removed, snap frozen and stored at -80°C until processing. The left kidney, 
removed after PFA perfusion, was stored in 4% PFA at 4°C until processed for histology and 
immunohistochemistry. One animal from the LPS +recAP group and one urine sample from 
the placebo group were excluded because of injection and collection difficulties, respectively.
Renal function measurements
Renal function was assessed in freely moving awake rats through transcutaneously measured 
elimination kinetics of FITC-sinistrin (Fresenius Kabi, Linz, Austria), a commercially available 
marker of glomerular filtration rate (GFR), by using a novel measurement device as described 
previously.22,23 Briefly, rats were anaesthetized by isoflurane inhalation (5% induction, 1.5–2% 
maintenance; Abbott Laboratories, Illinois, USA) and shaved on the back. The optical part 
of the device was fixed on this depilated region using a specifically designed double-sided 
adhesive patch (Lohmann GmbH, Neuwied, Germany), whereas the electronic part of the 
device was incorporated into a rodent jacket (Lomir Biomedical, New York, USA). After the 
baseline signal had been established, FITC-sinistrin (5 mg/100 g BW, diluted in buffered saline) 
was injected in the tail vein. Thereafter, the animals were allowed to recover from anaes-
thesia, while the measurement continued for approximately 120 min post-injection. Half-life 
was calculated by a one-compartment model applied on the transcutaneously measured 
FITCsinistrin elimination kinetics.23 Parameters of renal function were determined in plasma 
and urine samples using the Cobas c311 chemistry analyser (Roche Diagnostics, Mannheim, 
Germany). Fractional urea excretion and endogenous creatinine clearance were calculated 
with average plasma values obtained at 1.5 and 24 h.
Histology and immunohistochemistry
After fixation for at least 24 h, tissue was processed, embedded in paraplast and sectioned 
at 3 μM thickness. For routine histology, periodic acid-Schiff (PAS) and haematoxylin and 
eosin (H&E) staining were performed on renal tissue. Renal injury was assessed using a 
scoring system with a scale from 0 to 4 (0 = no changes; 4 = severe damage, e.g. marked 
changes to the tubule cell). Kidney injury molecule (KIM)-1 was detected by primary anti-
body goat-anti-rat KIM-1 (1:50; AF3689, R&D Systems, Abingdon, UK) and secondary antibody 
rabbit-anti-goat IgG (1:200; P0449, DAKO, Heverlee, Belgium). Immunostaining was visualized 
with VECTASTAIN Eline ABC system reagents (Vector Labs, Amsterdam, the Netherlands) and 
3,3′-diaminobenzidine (Sigma-Aldrich, Zwijndrecht, the Netherlands), followed by H&E coun-
terstain. All scoring was performed in a blinded fashion.
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Tissue homogenization
Snap frozen kidneys were homogenized by the TissueLyser LT (Qiagen, Venlo, The Nether-
lands) according to manufacturer’s instructions, in Tissue Protein Extraction Reagent (Thermo 
Scientific, Illinois, USA), supplemented with complete EDTA-free protease inhibitor cocktail 
tablets (Roche Applied Science, Almere, the Netherlands). Total protein content was deter-
mined using the bicinchonicic acid protein assay kit (Thermo Scientific), and samples were 
stored at -80°C until assayed.
Urinary purine content
Adenosine, AMP, ADP, ATP and cAMP content was determined by HPLC. In brief, 4 volumes of 
urine were mixed with 1 volume of chloroacetaldehyde (6× diluted in 1 M acetate buffer, pH 
4.5; Sigma-Aldrich), followed by derivatization (60 min, 70°C, 20 g) and centrifugation (3 min, RT,
12045 g), whereafter the supernatant was transferred to a HPLC vial and injected. Purines were 
separated by HPLC system (Agilent Technologies) using a Polaris C18-A column (150 × 4.6 mm) 
with gradient elution using eluent A (0.1 M K2HPO4, 10 mM tetrabutylammonium bisulphate 
(TBAHS) (pH 6.5), and 2% MeOH) and eluent B (H2O: ACN: THF; 50:49:1). Retention times were 
7.1 (adenosine), 8.4 (AMP), 12.5 (ADP), 16.2 (ATP) and 14.8 min (cAMP). Quantification was based 
on peak areas of the samples and reference standards measured with fluorescence (excitation 
and emission wavelengths set at 280 and 420 nm, respectively). 
Cell culture
Routinely, ciPTEC were cultured at 33°C as described.14 Preceding an experiment, cells were 
seeded in a wells plate (48 400 cells/cm2), incubated for 1 day at 33°C followed by a 7-day 
maturation period at 37°C. On the day of the experiment, cells were pre-incubated for 2 h 
with recAP (1, 5 or 10 U/mL), also referred to as chimeric AP24, followed by incubation for 24 h 
with 10 μg/mL LPS (E. coli 0127:B8; Sigma-Aldrich; n = 5) dissolved in 10 mM HEPES HBSS, pH 7.4 
(HEPES: Roche Diagnostics; HBSS: Gibco, Life Technologies, Bleiswijk, the Netherlands). Alter-
natively, 10 U/mL recAP (17 μg/mL) was administered to LPS-incubated cells simultaneously or 
after 2 h. Control cells were incubated with culture medium solely. Detoxified LPS (dLPS; E. coli 
055:B5; Sigma-Aldrich, 10 μg/mL) and inactive recAP (17 μg/mL, kind gift from AM-Pharma) 
were used as negative controls. In different sets of experiments (n = 5), LPS was substituted for 
human TNF-α recombinant protein (Ebioscience, Vienna, Austria), or supernatant of periph-
eral blood mononuclear cells [PBMCs, prestimulated for 24 h with or without LPS (1 ng/mL)]. 
In addition, cells were pre-incubated for 45 min with TLR-4 receptor antagonist LPS from R. 
sphaeroides (LPS-RS; 5–500 μg/mL; Invivogen, Toulouse, France; n = 5), dissolved in culture 
medium, or with A2A receptor agonist CGS-21680 (0.001–10 μM; Sigma-Aldrich) or antago-
nist ZM-241385 (0.001–10 μM; Tocris, Abingdon, UK; n = 4), dissolved in DMSO (Sigma-Aldrich), 
followed by the administration of LPS (10 μg/mL) for 24 h. RecAP (10 U/mL) was added 90 min 
after ZM-241385 administration. All experiments were at least performed in duplicate.
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Isolation of peripheral blood mononuclear cells
PBMCs were isolated from buffy coats obtained from healthy blood donors (blood bank 
Nijmegen, n = 5) by differential centrifugation over Ficoll-Pague Plus (GE Healthcare, Diegem, 
Belgium). PBMCs were resuspended in RPMI-1640 medium (Gibco) enriched with 0.5 mg/mL 
gentamicin (Sigma-Aldrich), 1 mM pyruvate (Gibco) and 2 mM glutamax (Gibco). Cells were 
seeded in 96-well plates at a density of 0.5 × 106 cells per well, pre-incubated with or without 
AP (10 U/mL) for 2 h, followed by LPS incubation (1 ng/mL) for 24 h. All experiments (n = 5) 
were performed in duplicate.
Purine release and cell viability assay
Supernatant was collected 20 min after LPS administration, with or without recAP-pre-
treatment, followed by direct measurement of ATP production using the ATP Biolumines-
cence Assay Kit CLS II (Roche Diagnostics, Mannheim, Germany) according to manufacturer’s 
protocol, and measurement of total purine content, by HPLC as described earlier, in Krebs–
Henseleit buffer containing 10 mM HEPES (pH 7.4). Cell viability was assessed after 20 min and 
24 h of LPS incubation by performing the MTT assay, as described.25
Cytokines, AP and renal injury markers
Human ELISA kits (R&D Systems, Abingdon, UK) were used to determine TNF-α, IL-6 and IL-8 in 
supernatant according to manufacturer’s instructions. Plasma cytokine levels (IL-1β, IL-6, IL-10, 
TNF-α, INF-γ) were determined by a simultaneous Luminex assay according to the manufactur-
er’s instructions (Millipore, Cork, Ireland). KIM-1 and neutrophil gelatinase-associated lipocalin 
(NGAL) were determined by ELISA (R&D Systems) according to manufacturer’s instructions. AP 
activity levels (AP IFCC Gen.2; Roche Diagnostics, Mannheim, Germany) were determined in 
plasma using the Cobas c311 chemistry analyser (Roche Diagnostics, Mannheim, Germany).
Real-time PCR analyses
RNA was extracted from frozen cell pellet or pulverized kidneys (2000 rpm, 30 s; Mikro-dis-
membrator U, Sartorius Stedim Biotech, Aubagne Cedex, France) by Trizol reagent. RNA was 
reverse-transcribed into cDNA using Moloney Murine Leukemia Virus (M-MLV) Reverse Tran-
scriptase (Invitrogen, Breda, The Netherlands). Real-time quantitative PCR was performed 
using Taqman® (Applied Biosystems, California, USA). Genes were amplified and normalized 
to the expression of GAPDH (ciPTEC: Ct: 18.9 ± 0.1; renal tissue: Ct: 24.8 ± 0.2). Differences 
between groups were calculated by the comparative ΔΔCt method. Primers/probe sets are 
summarized in Supplemental Table 1.
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Table 1. Plasma and urinary parameters
PLACEBO LPS LPS + RECAP
Plasma parameters
     Creatinine (mg/dl) 0.20 [0.18-0.23] 0.25 [0.21-0.28] 0.20 [0.18-0.23]
     Urea (mg/dl)        28 [24-31] 49 [38-59]# 34 [32-41]
     Lactate (mg/dl) 10 [8-31] 14 [12-21] 12 [10-14]
     Glucose (mg/dl) 144 [131-159] 132 [107-151] 162 [154-169]
     Protein (mg/ml) 56 [54-57] 56 [52-57] 54 [54-58]
     Calcium (mmol/l) 2.8 [2.7-3.1] 2.7 [2.6-2.7] 2.7 [2.6-2.8]
     Inorganic Phosphorus (mmol/l) 2.91 [2.77-3.20] 3.06 [2.88-3.31] 2.90 [2.80-3.13]
     Sodium (mmol/l) 150 [148-157] 154 [147-155] 150 [141-154]
     Potassium (mmol/l) 4.25 [4.16-4.31] 4.33 [4.17-4.53] 4.28 [3.97-4.93]
Urinary parameters
     Creatinine (mg) 5.7 [4.7-5.8] 6.2 [5.3-6.6] 5.8 [5.1-6.2]
     Urea (mg)        272 [215-317] 489 [450-524]# 442 [402-476]
     Albumin (µg) 0 [0-54] 0 [0-663] 310 [0-419]
     Glucose (mg) 1.6 [1.0-2.1] 1.6 [1.1-2.3] 0.8 [0.5-1.6]
     Protein (µg) 37 [28-50] 71 [42-87]# 56 [41-83]
     Calcium (µmol) 3.4 [3.0-5.6] 6.3 [5.4-9.1] 5.9 [4.1-11]
     Inorganic Phosphorus (mmol) 0.50 [0.31-0.93] 0.63 [0.61-0.97] 0.64 [0.56-0.76]
     Sodium (mmol) 1.6 [1.3-2.0] 1.5 [1.3-1.7] 1.5 [1.4-2.4]
     Potassium (mmol) 1.3 [1.2-2.2] 2.0 [1.7-2.8] 1.9 [1.8-2.0]
 Plasma parameters were determined 24 hrs after LPS administration. Urinary parameters were determined 
between 5 and 21 hrs after LPS administration. Data is expressed as median [25th percentile, 75th percentile]. 
Significant differences estimated using Kruskal-Wallis test with Dunns post-test. Placebo, LPS n=6; LPS+recAP 
n=5; urinary parameters: Placebo n=5. # p<0.05 compared to placebo.  
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Statistical analysis
Normal distribution of the in vivo data could not be assumed because of the sample size, 
and therefore, data are expressed as median (25th percentile, 75th percentile). Normality of 
the in vitro data was assessed by Kolmogorov–Smirnov test and expressed as mean ± SEM 
or median (25th percentile, 75th percentile). Differences between groups were estimated by 
ANOVA with post hoc comparisons using Bonferroni’s multiple comparison test or by Kruskal–
Wallis test with Dunn’s post-test. A two-sided P-value less than 0.05 was considered statisti-
cally significant. All tests were performed with Graphpad Prism 5.00 for Windows (Graphpad 
Software Inc., California, USA).
Results
RecAP treatment during LPS-induced AKI in rats attenuates impaired 
renal function
To investigate the renal protective effects of recAP in detail in vivo, AKI was induced in rats by 
LPS, and renal function was assessed by measurement of the FITC-labelled sinistrin kinetics, 
as previously reported.22 FITC-sinistrin is cleared by the kidneys only through filtration, and 
its disappearance from the plasma compartment can be measured transcutaneously in real 
time.22,23 This allows the progression of AKI to be investigated in a more accurate manner as 
compared with the commonly used creatinine clearance.26 Preceding LPS injection, a base-
line blood sample was drawn to determine physiological parameters and plasma cytokines, 
and baseline FITC-sinistrin half-life (t1/2) was determined from the kinetics measured to ascer-
tain homogeneity between groups (data not shown). After 1.5 h, LPS treatment resulted in 
increased plasma cytokine levels, abnormalities in several plasma parameters (Supplemental 
Table 2), piloerection, diarrhoea and reduced spontaneous activity, confirming the presence 
of systemic inflammation. Two hours after LPS administration, rats were treated with recAP 
(1000 U/kg BW) or placebo (saline), directly followed by transcutaneous renal function meas-
urements. LPS prolonged FITC-sinistrin half-life, revealing a significant reduction in renal func-
tion. This trend was attenuated by recAP treatment (Figure 1A). In all groups, renal function 
fully recovered within 24 h (Figure 1B). Also, recAP treatment prevented the LPS-induced 
increase in plasma urea levels (Table 1) and fractional urea excretion (Figure 1C), whereas no 
differences were observed in endogenous creatinine clearance (Figure 1D). RecAP bio-activity 
was confirmed in plasma by an eightfold increase 22 h after injection [placebo: 286 (266–329) 
U/mL, LPS: 254 (243–285) U /mL, LPS + recAP: 2158 (2012–2274) U/mL; P < 0.001].
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Figure 1.
 RecAP prevents the LPS-induced deterioration of renal function in vivo. 
 Renal function was assessed by the transcutaneous measurement of FITC-sinistrin t1/2. AKI was induced in rats 
by LPS (0.3 mg/kg b.w., t=0 h), followed by recAP treatment (1000 U/kg b.w.) at t=2. T1/2 measurements were 
performed at t=2 hrs and t=21.5 hrs (A, B: examples of FITC-sinistrin kinetics obtained for one rat at the two 
respective time-points). Urine was collected between t=5 and t=16 hrs, and plasma was sampled at t=1.5 and 
t=24 hrs, allowing calculation of (C) Fractional Urea excretion and (D) Creatinine clearance with the average 
plasma value of t=1.5 and t=24 hrs. Data is expressed as median [25th percentile, 75th percentile] (Placebo, LPS 
n=6; LPS+recAP n=5), # p<0.05 compared to placebo.
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RecAP prevents renal injury during LPS-induced AKI in vivo
The renal protective effect of recAP on LPS-induced AKI was investigated further through 
evaluation of specific tubular injury markers and renal histology. LPS administration resulted 
in a significant increase in renal IL-6 expression levels, while other cytokines and injury 
markers (MPO; BAX, Bcl2-associated X protein; iNOS) were not affected (Table 2). RecAP could 
not reduce renal IL-6 expression levels, but did enhance renal expression of the anti-inflam-
matory cytokine IL-10 (Table 2). Furthermore, LPS administration resulted in a significant 
increase in the urinary excretion of KIM-1, which was accompanied by increased renal gene 
expression levels. This effect was prevented by recAP co-administration (Figure 2A, Table 2). 
Similar effects of recAP were observed for renal protein levels of KIM-1 (Figure 2B), which was 
localized primarily to the apical surface of the proximal tubules (Figure 2C). RecAP treatment 
had no effect on the urinary excretion and renal protein levels of NGAL, but could prevent the 
LPS-induced increase in renal NGAL expression (Figure 2D–E, Table 2). Despite these differ-
ences in renal injury, no differences in histology were found between the treatment groups. 
Changes observed ranged from no damage (graded 0) to minimal degenerative changes, 
like foamy appearance and minimal swelling of proximal tubular cells (graded 1) and foamy 
appearance and moderate swelling as well as a few cases of apoptosis (graded 2) [placebo: 1 
(0.75–2), LPS: 1.5 (0–2), LPS + recAP: 1 (0–1.0); Figure 2F]. 
LPS-induced AKI in vivo leads to reduced urinary adenosine excretion 
To elucidate the renal protective mechanism of recAP, we investigated the role of the aden-
osine, which has previously been demonstrated to exert anti-inflammatory and tissueprotec-
tive effects in the kidney through binding to one of the adenosine receptors A1, A2A and A2B, 
whereas binding to the A3 receptor has antiprotective effects.13,27 LPS treatment tended to 
reduce the gene expression levels in the kidney for all four adenosine receptors, of which only 
the A3 receptor reached statistical significance (Table 2). Interestingly, LPS administration signif-
icantly decreased the urinary excretion of adenosine [placebo: 77 (50–82) pg adenosine/10 μg 
creatinine, LPS: 17 (6–33) pg adenosine/10 μg creatinine; P < 0.01], without affecting the excretion 
of cAMP, ATP, ADP and AMP (data not shown). This may suggest translocation of adenosine to 
the proximal tubule cells where it is taken up by equilibrative nucleoside transporter-1, thereby 
restoring intracellular ATP levels.28,29 RecAP treatment had no effect on adenosine receptor gene 
expression (Table 2), or on urinary adenosine excretion [LPS + recAP: 11 (5–32) pg adenosine/10 
μg creatinine; P < 0.01 compared with placebo] compared with LPS alone.
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Figure 2.
 RecAP prevents renal injury during LPS-induced AKI in vivo. 
 Urinary excretion and renal protein content of KIM-1 (A-B) and NGAL (D-E) were determined by ELISA. Paraffin 
kidney sections were stained with (C) anti-KIM-1 to visualize KIM-1 protein expression or (F) with PAS. Scale bars 
(E) 40 µm (left panel), 20 µm (right panel), (F) 40 µm. Arrows present cell swelling/foamy appearance, asterisks 
present debris. Data is expressed as median [25th percentile, 75th percentile] (Placebo, LPS n=6; LPS+recAP n=5; 
urinary parameters: Placebo n=5), # p<0.05 compared to placebo. 
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Table 2. Renal gene expression levels     
CT VALUES FOLD INCREASE (2^ΔΔCT)
Placebo LPS LPS + recAP Placebo LPS LPS + recAP
Cytokines
     IL-1β 27.5 [26.8-28.9] 26.5 [26.1-27.2] 27.1 [26.2-27.6] 1.2 [0.5-1.8] 1.3 [0.7-2.6] 1.5 [0.9-2.6]
     IL-6 37.4 [36.3-38.0] 33.5 [33.3-34.8] 34.7 [34.4-36.4] 1.0 [0.7-1.6] 4.7 [3.8-6.3]# 4.1 [2.9-8.1]#
     IL-10 34.9 [34.0-35.7] 32.5 [32.1-32.7] 32.8 [32.3-33.4] 1.0 [0.6-1.8] 2.9 [1.4-4.6] 4.7 [3.0-8.5]#
     TNF-α 36.6 [36.2-37.3] 35.5 [35.2-36.3] 37.0 [36.4-38.1] 1.1 [0.8-1.5] 1.1 [0.8-1.2] 0.9 [0.6-1.5]
     INF-γ 36.2 [35.7-37.1] 35.3 [34.7-36.3] 35.4 [35.2-36.1] 1.1 [0.6-1.6] 1.2 [0.7-2.0] 1.6 [1.1-2.2]
Injury markers
     KIM-1 31.7 [30.9-32.5] 22.5 [21.4-24.5] 24.6 [24.4-26.5] 0.8 [0.6-1.9] 430 [195-530]# 113 [43-336]
     NGAL        29.0 [28.5-29.6] 22.8 [22.1-25.9] 23.8 [23.3-28.6] 1.2 [0.4-1.9] 41 [9-53]# 28 [12-44]
     MPO 32.2 [32.8-33.3] 31.1 [30.0-32.7] 32.7 [30.9-35.1] 1.0 [0.4-2.9] 1.4 [0.4-3.9] 0.6 [0.3-3.2]
     BAX 25.0 [24.7-25.7] 24.8 [24.5-25.2] 25.1 [24.4-25.9] 0.9 [0.7-1.5] 0.7 [0.3-2.1] 1.0 [0.5-1.3]
     iNOS 36.0 [35.4-36.9] 35.0 [34.7-35.4] 35.4 [33.1-36.2] 0.9 [0.7-1.6] 1.5 [0.5-3.2] 1.8 [1.3-4.3]
Adenosine receptors
     A1 28.6 [28.1-29.2] 27.9 [27.3-28.6] 29.1 [28.2-30.4] 1.3 [0.4-2.3] 0.7 [0.5-1.4] 0.8 [0.3-1.5]
     A2A 27.1 [26.7-27.2] 26.3 [26.0-27.0] 27.4 [26.7-27.9] 1.2 [0.5-1.9] 0.6 [0.5-1.1] 0.8 [0.6-1.2]
     A2B 29.0 [28.9-29.3] 28.4 [28.1-29.0] 29.0 [28.9-30.2] 1.1 [0.6-1.7] 0.7 [0.5-1.2] 0.8 [0.7-1.0]
     A3 34.3 [33.5-34.9] 34.3 [33.2-35.0] 35.0 [33.8-36.1] 1.0 [0.9-1.2] 0.5 [0.4-0.7]# 0.6 [0.4-1.0]
 Data is expressed as median [25th percentile, 75th percentile]. Significant differences estimated using Kruskal-Wallis 
test with Dunns post-test. Placebo, LPS n=6; LPS+recAP n=5. # p<0.05 compared to placebo. 
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Table 2. Renal gene expression levels     
CT VALUES FOLD INCREASE (2^ΔΔCT)
Placebo LPS LPS + recAP Placebo LPS LPS + recAP
Cytokines
     IL-1β 27.5 [26.8-28.9] 26.5 [26.1-27.2] 27.1 [26.2-27.6] 1.2 [0.5-1.8] 1.3 [0.7-2.6] 1.5 [0.9-2.6]
     IL-6 37.4 [36.3-38.0] 33.5 [33.3-34.8] 34.7 [34.4-36.4] 1.0 [0.7-1.6] 4.7 [3.8-6.3]# 4.1 [2.9-8.1]#
     IL-10 34.9 [34.0-35.7] 32.5 [32.1-32.7] 32.8 [32.3-33.4] 1.0 [0.6-1.8] 2.9 [1.4-4.6] 4.7 [3.0-8.5]#
     TNF-α 36.6 [36.2-37.3] 35.5 [35.2-36.3] 37.0 [36.4-38.1] 1.1 [0.8-1.5] 1.1 [0.8-1.2] 0.9 [0.6-1.5]
     INF-γ 36.2 [35.7-37.1] 35.3 [34.7-36.3] 35.4 [35.2-36.1] 1.1 [0.6-1.6] 1.2 [0.7-2.0] 1.6 [1.1-2.2]
Injury markers
     KIM-1 31.7 [30.9-32.5] 22.5 [21.4-24.5] 24.6 [24.4-26.5] 0.8 [0.6-1.9] 430 [195-530]# 113 [43-336]
     NGAL        29.0 [28.5-29.6] 22.8 [22.1-25.9] 23.8 [23.3-28.6] 1.2 [0.4-1.9] 41 [9-53]# 28 [12-44]
     MPO 32.2 [32.8-33.3] 31.1 [30.0-32.7] 32.7 [30.9-35.1] 1.0 [0.4-2.9] 1.4 [0.4-3.9] 0.6 [0.3-3.2]
     BAX 25.0 [24.7-25.7] 24.8 [24.5-25.2] 25.1 [24.4-25.9] 0.9 [0.7-1.5] 0.7 [0.3-2.1] 1.0 [0.5-1.3]
     iNOS 36.0 [35.4-36.9] 35.0 [34.7-35.4] 35.4 [33.1-36.2] 0.9 [0.7-1.6] 1.5 [0.5-3.2] 1.8 [1.3-4.3]
Adenosine receptors
     A1 28.6 [28.1-29.2] 27.9 [27.3-28.6] 29.1 [28.2-30.4] 1.3 [0.4-2.3] 0.7 [0.5-1.4] 0.8 [0.3-1.5]
     A2A 27.1 [26.7-27.2] 26.3 [26.0-27.0] 27.4 [26.7-27.9] 1.2 [0.5-1.9] 0.6 [0.5-1.1] 0.8 [0.6-1.2]
     A2B 29.0 [28.9-29.3] 28.4 [28.1-29.0] 29.0 [28.9-30.2] 1.1 [0.6-1.7] 0.7 [0.5-1.2] 0.8 [0.7-1.0]
     A3 34.3 [33.5-34.9] 34.3 [33.2-35.0] 35.0 [33.8-36.1] 1.0 [0.9-1.2] 0.5 [0.4-0.7]# 0.6 [0.4-1.0]
 Data is expressed as median [25th percentile, 75th percentile]. Significant differences estimated using Kruskal-Wallis 
test with Dunns post-test. Placebo, LPS n=6; LPS+recAP n=5. # p<0.05 compared to placebo. 
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Figure 3. 
 RecAP treatment attenuates the LPS-induced cytokine production in human proximal tubule epithe-
lial cells (ciPTEC). 
 CiPTEC were pre-treated with recAP (1-5-10 U/ml) followed by LPS-incubation (10 µg/ml) for 24 hrs and subse-
quently TNF-α, IL-6 and IL-8 production was measured (A) on gene level in cells by qPCR (10 U/ml recAP) and 
(B) on protein level in supernatant by ELISA. (C) recAP (10 U/ml) was administered 2 hrs preceding LPS exposure, 
simultaneously with LPS or 2 hrs after LPS exposure, followed by measurement of TNF-α, IL-6 and IL-8 protein 
content. (D) ciPTEC were pre-treated with inactive AP for 2 hrs, lacking hydrolyzing properties, followed by LPS 
incubation (10 µg/ml) for 24 hrs, whereafter TNF-α, IL-6 and IL-8 protein content was measured. Control cells were 
incubated with culture media. Data is expressed as mean±SEM (n=5), # p<0.05 compared to control, * p<0.05 
compared to LPS.
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RecAP attenuates the LPS-induced inflammatory response in vitro
After establishing the renal protective of recAP during LPS-induced AKI in vivo, we aimed to 
unravel the molecular mechanism behind these effects in ciPTEC. Pre-treatment of ciPTEC14 
with recAP attenuated the LPS-induced cytokine production of TNF-α, IL-6 and IL-8 at the 
gene and protein level (Figure 3A-B). Doses above 10 U/mL recAP did not provide additional 
protection (not shown). DLPS was used as a negative control and had no effect. Similar protec-
tive results at the protein level were obtained when recAP was administered simultaneously 
with LPS or 2 h after LPS exposure (Figure 3C). A control experiment was performed to verify 
whether recAP dephosphorylates the cytokines excreted in the medium, which was not the 
case (not shown). To confirm that the recAP-induced reduction in cytokine production was 
due to the dephosphorylating nature of the enzyme, the effect of inactive recAP that lacks 
hydrolyzing properties was investigated. Inactive recAP did not attenuate the LPS-induced 
inflammatory response in ciPTEC (Figure 3D). 
The in vitro effects of recAP may be renal specific and not restricted 
to LPS-induced  inflammation
The renal protective mechanism of recAP was investigated further by incubating ciPTEC 
with the pro-inflammatory cytokine TNF-α, which cannot be dephosphorylated by calf 
IAP.30 The TNF-α induced cytokine production of IL-6 and IL-8 was also attenuated by recAP 
pretreatment, whereas inactive recAP had no effect (Figure 4A). In the pathogenesis of 
sepsis-associated AKI, LPS induces a local inflammatory response through binding to TLR4 
expressed on PTEC (ciPTEC Ct: 30.5 ± 3.9; n = 5; Supplemental Figure 1).6 Another hallmark 
of the disease is the systemic inflammatory response, which affects both renal epithelial 
and endothelial cells causing the development of AKI.7 To mimic this endotoxin-induced 
renal inflammation, ciPTECs were incubated with the supernatant of LPS-stimulated PBMCs 
(1 ng/mL LPS). This induced the production of IL-6 and IL-8, which was decreased when 
ciPTECs were pretreated with recAP (Figure 4B, TNF-α was not detectable). To exclude this 
cytokine production to be caused by LPS present in the cytokine mix itself, ciPTECs were 
directly incubated with the 10 000-fold lower LPS dose (1 ng/mL), which had no effect on 
the cytokine production (Figure 4B). Together with the finding that inflammatory responses 
mediated by TNF-α were attenuated by recAP treatment, this suggests the presence of 
another mediator targeted by recAP. In contrast, pretreatment of PBMCs with recAP did not 
affect the LPS-induced inflammatory response in these cells (Figure 4C), which suggests 
that the effects of recAP might be kidney specific.
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Figure 4.
 The effects of recAP are not restricted to LPS-induced inflammation and can be renal specific.
 CiPTEC were pre-treated with recAP (10 U/ml) for 2 hrs followed by a 24-hour incubation with (A) TNF-α (10 ng/ml) 
or (B) supernatant of LPS-stimulated peripheral blood mononuclear cells (PBMCs, 1 ng/ml LPS) or directly with 
1 ng/ml LPS, whereafter IL-6 and IL-8 production was measured on protein level by ELISA. (C) PBMCs were prein-
cubated for 2 hrs with recAP (10 U/ml) followed by LPS exposure (1 ng/ml) for 24 hrs. IL-6 and TNF-α production 
was measured by ELISA. Control cells were incubated with culture media. Data is expressed as mean±SEM (n=5), 
# p<0.05 compared to control, * p<0.05 compared to corresponding stimuli without recAP. 
Figure 5. 
 The effect of recAP on LPS-induced ATP and ADP release in vitro. 
 CiPTEC were pre-treated with recAP (10 U/ml) followed by LPS-incubation (100 µg/ml) in Krebs-Henseleit buffer 
containing 10 mM HEPES (pH 7.4). After 20 min, supernatant was collected to determine the purine content by 
HPLC. Control cells were incubated with buffer. Data is expressed as mean±SEM (n=5), # p<0.05 compared to 
control, * p<0.05 compared to LPS.
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RecAP exerts renal protective effects in vitro through ATP/ADP removal
A second potential target of recAP is ATP, released during cell stress caused by, for example, 
inflammation and hypoxia.12 Extracellular ATP has detrimental effects, but can be converted 
by ectonucleotidases (amongst which AP) into AMP and eventually into adenosine. Interest-
ingly, we observed increased extracellular ATP concentrations following LPS incubation, which 
was more pronounced with a higher LPS concentration but reversed by recAP pre-incubation. 
The increase relative to control after a dose of 10 μg/mL LPS was 127 ± 21%, and after co-ad-
ministration of recAP 72% ± 13% (P < 0.05). After a dose of 100 μg/mL LPS, this increased even 
further to 320 ± 36%, which was attenuated by co-treatment with recAP to 94 ± 21% (P < 0.001). 
Subsequently, ATP and ADP are directly converted into AMP and adenosine by recAP (Figure 
5). LPS did not affect cell viability after 24 h of exposure (not shown). Furthermore, while the A1, 
A2B and A3 receptor expression levels in ciPTEC were not affected by LPS incubation (Table 3), 
the A2A receptor expression was up-regulated upon LPS treatment and, subsequently, atten-
uated by recAP co-treatment (Table 3). Inhibition of this receptor by the A2A receptor antago-
nist ZM-241385 could not prevent the recAP-mediated protection, whereas A2A receptor stim-
ulation by the agonist CGS-21680 had no effect on the LPS-induced inflammatory response 
(Supplemental Figure 2). This suggests that recAP exerts its renal protective effect primarily 
through removal of ATP and ADP rather than enhanced A2A receptor signalling (Figure 6). 
Figure 6.
 Proposed renal protective mechanism of recAP.
 Lipopolysaccharide (LPS) binds to Toll-like receptor 4 (TLR4), expressed on the apical membrane of proximal 
tubule epithelial cells, provoking an inflammatory response, resulting in the release of pro-inflammatory cyto-
kines and adenosine di- and triphosphate (APD/ATP). Both purines signal through purinergic P2 receptors (P2R), 
further enhancing the pro-inflammatory cascade. RecAP can dephosphorylate and detoxify LPS by removing 
one phosphate group, resulting in an LPS molecule which still binds to TLR4 but cannot activate the inflam-
matory cascade. Also, recAP can dephosphorylate ATP and APD into adenosine, which may bind to adenosine 
receptors resulting in tissue-protective and anti-inflammatory effects.
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Discussion and conclusions
In this study, a direct protective effect of recAP during LPS-induced renal inflammation was 
demonstrated in vivo and in vitro. First, the renal protective effect of recAP was confirmed in 
rats, which were protected from LPS-induced renal damage by recAP. These findings corrob-
orate the results of two phase-II clinical trials, which demonstrated that bovine IAP treatment 
resulted in a swifter recovery of renal function and less urinary excretion of markers of tubular 
injury in patients with sepsis-associated AKI.8,9 Second, recAP provided protection during the 
LPS-induced cytokine response in ciPTEC. Our results suggest that these effects can be attrib-
uted to the dephosphorylating nature of recAP, as enzymatically inactive recAP had no effect. 
In our rat model, renal dysfunction after LPS administration was proven by increased FITC-sin-
istrin half-life, that is, decreased GFR, as well as increased fractional urea excretion. These 
effects were counteracted by recAP treatment. Half-life was determined reliably by transcuta-
neous measurement, allowing renal function to be determined in freely moving, awake, 
animals sequentially, and is therefore superior to currently used methods like creatinine clear-
ance.22,23,26 In the complex pathogenesis of sepsis-associated AKI, the interaction between LPS 
and TLR4, specifically present on PTEC, induces a local inflammatory response within the 
kidney, which leads the development of AKI.31 To investigate if recAP can affect this pathway, 
we mimicked LPS-induced renal inflammation in our human ciPTEC model and could demon-
strate a recAP-mediated decrease in the LPS-induced cytokine production of TNF-α, IL-6 and 
Table 3. Adenosine receptor gene expression levels in ciPTEC
CT VALUES FOLD INCREASE (2^-ΔΔCT)
Control LPS recAP recAP
+ LPS
Control LPS recAP recAP
+ LPS
A1 28.9
[28.4-30.6]
29.5 
[29.3-30.1]
28.9 
[28.1-29.8]
29.6 
[28.9-29.9]
1±0 0.6±0.1 1.2±0.2 0.7±0.1
A2A 31.5 
[30.6-33.0]
29.2 
[29.0-30.4]
32.1 
[31.4-32.8]
30.1 
[29.4-30.3]
1±0 4.1±0.4# 0.8±0.1 2.9±0.2#*
A2B 27.9 
[27.1-29.3]
27.9 
[27.7-28.8]
28.2 
[27.6-29.2]
28.6 
[27.7-28.7]
1±0 0.8±0.1 0.8±0.1 0.7±0.1
A3 36.3 
[35.9-36.8]
35.9 
[35.4-36.7]
36.9 
[36.3-37.8]
36.8 
[35.7-38.1]
1±0 0.6±0.2 1.3±0.4 0.6±0.1
 Data is expressed as mean±SEM, and median [25th percentile, 75th percentile], depending on the distribution of 
each parameter. Significant differences of the fold increase was estimated using one-way ANOVA with Bonfer-
roni post-test. n=5. # p<0.05 compared to control. * p<0.05 compared to LPS. 
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IL8. These effects were not restricted to solely LPS-induced inflammation, because recAP 
attenuated the TNF-α-induced cytokine response as well. According to earlier findings, calf 
IAP incubation with TNF-α does not result in free phosphate release30, suggesting the pres-
ence of another target molecule of recAP in addition to TNF-α. Intracellular ATP is a vital 
source of energy essential for several functions, including membrane transport. ATP levels 
within the cell are tightly regulated and transport to the extracellular compartment is low, but 
may occur through, for example, ion channels, exocytosis and gap junction hemichannels.32 
Under pathophysiological conditions, induced by, for example, inflammation or hypoxia, 
extracellular ATP release is enhanced and binding to the purine P2X and P2Y receptors can 
accelerate inflammation and tissue injury through NLRP3 inflammasome activation and the 
attraction of phagocytes and inflammatory cells.12 Also, ATP-P2 receptor signalling is 
suggested to have an important role during the development and progression of several 
kidney diseases, including diabetic nephropathy, glomerulonephritis, kidney allograft rejec-
tion and polycystic kidney disease.32 As inflammation is of major importance in the pathogen-
esis of these nephropathies and LPS can enhance ATP release, as demonstrated in 
macrophages33, dephosphorylation of ATP in addition to LPS may potentially be an effective 
therapeutic approach. The capacity of recAP to dephosphorylate both molecules was 
demonstrated previously in vitro.24 Here, we provide additional evidence in a human renal cell 
line in which recAP pretreatment rapidly converted the LPS-induced cellular release of not 
only ATP but also ADP, into the cytoprotective adenosine within 20 min after LPS stimulation. 
ADP is known to be released during cellular distress and enhances inflammation through 
platelet activation via P2 receptor signalling.12 The recAP-mediated dephosphorylation of ATP 
and ADP most likely also explains the reduction of IL-6 and IL-8 when only recAP was admin-
istered. As ATP release upon LPS incubation peaks within 20 min, and recAP stills provides 
protection when administered 2 h after LPS administration, we believe that dephosphoryla-
tion of both compounds contributes to the cytoprotective effect of the enzyme. This is 
supported by the finding that LPS, but not monophosphorylated lipid A, is a substrate for 
human placental AP.10 As recAP was developed by replacing the crown domain of a human 
intestinal AP with the crown domain of human placental AP, recAP most likely also discrimi-
nates between di- and monophosphorylated lipid A.24 Adenosine, derived from ATP and ADP 
hydrolysis, exerts renal protective and anti-inflammatory effects through binding to the A1, 
A2A, A2B and A3 receptors.34 In ciPTEC, LPS-treatment increased the expression levels of the 
A2A receptor, which was attenuated by recAP co-treatment. The finding that inhibition of this 
receptor could not prevent the recAP-mediated protection, whereas A2A receptor stimula-
tion had no effect on the LPS-induced inflammatory response, suggests that recAP exert its 
renal protective effect primarily through removal of ATP and ADP rather than enhanced aden-
osine formation. Probably, the reduction in A2A receptor expression levels by recAP co-treat-
ment is a reflection of the attenuated inflammatory response.12 In contrast to the in vitro data, 
LPS tended to reduce the expression of all four adenosine receptors in vivo. This finding could 
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be explained by the differences in the distribution of adenosine receptors within the kidney. 
In vitro, we were able to determine the effects of LPS on PTEC solely; whereas in vivo, the 
complete organ was evaluated, with adenosine receptors present on glomeruli, arterioles and 
various parts of the tubular and collecting duct system.35 This, together with inter-species 
differences and a different experimental set-up, does not allow a direct translation of these 
results. During systemic inflammation, circulating levels of endogenous AP are depleted10, 
whereas renal injury results in decreased AP enzyme activity levels on the brush-border 
membranes in the kidney.36 RecAP treatment could not prevent LPS-induced cytokine release 
by human peripheral blood mononucleated cells, while recAP did show protective effects in 
the ciPTEC, which may suggest that the beneficial effects of recAP treatment could be limited 
to the kidney. This is in contrast to earlier findings, which showed that the systemic effects of 
bovine IAP weremediated by reducing circulating levels of C-reactive protein, IL-6 and 
LPS-binding protein in patients with sepsis-associated AKI.9 However, our results support the 
finding that bovine IAP could not prevent or cure sepsis itself.8 RecAP treatment could prevent 
the LPS-induced increases in urinary KIM-1 excretion and renal protein and gene expression 
levels. These results are in accordance with the results of the phase-II trials, showing that 
bovine IAP treatment reduced the urinary excretion of proximal tubule injury markers KIM-1 
and glutathione S-transferase (GST)-A1. During AKI, KIM-1 is readily upregulated, and the 
protein is transferred to the proximal tubule apical membrane.37 In contrast, recAP treatment 
could not prevent the LPS-induced urinary NGAL excretion and renal protein levels in rats but 
did prevent the increase in renal gene expression levels. NGAL production by both proximal 
and distal tubules is significantly increased by ischaemic, septic or nephrotoxic injury, resulting 
in enhanced secretion of the marker into plasma and urine.38 As NGAL is derived from multiple 
segments of the tubule, and can be released systemically from other organs as well, it appears 
plausible that the protective effects of recAP are less pronounced compared with KIM-1. In 
addition, in humans, the excretion of the distal tubule injury marker GST-P1 was not attenu-
ated by bovine IAP. Together, these findings suggest that the protective effects specifically 
take place in the proximal segment. In vivo, LPS injection results in systemic inflammation, but 
does not completely reflect human sepsis as it only mimics a Gram-negative bacterial part. 
Thereby, our model presented as relatively mild AKI, with a full recovery of GFR within 24 h for 
all groups. Whether the protective effects of recAP can be observed in a more severe form of 
septic AKI is currently being investigated in a large multicentre phase II clinical trial (Clinical 
Trial Register number: NCT02182440). In summary, we are the first to show that recAP’s mech-
anism of action in the pathogenesis of sepsis-associated AKI encompasses a dual mode of 
action and that recAP is a suitable replacement for bovine IAP. LPS triggers the inflammatory 
cascade by binding to TLR4 on the apical membrane of PTEC, resulting in the release of 
several inflammatory mediators, including ATP and ADP, which further enhance the proin-
flammatory cascade through purine P2 receptor signalling. RecAP dephosphorylates ATP and 
ADP into adenosine, thereby providing protective effects by attenuating P2 receptor activa-
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tion. In addition, recAP possibly dephosphorylates, and thereby detoxifies, LPS, preventing 
activation of TLR4. These results explain the observed attenuated AKI in sepsis patients, 
supporting the notion that recAP is a promising treatment for these patients. Our observation 
that the renal protective effects of recAP were not restricted to LPS-induced inflammation 
may pave the way for investigating beneficial effects of recAP treatment for other inflamma-
tory-based nephropathies.
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Supplemental Figures
Supplemental Figure 1. 
 LPS-induced cytokine release through TLR4 binding. 
 Cells were incubated with increasing doses of TLR4 receptor antagonist LPS from R. sphaeroides (LPS-RS; 5, 50 
and 500 µg/ml) followed by the administration of LPS (10 μg/ml) after 45 minutes. IL-6 production was measured 
on protein level by ELISA 24 hrs post LPS treatment. Control cells were incubated with culture media. Data is 
expressed as mean±SEM (n=5), # p<0.05 compared to control, * p<0.05 compared to LPS.
Supplemental Figure 2.
 Protective effect of recAP in vitro most likely not mediated through adenosine receptor A2A signaling. 
 Cells were incubated with adenosine receptor A2A agonist CGS-21680 (0.001-10 μM; left panel) or antagonist 
ZM-241385 (0.001-10 μM; right panel) followed by the administration of LPS (10 μg/ml) after 45 minutes, and 
recAP (10 U/ml) after another 45 minutes. IL-6 production was measured on protein level by ELISA 24 hrs post 
LPS treatment. Control cells were incubated with culture media. Data is expressed as mean±SEM (n=4), # p<0.05 
compared to control, * p<0.05 compared to LPS.
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Supplemental Tables
 
Supplemental Table 1.  Primer/probe specifications
GENE SYMBOL GENE NAME ASSAY ID
ciPTEC
     GAPDH glyceraldehyde-3-phosphate dehydrogenase Hs02758991_g1
     TNF-α tumor necrosis factor Hs01113624_g1
     IL-6 interleukin 6 Hs00985639_m1
     IL-8 interleukin 8 Hs00174103_m1
     TLR4 toll-like receptor 4 Hs00152939_m1
     ADORA1 adenosine A1 receptor Hs00379752_m1
     ADORA2A adenosine A2a receptor Hs00169123_m1
     ADORA2B adenosine A2b receptor Hs00386497_m1
     ADORA3 adenosine A3 receptor Hs01560269_m1
Rat kidney
     GAPDH glyceraldehyde-3-phosphate dehydrogenase Rn01775763_g1
     IL-1β interleukin 1 beta Rn00580432_m1
     IL-6 interleukin 6 Rn01410330_m1
     IL-10 interleukin 10 Rn00563409_m1
     TNF-α tumor necrosis factor Rn99999017_m1
     IFN-γ interferon gamma Rn00594078_m1
     HAVCR1 hepatitis A virus cellular receptor 1 Rn00597703_m1
     LCN2 lipocalin 2 Rn00590612_m1
     MPO myeloperoxidase Rn01460204_m1
     BAX Bcl2-associated X protein Rn02532082_g1
     NOS2 nitric oxide synthase 2, inducible Rn00561646_m1
     ADORA1 adenosine A1 receptor Rn00567668_m1
     ADORA2A adenosine A2a receptor Rn00583935_m1
     ADORA2B adenosine A2b receptor Rn00567697_m1
     ADORA3 adenosine A3 receptor Rn00563680_m1
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Supplemental Table 2. Plasma cytokines and experimental parameters
PLACEBO LPS LPS + RECAP
Cytokines 
     IL-1β (pg/ml) 0 [0-13] 6233 [4444-9816]# 4673 [3369-8704]#
     IL-6 (pg/ml) ND 72276 [56592-91346]# 61948 [42326-102317]#
     IL-10 (pg/ml) 0 [0-26] 8797 [5864-14456]# 6358 [4923-13631]#
     TNF-α (pg/ml) 0 [0-2] 19003 [14743-26602]# 10984 [8614-12180]  
     INF-γ (pg/ml) ND ND ND
Plasma parameters
     Creatinine (mg/dl) 0.18 [0.13-0.19] 0.35 [0.16-0.40] 0.28 [0.16-0.33]
     Urea (mg/dl)        27 [26-33] 40 [36-42] 48 [42-54]# 
     Lactate (mg/dl) 23 [15-32] 35 [28-38] 36 [27-37]
     Glucose (mg/dl) 146 [134-150] 280 [195-301]# 225 [188-240]
     Protein (mg/ml) 58 [56-58] 58 [48-61] 56 [56-58]
     Calcium (mmol/l) 2.59 [2.51-2.66] 2.41 [2.37-2.48] 2.40 [2.31-2.52]#
     Inorganic Phosphorus (mmol/l) 3.06 [2.80-3.18] 2.76 [2.66-2.90] 2.68 [2.67-3.01]
     Sodium (mmol/l) 149 [145-153] 149 [145-151] 148 [139-152]
     Potassium (mmol/l) 5.89 [5.66-6.21] 4.87 [4.66-5.23]# 5.08 [4.76-5.18]#
 Plasma parameters were determined 1.5 hrs after LPS administration. Data is expressed as median [25th percen-
tile, 75th percentile]. Significant differences estimated using Kruskal-Wallis test with Dunns post-test. Placebo, 
LPS n=6; LPS+recAP n=5. # p<0.05 compared to placebo. LPS, Lipopolysaccharide; recAP, recombinant Alkaline 
Phosphatase; ND: not detected. 
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Abstract
S  epsis-associated acute kidney injury is a multifactorial syndrome in which inflamma-tion and renal microcirculatory dysfunction play a profound role. Subsequently, renal tubule mitochondria reprioritize cellular functions to prevent further damage. 
Here, we investigated the putative protective effects of human recombinant alkaline phos-
phatase (recAP) during inhibition of mitochondrial respiration in conditionally immortal-
ized human proximal tubule epithelial cells (ciPTEC). Full inhibition of mitochondrial oxygen 
consumption was obtained after 24 h antimycin A treatment, which did not affect cell 
viability. While recAP did not affect the antimycin A-induced decreased oxygen consump-
tion and increased hypoxia-inducible factor-1α or adrenomedullin gene expression levels, the 
antimycin A-induced increase of pro-inflammatory cytokines IL-6 and IL-8 was attenuated. 
Antimycin A tended to induce the release of detrimental purines ATP and ADP, which reached 
statistical significance when antimycin A was co-incubated with lipopolysaccharide, and 
were completely converted into cytoprotective adenosine by recAP. As the adenosine A2A 
receptor was up-regulated after antimycin A exposure, an adenosine A2A receptor knockout 
ciPTEC cell line was generated in which recAP still provided protection. Together, recAP did 
not affect oxygen consumption but attenuated the inflammatory response during impaired 
mitochondrial function, an effect suggested to be mediated by dephosphorylating ATP and 
ADP into adenosine.
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Introduction
Acute kidney injury (AKI) is a serious complication in critically ill patients that is independently 
associated with poorer outcomes. Consequently, AKI results in a tremendous burden for both 
patient and society.1 In patients in the Intensive Care Unit (ICU), the incidence of AKI is 55-60% 
with an associated mortality of approximately 30%.2 AKI may develop following cardiovascular 
surgery, administration of nephrotoxic drugs, trauma, and sepsis, with the latter representing the 
most prevalent cause.3 Sepsis-associated AKI increases mortality up to 70% and survivors have a 
higher risk to develop end-stage renal disease.4,5 Despite the conduct of numerous clinical trials6, 
pharmacological therapeutic options are still unavailable and treatment is limited to supportive 
measures like renal replacement therapy.  Sepsis-associated AKI is a complex interplay of inflam-
mation, microvascular dysfunction, and unbalanced renal bioenergetics.7 Sepsis is accompa-
nied by the systemic release of inflammatory mediators, endothelial leukocyte adhesion and 
activation of coagulation pathways, thereby promoting inflammation.8 Within the kidney, the 
vascular endothelium and tubular cells are directly exposed to pathogens and danger-asso-
ciated molecular patterns (PAMPS and DAMPS) inducing a local inflammatory response. The 
release of mediators like cytokines, reactive oxygen (ROS) and nitrogen species (RNS) charac-
terize this response which, together with endothelial swelling and arteriolar vasoconstriction, 
leads to a compromised renal microcirculation.9 In response to this inflammatory and hypoxic 
insult, tubular cells reprioritize and downregulate cellular functions in order to prevent further 
damage. This adaptive response is mainly orchestrated by the mitochondria, organelles primarily 
responsible for providing energy, in the form of ATP, through oxidative phorphorylation.10,11 
When exposed to stress, mitochondria trigger several protective cellular processes: reprioriti-
zation of energy consumption, removal and digestion of dysfunctional organelles (autophagy 
and mitophagy) and initiation of cell cycle arrest.7 In case of overwhelming or sustained cellular 
stress, as observed during sepsis, the protective capacity of mitochondria might be exhausted, 
thereby limiting their ability to prevent further renal impairment.12 In addition, this may induce 
the release of mitochondrial constituents (e.g. mitochondrial DNA, ROS and ATP), which are indi-
cated as potent DAMPs and activate cells of the innate immune system.13,14 
It appears plausible that a pharmaceutical compound eliciting a multimodal mode of action 
might be needed to treat a multifaceted disease like sepsis-associated AKI. One of the limited 
number of candidate drugs facilitating such an approach, may be the enzyme alkaline phos-
phatase (AP). Two small patient studies demonstrated that treatment with bovine intestinal AP 
was associated with renal protective effects during sepsis-associated AKI.15,16 To follow-up on 
these results, a human recombinant AP (recAP) was developed, which is highly stable as well as 
biologically active.17 Previous data demonstrated that recAP provides protection during LPS-in-
duced inflammation in human renal proximal tubule cells (PTEC) through dephosphorylation of 
endotoxin (LPS, lipopolysaccharide), involved in sepsis pathogenesis, and detrimental purines 
adenosine triphosphate (ATP) and adenosine diphosphate (ADP), released during inflamma-
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tion and hypoxia.18 In addition, in vivo, recAP could not modulate LPS-induced changes in 
systemic hemodynamics and renal oxygenation, but recAP did exert a clear renal protective 
anti-inflammatory effect.18,19 Considering the diverse processes involved in the pathogenesis 
of sepsis-associated AKI, the aim of this study was to investigate the putative renal protective 
effects of recAP upon impaired mitochondrial function. Mitochondrial dysfunction is effec-
tively induced by inhibition of the mitochondrial oxidative phosphorylation (OXPHOS) system, 
as it is the major mitochondrial energy generating system.20 We achieved such a block of the 
respiratory chain using antimycin A, a bona fide inhibitor of the third OXPHOS complex in a 
unique human conditional immortalized PTEC model, ciPTEC.21
Material and methods  
Cell culture
Routinely, ciPTEC were cultured at 33°C as described previously.21 Preceding each experiment, 
cells were seeded at a 55,000 cells/cm2 density, incubated for 1 day at 33°C followed by a 7-day 
maturation period at 37°C. On the day of the experiment, cells were either directly harvested 
(titration experiments) or incubated for 24 h with 10 nM antimycin A from streptomyces sp. 
(5mM in ethanol; Sigma-Aldrich, Zwijndrecht, The Netherlands) or 50 nM myxothiazol (5mM 
in ethanol; Sigma-Aldrich, Zwijndrecht, The Netherlands), to completely inhibit oxygen 
consumption as described below (see high-resolution respirometry section). The latter incu-
bations were performed with or without recAP (10 U/ml18; 19 µg/ml; kind gift from AM-Pharma, 
Bunnik, The Netherlands), also referred to as chimeric AP (ChimAP).17 Control cells were incu-
bated with culture medium solely. Inactive recAP (19 µg/ml, kind gift from AM-Pharma) was 
used as a negative control. In a different set of experiments, cells were co-incubated with 10 
µg/ml LPS (E. coli 0127:B8; Sigma-Aldrich, Zwijndrecht, The Netherlands) dissolved in 10 mM 
HEPES (Roche Diagnostics, Almere, The Netherlands) buffered HBSS (Gibco, Thermo Fisher 
Scientific, Bleiswijk, The Netherlands), pH7.4, a dose which does not affect cell viability.18
Adenosine A2A receptor knockout cell line
An adenosine A2A receptor ciPTEC knockout cell line was developed using the CRISPR-Cas9 
gene-editing system. SgRNA directed against a 5' prime target site in the ADORA2A coding 
sequence was developed using the optimized algorithms of the Zhang-lab (available at 
www.crispr.mit.edu). Template and non-template sequences of the target site, with addi-
tional overhanging sequences (5’-accgGGCGGCGGCCGACATCGCAG- 3’ and 3’-aaacCTGCGAT-
GTCGGCCGCCGCCc-5’) were  cloned  into the plasmid pSpCas9(BB)-2A-GFR (PX458), which 
was a gift from Feng Zhang (Addgene plasmid #48138).22 First, the oligos (10 µM each) were 
phosphorylated for 30 min at 37 °C with 5 units 3'-phosphatase minus PNK (NEB) and subse-
quently annealed by denaturation at 95°C for 5 min followed by cooling to 25°C at 5°C/min. 
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The annealed  oligos were then diluted 1:250 and  ligated using the golden-gate assembly 
method using digestion enzyme Bbsl to digest the plasmid, followed by transformation into 
MachI competent cells (Thermo Fisher Scientific, Bleiswijk, The Netherlands) using the heat 
shock method (35 s at 42 °C). Subsequently, ciPTEC cells were seeded in a 6-well plate 24 h 
before transfection at 33 ºC and were 70-80% confluent at transfection. Cells were incubated 
in serum free culture medium with pre-mixed 2.5 µg pSpCas9(BB)-2A-GFR-sgRNA and 7.5 µl 
Lipofectamine® 3000 Reagent per well for 3.5 h, according to manufacturer's protocol. After 
24 h, GFP-positive, life cells were FACS sorted using the Aria flow-cytometer and plated as 
single cells in 96-well plates. After approximately three weeks, colonies formed from which 
genomic DNA was extracted with the QIAamp DNA mini kit  (Qiagen, Venlo, The Nether-
lands), the sequence surrounding the intended mutation was pre-amplified using PCR (fwd 
primer: agcctgcctgtcgtctgt; rvs primer: gccaggagactgaagatgga ; at 67 °C for 35 cycles with Q5 
high-fidelity polymerase) and sequenced using either the forward or the reverse primer of 
aforementioned PCR. Finally, one clone was obtained with a frame-shift mutation introducing 
a pre-mature stop-codon at amino acid 115 (Supplemental Table 1).
High-resolution respirometry
Cellular respiration was measured at 37°C using a two-chamber Oxygraph equipped with 
Datlab 5 recording and analysis software (Oroboros Instruments, Innsbruck, Austria), as 
described previously.23 For antimycin A and myxothiazol titrations, cells were harvested and 
approximately 3.0⋅106 cells were resuspended in their own culture medium, collected prior 
to harvesting. After addition of the cells to the chambers of the respirometer the oxygen 
consumption rates were allowed to reach a stable (routine) level. Next, increasing antimycin 
A or myxothiazol concentrations were added until the oxygen consumption rates could not 
be further reduced. To determine cellular respiration after 24 h exposures, approximately 
1.5⋅106 cells were resuspended in their own culture medium, collected prior to harvesting. 
After routine oxygen consumption rates were reached a high antimycin A (2.5 µM) or myxo-
thiazol  (1 µM) concentration was added to determine non-mitochondrial respiration. Oxygen 
consumption rates were corrected for non-mitochondrial respiration by subtraction of these 
antimycin A or myxothiazol-inhibited rates.
Cell viability analysis
The effects of antimycin A on cell viability were evaluated as described before.24 Briefly, cells 
were seeded in 96-wells black/clear imaging plates (Greiner Bio-one B.V., Alphen aan de 
Rijn, The Netherlands) and cultured as described above (see cell culture section). Cells were 
exposed to a serial-dilution of antimycin A (1 nM to 10 µM). After 24 h incubation, all nuclei 
were stained using Hoechst 33342 (20 µg/ml, Thermo Fisher Scientific, Bleiswijk, The Nether-
lands), and additionally Yo-Pro-1-iodide (2 µM, Thermo Fisher Scientific, Bleiswijk, The Neth-
erlands) was used to stain nuclei for early apoptosis and necrosis. After 20 min of staining at 
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37°C, fluorescence was imaged on a BD Pathway 855 high-throughput microscope (Becton 
Dickinson (BD) Bioscience, Breda, The Netherlands). Next, the total number of nuclei was 
analyzed using Image J25 and Hoechst-stained nuclei were also used to create a mask. This 
mask was subsequently used to identify Yo-Pro-1-iodide-positive nuclei.  Finally, cell viability 
was calculated as the percentage of Yo-Pro-1-iodide-negative nuclei.
Cytokine and purine release 
IL-6 and IL-8 concentrations were quantified in supernatant using human ELISA kits (Duosets; 
R&D Systems, Abingdon, UK) according to manufacturer’s instructions. Supernatant was 
collected 20 min after antimycin A or LPS administration, with or without recAP co-incuba-
tion, in Krebs-Henseleit buffer containing 10 mM HEPES (pH 7.4), followed by measurement of 
total purine content by HPCL as described previously.18
 
Real-time PCR analyses
To determine gene expression levels, cell pellets were collected after 6 or 24 h of incuba-
tion and stored at -20 ºC until processed. RNA was extracted from frozen cell pellet by Trizol 
reagent. RNA was reverse-transcribed into cDNA using Moloney Murine Leukemia Virus 
(M-MLV) Reverse Transcriptase (Invitrogen, Breda, The Netherlands). Real-time quantitative 
PCR (RQ-PCR) was performed using Taqman® (Applied Biosystems, Bleiswijk, The Nether-
lands). Genes were amplified and normalized to the expression of RPL27 (Ct: 23.1 ± 0.4; n = 
5). Differences between groups were calculated by the comparative ΔΔCt method. Primers/
probe sets are summarized in Supplemental Table 2.
Statistical analysis
Normality of the data was assessed by Kolmogorov-Smirnov test and expressed accordingly 
as mean ± SEM or median [25th percentile, 75th percentile]. Unless indicated otherwise, differ-
ences between groups were compared by ANOVA with post-hoc comparisons using Bonfer-
roni’s or Dunnet’s multiple comparison test. A two-sided p-value less than 0.05 was consid-
ered statistically significant. All tests were performed with Graphpad Prism 5.03 for Windows 
(Graphpad Software Inc., California, USA).
Results 
Antimycin A-inhibited respiration is not influenced by recAP treatment
Respiratory inhibition in ciPTEC was achieved using antimycin A, an inhibitor of the Qi-binding 
site of the third multi-protein complex of the mitochondrial OXPHOS system.26 Antimycin A 
administration has, however, been associated with high levels of cytotoxicity in primary mouse 
renal epithelial cells upon long-term (≥ 24 h) treatment.27 To exclude the influence of such 
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rather non-specific cytotoxic effects, we first determined the lowest antimycin A concentra-
tion giving full respiratory inhibition. Titration demonstrated that 10 nM is sufficient to inhibit 
the cellular oxygen consumption directly after administration (Figure 1A). Moreover the full 
respiratory complex inhibition was still present after 24 h treatment (Figure 1B), without a 
significant effect on cell viability (Figure 1C). In the presence of sufficient extracellular glucose 
this may indicate a shift towards anaerobic metabolism, according to the Warburg effect.28 
Inhibition of mitochondrial oxygen consumption was confirmed by the antimycin A-induced 
gene expression levels of hypoxia-dependent genes, such as adrenomedullin and hypox-
ia-inducible factor (HIF)-1α (Table 1). RecAP treatment did not affect the oxygen consumption 
after 24 h (Figure 1B), or the increased adrenomedullin and HIF-1α expression levels (Table 1).
Table 1. Gene expression levels following antimycin A exposure in ciPTEC 
CT VALUES FOLD INCREASE (2^-ΔΔCT)
Control recAP Anti-
mycin A
recAP and 
Antimycin A
Control recAP Anti-
mycin A
recAP and 
Antimycin A
6 h
ADM 24.7 ± 0.2 24.2 ± 0.4 23.6 ± 0.3 23.8 ± 0.4 1 ± 0 1.3 ± 0.1 1.3 ± 0.3 1.6 ± 0.3
HIF-1α 21.2 ± 0.3 21.0 ± 0.4 20.2 ± 0.3 20.6 ± 0.5 1 ± 0 1.4 ± 0.4 1.4 ± 0.2 1.2 ± 0.2
A1 27.0 ± 0.2 26.8 ± 0.3 27.5 ± 0.3 27.0 ± 0.4 1 ± 0 1.6 ± 0.3 0.5 ± 0.1 1.0 ± 0.1
A2A 29.4 ± 0.1 31.1 ± 0.3 27.1 ± 0.5 29.5 ± 0.3 1 ± 0 0.4 ± 0.1 3.8 ± 0.5# 0.8 ± 0.1*
A2B 26.2 ± 0.4 26.7 ± 0.3 25.9 ± 0.6 26.8 ± 0.2 1 ± 0 0.9 ± 0.1 0.9 ± 0.1 0.7 ± 0.1
A3 35.7 ± 0.3 35.2 ± 0.3 35.7 ± 0.4 35.5 ± 0.4 1 ± 0 2.0 ± 0.5 0.8 ± 0.2 1.2 ± 0.2
24 h
ADM 23.9 ± 0.2 24.1 ± 0.3 22.5 ± 0.5 22.3 ± 0.3 1 ± 0 1.1 ± 0.1 5.2 ± 0.3# 6.1 ± 0.7#
HIF-1α 21.1 ± 0.3 21.4 ± 0.2 21.2 ± 0.5 21.1 ± 0.3 1 ± 0 0.9 ± 0.1 1.6 ± 0.2# 1.8 ± 0.2#
A1 28.0 ± 0.3 28.1 ± 0.3 30.6 ± 0.6 30.1 ± 0.4 1 ± 0 1.3 ± 0.1 0.3 ± 0.0# 0.3 ± 0.1#
A2A 30.1 ± 0.2 30.6 ± 0.3 27.9 ± 0.6 26.9 ± 0.6 1 ± 0 0.8 ± 0.1 9.0 ± 0.8# 14.7 ± 1.9#*
A2B 27.7 ± 0.2 28.0 ± 0.2 29.7 ± 0.5 29.0 ± 0.3 1 ± 0 1.0 ± 0.9 0.9 ± 0.9 0.8 ± 0.1
A3 36.7 ± 0.2 37.5 ± 0.6 38.1 ± 0.6 37.6 ± 0.5 1 ± 0 1.0 ± 0.4 0.7 ± 0.2 1.0 ± 0.3
 Data is expressed mean ± SEM. Significant differences of the fold increase were calculated using one-way ANOVA 
with Bonferroni post-test. n=5, n=4 for A2A 24 h due to a significant outlying control sample.  # p<0.05 compared 
to control. * p<0.05 compared to antimycin A. ADM, adrenomedullin; HIF-1α, hypoxia-inducible factor 1, alpha 
subunit; A1, adenosine A1 receptor; A2A adenosine A2A receptor; A2B, adenosine A2B receptor; A3, adenosine A3 
receptor.
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Figure 1.
 Concentration-dependent inhibition of O2 consumption by antimycin A in ciPTEC and effects of 24 h 
exposure on cellular respiration and viability. 
 (A) O2 consumption rates of ciPTEC in culture medium upon titration with antimycin A (AA). Respiration rates 
were normalized to basal respiration in the absence of inhibitor (25 ± 3 pmol/s/106 cells). (B) Routine O2 consump-
tion rates of ciPTEC in culture medium after 24 h exposure to 10 nM AA with or without recAP (10 U/mL). Respi-
ration rates were normalized to basal respiration in the absence of inhibitor (CT, 15 ± 1 pmol/s/106 cells). (C) Cell 
viability after 24 h AA exposure of ciPTEC, expressed as the number of viable cells as a percentage of the total 
number of cells. Statistical analysis: one-way ANOVA with Bonferroni’s (Panel B) or Dunnet’s (Panels A and C) 
post hoc test, *p<0.05, *** p<0.001, mean ± SEM, n=3
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Figure 2.
 Effects of recAP on antimycin A-induced production and gene expression of cytokines in ciPTEC. 
Cells were treated with 10 nM antimycin A (AA), with or without recAP (10 U/mL, 19 µg/mL), administered simul-
taneously with or 2 h preceding AA, or with inactive AP (0 U/mL, 19 µg/mL), lacking hydrolyzing properties. After 
24 h, IL-6 (top panel) and IL-8 (bottom panel) were measured on protein level in supernatant by ELISA after 24 h 
of AA exposure (A) or on gene level in cells by qPCR following 6 h (B) or 24 h (C) of AA exposure. Control cells 
were incubated with culture media. Statistical analysis: one-way ANOVA with Bonferroni’s post hoc test, * p<0.05 
compared to CT (control), ** p<0.01 compared to CT, *** p<0.001 compared to CT, # p<0.05 compared to AA, 
### p<0.001 compared to AA, mean ± SEM, n=5.
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RecAP attenuates the antimycin A-induced inflammatory response 
Impaired mitochondrial function is a known trigger of inflammation29, as confirmed in our 
model by the antimycin A-induced production and increased gene expression levels of 
pro-inflammatory mediators IL-6 and IL-8 (Figure 2A-B). The cytokine production after 24 
h was attenuated when cells were pre-incubated with recAP (10 U/ml) for 2 h (Figure 2A). 
Similar results were obtained when recAP was added simultaneously with antimycin A. In 
addition, enzymatically inactive recAP had no effect, indicating that the protective effects are 
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related to the dephosphorylating nature of recAP. After 6 h of antimycin A treatment, when 
adrenomedullin and HIF-1α were not yet significantly up-regulated (Table 1), recAP reduced 
the pro-inflammatory gene expression levels (Figure 2B), whereas cytokine gene expres-
sion levels were not attenuated by recAP co-incubation after 24 h of antimycin A treatment 
(Figure 2C). Vehicle (ethanol) was used as a negative control and had no effect (not shown). 
Alternatively, impaired mitochondrial function can also be induced by myxothiazol, another 
complex III inhibitor acting via the second substrate pocket of complex III (Qo-site) (Supple-
mental Figure 1A). After 24 h of full respiratory inhibition (Supplemental Figure 1B), recAP 
treatment had similar effects on the IL-8 cytokine production (Supplemental Figure 1C), indi-
cating that recAP does not exert its effects via a direct interaction with antimycin A. IL-6 was 
not induced by myxothiazol (not shown). Subsequently, considering the role of renal inflam-
mation in the pathogenesis of sepsis-associated AKI30, the effects of recAP were investigated 
during a co-incubation of LPS and antimycin A during which recAP still attenuated the inflam-
matory response (Figure 3).
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Figure 3. 
 Effects of recAP on antimycin A- and LPS-induced cytokine production in ciPTEC.
 Protein level in supernatant of IL-6 and IL-8 following 24 h exposure of 10 nM antimycin A (AA), LPS (10 µg/mL) or 
AA with LPS, with or without recAP (10 U/mL) was measured by ELISA. Control cells were incubated with culture 
media. Statistical analysis: one-way ANOVA with Bonferroni’s post hoc test, * p<0.05 compared to CT (control), 
** p<0.01 compared to CT, *** p<0.001 compared to CT, ### p<0.001 compared to AA+LPS, mean ± SEM, n=4.
A B
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Effects of recAP are mediated by dephosphorylation of ATP and ADP
Another hallmark of cellular stress is the release of the endogenous pro-inflammatory mole-
cules ATP and ADP.31,32 Whereas antimycin A alone did not significantly increase the extracel-
lular release of ATP and ADP compared to control after 20 min incubation, upon co-incuba-
tion with LPS, the release of these molecules was significantly increased (Figure 4A-B). This 
was similar for AMP (Figure 4C). Co-incubation with recAP resulted in a significant increase 
in adenosine compared to antimycin A treatment only (control: 100%; recAP + antimycin A: 
222 ± 29% vs. antimycin A: 109 ± 9%, p<0.05). RecAP combined with antimycin A and LPS 
resulted in a 3.2-fold increase compared to antimycin A and LPS (Figure 4D). Adenosine exerts 
Figure 4.
 Effect of recAP on antimycin A- and LPS-induced ATP and ADP release in ciPTEC. 
 CiPTEC were incubated with 10 nM antimycin A (AA), LPS (10 µg/mL) or AA with LPS, with or without recAP (10 
U/mL) in Krebs-Henseleit buffer containing 10 mM HEPES (pH 7.4). After 20 min, supernatant was collected to 
determine ATP (A), ADP (B), AMP (C) and adenosine (D) content by HPLC. Control cells were incubated with buffer. 
Statistical analysis: one-way ANOVA with Bonferroni’s post hoc test, * p<0.05 compared to control, *** p<0.001 
compared to control, ### p<0.001 compared to AA+LPS, mean ± SEM, n = 4.
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its protective effects through binding to one of the four adenosine receptor A1, A2A, A2B and 
A333, of which only the adenosine A2A receptor was up-regulated after 6 h antimycin A expo-
sure, and reduced when recAP was co-administered, but not after 24 h co-exposure (Table 1). 
Here, recAP co-administered with antimycin A increased the adenosine A2A receptor expres-
sion levels. To further explore the role of the adenosine A2A receptor in the renal protective 
effect of recAP, an adenosine A2A receptor knockout ciPTEC cell line was generated using 
CRISPR-Cas technology 22. A frameshift deletion (c161del, counted from ATG) was introduced, 
resulting in a premature stop-codon at amino acid 115 (Supplemental Table 1) and conse-
quently, to a expression of a truncated receptor lacking all predicted agonist binding sites. In 
the adenosine A2A receptor knockout cells, recAP treatment still attenuated the inflammatory 
response induced by antimycin A and LPS, alone and when combined (Figure 5), suggesting 
that adenosine A2A receptor signalling solely may not have a key role in the anti-inflamma-
tory effect of recAP in ciPTEC. 
Figure 5. 
 Effect of recAP on antimycin A- and LPS-induced cytokine production in adenosine A2A receptor 
knockout ciPTEC. 
 An adenosine A2A receptor knockout ciPTEC cell line was generated using the CRISPR-Cas technology, by which 
a frameshift deletion (c161del) was introduced, resulting in a premature stopcodon at amino acid 115. Protein 
level in supernatant of IL-6 and IL-8 following 24 h exposure of 10 nM antimycin A (AA), LPS (10 µg/mL) or AA 
with LPS, with or without recAP (10 U/mL, 19 µg/mL) was measured by ELISA. Cells exposed to AA and LPS were 
also co-incubated with inactive AP (inact recAP) (0 U/mL, 19 µg/mL), lacking hydrolyzing properties. Control cells 
were incubated with culture media. Statistical analysis: one-way ANOVA with Bonferroni’s post hoc test, * p<0.05 
compared to CT (control), *** p<0.001 compared to CT, ## p<0.01 compared to AA,  ### p<0.001 compared to 
corresponding stimuli without recAP, mean ± SEM, n = 4.
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Discussion
Sepsis-associated AKI is a multifactorial syndrome in which several processes, including 
inflammation and renal microcirculatory dysfunction play a profound role.7,9 Tubular cells 
respond to these stressors by down-regulation and reprioritization of cellular functions to 
prevent further injury, processes which are orchestrated by mitochondria\.10,11,34 Here, we 
investigated the effects of recAP, a potential new treatment option for sepsis-associated AKI, 
during impaired mitochondrial function and demonstrate that recAP attenuates the inflam-
matory response, without affecting oxygen consumption. 
Despite a marked decline in renal function and the occurrence of tubular dysfunction, histo-
logical signs of apoptosis or necrosis are barely present in patients with sepsis-associated AKI.35 
Considering the severity of injury, cells are likely to have a mechanism to limit activation of cell 
death pathways, which might be arranged by mitochondria.7 Mitochondria are most abun-
dantly expressed in the heart, followed by the renal proximal tubule cells, where there is a 
high need for ATP in order to facilitate solute exchange.12 During stress, mitochondria reduce 
the metabolic activity of cells by reducing energy requirements. To this end, mitochondria 
remove and digest dysfunctional organelles and initiate cell cycle arrest to prevent further 
damage.7 During this state, akin to hibernation, mitochondria do not function normally, but do 
produce enough ATP to prevent activation of cell death pathways.34 Exactly how mitochon-
drial dysfunction contributes to the development of AKI is poorly understood, but during over-
whelming cellular stress, the protective capacity of mitochondria might be exhausted.12
To mimic impaired mitochondrial function, respiration was inhibited in human proximal 
tubule cells by antimycin A. This compound inhibits the Qi-binding site of mitochondrial 
complex III of the OXPHOS system, thereby completely inhibiting cellular oxygen consump-
tion as confirmed by respiration experiments.26 Impaired mitochondrial function promotes 
the inflammatory response29 as observed by an increased production of the pro-inflamma-
tory cytokines IL-6 and IL-8 in our experiments, which was even more pronounced upon 
co-incubation with LPS. Alternatively, as 24 h of oxygen consumption inhibition did not affect 
cell viability, cells may have shifted to anaerobic metabolism according to the Warburg effect, 
where cells rely on glycolysis for energy production, even in the presence of oxygen.28 This 
process by itself could also induce inflammation via accumulation of succinate, an interme-
diate metabolite of the citric acid cycle, thereby stabilizing the transcription factor HIF-1α, 
resulting in the production of pro-inflammatory cytokines.36 We report that recAP treatment 
attenuates the inflammatory response induced by antimycin A, which corroborates previous 
results when inflammation was induced by LPS administration.18 These effects were explained 
by dephosphorylation of LPS37 and the conversion of extracellular detrimental purines ATP 
and ADP into the cytoprotective molecule adenosine.18 Also, inhibition of oxygen consump-
tion induces cellular purine release38, as confirmed here by significant antimycin A-induced 
increase of ATP and ADP release when combined with inflammation, which were completely 
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converted into adenosine by recAP. RecAP attenuated pro-inflammatory cytokine gene 
expression levels after 6 h of antimycin A treatment, whereas recAP had no effects when cells 
were incubated for 24 h with antimycin A. Since purines are rapidly released upon cellular 
stress39 and a sustained period of oxygen consumption inhibition induces intracellular ATP 
depletion40 (thereby limiting extracellular release of ATP), it appears plausible that recAP is 
only able to provide protection during the initial phase. Removal of these purines prevents 
further injury, potentially provoked by purinergic P2X and P2Y receptor signalling, thereby 
accelerating inflammation and tissue injury by phagocyte recruitment and NLRP3 inflam-
masome activation.41 
Another effect of antimycin A administration was a profound up-regulation of the adenosine 
A2A receptor. Adenosine exerts renal protective and anti-inflammatory effects upon binding 
to the adenosine A1, A2A, A2B and A3 receptors.42 As the adenosine A2A receptor is known to 
be induced by inflammation41, and adenosine A2A receptor expression levels were attenuated 
by recAP after 6 h and not 24 h, comparable to cytokine gene expression level, this is likely to 
reflect a cellular response on inflammation.18 To further explore whether or not the adenosine 
A2A receptor is involved in the renal protective effects of recAP, an adenosine A2A receptor 
knockout cell line was generated with CRISPR-CAS technology. This recently developed 
genome editing technology is superior to other techniques, like zinc-finger nucleases (ZFNs), 
transcription activator-like effector nucleases (TALENs) and small interfering RNA (siRNA), as it 
is permanent, easier to design and highly specific.22,43 RecAP still attenuated the inflammatory 
response in this model, suggesting that adenosine A2A receptor signalling solely may have 
no key role in the anti-inflammatory effect of recAP in ciPTEC. This confirms earlier findings 
where blocking the adenosine A2A receptor by the specific antagonist ZM-241385 did not 
prevent the recAP-mediated protection on the LPS-induced inflammatory response in these 
cells.18 Yet, based on these results, we cannot exclude that adenosine exerts protective effects 
via signalling through one of the other three adenosine receptors, possibly combined with 
adenosine A2A receptor signalling.42 Moreover, the protective effects observed in vivo could 
also be due to the effect of adenosine on other cell types. For instance, bone marrow-derived 
cell signalling through the adenosine A2A receptor has been implicated in kidney protection 
upon ischemia through their anti-inflammatory effects.44 However, it was beyond the scope 
of the current studies to investigate these possibilities. 
Despite a renal anti-inflammatory effect, recAP did not affect the antimycin A-induced 
decreased oxygen consumption and subsequent increase in hypoxia-inducible gene expres-
sion levels of HIF-1α or adrenomedullin. During a prolonged period of reduced oxygen 
consumption, cells activate adaptive mechanisms for survival during which HIFs are key. 
The most commonly studied factor HIF-1 consists of an α and β subunit, of which HIF-1α 
is oxygen-sensitive and heterodimerizes with HIF-1β to bind DNA.45 During hypoxia, HIF-1 
breakdown is prevented resulting in stabilization of HIF-1, which actively represses oxygen 
consumption by preventing entrance of pyruvate into the citric acid cycle, thereby increasing 
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oxygen availability and preventing cell death.46 Furthermore, HIF-1 induces an increase of 
adrenomedullin gene expression levels47,48, another survival factor against hypoxic cell death 
of which the exact mechanism of action remains to be elucidated.49 Whether or not recAP 
may improve oxygen consumption in patients with sepsis-associated AKI is difficult to extrap-
olate from our in vitro model. Here, mitochondrial function is inhibited in all cells simultane-
ously, whereas in the in vivo situation, AKI presents as patchy areas of injured cells, with some 
cells being affected whereas others are not.35 
Moreover, one may argue that a more representative model of the in vivo situation would be 
a condition of reduced oxygen delivery, rather than reduced cellular oxygen consumption 
whereas oxygen is still available. While mitochondrial inhibition can also be achieved during 
oxygen deprived settings50, hypoxia is an inflammatory stimulus by itself. As such, exposing 
cells to low oxygen conditions induces a pro-inflammatory response, as well as the activation 
of several counter-regulatory mechanisms (e.g. anti-inflammatory pathways).51 As we only 
aimed to study the effects of recAP on mitochondrial inhibition, exclusive inhibition of the 
mitochondrial respiratory chain provides the simplest and most direct model.
Conclusion
Mitochondrial dysfunction plays an important role in sepsis patients suffering from organ 
dysfunction.52 We report that recAP attenuates the initial inflammatory response provoked 
by mitochondrial dysfunction, thereby confirming the previous observed renal protective 
anti-inflammatory effect of recAP in vitro and in vivo and of bovine intestinal AP in patients 
with sepsis and associated AKI.16,18 These effects are presumably mediated by dephospho-
rylating ATP and ADP into adenosine. The potential clinical value of recAP to treat critically ill 
patients with sepsis-associated AKI is currently being investigated in a large phase IIa/b clin-
ical trial with outcomes expected in the second half of 2017.53 
 
Acknowledgments
We are grateful to Feng Zhang for creating the plasmid pSpCas9(BB)-2A-GFR (PX458). Also, we 
thank Stijn van Beek for conducting the cellular respiration assays with myxothiazol.
139
Supplemental Figure 
co
nc
en
tr
at
io
n 
IL
-8
 (n
g/
m
L)
0
20
60
40
80
CT
re
cA
P
my
xo
th
iaz
ol
re
cA
P +
ina
ct 
re
cA
P +
 
my
xo
th
iaz
ol
my
xo
th
iaz
ol
**
***
# # #
20
60
80
120
ce
llu
la
r o
xy
ge
n 
co
ns
um
pt
io
n 
(%
 o
f v
eh
ic
le
 c
on
tr
ol
)
50
75
100
125
0
CT
my
xo
th
iaz
ol
25
40
100
ce
llu
la
r o
xy
ge
n 
co
ns
um
pt
io
n 
(%
 o
f c
on
tr
ol
)
 
 [myxothiazol] (nM)
10-610-8 10-4 100 102 104
0
10-2
IC50: 8.1 nM (6.8-9.7)
*****
***
Supplemental Figure 1. 
 Concentration-dependent inhibition of O2 consumption by myxothiazol in ciPTEC and effects of 24 
h exposure on cellular respiration and cytokine production. 
 (A) O2 consumption rates of ciPTEC in culture medium upon titration with myothiazol. Respiration rates were 
normalized to basal respiration in the absence of inhibitor (26 ± 1 pmol/s/106 cells). (B) Routine O2 consumption 
rates of ciPTEC in culture medium after 24 h exposure to 50 nM myxothiazol. Respiration rates were normalized to 
basal respiration in the absence of inhibitor (CT, 28 ± 3 pmol/s/106 cells). (C) Cells were treated with 50 nM myxo-
thiazol, with or without recAP (10 U/mL, 19 µg/mL), or with inactive AP (0 U/mL, 19 µg/mL), lacking hydrolyzing 
properties. After 24 h, IL-8 release was measured in supernatant by ELISA. Statistical analysis: (panel A, C) one-way 
ANOVA with Bonferonni’s post hoc test (panel B) Student’s t-test, ** p<0.01 compared to CT (control), *** p<0.001 
compared to CT, ### p<0.001 compared to myxothiazol, mean ± SEM, panel A, B n = 3, panel C n = 4.
A B
C
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Supplemental Tables
 
Supplemental Table 1. Mutation position  
Position 22:24433565 in GRCh38.p7
Alleles C
cDNA position 161
Protein position 54 – isoform 1
Amino acids Ala
Basecalling TGGGCTCCTCGGTGTACATCACGGTGGAGCTGGTCCATTGCTGTGCT 
GGCCATCCTGGGCATGTGCTGGTGTGCTGGGCCGTGTGGCTCAACA 
GCAACCTGCAGAACGTCACCAACTACTTTGTGGTGTCACTGGCGGCG 
GCCGACATCG - AGTGGGTGTGCTCCCATCCCCTTTGCCATCACCATCA 
GCACCGGGTTCTGCGCTGCCTGCCAGGCTGCCTCTTCATTGCCTGCTT 
CGTCCTGGTCCT
Supplemental Table 2. Primer/probe specifications
GENE SYMBOL GENE NAME ASSAY ID
RPL27 ribosomal protein L27 Hs03044961_g1
ADM adrenomedullin Hs00969450_g1
HIF1A hypoxia-inducible factor 1, alpha subunit Hs00153153_m1
IL6 interleukin 6 Hs00985639_m1
IL8 interleukin 8 Hs00174103_m1
ADORA1 adenosine A1 receptor Hs00379752_m1
ADORA2A adenosine A2a receptor Hs00169123_m1
ADORA2B adenosine A2b receptor Hs00386497_m1
ADORA3 adenosine A3 receptor Hs01560269_m1
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Abstract
T  wo small clinical trials indicated that administration of bovine intestinal alka-line phosphatase (AP) improves renal function in critically ill patients with sepsis-associated acute kidney injury (AKI), for which the mechanism of action 
is not completely understood. Here, we investigated the effects of a newly developed human 
recombinant AP (recAP) on renal oxygenation and hemodynamics and prevention of kidney 
damage and inflammation in two in vivo AKI models. To induce AKI, male Wistar rats (n=18) 
were subjected to renal ischemia (30 min) and reperfusion (I/R), or sham-operated. In a second 
model, rats (n=18) received a 30 min infusion of lipopolysaccharide (LPS; 2.5 mg/kg), or saline, 
and fluid resuscitation. In both models, recAP (1000 U/kg) was administered intravenously (15 
min before reperfusion, or 90 min after LPS). Following recAP treatment, I/R-induced changes 
in renal blood flow, renal vascular resistance and oxygen delivery at early, and cortical micro-
vascular oxygen tension at late reperfusion were no longer significantly affected. RecAP did 
not influence I/R-induced effects on mean arterial pressure. During endotoxemia, recAP 
treatment did not modulate the LPS-induced changes in systemic hemodynamics and renal 
oxygenation. In both models, recAP did exert a clear renal protective anti-inflammatory effect, 
demonstrated by attenuated immunostaining of inflammatory, tubular injury and pro-apop-
tosis markers. Whether this renal protective effect is sufficient to improve outcome of patients 
suffering from sepsis-associated AKI is being investigated in a large clinical trial.
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Introduction
Sepsis-associated acute kidney injury (AKI) is a serious complication in critically ill patients and 
is accompanied by high morbidity and mortality rates.1 Treatment is limited to supportive 
care, as up to now pharmacological interventions are not available. The current lack of treat-
ment options appears primarily due to the multifactorial pathogenesis of AKI, in which inflam-
mation, hemodynamic instability, renal microcirculatory dysfunction and unbalanced renal 
bioenergetics play pivotal roles.2 Sepsis is accompanied by the systemic release of pro-in-
flammatory mediators, activation of complement and coagulation pathways, and endo-
thelial leukocyte adhesion and extravasation, thereby promoting inflammation.3 Within 
the kidney, the vascular endothelium is directly exposed to pathogens and danger-as-
sociated molecular patterns that induce a local inflammatory response. The release of 
harmful mediators like cytokines, reactive oxygen (ROS) and nitrogen species (RNS) char-
acterize this response which, together with endothelial swelling and arteriolar vasocon-
striction, leads to a compromised renal microcirculation and renal hypoxia.4 However, the 
role of renal vasoconstriction and a reduced renal blood flow (RBF) is still under debate 
since animal and human data suggest that during sepsis, AKI can develop in the setting 
of sustained or even increased renal blood flow (RBF).5,6 This is in contrast to renal isch-
emia/reperfusion (I/R) injury, during which hemodynamic instability, hypoperfusion and 
a dysbalance of renal oxygen delivery and oxygen consumption may play key roles.7,8 
Considering its complex pathogenesis, a new treatment option for AKI should be able to 
modulate the various processes involved in disease development. One of a limited number 
of candidate drugs that might facilitate such a multimodal approach is the enzyme alka-
line phosphatase (AP). According to two patient studies, treatment with bovine intes-
tinal AP increased endogenous creatinine clearance, reduced the need for and duration 
of renal replacement therapy and decreased the urinary excretion of renal injury markers 
during sepsis-associated AKI.9,10 Following these promising results, a human recombi-
nant AP (recAP) was developed, which is both highly stable and biologically active.11 
The possible mechanism of action that accounts for the renal protective effects of AP is still not 
completely understood and requires further investigation. Recently, using human renal prox-
imal tubule cells it was demonstrated that recAP exerts protective effects through dephos-
phorylation of endotoxin (LPS, lipopolysaccharide), part of the outer membrane of gram-neg-
ative bacteria involved in sepsis pathogenesis, as well as by dephosphorylation of detrimental 
purines adenosine triphosphate (ATP) and adenosine diphosphate (ADP), released during 
inflammation.12 These results offer a plausible explanation of the anti-inflammatory effects of 
recAP locally in the kidney. Considering the various processes involved in the development of 
sepsis-associated AKI, we now investigated whether recAP can modulate renal microcircula-
tory dysfunction and hemodynamic changes following I/R- or endotoxin-induced AKI.  
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Material and methods 
Animals
All experiments in this study were approved and reviewed by the Animal Research Committee 
of the Academic Medical Center at the University of Amsterdam (DFL 102669). Care and 
handling of the animals were in accordance with the guidelines for Institutional and Animal 
Care and Use Committees (NIH Publication 85-23, 1985). Experiments were performed with 36 
male Wistar rats (Harlan, Horst, the Netherlands) with a mean ± SD body weight of 402 ± 74 g. 
Anesthesia and surgical preparation 
Rats were anesthetized and instrumented as described previously.13,14 Rats received an 
intraperitoneal injection of 90 mg/kg b.w. ketamine (Nimatek®; Eurovet, Bladel, the Neth-
erlands), 0.5 mg/kg b.w. medetomidine (Domitor®; Pfizer, New York, NY) and 0.05 mg/
kg b.w. atropine-sulfate (Centrafarm, Etten-Leur, the Netherlands). After tracheotomy, rats 
were mechanically ventilated with a fraction of inspired O2 (FiO2) of 0.4. Body tempera-
ture was maintained at 37 ± 0.5 ºC during the entire experiment using a heating pad. 
The ventilator settings were adjusted to maintain an end-tidal partial pressure of carbon 
dioxide (PCO2) between 30 and 35 mmHg and an arterial PCO2 between 35 and 40 mmHg. 
Blood vessels were cannulated with polyethylene catheters (outer diameter 0.9 mm; Braun, 
Melsungen, Germany). A catheter in the right carotid artery was connected to a pressure trans-
ducer to monitor mean arterial pressure (MAP). The right jugular vein was cannulated for contin-
uous infusion of Ringer’s lactate (Baxter, Utrecht, the Netherlands) at a rate of 15 mL/kg/h and 
maintenance anesthesia (50 mg/kg ketamine dissolved in Ringer’s lactate, 5 mL/kg/h). The right 
femoral artery was cannulated for blood sampling, and the right femoral vein was cannulated 
to enable fluid resuscitation, oxyphor G2, recAP and Lipopolysaccharide (LPS) administration. 
The left kidney was exposed, decapsulated, and immobilized in a Lucite kidney cup (K. 
Effenberger, Pfaffingen, Germany) via a ~4 cm incision of the left flank. Renal vessels 
were carefully separated under preservation of nerves and adrenal gland. A perivas-
cular ultrasonic transient time flow probe (type 0.7 RB; Transonic Systems Inc., Ithaca, 
NY) was placed around the left renal artery and connected to a flow meter (T206; 
Transonic Systems Inc.) to allow continuous measurement of renal blood flow (RBF). 
After the surgical protocol (approximately 60 min) one optical fiber was placed 1 mm above 
the decapsulated kidney and another optical fiber 1 mm above the renal vein to measure 
oxygenation using the phosphorescence decay time technique (as described below). A small 
piece of aluminum foil was placed on the dorsal site of the renal vein to prevent contribution 
of underlying tissue to the phosphorescence signal in the venous partial pressure of oxygen 
(PO2) measurements. The operation field was covered with a humidified gauze compress 
throughout the entire experiment to prevent desiccation of the tissue exposed. At the end of 
the experiments, animals were sacrificed by systemic administration of 1 mL/kg 20% pento-
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barbital sodium (Euthasol; AST Farma, Oudewater, the Netherlands) through the femoral vein. 
Kidneys were harvested, weighed, and sectioned into two parts. One part was fixed in 10% 
buffered formalin for immunohistochemical anal ysis and the other part of the kidney was 
snap frozen in liquid nitrogen and stored at -80 °C before homogenization. 
Ischemia/reperfusion protocol
Instrumented rats (369 ± 72 g) were randomized and divided into two groups: I/R (n=12) or 
sham control (n=6). Rats were subjected to renal ischemia for 30 min by supra-renal aortic 
occlusion with a custom-made vascular occluder, followed by 2.5 h reperfusion as described 
previously.13 The vascular occluder was placed on the aorta above the renal arteries, and 
beneath the mesenteric artery. The sham control group was instrumented and surgically 
prepared without subsequent cross-clamping of the aorta. Subsequently, ischemic rats were 
randomized to receive an intravenous bolus injection in the femoral vein with 1000 U/kg b.w. 
recAP (n=6) or saline (n=6) 15 min after initiation of ischemia (Supplemental Fig. 1A). Previous 
dose-response experiments in different animal models indicated this dose to be optimal to 
modulate AKI (not shown). The sham control group received saline. Arterial blood samples 
(0.5 mL) were taken at 1) before aortic occlusion (T0), 2) 15 min after reperfusion (T15), and 
3) 150 min after reperfusion (T150). Blood samples were replaced by the same volume of 6% 
HES130/0.4 (Voluven®; Fresenius Kabi Nederland B.V., Schelle, Belgium). 
Endotoxemia protocol
Endotoxemia was induced on fully instrumented rats (430 ± 65 g) as described previously.15 
Rats were randomized at baseline (T0) to receive an intravenous 30 min infusion of 2.5 mg/
kg b.w. LPS (E. coli 0127:B8; Sigma-Aldrich, Paris, France; n=12), or placebo (saline; n=6). Fluid 
resuscitation was performed with 20 mL/kg/h 6% HES130/0.4 and continued after cessation 
of the LPS infusion for a period of 1 h. After this period, LPS-treated groups were randomized 
to receive either an intravenous infusion of recAP (1000 U/kg b.w.) or saline (n=6 per group) 
over 30 min. Control groups received saline. Arterial blood (0.5 mL) was sampled at 1) baseline 
(T0), 2) 90 min after start of LPS administration (T1.5), 3) 120 min post LPS (T2; 30 min after start 
of recAP treatment), and 4) 4.5 h post-LPS (T4.5; 3 h after recAP infusion) (Supplemental Fig. 
1B). Each blood sample drawn was replaced by the same volume of 6% HES130/0.4.
Phosphorimetric measurement renal microvascular and venous PO
2
The oxygen-quenched phosphorescent decay time of a systemically infused albumin-tar-
geted phosphorescent dye (Oxyphor G2; Oxygen Enterprsis, Ltd. Philadelphia, PA) was used 
for measuring the microvascular oxygen tension in the renal cortex (Cortical µPO2), outer 
medulla (Medullar µPO2) and renal venous oxygen tension (PrvO2). Oxyphor G2 was infused 
(6 mg/kg b.w.) intravenously for 15 min followed by 30 min stabilization time. Oxyphor G2 
has two excitation peaks (440 and 632 nm) and one emission peak (800 nm), which allowed 
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simultaneous decay time measurements in the kidney cortex and the outer medulla due to 
different optical penetration depths of the light excitated by dual-wavelength phosphorim-
etry.16 For the measurement of PrvO2, a mono-wavelength frequency-domain phosphorimeter 
was used.17 Phosphorescence was quenched by energy transfer to oxygen, resulting in short-
ening of the phosphorescence decay time. PO2 was calculated by determining the correlation 
between reciprocal phosphorescence decay time and oxygen tension (Stern-Volmer rela-
tion).18 Decay curves of phosphorescent intensity were analyzed using software programmed 
in Labview 6.1 (National Instruments, Austin, TX)
Renal vascular resistance and derivative oxygen parameters 
Blood samples were used to determine blood gas values (ABL505 blood gas analyzer; Radiom-
eter, Copenhagen, Denmark) as well as hemoglobin concentration and hemoglobin oxygen 
saturation. Renal vascular resistance (RVR) was estimated by the formula MAP/RBF x 100. Renal 
oxygen delivery (DO2) was determined by the formula RBF x arterial oxygen content (CaO2 
= hemoglobin x 1.31 x SaO2 + 0.003 x PaO2), where SaO2 is the arterial oxygen saturation and 
PaO2 the arterial partial oxygen pressure. Renal oxygen consumption (VO2) was determined by 
the formula RBF x (CaO2 – CvO2), where renal venous oxygen content (CvO2) was calculated as 
hemoglobin x 1.31 x SrvO2  + 0.003 x PrvO2. The SrvO2 (renal venous O2 saturation) was estimated 
with the Hill equation, with P50 = 37 Torr (4.9 kPa) and Hill coefficient = 2.7. The renal oxygen 
extraction ratio (ER) was estimated as VO2/DO2 x 100. 
NO metabolism 
Kidney tissue samples were homogenized in ice-cold 5 mM sodium phosphate buffer using 
the Heidolph homogenizer DIAX 900 (Sigma-Aldrich, St. Louis, MO). Homogenates were 
centrifuged at 12,000 g for 15 min at 4 ºC, and supernatant was used for NO determination. 
The index of total NO production is the sum of NO and its reaction products nitrite, nitrate 
and nitrosothiols accumulated in tissue samples. The reducing agent used for total NO anal-
ysis was a saturated solution of vanadium (III) chloride (VCL3) in 1 M HCL. At a temperature of 
90 ºC, VCL3 reagent quantitatively converts all reaction products into NO in a glass vial vessel. 
NO is flushed out of the reaction vessel by flow of helium gas, which is then measured by the 
NO chemiluminescense signal analyzer (Sievers 280i, GE Analytical Instruments, Manchester, 
United Kingdom) as the amount of light from the ozone-NO reaction in the NO measurement 
chamber. NO tissue protein content was expressed as NO release per g protein, determined 
by the Bradford assay (ThermoFisher Scientific, Chicago, IL).  
Oxidative stress, inflammatory cytokines and AP
Supernatant of kidney homogenates were obtained as described above. Supernatant was 
used to measure tissue malondialdehyde (MDA) levels to quantify oxidative stress by assessing 
lipid peroxidation by tandem mass spectrometry as described previously.13 Lipid peroxide 
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content was expressed as MDA content per g protein, determined by the Bradford assay. 
TNF-α and IL-6 were determined by ELISA (DY510, DY506; R&D Systems, Minneapolis, MN). 
Immunohistochemical analysis 
After fixation in 10% formalin, tissue was processed and embedded in paraffin. Kidney sections 
(5 µm) were deparaffinized, antigen retrieval was accomplished using citrate buffer (pH 6.0) 
and endogenous peroxidase activity was blocked using 3% H2O2. Sections were incubated 
o/n at 4 ºC with antibody rabbit anti-rat inducible nitric oxide synthase (iNOS) (RB-1605-P; 
NeoMarkers Fremont, CA) or rabbit-anti-human IL-6 (ab6672; Cambridge, UK; cross-reactive to 
rat), or incubated for 1 h at RT with antibody rabbit anti-rat myeloperoxidase (MPO) (RB-373-A; 
NeoMarkers), rabbit anti-human Lipocalin-2 (NGAL, neutrophil gelatinase-associated lipo-
calin) (ab41105; Abcam; cross-reactive to rat), rabbit-anti-rat liver-type fatty acid binding 
protein (L-FABP) (HP8010; Hycult Biotect, Uden, The Netherlands), or rabbit-anti-rat Bcl-2-asso-
ciated X protein (Bax) (4 µm; sc-493; Santa Cruz, Heidelberg, Germany). Antibodies were used 
at a 1:100 dilution in UltraAb Diluent (TA-125-UD; LabVision, Thermo Scientific, Chicago, Illi-
nois), or 1:50 in case of Bax. Subsequently, sections were stained with secondary biotinylated 
goat-anti-rabbit antibody (1:100; TR-125-BN; LabVision) for 30 min at RT. Immunostaining was 
visualized with AEC substrate (TA-007-HAC; LabVision), followed by hematoxylin counterstain. 
Both intensity and distribution were scored in a semiquantitative fashion. Positively stained 
cells were counted and graded according to staining intensity: 0 (no staining), 1+ (weak but 
detectable above control, 2+ (distinct), 3+ (intensive). A histological score (HSCORE) value was 
derived by counting cumulative percentages of cells that stained at each intensity multiplied 
by the weighted intensity of the staining (HSCORE = S Pi (i+1), where i is the intensity score 
and Pi is the corresponding percentage of the cells).19 MPO was scored in 240 selected glom-
eruli and peritubular areas in each group using a binary scoring system; 1 if leukocytes were 
observed, 0 if not. Scoring was performed by investigators blinded to the treatment protocol. 
Statistical analysis
Normal distribution of the data could not be assumed due to the small sample size. There-
fore, data is expressed as median [25th percentile, 75th percentile]. Significant differences within 
groups were estimated using Friedman test with Dunn’s post-test, differences between 
groups were estimated using two-way repeated measures ANOVA with Bonferonni’s post-test 
on log-transformed data. Chi-square test was used to analyze binary outcomes. A two-sided 
p-value less than 0.05 was considered statistically significant. All tests were performed with 
Graphpad Prism 5.00 for Windows (Graphpad Software Inc., Ja Lolla, CA).
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Results
 
RecAP prevents I/R-induced alterations of renal hemodynamics 
immediately following reperfusion
The renal protective effect of recAP was investigated during I/R-induced AKI in rats, performed by 
30 min suprarenal aortic clamping followed by a 2.5 h reperfusion period (Supplemental Figure 
1A). MAP was reduced at the end of reperfusion period in all groups compared to baseline (p<0.05), 
which was more pronounced in the I/R group, and not affected by recAP treatment (Figure 1A), 
administered 15 min preceding reperfusion. Immediately following reperfusion (T15), recAP treat-
ment attenuated the detrimental effect of I/R on RVR and I/R-induced changes in RBF was not 
longer significantly affected. At 2.5 h post-reperfusion (T150), RBF was impaired in all three groups 
compared to baseline (T0) (Figure 1A) and to a greater extent in the I/R groups. 
Figure 1. 
 Hemodynamic parameters during I/R-induced AKI (A) or LPS-induced AKI (B). 
 (A) Parameters were determined at baseline (T0) and after 15 min (T15) and 150 min (T150) reperfusion. RecAP 
was administered 15 min preceding reperfusion. (B) Parameters were determined at baseline (T0) and 1.5 (T1.5), 
2 (T2) and 4.5 h (T4.5) after start of LPS infusion, which was followed by fluid resuscitation until T1.5. RecAP was 
administered directly after T1.5. Data is expressed as median [25th percentile, 75th percentile]. Significant differ-
ences were estimated using two-way repeated measures ANOVA with Bonferonni’s post-test on log-transformed 
data (n=6 per group). # p<0.05 Control vs. I/R or Control vs. LPS, * p<0.05 I/R vs. I/R+recAP, ‡ p<0.05 Control vs. I/
R+recAP or Control vs. LPS+recAP. 
T0 T15 T150
0
50
100
150
M
ea
n 
ar
te
ria
l p
re
ss
ur
e 
(m
m
H
g)
T0 T15 T150
0
2
4
6
8
Re
na
l b
lo
od
 
ow
 (m
L/
m
in
) 
T0 T15 T150
0
2000
4000
6000
Re
na
l v
as
cu
la
r r
es
is
ta
nc
e
(D
yn
.s
.c
m
-5
)
T0 T1.5 T2 T4.5
0
50
100
150
M
ea
n 
ar
te
ria
l p
re
ss
ur
e 
(m
m
H
g)
T0 T1.5 T2 T4.5
0
5
10
15
Re
na
l b
lo
od
 
ow
 (m
L/
m
in
)
T0 T1.5 T2 T4.5
0
1000
2000
3000
4000
Re
na
l v
as
cu
la
r r
es
is
ta
nc
e
(D
yn
.s
.c
m
-5
)
#
#
‡
‡
‡
# ‡
# ‡
#
*#
I R I R I R
LPS LPS
I/R I/R+recAPControl
LPS LPS+recAPControl
LPS
A
B
152  |  CHAPTER 6  |  Effects of recAP in two models of AKI
Table 1. Renal oxygenation during I/R-induced AKI 
T0 T15 T150
Cortical µPO2 (mmHg) Control 79 [62-89] 76 [69-87] 68 [64-77]
 I/R 80 [75-87] 70 [64-75] 54 [46-60]‡#
I/R+recAP 85 [80-86] 79 [67-89] 67 [56-79]‡*
Medullar µPO2 (mmHg) Control 60 [55-66] 56 [50-62] 49 [46-53]‡
I/R 63 [58-64] 53 [51-58] 44 [39-48]‡
I/R+recAP 65 [62-68] 54 [51-57] 44 [39-53]‡
DO2 (mL O2 min
-1) Control 4.2 [3.9-6.4] 3.4 [2.6-4.5] 3.0 [2.5-3.7]‡
I/R 4.4 [3.9-5.4] 2.1 [1.7-2.5]‡# 1.9 [1.6-2.4]‡#
I/R+recAP 4.3 [3.5-6.1] 2.7 [2.1-4.0] 1.6 [1.2-2.2]‡#
VO2 (mL O2 min
-1) Control 2.3 [2.0-3.4] 1.9 [1.5-2.1] 1.8 [1.5-2.3]
I/R 2.4 [2.3-2.7] 1.2 [1.0-1.6]‡ 1.2 [1.2-1.7]‡
I/R+recAP 2.4 [1.7-3.2] 1.6 [1.0-2.2] 0.9 [0.7-1.4]‡#
ER (%O2) Control 52 [46-57] 56 [50-60] 61 [55-63]‡
I/R 53 [50-62] 60 [56-68] 67 [62-76]‡
I/R+recAP 52 [49-58] 54 [50-58] 65 [51-71]‡
 Parameters were determined at baseline (T0) and after 15 min (T15) and 150 min (T150) reperfusion, which 
followed a 30 min period of ischemia. RecAP was administered 15 min preceding reperfusion. Data is expressed 
as median [25th percentile, 75th percentile]. Significant differences within groups were estimated using Friedman 
test with Dunn’s post-test, differences between groups were estimated using two-way repeated measures ANOVA 
with Bonferonni’s post-test on log-transformed data (n=6 per group). ‡ p<0.05 compared to baseline within a 
group, # p<0.05 compared to Control, * p<0.05 compared to I/R. DO2, oxygen delivery; ER, oxygen extraction 
ratio; µPO2, microvascular oxygen tension; VO2, oxygen consumption.
Regarding renal oxygenation (Table 1), both renal oxygen delivery (DO2) and oxygen consump-
tion (VO2) were significantly reduced post-reperfusion compared to baseline. Following 
recAP treatment, this was not observed immediately following reperfusion (T15). The oxygen 
extraction ratio (ER%) increased in all three groups at the end of reperfusion, with no differ-
ences between groups. While cortical microvascular oxygen tension (µPO2) was impaired in 
both I/R groups at the end of reperfusion, recAP treatment significantly improved this param-
eter compared to the I/R group. Medullar µPO2 was decreased in all groups after the 2.5 h 
reperfusion period compared to baseline, and remained unaffected by recAP administration.
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Figure 2.
 Immunohistochemical results during I/R-induced AKI. 
 Kidneys were harvested after the 2.5 h reperfusion period. A histological score (HSCORE) value was derived 
counting cumulative percentages of cells that stained at each intensity multiplied by the weighted intensity of 
the staining. Data is expressed as box and whiskers plots with 10-90 percentile. Significant differences were esti-
mated using Kruskal-Wallis test with Dunn’s post-test (n=6 per group). # p<0.05 Control vs. I/R+recAP, * p<0.05 
I/R vs. I/R+recAP. 
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Table 2.  Renal tissue levels of inflammatory and oxidative stress during AKI  
I/R PROTOCOL ENDOTOXEMIA PROTOCOL 
Control I/R I/R+recAP Control LPS LPS+recAP
MDA (µmol/g) 4.3 [3.4-4.6] 5.5 [4.6-6.0] 4.7 [4.4-5.0] 1.5 [1.1-1.7] 3.0 [2.9-3.7]# 2.9 [2.1-3.6]#
NO (µmol/g) 2.4 [1.4-2.9] 3.8 [2.9-4.5] 3.3 [1.9-4.9] 0.9 [0.6-1.1] 2.5 [1.8-3.7]# 2.3 [1.3-2.5]#
TNF-α (pg/µg) 1.5 [1.3-2.2] 6.9 [6.4-7.9]# 5.8 [2.9-6.6] 0.9 [0.8-1.2] 0.8 [0.6-0.8] 0.8 [0.6-0.9]
IL-6 (pg/µg) 5.3 [4.2-6.8] 22.8 [16.9-26.2]# 18.6 [10.1-21.1] 7.6 [5.7-9.4] 5.7 [4.8-6.9] 5.7 [4.7-6.8]
 Data is expressed as median [25th percentile, 75th percentile]. Significant differences were estimated using Krus-
kal-Wallis test with Dunn’s post-test (n=6 per group). # p<0.05 compared to Control. 
RecAP treatment prevents I/R injury-induced renal inflammation 
Renal MDA and NO levels, markers of oxidative and nitrosative stress respectively, were not 
affected by I/R itself or by I/R+recAP treatment (Table 2). However, immunohistochemistry 
demonstrated that recAP treatment attenuated iNOS staining, representing nitrosative stress, 
which was not significantly increased by I/R injury alone (Figure 2). The renal content of pro-in-
flammatory mediators TNF-α and IL-6 was significantly increased following I/R injury, which 
was not observed following recAP treatment (Table 2). Immunohistochemistry data showed 
that IL-6 tended to be increased by I/R and was significantly reduced in recAP treated kidneys 
(Figure 2). As biomarkers of renal injury, staining of L-FABP and proapoptotic protein Bax was 
not affected by I/R compared to control animals, but was significantly reduced in the recAP-
treated kidneys (Figure 2). NGAL expression was not increased by I/R injury, nor influenced by 
recAP treatment (data not shown). 
As another marker of acute inflammation, MPO-stained leukocyte influx20 was assessed in 
the glomerulus and in the peritubular areas. MPO staining was similar in the glomeruli of 
the control group compared to the I/R group (positive areas: 80 vs. 75%; p=NS), while it was 
decreased in the I/R+recAP group compared to control (68%; p=0.01). In the peritubular 
areas, I/R injury decreased leukocyte influx compared to control (83 vs. 65%; P<0.0001), which 
was further attenuated by recAP treatment (52%; p<0.0001 compared to control; p<0.05 
compared to I/R). 
LPS-induced systemic hemodynamic instability and impaired renal 
oxygenation is not influenced by recAP
In a second rat AKI model, the renal protective effect of recAP was assessed following shock 
induced by LPS infusion in rats (Supplemental Figure 1B). LPS administration decreased MAP 
(p<0.01) compared to placebo, and this decrease in MAP was not affected by recAP admin-
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istration (Figure 1B). RVR was not different between the groups (Figure 1B), but was reduced 
in the LPS+recAP group 2 h post-LPS (T2, 30 min after recAP administration) compared 
to baseline (p<0.05). RBF remained stable over time in all groups compared to baseline. 
Endotoxemia did not affect DO2 or VO2 significantly, but DO2 was significantly lower in the 
LPS+recAP group at T1.5 and T4.5 compared to control (Table 3). The oxygen extraction ratio 
was increased in all groups at T4.5 compared to baseline, and was higher in the LPS and the 
LPS+recAP group compared to control (Table 3). Similar results were observed for cortical and 
medullar µPO2, which were impaired during endotoxemia at T4.5, with no effect of recAP 
administration (Table 3). 
Table 3.  Kidney oxygenation during LPS-induced AKI
T0 T1.5 T2 T4.5
Cortical µPO2 (mmHg) Control 84 [78-95] 74 [68-83] 69 [66-77]‡ 65 [60-72]‡
LPS 88 [82-92] 79 [73-84] 78 [76-80] 56 [53-59]‡#
LPS+recAP 88 [84-93] 81 [74-84] 70 [66-75]‡ 50 [46-55]‡#
Medullar µPO2 (mmHg) Control 66 [61-71] 56 [52-62] 54 [49-57]‡ 50 [44-55]‡
LPS 68 [64-70] 62 [55-64] 61 [57-62] 42 [39-47]‡#
LPS+recAP 65 [64-72] 61 [58-65] 55 [52-56]‡ 41 [35-44]‡#
DO2 (mL O2 min
-1) Control 4.1 [3.5-5.0] 3.7 [3.0-4.2] 3.1 [2.8-4.5] 3.2 [2.4-4.4]
LPS 4.6 [4.3-4.8] 2.1 [2.0-3.0] 6.0 [3.8-8.2] 2.3 [1.3-3.7]
LPS+recAP 4.0 [3.2-5.5] 2.0 [1.4-2.9]‡# 4.2 [3.4-5.0] 1.2 [1.0-3.1]‡#
VO2 (mL O2 min
-1) Control 1.9 [1.5-2.3] 1.9 [1.5-2.3] 1.8 [1.5-2.7] 2.3 [1.4-3.4]
LPS 2.0 [1.9-2.3] 1.3 [1.2-1.4] 3.6 [2.5-4.8] 2.0 [1.1-3.3]
LPS+recAP 1.9 [1.3-2.5] 1.0 [0.6-1.9] 2.9 [1.8-3.2] 1.0 [0.9-2.8]
ER (%O2) Control 44 [43-46] 49 [49-53] 56 [51-62]‡ 72 [55-79]‡
LPS 45 [41-51] 59 [51-61] 67 [57-69]‡ 87 [84-91]‡#
LPS+recAP 43 [41-48] 52 [44-58] 65 [53-74] 88 [84-93]‡#
 Parameters were determined at baseline (T0) and 1.5 (T1.5), 2 (T2) and 4.5 h (T4.5) after start of LPS infusion. RecAP 
was administered directly after T1. Data is expressed as median [25th percentile, 75th percentile]. Significant   differ-
ences within groups were estimated using Friedman test with Dunn’s post-test, differences between groups were 
estimated using two-way repeated measures ANOVA with Bonferonni’s post-test on log-transformed data (n=6 
per group). ‡ p<0.05 compared to baseline within a group, # p<0.05 compared to Control. DO2, oxygen delivery; 
ER, oxygen extraction ratio; µPO2, microvascular oxygen tension; VO2, oxygen consumption.
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RecAP inhibits markers of renal inflammation and damage during 
endotoxin-induced shock 
Tissue NO and MDA levels were significantly increased by LPS treatment, irrespective of recAP 
co-administration (Table 1). However, recAP treatment attenuated LPS-induced iNOS reac-
tivity (Figure 3). While LPS had no effect on tissue levels of TNF-α and IL-6, immunohistochem-
istry data demonstrated a significant increase in expression of IL-6, L-FABP and Bax, which was 
ameliorated by recAP treatment (Figure 3). Similar results were shown for NGAL immunoreac-
tivity (HSCORE Control: 90 [60-200], LPS: 200 [135-310], LPS+recAP:100 [60-160]; p<0.0001), and 
for leukocyte infiltration. LPS administration induced leukocyte influx in both the glomer-
ulus (positive areas: 93 vs. 75% in the control group; p<0.0001) and the peritubular areas (77 
vs. 65%; p<0.01). RecAP treatment did not reduce the influx in the glomerulus (87%; p=NS 
compared to the LPS group), but did prevent the peritubular influx (66%, p<0.05). 
Discussion
Sepsis-associated AKI is a multifactorial syndrome in which several processes, including 
inflammation, hemodynamic instability, renal microcirculatory dysfunction and unbal-
anced renal bioenergetics play a crucial role.2 RecAP represents a potential therapy targeting 
these multiple processes, which was previously shown to exert anti-inflammatory effects on 
cultured tubular cells.12 The effects of recAP on hemodynamics and renal oxygenation were 
not assessed previously. Here, we demonstrate mild modulatory effects of recAP on these 
parameters during I/R-induced AKI, while hemodynamics and renal oxygenation are not 
affected by recAP during endotoxemia-induced AKI. However, in both models, recAP atten-
uated renal injury and inflammation, confirming the protective effects observed previously 
during LPS-induced renal inflammation in vivo.12
The kidney is highly susceptible to hypoxic injury as the organ is borderline ischemic and has 
to meet high energy demands.21 As such, tissue oxygenation within the kidney is strictly regu-
lated. Under normal conditions, there is a delicate balance between oxygen delivery, mainly 
determined by RBF, local tissue perfusion and blood oxygen content; and oxygen consump-
tion, influenced by GFR, sodium reabsorption, mitochondrial function and tubular integrity.22 
I/R-induced injury disturbs this balance by reducing RBF and causing hypoperfusion in the 
ischemic phase, followed by a decreased renal oxygen delivery and oxygen consumption and 
increased intrarenal oxygen shunting during the reperfusion phase.23 However, in daily clin-
ical practice, AKI may also occur without clear signs of hypoperfusion.24 Animal and human 
data suggest that during sepsis, AKI can develop in the setting of sustained or even increased 
RBF.5,6 Due to this discrepancy in kidney perfusion, the effects of recAP were investigated in 
two distinct models of AKI.
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Figure 3. 
 Immunohistochemical results during LPS-induced AKI.
 Kidneys were harvested 4.5 h after initiations of LPS treatment. A histological score (HSCORE) value was derived 
counting cumulative percentages of cells that stained at each intensity multiplied by the weighted intensity of 
the staining. Data is expressed as box and whiskers plots with 10-90 percentile. Significant differences were esti-
mated using Kruskal-Wallis test with Dunn’s post-test (n=6 per group). # p<0.05 Control vs. LPS, * p<0.05 LPS vs. 
LPS+recAP. 
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In the I/R model, RBF was impaired during the post-reperfusion period. After recAP treatment, 
RBF was not longer significantly affected immediately following reperfusion and neither 
were  renal oxygen delivery and consumption at this time-point. Although these microcir-
culatory improvements were modest and were not maintained until the end of reperfusion, 
the anti-inflammatory effect of recAP may have reduced arterial to venous shunting, resulting 
in an improved cortical microvascular oxygen pressure during the 2.5 h reperfusion period. 
In contrast, recAP was found not to improve renal oxygenation during endotoxemia. 
Apart from the timing of the intervention (recAP was administrated 15 min following isch-
emia and 60 min following LPS administration), the nature of the inflammatory response 
may account for this observed discrepancy. I/R-induced hypoxia triggers renal inflamma-
tion via several mechanisms, including structural alterations of proteins and cell surfaces, 
active synthesis of pro-inflammatory mediators and downregulation of anti-inflamma-
tory molecules.7 In addition, ischemic stress induces the release of cellular factors such as 
high mobility group 1 protein25 and heat shock proteins.26 Toll-like receptor (TLR)-2 and 
TLR4, pattern recognition receptors (PRR) localized on proximal tubule epithelial cells, 
are triggered by these endogenous ligands, thereby further exacerbating renal injury 
together with complement system activation, oxidative and nitrosative stress and mito-
chondrial dysfunction.27,28 This is in contrast to endotoxemia-induced AKI, during which 
renal inflammation is not only triggered by endogenous PRR ligands, but mainly by the 
bacterial ligand LPS which induces a profound inflammatory insult upon binding to TLR4 
on multiple cells including proximal tubular epithelial cells.29 In addition, binding of LPS to 
TLR4 on immune cells elicits systemic release of inflammatory mediators30, to which both 
vascular endothelium and renal tubular cells respond. In concert with a prolonged leuko-
cyte transit time in dysfunctional capillaries31,32, this may further amplify renal inflammation. 
RecAP affected the inflammatory response induced by IR, as protein levels of IL-6 and TNF-α 
were not longer significantly increased and the expression of renal injury parameters was 
lower, although these were not significantly increased by I/R-injury itself. Possibly, renal 
injury partially recovered after the 2.5 h reperfusion period in this relatively mild model.13,33,34 
Also during endotoxemia, administration of recAP attenuated renal inflammation, as was 
shown by a less pronounced peritubular influx of leukocytes and IL-6 expression. More-
over, recAP inhibited proximal tubule injury and markers of apoptosis, reflected by L-FABP 
and BAX immunostaining. Likely, these protective effects may be attributed to dephos-
phorylation of LPS and the endogenous proinflammatory molecules ATP and APD, released 
by proximal tubule cells during inflammation.12 Of note, and  in contrast to the I/R-model, 
we did not find an increase in renal cytokine protein levels, but did detect a high level of 
oxidative and nitrosative stress. Despite its anti-inflammatory effects following LPS-in-
duced shock, recAP treatment did not result in improved renal oxygenation in this model. 
This might be explained by the finding that in a rat model of severe shock recAP cannot 
restore the imbalance between NO, a major regulator of the microvascular oxygen supply, 
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ROS and oxygen, which is key for an adequate physiological control of renal function.22 
Several limitations have to be acknowledged. First, although recAP modulated renal hemody-
namics and oxygenation during I/R-induced AKI, these effects were modest and the clinical 
relevance of these findings might be limited. Second, following endotoxin administration, RBF 
remained stable over time, thereby limiting the possibility to demonstrate effects of recAP on 
renal hemodynamics. Although one may argue that the LPS dose administered is not high 
enough to severely affect renal hemodynamics, we aimed to investigate the effects of recAP 
in a clinically relevant model. As recently demonstrated in an intensive care-supported model 
of E. coli-induced septic shock in sheep, early AKI is not associated with changes in renal 
blood flow, oxygen delivery or histological changes, suggesting other mechanisms contrib-
uting to septic AKI.35 These findings corroborate previous studies.5,6 As our model presents 
with signs of impaired systemic hemodynamics, renal oxygenation, as well as clear signs of 
renal injury, we believe that this is a representative model of endotoxemia-induced AKI in 
which we were able to confirm the renal protective effect of recAP. Third, the fact that recAP is 
administered not preventively but therapeutically, namely following initiation of the ischemic 
or endotoxic insult, may have hampered the potential of recAP to modulate renal microcircu-
latory dysfunction and hemodynamic changes. However, this protocol is more clinically rele-
vant as it is in line with the ongoing phase II trial, in which recAP is administered to patients 
with confirmed sepsis-associated AKI. Moreover, previous findings demonstrate that recAP 
provides renal protection when administered two hours after administration of LPS12, indi-
cating that recAP can still exert protective effects when LPS-induced inflammation is fully 
developed.36,37 Also, the renal protective anti-inflammatory effects were primarily determined 
by immunostaining, a non-quantitative method. Although these results could have been 
corroborated by employing quantitative assays (e.g. assessing renal gene expression levels), 
the primary aim of this study was to investigate the effect of recAP on renal hemodynamics 
and oxygenation as the renal protective effect of recAP has already been demonstrated in 
vivo previously.12 Finally, as sepsis-associated AKI is a complex syndrome, the potential activity 
of recAP on other inflammatory components, such as the complement and coagulation path-
ways, eicosanoids, PRR ligands, and platelet activation factors, would be relevant to assess, 
but was beyond the scope of the current study. Of interest, the protective potential of AP 
has been confirmed in several other inflammatory models. AP administration reduced fever 
after Escherichia coli-induced inflammation in mice38, improved gas exchange (PaO2:FiO2 
ratio) during  septic shock induced in sheep39, prevented liver and lung damage in mice 
after cecal ligation and puncture40 and increased thrombocyte counts in piglets following 
LPS administration.38 Also, AP attenuated circulating cytokine levels in mice40 and sheep39, 
which was confirmed in a phase 2 clinical study in which bovine intestinal AP more swiftly 
reduced several systemic inflammatory parameters in patients with sepsis-associated AKI.10 
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Conclusion
RecAP can modulate renal oxygenation and hemodynamics immediately following 
I/R-induced AKI, but did not influence these during endotoxemia-induced AKI. RecAP 
did exert a clear renal protective anti-inflammatory effect in both models. Whether 
this renal protective effect is sufficient to improve outcome of patients suffering from 
sepsis-associated AKI is currently being investigated in a large phase II a/b clinical trial.41 
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Supplemental Figure
Supplemental Figure 1.
  Schematic set-up of rat models of I/R-induced AKI (A) or endotoxemia-induced AKI (B). FR, fluid resuscitation.
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Abstract
S  epsis-associated acute kidney injury (AKI) is associated with high morbidity and mortality. Excessive platelet activation contributes to AKI through the formation of microthrombi and amplification of systemic inflammation. Two phase II trials demon-
strated that bovine-intestinal alkaline phosphatase (AP) improved renal function in critically 
ill patients with sepsis-associated AKI. In this study, we characterised the platelet-inhibiting 
effects of a human recombinant AP. Whole blood and platelet-rich plasma (PRP) of healthy 
volunteers (n=6) was pre-treated ex vivo with recAP, whereafter platelet reactivity to ADP, 
collagen-related peptide (CRP-XL) and Pam3CSK4 was determined by flow cytometry. RecAP 
(40 U/ml) reduced the platelet reactivity to ADP (inhibition with a median of 47%, interquartile 
range 43-49%; p<0.001) and tended to reduce platelet reactivity to CRP-XL (9%, 2-25%; p=0.08) 
in whole blood. The platelet-inhibiting effects of recAP were more pronounced in PRP both for 
ADP- (64%, 54-68%; p=0.002) and CRP-XL-stimulated samples (60%, 46-71%; p=0.002). RecAP 
rapidly converted ADP into adenosine, whereas antagonism of the A2A adenosine receptor 
partially reversed the platelet inhibitory effects of recAP. Platelets of septic shock patients 
(n=5), showed a 31% (22-34%; p=0.03) more pronounced reactivity compared to healthy 
volunteers, and this was completely reversed by recAP treatment. In conclusion, we demon-
strate that recAP inhibits ex vivo human platelet activation through dephosphorylation of 
ADP and formation of adenosine as its turnover product. RecAP is able to reverse the platelet 
hyperreactivity present in septic shock patients. These effects may contribute to the beneficial 
effects of recAP as a new therapeutic candidate for sepsis-associated AKI.in the critically ill.5
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Introduction
The morbidity and mortality of severe sepsis and septic shock remains high despite advances 
in medical care.1 A frequent consequence of sepsis is the development of acute kidney injury 
(AKI), which increases mortality to >50% and progresses to chronic kidney disease in up to 
one-third of critically ill patients.2,3 New therapies to improve the prognosis of sepsis and 
sepsis-associated AKI patients are therefore urgently needed. An example of a promising 
novel therapy is the dephosphorylating enzyme alkaline phosphatase (AP). AP is a membrane-
bound homodimeric glycoprotein of which four isozymes are known: placental, germ cell, 
intestinal, and tissue-nonspecific (liver/bone/kidney).4 In two phase II trials, bovine-derived AP 
was shown to have a renal protective effect in critically ill patients with sepsis-associated AKI.5,6
Subsequently, a human recombinant AP (recAP) was developed with important advances 
over bovine-derived AP in terms of immunity, stability and enzymatic activity.7 This novel 
chimeric enzyme was developed by replacing the crown domain of a human intestinal AP 
with the crown domain of human placental AP. How exactly AP exerts its beneficial effects 
is still incompletely understood. In vitro studies indicate that the anti-inflammatory effects 
of recAP is related to its dephosphorylating activity on lipopolysaccharide (LPS), which is 
involved in the inflammatory cascade observed in sepsis patients, and the conversion of the 
pro-inflammatory molecule adenosine triphosphate (ATP) and adenosine diphosphate (ADP) 
into tissue-protective adenosine.4,8-10 ADP is one of the most potent platelet activators which 
interacts with the P2Y12 and P2Y1 receptors. P2Y12 is the major target of platelet inhibitory 
drugs such as clopidogrel, prasugrel and ticagrelor.11,12 Platelets themselves also contain large 
quantities of ATP and ADP in dense granules, which are released when they are activated. In 
contrast, adenosine inhibits platelet activation through the A2A and A2B adenosine receptor.13 
Three studies from the late 1980s showed that bovine-derived kidney AP inhibited platelet 
aggregation14-16, but since then, the platelet-modulating effects of AP has not received much 
attention. Nevertheless, these effects may be relevant as accumulating evidence supports a 
key role for platelets in sepsis and subsequent kidney damage. First, excessive platelet acti-
vation during sepsis leads to platelet sequestration and platelet-rich microthrombi, blocking 
the microcirculation and thereby compromising the kidney function. Second, activated plate-
lets release an array of proteins with immune modulatory properties that contribute to the 
amplification of systemic inflammation, and form complexes with leukocytes, altering their 
phenotype.17-19
The aims of our study were to investigate the effects of recAP on platelet activation, identify 
involved pathways with special emphasis on ADP and adenosine, and determine the effect of 
recAP on sepsis-associated platelet hyperreactivity.  
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Methods
Materials
Human recombinant alkaline phosphatase (recAP) and inactivated recAP were kindly provided 
by AM-Pharma (Bunnik, The Netherlands). Adenosine 5′-diphosphate (ADP) was purchased 
from Sigma-Aldrich (St Louis, MO, USA), cross-linked collagen-related peptide (CRP-XL) was 
a generous gift from Prof. dr. R. Farndale (Cambridge, UK). Pam3CSK4 (N-palmitoyl-S-[2,3-
bis(palmitoyloxy)-(2RS)-propyl]-[R]-cysteinyl-[S]-seryl-[S]-lysyl-[S]-lysyl-[S]-lysyl-[S]-lysine × 3 
HCl) was purchased from InvivoGen (San Diego, CA, USA). The A2A adenosine receptor (AR) 
antagonist ZM-241385 and A2BAR antagonist PSB-1115 were purchased from Tocris Bioscience 
(Bristol, UK). HEPES-buffered saline was used as control medium. 
Platelet function assays
Platelet reactivity 
Whole blood was collected from six consenting healthy volunteers for the ex vivo experiments 
by using venipuncture from the antecubital vein into citrate-anticoagulated tubes (3.2%; BD 
Vacutainer, Becton Dickinson). In addition, platelet-rich plasma (PRP) for selected experiments 
was obtained by centrifuging citrated-whole blood (n=6) for 15 minutes at 156 g without brake, 
and platelet concentration was adjusted to 1x108/ml. Whole blood or PRP was pre-treated 
with different concentrations of recAP (10-100 U/ml) at 37°C for 45 minutes in 1.5 ml Eppen-
dorf tubes (Eppendorf Biopur, Hamburg, Germany) and platelet reactivity to different platelet 
agonists was subsequently determined by flow cytometry. Pre-treatment was also performed 
with HEPES-buffered saline, inactivated recAP (in protein concentration equivalent to recAP) 
and potato apyrase as controls. Platelet reactivity was determined by flow cytometric quan-
tification of the platelet membrane expression of P-selectin (CD62P) and platelet-fibrinogen 
binding, which correspond with platelet activation and aggregation, respectively, as previ-
ously described.20,21 In short, pre-treated samples were added to a mixture of HEPES-buffered 
saline and saturating concentrations of the following combinations of monoclonal antibodies: 
PE-labeled anti-CD62P (FITC-labeled Bio-Legend, San Diego, USA), FITC-labeled anti-fibrinogen 
(DAKO Ltd., High Wycombe, UK) and PC7-labeled anti-CD61 (platelet identification marker; 
Beckman Coulter, France). Platelets were activated with ADP (7.8 μM and 31.2 μM), CRP-XL (39 
μM and 625 μM) or Pam3CSK4 (60 ug/ml). After incubation for 20 minutes at room tempera-
ture (RT), a fixative solution (0.2% paraformaldehyde) was added and samples were analyzed 
using an FC500 flow cytometer (Beckman Coulter, France). Platelets were gated based on their 
forward- and sideward-scatter (FSC/SSC) properties and positivity for CD61, which was defined 
as a median fluorescence intensity (MFI) exceeding the MFI of the matched isotype control. 
Next, the MFI of CD62P and fibrinogen on CD61-positive events were determined. 
To study the washed-out effect of recAP on platelet membrane proteins, PRP was exposed 
to recAP (40 U/ml) at 37°C for 45 minutes, samples were centrifuged for 15 minutes at 330 g 
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without brake to pellet platelets, and the supernatant was removed. Pelleted platelets were 
subsequently resuspended in fresh-autologous plasma to its original PRP volume and platelet 
reactivity was determined. In experiments where the adenosine receptor antagonists were 
used, whole blood and PRP was co-incubated with ZM-241385 and PSB-1115 (30 μM) for 15 
minutes prior to recAP pre-treatment at 37°C. 
Platelet-monocyte complex formation
Platelet-monocyte complex formation leads to reciprocal activation of both cells and is 
regarded as a sensitive marker of platelet activation.22,23 Platelet-monocyte complex forma-
tion was determined by adding whole blood samples to HEPES-buffered saline mixture 
containing saturating concentrations of PE-labelled anti-CD14 (a glycosyl-phosphatidylinositol 
(GPI)-linked membrane glycoprotein; Biolegend) and PC7-labelled anti-CD61 as monocyte 
and platelet markers, respectively. After 20 minutes of incubation at RT, Optilyse B (Beckman 
Coulter, CA, USA), a lysing solution which also contains 3.4% formaldehyde, was added to lyse 
erythrocytes. Monocytes were gated based on CD14 positivity. Platelet-monocyte complex 
formation was determined by quantifying the MFI of CD61 on the CD14-positive cells. In our 
experiments, whole blood was incubated for 45 minutes at 37°C in the presence or absence 
of recAP. Platelets may be pre-activated by ex vivo handling prior to the start of the experi-
ments or by the use of lysing buffer. We therefore determined the extent of platelet activa-
tion in whole blood with or without 45 minutes of incubation in 37°, and whether differential 
platelet activation occurred when Optilyse B was used as a lysing buffer. 
Measurement of purine content
In a set of control experiments using PRP from 4 healthy volunteers, adenosine, AMP, ADP and 
ATP content was determined by HPLC. In brief, PRP were pre-treated for 45 minutes in 37 with 
medium, recAP (40 U/ml) or inactivated recAP (in equivalent protein content). Subsequently, 
platelet activation was induced by incubation with ADP or CRP-XL for 20 minutes in room 
temperature, and samples were centrifuged for 15 minutes at 330 g without brake to obtain 
the supernatant. Thereafter, four volumes of supernatant (400 µl) were mixed with 1 volume 
of chloroacetaldehyde (6x diluted in 1M acetate buffer, pH 4.5; Sigma-Aldrich, Zwijndrecht, 
Netherlands), followed by derivatization (60 min, 70 °C, 500rpm) and centrifugation (3 min, RT, 
13400 rpm), whereafter the supernatant was transferred to a HPLC vial and injected. Purines 
were separated by HPLC system (Thermo Scientific, Illinois, USA) using a Polaris C18-A column 
(150 x 4.6 mm) with gradient elution using eluent A (0.1M K2HPO4, 10 mM TBAHS (pH 6.5), and 
2% MeOH) and eluent B (H2O: ACN: THF; 50:49:1). Retention times were 7.1 (adenosine), 8.4 
(AMP), 12.5 (ADP), 16.2 (ATP) and 14.8 min (cAMP). Quantification was based on peak areas of 
the samples and reference standards measured with fluorescence (excitation and emission 
wavelengths set at 280 and 420 nm, respectively).
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Ex vivo study of sepsis patients
A total of five patients with septic shock according to the definitions stated by ACCP and SCCM 
consensus conference24 admitted to the Intensive Care Unit of the Radboud university medical 
center (Radboudumc) were enrolled between July 2014 and February 2015. Exclusion criteria 
were the use of any medication which could affect platelet count and function. The study was 
carried out in accordance with the applicable rules concerning the review of the local ethical 
committee and informed consent. Citrate-anticoagulated whole blood was collected on day 1, 
3, 5 and 7 and was directly pre-treated with recAP (40 U/ml) or HEPES-buffered saline as a control 
at 37°C for 45 minutes. Platelet reactivity to ADP (31 uM) and CRP-XL (39 uM), as well as plate-
let-monocyte complex formation were measured by flow cytometry, as previously described. 
Statistical analyses
Data are expressed as mean (SD) or as medians [25th percentile, 75th percentile]. This is an explor-
atory study and non-parametric statistical analyses was selected due to the small sample 
size. For the experiments with healthy volunteers, differences between multiple groups were 
tested using the Kruskall-Wallis test with Dunn’s post hoc test. Data from the patient study 
were analyzed using the Mann-Whitney U test. Statistical analyses were performed using 
Graphpad Prism 6 (San Diego, USA). P<0.05 was considered statistically significant. 
Results 
RecAP inhibits ex vivo platelet activation in whole blood of healthy 
volunteers
The extent of which recAP inhibits platelet activation was determined by pre-treatment of 
whole blood with recAP, followed by stimulation with the platelet agonists ADP (31 μM) and 
CRP-XL (39 μM). Whole blood samples pre-treated with 40 U/ml of recAP demonstrated an 
impairment in ADP-induced platelet reactivity with the median (25th percentile, 75th percentile) 
maximum inhibition of 47% (43-49%; p=0.0009) in P-selectin expression on platelets, while 
the reactivity to CRP-XL stimulation was reduced to a lesser extent (9%, 2-25%; p=0.08). Similar 
trends were observed in the platelet-fibrinogen binding (Figure 1A; representative histograms 
are presented in Figure 1B, with gating strategies described in Supplemental Figure 1). We 
explored the use of increasing concentrations and pre-treatment duration of recAP, as well 
as different concentrations of ADP and CRP-XL. Increasing the recAP concentration beyond 
40 U/ml or the pre-treatment duration beyond 45 minutes did not further augment the inhi-
bition of platelet activation and these aforementioned conditions were therefore chosen for 
subsequent experiments (Supplemental Figure 2). 
Platelet-monocyte complex formation induced by ADP and CRP-XL was strongly inhibited by 
recAP (Figure 1C). We additionally tested the platelet response to immunological stimulation 
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Figure 1.
 RecAP inhibits platelet activation by ADP and CRP-XL.  
 (A) Whole blood from healthy volunteers was pre-treated with medium or recAP (40 U/ml) for 45 minutes and 
subsequently stimulated with the platelet agonists adenosine diphosphate (ADP; 31 µM) and collagen-related 
peptide (CRP-XL; 39 µM). The medi an fluorescence intensity (MFI) of the platelet surface expression of P-selectin 
and platelet-fibrinogen binding was measured by using flow cytometry. (B) Representative histograms for ADP 
and CRP-XL stimulation. (C) Platelet-monocyte complex formation after exposure to ADP and CRP-XL was deter-
mined by quantifying the MFI of the platelet marker CD61 on CD14+ cells. Data are presented as medians [25th 
percentile, 75th percentile] from 6 healthy donors. * p<0.05, ** p<0.001.
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by using Pam3CSK4 (60 μg/ml), a synthetic agonist of Toll-like-receptor 2 (TLR2). RecAP also 
demonstrated strong inhibition of Pam3CSK4-induced platelet expression of P-selectin, plate-
let-fibrinogen binding and platelet-monocyte complex formation (Supplemental Figure 3). 
Pre-activation of unstimulated platelets may occur by ex vivo handling prior to the start 
of experiments. However, in our setting, the percentage of platelets expressing P-selectin 
between samples with and without 45 minutes of incubation in 37° C were comparable (4.3%, 
3.3-4.7% vs. 4.1%, 3.2-4.7%; p=0.8). Whole blood samples fixated and lysed with Optilyse B for 
the measurement of platelet-monocyte complex also did not show increased platelet pre-ac-
tivation when compared with the 0.2% paraformaldehyde-fixated samples (data not shown). 
Figure 2. 
 RecAP inhibition of platelet activation is dependent on its enzymatic dephosphorylating activity. 
(A) Whole blood was pre-treated for 45 minutes with medium, recAP (40 U/ml) or inactivated recAP (in equiva-
lent protein content) prior to stimulation with ADP (31 µM) or CRP-XL (39 µM). Platelet expression of P-selectin and 
binding with fibrinogen was determined by flow cytometry. (B) Whole blood was pre-treated with medium, recAP, 
apyrase (5 U/ml), or a combination of both recAP and apyrase, before exposure to ADP or CRP-XL. (C) Platelet-rich 
plasma (PRP) was pre-treated for 45 minutes with either medium or recAP. RecAP in the PRP samples was subse-
quently either washed-out, with the remaining platelets resuspended in fresh autologous platelet-poor plasma 
(washed-out recAP samples), or not (recAP samples). Samples are subsequently incubated with medium, ADP or 
CRP-XL. Data are presented as medians [25th percentile, 75th percentile]from 6 healthy donors.  * p<0.05, ** p<0.01.
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The effect of recAP is dependent on its dephosphorylating activity
To determine whether the enzymatic dephosphorylating activity of recAP is required for its 
platelet-inhibitory effect, whole blood was pre-treated with recAP or inactivated recAP, the 
latter having no enzymatic dephosphorylating activity10, and subsequently stimulated with 
ADP and CRP-XL. No reduction of platelet P-selectin or platelet-fibrinogen binding was found 
in samples containing inactivated recAP (Figure 2A).
Next, we compared the effects of recAP with those of apyrase as both compounds demon-
strate ADP-degrading activity. Apyrase is also known to inhibit ADP-dependent platelet aggre-
gation.25,26 Pre-treatment of whole blood with recAP and potato-derived apyrase had a compa-
rable platelet-inhibiting effect on samples stimulated with ADP and CRP-XL (Figure 2B). The 
combination of both compounds had no synergistic effect, suggesting that both shared similar 
ADP-dependent mechanism and already fully inhibited ADP-dependent platelet activation. 
A previous study suggested that AP might also exert its platelet-inhibitory effects through the 
dephosphorylation of platelet membrane proteins.15 To study this mechanism, we pre-treated 
PRP with recAP, thereby exposing the membrane of platelets to recAP. We subsequently 
isolated the platelets from PRP and resuspended them in fresh autologous platelet-poor 
plasma, thereby washing out any potentially remaining recAP. No platelet inhibition occurred 
once the recAP-containing plasma was washed out and replaced with fresh plasma, indi-
cating that there is no persisting, residual dephosphorylating effect of recAP on the platelet 
membrane, and that the platelet-inhibiting activity of recAP is dependent on its presence in 
test medium (Figure 2C). 
The effect of recAP is exerted directly on platelets 
Leukocytes can secrete inflammatory mediators that activate platelets or the coagulation 
system. Furthermore, ADP can also alter the function of leukocytes, which in turn can affect 
platelet activation.9,23 In order to explore the direct effect of recAP on platelets, we performed 
experiments on platelet-rich plasma (PRP). RecAP pre-treatment on PRP resulted in platelet 
inhibition of ADP-stimulated (64%, 54-68%; p=0.002). Interestingly, in PRP samples, those stim-
ulated with CRP-XL showed significant platelet hyporeactivity after pre-treatment with recAP 
(60%, 46-71%; p=0.002), a finding not present in whole blood samples. These data confirmed 
that recAP acts directly on platelets. Similar to data from whole blood, inactivated recAP did 
not demonstrate any platelet-inhibiting effect, and potato-derived apyrase had a comparable 
inhibiting effect on both ADP- and CRP-XL-induced platelet activation in PRP (Figure 3). Data 
on the effect of different doses and pre-treatment duration of recAP on PRP is presented on 
Supplemental Figure 4.
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Figure 3.
 RecAP exerts its inhibitory activity directly on platelets. 
 (A) Platelet-rich plasma (PRP) was pre-treated for 45 minutes with medium, recAP (40 U/ml) or inactivated 
recAP (in equivalent protein content) prior to stimulation with ADP (31 µM) or CRP-XL (39 µM). Platelet expres-
sion of P-selectin and binding with fibrinogen was determined by flow cytometry. (B) PRP was pre-treated with 
medium, recAP, apyrase (5 U/ml), or a combination of both recAP and apyrase, before exposure to ADP or CRP-XL. 
Data are presented as medians [25th percentile, 75th percentile] from 6 healthy donors.  ** p<0.01.
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Formation of adenosine contributes to the platelet-inhibiting effect 
of recAP
Next to a direct dephosphorylating effect of recAP on ADP, we studied whether increased 
adenosine formation may also contribute to the observed platelet-inhibiting effects. APs 
are the only known ectonucleotidases which can degrade extracellular ATP, ADP and AMP 
into adenosine.9 Adenosine exerts both anti-inflammatory and tissue-protective effects, 
and signals by binding with 1 of its 4 receptors: A1AR, A2AAR, A2BAR or A3AR. Adenosine 
signaling via the A2AAR and A2BAR was reported to inhibit platelet activation.13,27 In our expe-
riments, blocking the A2AAR receptor by an A2AAR antagonist partially reversed the platelet 
inhibiting effects by recAP in whole blood (data not shown) as well as in PRP (Figure 4A). 
In contrast, the use of an A2BAR antagonist had no effect (data not shown). RecAP might 
convert ADP into AMP and adenosine, with the latter contributing its effect via the A2AAR. 
To confirm that adenosine was indeed generated by the turnover from ADP, we measured 
purine content from the supernantant of the PRP pre-treated with recAP or inactivated recAP 
that had subsequently been stimulated with ADP and CRP-XL. ADP-stimulated samples 
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Figure 4. 
 Adenosine formation contributes to the platelet-inhibiting activity of recAP.
 (A) PRP was pre-treated with the selective A2AAR antagonist (ZM-241385; 30 µM) for 15 minutes, followed by 
incubation with recAP (40 U/ml). Platelet P-selectin (left panel) and fibrinogen binding to platelets (right panel) 
was determined by flow cytometry after stimulation with ADP (31 µM). Presented data are medians [25th percen-
tile, 75th percentile] from 6 healthy donors. ** p<0.01. (B) Purine levels were determined in the supernatant of PRP 
pre-treated with recAP (40 U/ml) or inactive recAP (in equivalent protein content) and subsequently stimulated 
with ADP (31 µM). Presented data are medians [25th percentile, 75th percentile] from 4 healthy donors. 
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demonstrate increased adenosine levels when pre-treated with recAP (27-fold, 17-49-fold, 
p=0.02) with negligible ATP and ADP levels, indicating their full turnover into AMP and adenosine 
(Figure 4B). Interestingly, CRP-XL induced ADP release when compared to non-stimulated 
samples (11-fold [2-69-fold, p=0.02), which was completely removed upon pre-treatment 
with recAP (Supplemental Figure 5). Taken together, these data suggest that not only the 
dephosphorylation of ADP inhibits platelet activation and reactivity, but the concomitant 
formation of adenosine also augments the inhibitory effect of recAP on platelet function. 
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Figure 5.
 Platelet hyperreactivity in sepsis patients.
 (A) A total of five septic shock patients were followed up on day 1, 3, 5 and 7. Whole blood was collected and 
pre-treated ex vivo with or without recAP (40 U/ml) and stimulated with ADP (31 µM) and CRP-XL (39 µM). 
Whole blood from healthy controls (n=6) was collected on a single time point. Platelet P-selectin and platelet-fi-
brinogen binding were measured by flow cytometry. (B) Platelet-monocyte complex formation was determined 
by quantifying the MFI of the platelet marker CD61 on CD14+ cells in whole blood. Data from 2 patients on day 
1 and day 3 were missing. Presented data are medians [25th percentile, 75th percentile]. * p<0.05 medium vs. recAP 
pre-treatment, ** p<0.01 medium vs. recAP pre-treatment, medium vs. recAP pre-treatment, # p<0.05 healthy 
controls vs. patient on day 1 (Mann-Whitney test). 
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Table 1.  Patient characteristics
ALL PATIENTS (n = 5)
Demographics M/F 4/1
Age (yrs) 68 [43-73]
Body mass index (kg/m2) 26.4 [25.5-28.5] 
Acute Physiology and
Chronic Health Evaluation II
24 [19-26]
Systemic 
inflammatory 
response syndrome
Temperature (ºC)
<36 -
36-38 37.6 [37.5-37.7]
>38 38.5 [38.5-38.6]
Leukocytes (x109/L)
<4 -
4-12 7.1 [5.4-8.7]
>12 17.0 [12.8-17.7]
Heart rate (bpm) 105 [102-116]
Patients on ventilator (%) 100
Platelet count 
(cellsx109/L)
Day 1 220 [139-307]
Day 3 178 [101-238]
Day 5 203 [90-248]
Day 7 312 [120-493]
Ex vivo exposure to recAP reverses sepsis-induced platelet 
hyperreactivity
We performed platelet function tests on whole blood of septic shock patients (n=5) collected 
on day 1, 3, 5 and 7 after the start of norepinephrine infusion, with or without ex vivo recAP 
pre-treatment. Patients’ characteristics are described in Table 1. Patients demonstrated a signi-
ficant increase of platelet activation and aggregation on day 1 compared to healthy controls 
which normalized upon measurement on subsequent days. Upon ex vivo pre-treatment with 
recAP, whole blood samples of these patients demonstrated reversal of the sepsis-associated 
platelet hyperreactivity as well as reduced platelet-monocyte complex formation (Figure 5). 
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Discussion
RecAP is a novel dephosphorylating enzyme currently under investigation as a new therapy 
for sepsis-associated AKI.28 Its exact mechanism of action is still incompletely understood. In 
the present study, we report that recAP reduces platelet reactivity to different platelet agonists 
in a threshold dose-fashion. RecAP strongly inhibited ADP-induced platelet activation in 
whole blood, and additionally CRP-XL-induced platelet activation in PRP. These data from PRP 
confirmed that recAP has a direct effect on platelets. Our data indicate that the dephospho-
rylation of ADP and the formation of adenosine as its turnover product are primarily respon-
sible for the observed platelet-inhibiting effects. Additionally, exposure of whole blood of 
patients with septic shock to recAP reversed the sepsis-associated platelet hyperreactivity, 
further substantiating that this mechanism of action may be of importance in septic patients. 
ADP directly activates platelets via the P2Y12 and P2Y1 receptors on the platelet membrane, 
resulting in degranulation and aggregation.11,29 To determine whether the platelet-inhibiting 
effects of recAP also occurs on different platelet activation pathway, we studied the platelet 
reactivity to CRP-XL which activate platelets via their GPVI receptor.30 In addition to measuring 
platelet reactivity to the thrombotic stimulation by the aforementioned agonists, we exam-
ined the platelet reactivity to immunological stimulation by using Pam3CSK4, which induces 
platelet activation through TLR2.31,32 The release of endogenous ADP from platelet dense 
granules forms an essential amplification mechanism for platelet activation via both GPVI and 
TLR230,32, which can explain the broad platelet-inhibiting effects of recAP. RecAP resulted in a 
strong inhibition of CRP-XL-induced platelet activation in PRP but not in whole blood. Upon 
CRP-XL-stimulation, ADP release by platelets is known to provide an amplification mechanism 
for platelet activatio.30 Indeed, our experiments confirm that CRP-XL induced the release of 
ADP from platelets. In addition, ADP can also be taken up by other blood cells like erythro-
cytes, monocytes and lymphocytes.33-35 RecAP exerts its effect through the dephosphoryl-
ation of ADP into adenosine; and we therefore speculate that the effect of recAP in whole 
blood is less striking because the relative abundance of ADP that is affecting platelets is lower 
in whole blood compared to PRP, thereby limiting the availability of adenosine. In addition, 
adenosine in whole blood is rapidly taken up by erythrocytes, neutrophils and lympho-
cytes.36 As a consequence, higher platelet inhibition by recAP observed in the CRP-XL-stimu-
lated PRP samples compared to the whole blood samples is a plausible result. Furthermore, 
there seemed to be a more pronounced platelet inhibition in samples stimulated with the 
TLR2 agonist Pam3CSK4 compared to the platelet agonist ADP. As is the case with ADP and 
CRP-XL stimulation, the extent of platelet activation and consequently its inhibition by recAP, 
in the Pam3CSK4-stimulated samples may be dose-dependent and as such, the percentage 
of reduction cannot be compared between the different stimuli. 
Our finding that antagonism of the A2A adenosine receptor partly reversed the platelet inhi-
bition by recAP underlines the importance of adenosine generation in the effects of recAP. 
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Adenosine is released from several different cells or generated from extracellular metabolism 
of ATP, ADP and AMP by different ectoenzymes.37 AP is the only known ectonucleotidases 
which can fully degrade ATP and ADP into adenosine9, and this was confirmed by our data. 
Platelet activation is known to be inhibited by the binding of adenosine to the platelet A2A13 
and A2B adenosine receptor.27 The A2A receptor is present in higher density on platelets, 
whereas the importance of the A2B receptor is limited to situations in which the A2B receptor 
density is strongly up-regulated or when pathophysiological adenosine concentrations are 
present.27 This could explain why the A2B antagonist PSB-1115 had no effect on recAP medi-
ated platelet-inhibition in our experiments. 
New pharmacological treatment options are urgently needed in sepsis. In this study, recAP 
was administered preceding ADP-induced platelet activation, thereby mimicking a prophy-
lactic setting. Whether recAP will also exert protective effects in a more clinically relevant 
setting, is currently investigated in a large multicenter randomized controlled phase II trial 
in patients with sepsis-associated AKI.28 Next to the dephosphorylation of endotoxin and 
ATP, prevention of excessive platelet activation may also contribute to the beneficial effects 
of recAP in sepsis and sepsis-associated AKI as platelets are highly activated during sepsis.38 
Increased platelet aggregation, platelet-endothelium binding, platelet-leukocyte complex 
formation and accelerated fibrin formation all contribute to renal microvascular thrombosis.39 
Platelet-derived P-selectin was identified as a key component in this process40 and it is well 
conceivable that this cascade is modulated by the observed effects of recAP as demonstrated 
by our observation that ex vivo recAP treatment reversed platelet hyperreactivity in sepsis 
patients. These results are in accordance with previous findings of Beumer and colleagues 
which showed that calf intestinal AP significantly reduced thrombocytopenia in piglets intra-
venously injected with LPS.41 In vitro exposure of platelets to LPS does not lead to strong 
platelet activation42,43 and we therefore refrained from performing experiments using LPS in 
the present study. It is therefore of interest to investigate the effect of recAP on platelet acti-
vation in sepsis patients in vivo.
Several studies reported that sepsis resulted in platelet hyporeactivity44-46, a finding dissimilar 
to that of ours and others.19,47-49 The seemingly conflicting data of platelet activation in sepsis 
may be explained by several things. Firstly, we used a flow-cytometry based assay to measure 
platelet function. Most studies reporting platelet hyporesponsiveness used light transmis-
sion aggregometry in PRP, which are less reliable when platelet counts are low50, as frequently 
occurring in sepsis. Moreover, as described by Woth and colleagues, it is difficult to detect 
platelet activation with secondary platelet exhaustion using this aforementioned technique.46 
The use of PRP when compared with whole blood flow cytometry is also a disadvantage as 
mechanical manipulation may cause artifactual pre-activation of platelets.50 Additionally, in 
the in vivo setting of sepsis and in that of ours, activated leukocytes and endothelial cells in 
the milieu of whole blood may interact with and influence the platelet microenvironment, in 
contrast to when PRP is used. Leukocytes possess ATP-ase which may convert ATP present in 
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whole blood into ADP, and in turn contribute to platelet hyperreactivity.51,52 
The ability of AP to inhibit platelet activation, as measured by light transmission aggregom-
etry, was first shown more than 20 years ago using bovine-derived kidney AP.14-16 Since then, 
no new data on the platelet effects of AP have emerged. Our current data add to the existing 
knowledge that the novel human recombinant product has similar platelet-inhibiting effects 
and that the dephosphorylation of ADP and generation of adenosine account for these 
effects. In the earlier studies, modification of platelet membrane receptors was speculated 
to mediate the platelet effects15,16, but our current experiments do not lend support for this 
mechanism. 
As reviewed recently by Thomas and Storey53, increasing data on the effects of platelet inhib-
itors on inflammation are available. However, these data are not easy to interpret as some 
studies have shown benefit of the P2Y12 inhibitors in sepsis patients54-56, whereas others did 
not.56-59 Regardless, the inhibition of platelet reactivity to ADP reduces the release of pro-in-
flammatory mediators from platelet α-granules.53,60 In addition, Ticagrelor, a P2Y12 receptor 
ADP antagonist, shows additional anti-inflammatory effects through a secondary inhi-
bition of adenosine reuptake.61 Recently, our group showed that platelets modulate the 
cytokine responses of monocytes, and that ticagrelor administration in healthy volunteers 
reversed these effects partly through the inhibition of platelet-monocyte interaction.42 These 
immune-modulating effects of platelets could explain the observation that bovine-intestinal 
alkaline phosphatase administration reduced systemic levels of several inflammatory media-
tors during sepsis-associated AKI.5,6
Conclusion
We demonstrated for the first time that recAP inhibits ex vivo human platelet activation 
through the dephosphorylation of ADP, an important platelet agonist, and the formation of 
adenosine as its turnover product. This platelet-inhibiting effect may, at least partly, account 
for the therapeutic potential of recAP as a new candidate to treat sepsis-induced AKI. In addi-
tion, these results may pave the way to further investigate the effects of recAP treatment in 
other diseases in which platelet-activation plays a relevant role.
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Supplemental Figures
Supplemental Figure 1.
 Flow cytometry gating strategy for determination of P-selectin expression on platelets and platelet- 
fibrinogen binding.
 Platelets are gated based on forward and side scatter characteristics (A) followed by positivity for the platelet 
marker CD61 (B). The median fluorescence intensity (MFI) of P-selectin and fibrinogen, after stimulation with ADP 
(31 µM) and CRP-XL (625 µM), was determined from the gated platelet population (C). 
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Supplemental Figure 2. 
 The platelet-inhibiting effect of recAP in whole blood is dose- and time-dependent. 
 (A) Whole blood from healthy volunteers was pre-treated with different concentrations of recAP for 45 minutes 
prior to stimulation using low and high concentrations of ADP or CRP-XL. (B) Whole blood from healthy volun-
teers was pre-treated with recAP (40 U/ml) with different incubation times prior to stimulation using ADP and 
CRP-XL. The medi an fluorescence intensity (MFI) of the platelet surface expression of P-selectin and platelet-fi-
brinogen binding was measured by using flow cytometry. Data are presented as medians [25th percentile, 75th 
percentile] from 6 healthy donors.  * p<0.05, ** p<0.01.
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Supplemental Figure 3. 
 The platelet-inhibiting effect of recAP on Pam3CSK4-stimulated whole blood. 
 (A) Whole blood was pre-treated for 45 minutes with medium or recAP (40 U/ml) prior to stimulation with 
Pam3CSK4. (B) Platelet-monocyte complex formation after exposure to Pam3CSK4 was determined by quan-
tifying the MFI of the platelet marker CD61 on CD14+ cells. Data are presented as medians [25th percentile, 75th 
percentile] from 6 healthy donors.  ** p<0.01.
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Supplemental Figure 4.
 The direct platelet-inhibiting effect of recAP in platelet-rich plasma (PRP) is dose- and time-dependent.
 (A) PRP from healthy volunteers was pre-treated with different concentrations of recAP for 45 minutes prior 
to stimulation using low and high concentrations of ADP or CRP-XL. (B) PRP from healthy volunteers was 
pre-treated with recAP (40 U/ml) with different incubation times prior to stimulation using ADP and CRP-XL. 
The medi an fluorescence intensity (MFI) of the platelet surface expression of P-selectin and platelet-fibrinogen 
binding was measured by using flow cytometry. Data are presented as medians [25th percentile, 75th percentile] 
from 6 healthy donors.  * p<0.05, ** p<0.01.
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Supplemental Figure 5. 
 Measurement of purine content in CRP-XL-induced PRP. 
 Purine levels were determined in the supernatant of PRP pre-treated with recAP (40 U/ml) or inactive recAP (in 
equivalent protein content) and subsequently stimulated with CRP-XL (39 µM). Presented data are medians [25th 
percentile, 75th percentile] from 4 healthy donors.
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Abstract
C 
linical trials showed renal protective effects of bovine intestinal alkaline phos-
phatase (AP) in patients with sepsis-associated acute kidney injury (AKI). Subse-
quently, a human recombinant chimeric AP (recAP) was developed as a pharma-
ceutically acceptable alternative. Here, we investigated the biodistribution and pharmacoki-
netics (PK) of recAP and developed a translational population PK model. Biodistribution was 
studied during LPS-induced AKI in rats. Iodine-125-labeled recAP was primarily taken up by 
liver, spleen, adrenals, heart, lungs and kidneys followed by the gastro-intestinal tract and 
thyroid. Tissue distribution was not critically affected by endotoxemia. PK parameters were 
determined in rats and minipigs during IV bolus injections of recAP, administered once, or 
once daily during seven consecutive days. Plasma concentrations of recAP increased with 
increasing dose and disappeared in a biphasic manner. Exposure to recAP, estimated by 
AUC and Cmax, was similar on days 1 and 7. Subsequently, population approach nonlinear 
mixed effects modeling was performed with recAP rat and minipig and biAP phase I PK data. 
Concentration versus time data was accurately described in all species by a two-compart-
mental model with allometric scaling based on body weight. This model provides a solid 
foundation for determining the optimal dose and duration of first-in-man recAP studies.
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Introduction
Alkaline phosphatase (AP) is an endogenous membrane-bound enzyme, ubiquitously 
present in the human body. Four different iso-enzymes exist, the nomenclature of which 
refers to the tissue that each was originally identified in, namely germ cell, intestinal, placental 
and tissue-nonspecific (liver/bone/kidney) AP.1 Endogenous AP has several functions under 
physiological conditions; intestinal AP is involved in e.g. regulation of bicarbonate secre-
tion, surface pH and lipid absorption2, while bone-derived AP plays a role in bone miner-
alization.1 Alternatively, there is increasing evidence that AP plays a significant role in regu-
lating intestinal barrier function as well as host defense and innate immunity, in particular 
protection against acute inflammatory reactions induced by endotoxins, such as lipopoly-
saccharides (LPS).3,4 LPS are embedded in the outer membrane of Gram-negative bacteria 
and are considered one of the principal biological substances causing sepsis.5 Sepsis is char-
acterized by the release of various pro-inflammatory molecules from damaged necrotic 
and apoptotic cells, exerting toxic effects, including ATP.6 Likely, AP exerts protective effects 
through the dephosphorylation of detrimental molecules, including LPS and extracellular 
ATP, thereby reducing the inflammatory response.7 The protective effects were demon-
strated in several animal models of systemic inflammation. In mice, treatment with placental 
and intestinal AP improved survival rates, reduced fever and attenuated serum nitric oxide 
levels during Escherichia coli-induced inflammation, and reduced systemic inflammation and 
organ damage induced by cecal ligation and puncture.3,8,9 In addition, treatment with intes-
tinal AP attenuated systemic cytokine levels in sheep and piglets with septic shock caused 
by fecal peritonitis and LPS injection, respectively.4,8 Subsequently, the anti-inflammatory role 
of AP was investigated in critically ill patients suffering from sepsis-associated acute kidney 
injury (AKI)10,11, a condition with substantial mortality.12 Prior to two exploratory phase IIa clin-
ical trials, conducted with bovine derived intestinal AP (biAP), the safety of this enzyme was 
evaluated in a phase I trial.13 BiAP administration in healthy male volunteers did not raise safety 
concerns and anti-drug antibodies were not detected. According to the clinical data available 
from two phase IIa studies, biAP infusion improved kidney function in patients with sepsis-as-
sociated AKI and showed a trend towards prevention of AKI development in patients diag-
nosed with sepsis, but that had no signs of AKI at inclusion.10,11 The precise mechanism of 
action underlying these protective effects remains to be elucidated further, but it is known 
that endogenous AP is lost from the brush border membrane of proximal tubular epithe-
lial cells in the kidney following an ischemic insult, while AP levels in urine are increased.14,15 
Although biAP administration showed promising effects during sepsis-associated AKI, appli-
cation of animal-derived enzymes in humans is not warranted as bovine spongiform enceph-
alopathy (BSE)-free sources of bovine-derived enzyme are difficult to obtain. Also, repeatedly 
administering animal-sourced AP is likely to provoke immune reactions. As an acceptable 
alternative to bovine-sourced AP for human application in sepsis-associated AKI, a human 
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recombinant chimeric AP (recAP) was developed by replacing the crown domain of a human 
intestinal AP with the crown domain of human placental AP, resulting in a stable and highly 
active enzyme.16 In validation studies, enzymatic properties and substrate specificity of biAP 
and recAP were comparable, but recAP was found to be more temperature-stable compared 
to biAP.16 Insight into the pharmacokinetic (PK) properties of biAP in human subjects could 
support understanding the translational PK properties of recAP, which will ultimately help to 
predict the human PK of recAP. Subsequently, simulations of plasma PK profiles will improve 
the design of first-in-man recAP studies. Therefore, the aim of this study was to analyze clin-
ical PK studies with biAP and preclinical PK studies with recAP to investigate recAP PK proper-
ties and translate these to a putative clinical application. In addition, to understand the rela-
tive distribution into various organs, a biodistribution study was performed with iodine-125 
(125I)-labeled recAP in rats during endotoxemia-induced AKI.
Methods
Animals 
For the biodistribution study, male Sprague–Dawley (SD) rats (Charles River Laboratories, L’Ar-
bresle, France; n = 43), weighing 285–329 g, were housed under routine laboratory condi-
tions at the Preclinical Image Centre of the Central Animal Laboratory at the Radboud univer-
sity medical center (Nijmegen, The Netherlands). For the pharmacokinetic studies, male SD 
rats (Charles River Laboratories, Portage, Michigan; n = 27), weighing 330–372 g, and male 
Göttingen Minipigs (Marshall BioResources, North Rose, NY; n = 18), weighing 7–13 kg, were 
housed under routine laboratory conditions at MPI Research (Mattawan, MI). Water was avail-
able ad libitum. Standard laboratory chow was available ad libitum to rats and was offered 
to minipigs twice daily via rationated feeding, except during fasting periods. Animal experi-
ments were performed according to the National Institutes of Health guidelines and proto-
cols were approved by the institutional review board for animal experiments.
125I labeling 
For the biodistribution study, recAP (AM-Pharma BV, The Netherlands) was radiolabeled with 
125I using the chloramine-T procedure.17 Briefly, 2 mg recAP (3873 U/ml), Na 125I solution (37 
MBq in 10 µL; PerkinElmer, Groningen, The Netherlands), 100 µL 5 mM Tris Buffer (pH 8.0; 
Sigma–Aldrich, Zwijndrecht, The Netherlands) and 14 µL of freshly prepared chloramine-T 
solution (10 mg/mL in sterile water; Sigma–Aldrich) were added into a 1.5 mL Lo-Bind Eppen-
dorf tube. Reaction was allowed to stir for 1 min at room temperature. The labeling reaction 
was quenched by addition of 30 µL tyrosine solution (10 mg/mL in water; Sigma–Aldrich) 
and purified by gel filtration (PD10 column; GE Healthcare, Hoevelaken, The Netherlands) 
eluted with saline (0.9%). Fractions of 0.5 mL were collected and radioactivity in each fraction 
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was measured in a dose calibrator (Capintec, Ramsey, NJ). Fractions containing the desired 
radio-iodinated product were pooled. Radiochemical purity was evaluated by thin layer chro-
matography (TLC) on silica gel-coated instant TLC strips (ITLC-SG; Agilent Technologies, Palo 
Alto, CA) with 10% trichloroacetic acid (Sigma–Aldrich) as eluent. Enzyme activity was veri-
fied by the AP colorimetric assay kit (Abcam, Cambridge, United Kingdom) and shown to be 
essentially unchanged after radiolabeling. The solution of radiolabelled 125I-recAP was then 
diluted to ~1 mg/mL with saline. The 125I-recAP dose prepared in saline for injection contained 
200 U/kg enzyme activity (approximately 111 µg, 444 kBq per animal). Radiochemical purity 
of all preparations was >99%.
Biodistribution study 
Rats received an IV bolus of 10 mg/kg LPS (E. coli 0127:B8; Sigma–Aldrich, Zwijndrecht, The 
Netherlands; dissolved in saline; group G8-G14), or placebo (saline, group G1–G7; n = 3 per 
group; group G14: n = 4; Supplemental Table 1) two h preceding the IV bolus injection of 
111 µg 125I-recAP (444 kBq, ~200 U/kg; n = 43). This dose of LPS demonstrated induction of 
renal nitric oxide and inducible nitric oxide synthase expression levels18, resulting in endotox-
emia-induced AKI.19 Blood was collected at 2, 10, 15 and 30 min, 1, 2, 3, 4, 6, 12 and 24 h post 
125I-recAP injection through a tail vein puncture using a Multivette (Sarstedt, Etten-Leur, the 
Netherlands). At 10 min, 30 min, 1, 2, 4, 6 or 24 h post 125I-recAP injection, animals were euth-
anized by CO2 inhalation, followed by exsanguination by cardiac puncture. Twelve hour after 
125I-recAP injection, the group of rats to be sacrificed at 24 h received 1 mL saline (subcuta-
neous) to prevent dehydration. From each animal, the adrenal gland, fat, heart, kidney, large 
and small intestines, liver, lung, muscle, stomach, spleen, and thyroid were harvested. Tissue 
and blood samples were weighed and radioactivity, expressed as percentage of injected dose 
per g of tissue (%ID/g), was measured using Wizard2 Gamma Counter (2480 model, Perkin 
Elmer, Groningen, The Netherlands). AP enzyme activity was determined in serum samples by 
the AP colorimetric assay kit according to manufacturer’s protocol (dilution range: 1:12–1:400). 
One rat was excluded from group G11 (see Supplementary Table 1) due to failed 125I-recAP 
injection. Data is represented as mean (SD). Statistical differences between groups were esti-
mated by an unpaired Student’s t-test, differences between groups over time were estimated 
by two-way ANOVA with post-hoc comparisons using Bonferroni’s multiple comparison test.
Pharmacokinetic biAP study 
Data describing human PK properties of biAP were previously published.13
Pharmacokinetic recAP studies 
In the first part, rats and minipigs received a single intravenous (IV) dose of 0.08 (50 U/kg), 0.32 
(200 U/kg) or 1.6 mg/kg (1000 U/ kg) recAP at a dose volume of 2.5 mL/kg, diluted in saline (n 
= 3 per group; Table 1). Blood was collected into tubes containing lithium heparin and apro-
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tinin from the jugular vein predose and 2.5 min, 5 min, 15 min, 30 min, 1, 2, 4, 8, 12, 24 and 48 
h postdose. In rats, the jugular vein was cannulated and following each blood sample the 
volume collected was replaced by sterile saline. In the second part, rats and minipigs received 
IV doses of respectively 0.08 (50 U/kg), 0.32 (200 U/kg) or 1.6 mg/kg (1000 U/kg) recAP, once 
daily for 7 consecutive days, at a dose volume of 2.5 mL/kg, diluted in saline (Table 1). In rats 
(n = 6 per group), blood was collected from the jugular vein predose and 2 min, 4 min, 10 
min, 30 min, 1, 6 and 24 h postdose at day 1 and 7, and prior to dosing at day 3–6 (alternating 
sampling per time-point in two cohorts of n = 3). In minipigs (n = 3 per group), blood was 
sampled from the anterior vena cava 2.5 min, 5 min, 15 min, 30 min, 1, 4, 12, and 24 h postdose 
at day 1 and 7, and prior to dosing at day 3–6. Blood was collected in tubes containing lithium 
heparin and aprotinin. Animals were observed at least twice a day for morbidity, mortality, 
injury and availability of food and water. A detailed clinical examination, including but not 
limited to evaluation of skin, fur, eyes, ears, nose, oral cavity, thorax, abdomen, external geni-
talia, limbs and feet, and respirato ry, circulatory, autonomic and nervous system effects, was 
conducted predose and just prior to euthanasia. After the final blood sample, rats were eutha-
nized by CO2 inhalation, followed by exsanguination by puncturing the abdominal vena cava. 
Minipigs were euthanized via an IV overdose of sodium pentobarbital under Telazol sedation 
(intramuscular). PK parameters, determined from serum concentration-time data for recAP, 
included maximum concentration (Cmax), time to reach Cmax (tmax), terminal elimination half-life 
(t1/2), area under the plasma concentration-time curve from time 0 to infinity (AUC0-∞), time 0 to 
24 h (AUC0-24), time 0 to 48 h (AUC0-48), clearance (CL) and volume of distribution at steady state 
(Vss). RecAP bioanalysis was performed using a validated electrochemiluminescent ligand-
binding procedure (lower limit of quantitation: 15.6 ng/mL and 25.6 ng/mL for rat and minipig 
serummatrix, respectively). The activity of AP was measured by routine laboratory analysis. All 
PK data, represented as mean (SD), were summarized in tabular or graphical form and descrip-
tive statistics were given. PK parameters were determined by non-compartmental methods 
using WinNonlinTM Professional, Version 6.1 (Pharsight Corporation, Mountain View, CA).
Population PK model development 
Population approach nonlinear mixed effects modeling was performed with the soft-
ware package NONMEM (version 7.2.0, Icon Development Solutions, Ellicott City, MD). First, 
models of biAP and recAP were built separately, where after an integrated model with all 
biAP and recAP data was developed. Nonlinear mixed effect modeling considered repeated 
PK observations as a function of  time in a population of individuals. The model to describe 
these observations adopted a common structural model and distribution of residuals, while 
allowing the parameters in the model to vary between individuals. The location (typical 
value or fixed effect) and spread between individuals (variability or random effect) were esti-
mated for the model parameters by fitting the model to the data by minimizing an objective 
function based on the log likelihood (-2×LL). The random effects structure that was applied 
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included a residual error distribution and distributions for the inter-individual variability of 
the PK parameters. Additive, proportional or combined residual error structures were inves-
tigated, while log-normal distribution for the inter-individual variability was assumed. The 
distribution of these individual parameters were compared per dataset with the theoretical 
distribution based on the population values (median and 80, 90, or 95% prediction interval) 
and residual variability and shrinkage were reported, which were considered acceptable when 
below 35%. Finally, various types of variance–covariance matrices were tested for the inter-in-
dividual variability. In order to find the simplest model adequately describing PK observations, 
different models were compared with increasing complexity in the structural model and the 
number of random effects. The likelihood ratio test was used, which compares the difference 
between -2*log-likelihoods of the models (difference in objective function value, ∆OFV) to a 
Chi-square distribution with degrees of freedom corresponding to the difference in number 
of parameters between the two models. Hence, with a difference of at least 6.63 points (P < 
0.01) the model with one additional parameter was preferred over its parent model. Graphical 
analysis was another tool used to help assessing differences between models. These good-
ness-of-fit plots included: (1) population predicted and individual predicted vs. observed 
concentrations, (2) conditional weighted residuals with interaction (CWRESI) vs. predicted 
concentration and vs. time, where most CWRESI should be normally distributed around zero 
and be within the acceptance criterion of -2 to 2, (3) frequency distribution of the CWRESI, (3) 
frequency distributions of the post hoc individual estimates of η’s, and (4) correlation plots 
with their Pearson’s correlation coefficient of all parameters with inter- individual variability.20 
The uncertainty of parameter estimates was determined by the relative standard error (RSE; 
standard error/parameter estimate × 100%) and considered acceptable when the RSE was 
less than 50%. For the parameter estimates of inter-individual variability (IIV), shrinkage was 
reported as a measure of identifiability and considered acceptable when below 35%. The 
translational population PK component focussed on identifying a compartmental structural 
model to describe the preclinical- and clinical datasets of biAP simultaneously by allometric 
scaling between species; the pharmacokinetic parameters CL and volume of distribution 
were scaled, based on bodyweight, according to Eq. (1),
(Eq. 1)
where θi is the PK parameter for CL or volume of distribution for the i
th individual, θTV its typical 
population value and BWi the bodyweight of the i
th individual in kg (normalized for the typical 
bodyweight of humans; 70 kg). The exponents were set at 0.75 and 1 for CL and volume of 
distribution, respectively.21 The biAP model was employed to describe the population PK of 
recAP in rats and minipigs, using the allometric scaling factors discovered for biAP. To investi-
gate the possibility of difference in PK properties between biAP en recAP, potential differences 
were quantified in terms of a scaling parameter for each PK parameter. The scaling parame-
θ θi TV
i
exponentBW
= ×




70
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ters were accepted when the 95% confidence intervals did not overlap with zero and utilized 
to translate the biAP PK in humans to a prediction of recAP PK in humans. Data analysis using 
the approach described was performed using NONMEM. The first-order method with condi-
tional estimation and interaction (FOCEI) was used for the maximum likelihood parameter esti-
mation. Additionally, R 2.12.0 was used for graphical presentation, evaluation of goodness of fit, 
covariate selection, and model evaluation.22 The analyses closely followed the FDA and EMA 
guidelines for performing and reporting population pharmacokinetic analyses.23,24
Table 1.  Dosing schedule of pharmacokinetic studies 
 
BIAP RECAP IV LOADING DOSE 
(U/KG)
IV INFUSION
n = 29 n = 36 day 1 day 2-7 Dose (U/kg/24h) Duration (h)
Animal cohort – Part 1a 18a
Group 1 - 3 50 - - -
Group 2 - 3 200 - - -
Group 3 - 3 1000 - - -
Animal cohort – Part 2a 18a
Group 1 - 3b 50 50 - -
Group 2 - 3b 200 200 - -
Group 3 - 3b 1000 1000 - -
Human cohort13 29
Group 1 6 - 7.5c - - -
Group 2 6 - 22.5c - - -
Group 3 6 - 67.5c - - -
Group 4 6 - - - 200 24
Group 5 5 - 67.5c - 177.5 72
 a  The studies of the animal cohort were conducted in rats and minipigs. bAlternating sampling per time-point in 
two cohorts of n = 3. c Loading dose was administered over 10 min. BiAP, bovine intestinal alkaline phosphatase; 
recAP, human recombinant alkaline phosphatase.
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Results
Biodistribution of recAP 
The biodistribution of 125I-recAP (111 µg, ~200 U/kg) was investigated in rats, pretreated with 
LPS (10 mg/ml) or placebo to determine the effect of systemic inflammation. Blood samples 
were collected and organs were harvested at several time-points after 125I-recAP administra-
tion (Supplementary Table 1). LPS treatment caused shivering, diarrhea, pilo-erection, polyuria, 
reduced spontaneous activity, and mean weight loss (SD) after 24 h (Placebo: 2 (1.6)% vs. LPS: 14 
(0.8)%; P < 0.05), consistent with the presence of systemic inflammation. Mean serum 125I-recAP 
radioactivity rapidly decreased after infusion and was higher in the LPS-group 2 and 10 min 
after injection compared to the placebo group (2 min: Placebo: 3.1 (0.3) vs. LPS: 4.2 (1.0) %ID/g; 
P < 0.001; 10 min: Figure 1 and Supplemental Table 2). Within the first 2 h after 125I-recAP admin-
istration, relative uptake was highest in the liver, followed by the spleen, adrenal gland, heart, 
lung and kidney (Figure 1 and Supplemental Table 2). LPS treatment increased accumulation 
in the heart 10 min post-125I-recAP injection (P < 0.001), in the kidney 24 h post administration 
(P < 0.05) and in the adrenal gland at several time-points (P < 0.05; Supplemental Figure 1). In 
addition, increased distribution was observed to the gastro-intestinal tract and thyroid gland 
(Figure 1 and Supplemental Table 2), which was more pronounced in septic animals compared 
to placebo at 4 h (large intestine, P < 0.001), 6 h (small intestine, P < 0.05) and 24 h (stomach, P 
< 0.05) post injection (Supplemental Figure 1). The absolute median accumulation in organs 
after LPS compared to placebo increased by a factor of 2.1 [1.6–6.4] (Figure 1). Accumulation in 
muscle and fat was negligible at all time-points (Supplemental Table 2).
RecAP pharmacokinetics in rats 
PK parameters, as presented in Table 2, were determined in rats during IV bolus injections 
of 50 U/kg, 200 U/kg or 1000 U/kg recAP (n = 3), administered once, or once daily during 
seven consecutive days. Repeated administration of recAP was well tolerated and no test arti-
cle-related changes in morbidity, mortality, clinical observations and food consumption were 
noted. Plasma concentrations of recAP increased with increasing dose and disappeared in 
a biphasic manner on days 1 and 7. After a single dose, AUC0-∞, AUC0-48 and AUC0-t increased 
more than in proportion to dose between 50 and 200 U/kg and in approximate proportion to 
dose between 200 and 1000 U/kg. Cmax increased in approximate proportion to dose over the 
entire dose range. CL was slightly higher and Vss and t1/2 were slightly lower at 50 U/kg than 
at the two higher doses. RecAP was not detectable after 12 h at the lowest dose. Following 
seven days of dosing, AUC0-∞, AUC0-24 and Cmax increased in approximate proportion to dose 
over the entire dose range. Tmax was 2.5 min (first sampling time) at all dose levels on day 1 
and day 7 and CL, Vss and t1/2 were similar across the dose range on both days. AUC0-24 and 
Cmax were similar on days 1 and 7; accumulation ratios ranged from 0.528 to 1.04. At termina-
tion, there were minimal to marked dose-dependent elevations in AP enzyme activity in all 
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treatment groups relative to expected ranges. Relative to rats receiving 50 U/kg, terminal AP 
activity was elevated 1.5-fold and 4.6-fold in animals receiving 200 and 1000 U/ kg, respec-
tively. These changes were anticipated and considered test-article related. In addition, during 
endotoxemia, while AP enzyme activity levels were significantly increased 2 min after injec-
tion compared to placebo (Placebo: 2273 (1614) vs. LPS: 4263 (1090) U/L; P < 0.001), no differ-
ences were observed between terminal t1/2 (Placebo: 16.5 (2.8) vs. LPS: 19.9 (2.6) h; NS).
Figure 1. 
 Tissue distribution of 125I-recAP in rats during endotoxemia. 
 Rats were pretreated for two h with LPS (lower panel) or placebo (upper panel), followed by the administration 
of an IV bolus injection of 125I-recAP. Animals were sacrificed at several time-points post 125I-recAP injection and 
radioactivity, expressed as % of injected dose per g of tissue, was determined. Data is expressed as mean with 
standard deviation. N = 3 per time-point, except for adrenal gland at t=30 min (n = 2; LPS) and for all organs at 
t=2 (LPS); n = 4 for t=24 h (LPS). * P < 0.05, ** P < 0.01, *** P < 0.001 compared to placebo, determined by two–
way ANOVA. 
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Table 2.  PK parameters after non-compartmental analysis
Part Dose
(U/kg)
C
max
f  
(ng/mL)
AUC
0-24
g, h
(h·ng/mL)
AUC
0-∞
g
(h·ng/mL)
CLi  
(mL/min/kg)
t
1/2
(h)
Vssj
(mL/kg)
Ratsa 1 50 1100
(155)
1730
(240)
1840
(268)
0.74
(0.12)
5.7
(1.2)
321
(46)
200 6740
(695)
9590
(1370)
10200
(1470)
0.53
(0.07)
12.7 
(1.2)
443 
(47)
1000 39900 
(4760)
48200
(9260)
51700
(9910)
0.53
(0.10)
13.5 
(2.2)
427 
(84)
2c,k 50 1910 3080 - 0.35 9.3 260
200 7100 9330 - 0.50 8.3 285
1000 37100 43500 - 0.48 9.7 381
Minipigsa 1 50 947
(249)
3880
(651)
4480
(782)
0.30
(0.06)
15.9
(4.1)
386
(71)
200 3700
(179)
18400
(1140)
32800
(3550)
0.16
(0.02)
44.3 
(10.4)
574
(90)
1000 24300
(3160)
88400
(6180)
203000
(111000)
0.16
(0.08)
60.8 
(43.1)
603
(220)
2c 50 814
(85)
7940
(1180)
- 0.10
(0.06)
24.1
(13.2)
157
(22)
200 4390
(173)
37700
(1920)
- 0.05
(0.01)
38.2
(3.4)
166
(7)
1000 28300 
(1380)
151000
(5680)
- 0.07
(0.02)
38.1
(20.9)
199
(37)
Humansb 13 7.5 82.8
(17.4)
- 364.4
(175.7)
1.6
(0.8)
12.2
(8.6)
-
22.5 167.3
(45.6)
- 405.7
(176.5)
4.1
(1.1)
5.0
(1.0)
-
67.5 501.2
(86.6)
- 642.5
(192.4)
7.8
(1.9)
3.8
(0.3)
-
200d 61.8
(13.2)
1,282.3
(345.3)
2,005.1
(375.7)
7.2
(1.5)
11.9
(5.9)
-
177.5e 272.4
(33.4)
1,084.3
(167.4)
3,472.8
(574.9)
4.7
(0.8)
8.3
(0.7)
-
 a recAP treatment. bbiAP treatment. cday 7. dU/kg/24h during 24h. eU/kg/24h during 72h, preceded by loading 
dose (67.5 U/kg). fU/L for biAP. gU·h/L for biAP. hAUC0-48 for part 1. 
iper 1.73 m2 (L/h) for biAP. jdetermined for recAP 
treatment only. kalternating sampling per time-point in two cohorts of n = 3. Data presented as mean (SD). 
AUC, area under curve; AUC0-24, AUC from time 0 to time 24 h; AUC0-∞, AUC from time 0 to infinity; Cmax, maximum 
concentration; CL, clearance; t1/2, terminal elimination half-life; Vss, volume of distribution at steady state.
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RecAP pharmacokinetics in minipigs 
Subsequently, PK parameters were investigated in minipig during IV bolus injections of 50 
U/kg, 200 U/kg or 1000 U/kg recAP (n = 3), administered once, or once daily during seven 
consecutive days (Table 2). RecAP administration was well tolerated without treatment-re-
lated effects on morbidity and mortality. Plasma recAP concentrations increased with 
increasing dose and disappeared in a biphasic manner (Figure 2). Plasma AP enzyme activity 
levels followed a similar pattern as plasma recAP concentrations; after reaching a maximum, 
AP activity decreased rapidly followed by a slower decline (Figure 2), and mean AP activ-
ity-time profiles displayed a dose-dependent increase in AP activity following administra-
tion of increasing doses of recAP. After a single dose, recAP PK parameters AUC0-∞, AUC0-48 
and AUC0-t ,Cmax, Vss and t1/2 in minipigs followed a comparable pattern to those in rats. 
Figure 2. 
 Plasma recAP and AP activity in healthy minipigs on day 1 and day 7. 
 Serum recAP concentrations (upper panel) and AP activity levels (lower panel) were determined several time-
points after IV bolus injection of recAP, once daily for 7 consecutive days. Data is expressed as mean with stan-
dard deviation (n = 3 per group). 
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Following seven-day recAP treatment, all animals had mild elevations in activated partial 
thromboplastin time (APTT; up to 1.4-fold) and mild elevations in urine pH relative to pretest 
values (pH range: 7.0–8.5 vs. 5.5–7.5). Based on the small magnitude, these changes are consid-
ered to be of minimal biologic relevance. RecAP AUC00-∞, AUC0-24 and Cmax increased more 
than in proportion to dose between 50 and 200 U/kg and in approximate proportion to dose 
between 200 and 1000 U/kg on days 1 and 7. Tmax occurred at the first or second sampling 
time. CL was higher at 50 U/kg than at the two higher doses on Days 1 and 7. Vss and t1/2 were 
similar across the dose range on day 1 and day 7. CL and Vss were slightly reduced on day 7 
as compared to day 1; t1/2 was similar on both days. Exposure to recAP, as estimated by AUC 
and Cmax, was similar on days 1 and 7; mean accumulation ratios ranged from 1.05 to 2.39. AP 
enzyme activity AUC0-∞, AUC0-24 and Cmax increased in approximate proportion to recAP dose 
between 50 and 1000 U/kg/day on day 1 and day 7 (data not shown). Tmax and t1/2 did not vary 
with dose or duration of recAP treatment (data not shown).
Pharmacokinetic modeling 
As initial assessment of the data suggested that a two-compartment PK model with first-
order elimination would be required to describe the concentration versus time data, model 
development started with this model. Data below the lower limit of quantification were 
removed from the data set (>25% per subset).25 For the separate translational PK models for 
biAP and recAP, two-compartmental models with proportional error and inter-individual vari-
ability on CL best described the observed data. For biAP, a quantifiable baseline concentra-
tion was identified in the initial assessment of the data for which was corrected accordingly 
(c0). Allometric scaling based on body weight (Eq. (1)) allowed accurate description of the 
PK observations in all species. The best model describing both biAP and recAP data simul-
taneously was therefore also parameterized in terms of CL, volume of distribution of the 
central compartment (V1), intercompartmental exchange (Q) and volume of distribution of 
the peripheral compartment (V2). A proportional error structure best described the residual 
error. This model was extended by (species-independent) inter-individual random effects 
to CL, V1 and Q, as the OFV decreased with 197, 98 and 115 points respectively. Consecu-
tive inclusion of a full variance covariance matrix to these three parameters improved the 
OFV by 33 points and was therefore kept in the best model structure. The parameter esti-
mates obtained are summarized in Table 3. Values for RSE and shrinkage were all well within 
the acceptance criteria. The goodness-of-fit plots are represented in Figure 3. The popula-
tion predicted versus observed concentrations plot indicates that the model is structurally 
sound, as the observations are mostly centred around the line of unity. After inclusion of 
inter-individual variability (individual predictions, IPRED) the observations are more closely 
aligned to the line of unity, indicating improved descriptive properties. The CWRESI is close 
to being normally distributed around zero for the entire concentration range, indicating 
no bias for specific concentration ranges. Also for CWRESI over time clear bias is absent, 
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Figure 3. 
 Goodness of fits plots. 
 Upper left: observed (DV) versus population predicted (PRED) concentrations, with a line of unity (black). Upper 
right: DV versus individual predicted concentrations (IPRE) with a line of unity (black). Lower left: conditional 
weighted residuals (CWRESI) versus population predicted concentrations (PRED), with acceptance criterion (grey 
line). Lower right: CWRESI versus time (TIME), with acceptance criterion (grey line). 
Table 3. Parameter estimates of the best population PK model for biAP and recAP 
 
PARAMETER UNITS TYPICAL VALUE 
BIAP (%RSE)
TYPICAL VALUE 
RECAP (%RSE)
IIV 
(%) 
SHRINKAGE 
(%) 
CL L/h 10.3 (10.1) 0.494 (4.11) 33.3a 5.5 
V1 L 8.30 (8.62) 4.22 (6.68) 32.2
a 15.1 
Q L/h 11.8 (13.0) 7.36 (9.64) 55.2a 8.95 
V2 L 39.9 (26.3) 23.6 (5.36) -- -- 
c0 ng/mL 4.73 (5.75) -- -- -- 
t1/2α
b h 0.25 0.32
t1/2β
b h 5.3 41.2
Proportional error 0.0788       
 aestimated species-independently. bderived parameter. c0, baseline concentration; IIV, inter-individual variability 
derived by 100*sqrt(exp(ω2)-1), where ω2 is the variance of IIV; RSE, Relative standard error derived by standard 
error/estimate×100%. 
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Figure 4. 
 Model performance on individual level. 
 Individual predicted (solid line), population predicted (dotted line) and observed (open circles) plasma recAP/
biAP concentrations over time. Per species, one typical individual is depicted for both a single and multiple 
dosing regimen. Part 1 represents the single dose regime, Part 2 represents the multiple dose regimen. 
0 2 4 6 8
0
50
15
0
BiAP in human 32.1 µg/kg 10 min 
IV infusion
TIME (h)
Co
nc
en
tr
at
io
n 
(n
g/
m
L)
0 5 10 15 20 25 30
0
10
20
30
BiAP in human 95.1 µg/kg/24h 
IV infusion
TIME (h)
Co
nc
en
tr
at
io
n 
(n
g/
m
L)
0 2 4 6 8 10 12
0
40
0
80
0
12
00
RecAP in rat 0.08 mg/kg, Part 1
TIME (h)
Co
nc
en
tr
at
io
n 
(n
g/
m
L)
0 50 100 150
0
50
0
15
00
RecAP in rat 0.08 mg/kg, Part 2
TIME (h)
Co
nc
en
tr
at
io
n 
(n
g/
m
L)
0 5 10 15 20
20
0
60
0
RecAP in minipig 0.08 mg/kg, Part 1
TIME (h)
Co
nc
en
tr
at
io
n 
(n
g/
m
L)
0 50 100 150
50
00
20
00
0
RecAP in minipig 1.6 mg/kg, Part 2
TIME (h)
Co
nc
en
tr
at
io
n 
(n
g/
m
L)
209
although there are a few outliers outside the acceptance criterion. The frequency distribution 
of the CWRESI was slightly skewed to the right, the frequency distributions for the inter-indi-
vidual variability parameters closely approached normal distributions (data not shown). From 
the correlation plots, a statistically significant relation between dose vs. IIV of V1 and dose vs. 
IIV on Q was found (r2: 0.32 and 0.34, respectively), hinting towards nonlinearity of AP, as did 
the results from the non-compartmental analysis. Therefore, a nonlinear Michaelis–Menten 
kinetics model was fitted to the data. The goodness-of-fits plots did not improve as was also 
concluded from the lack in improvement in fit (ΔOFV; -5.33). The estimated Km was approxi-
mately 20-fold higher than the highest observed concentration, and the coefficient of varia-
tion of Km and Vmax was >75%. The high uncertainty in the population parameter estimates 
resulted in overparameterization when attempts were made to add IIV on any of the param-
eters. Applying nonlinear PK to recAP or BiAP separately did also not improve the model fits. 
These results clearly indicate that the concentration range of the data lies within the range 
of the Michaelis–Menten elimination rate-concentration relationship that approaches a linear 
relationship. Hence, a nonlinear model approach was abandoned. Figure 4 represents indi-
vidual predictions and population predictions with their actual data points, for typical indi-
viduals from each species dataset. For biAP administered to humans, both the observed data 
after a short 10 min infusion as well as the data after 24 h IV infusion are well described. The 
same accounts for recAP after single- and multiple-dose administration. These results indi-
cate that kinetics of both biAP and recAP are accurately described by the two-compartmental 
population PK model with allometric scaling based on body weight.
Discussion 
In this study, we successfully developed a translational population PK model of recAP to 
support the design and selection of dose levels to be investigated in the first-in-man trial 
as novel treatment strategy of sepsis-associated AKI. RecAP was developed as a suitable 
alternative to bovine-sourced intestinal AP, which was previously demonstrated to improve 
renal function in critically ill patients with sepsis-associated AKI.11 In addition, we performed 
an animal study to investigate the tissue distribution of recAP in vivo. Rats received LPS (or 
placebo) to induce systemic inflammation and, subsequently, endotoxemia- induced AKI, 
to assess the pharmacokinetic behavior of recAP in a preclinical model more closely repre-
senting the targeted patient population. After two hours, when systemic inflammation 
reached its peak26, 125I-labeled recAP was injected, and at several time-points radioactivity 
levels in diverse tissues were determined. As circulating AP is normally cleared through 
uptake by the hepatic asialoglycoprotein receptor27,28, the liver was the major site of accu-
mulation and removal of 125I-recAP; most radioactivity was captured by this organ within 
10 min after injection and disappeared after two to four hours. In addition, spleen, adrenal 
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gland, heart, lung and kidney showed uptake shortly after 125I-recAP infusion, followed by 
the gastro-intestinal tract and thyroid gland. The presence of radioactivity in intestines can 
be explained by a fast distribution of 125I-recAP into the liver and subsequent excretion into 
the intestine via bile (enterohepatic circulation). The ductus choledochus ends at the begin-
ning of the duodenum. As the duodenum is in close proximity to the stomach, the stomach 
would have to be dissected carefully by an incision through the pyloric sphincter in order to 
assess the relative importance of enterohepatic circulation versus distribution to the stomach. 
Macroscopically during dissection we could not distinguish the pyloric sphincter from the 
duodenum, therefore enterohepatic circulation cannot be excluded as a possible explanation 
for the observed radioactivity in the stomach. 
Furthermore, serum recAP radioactivity and AP enzyme activity levels were significantly higher 
directly after 125I-recAP injection in endotoxemic rats compared to healthy rats, as was the radi-
oactive content in the heart. These differences are likely to be explained by LPS-induced reduc-
tion of the mean arterial blood pressure, which is known to occur in this model within one hour 
after the induction of endotoxemia.29 Beyond these observed differences, endotoxemia did not 
critically affect the 125I-recAP tissue distribution and enzymatic terminal half-life. 
Single and multiple doses of recAP (50, 200 or 1000 U/kg) were administered to rats and 
minipigs. Repeated dosing was well tolerated, without significant accumulation or discern-
ible effects on morbidity, mortality and clinical observations, indicating that in these species 
repeated dosing of recAP could be done without any safety concerns. Both plasma recAP 
concentrations and AP enzymatic activity increased with increasing recAP dose and disap-
peared in a biphasic manner. With respect to dose-proportionality, Cmax increased in propor-
tion to dose over the entire dose range in nearly all protocols after non-compartmental anal-
ysis, while AUC increased slightly more than dose-proportional between the lowest and 
middle dose, and in proportion to dose between the middle and highest dose. In accord-
ance, plasma clearance was higher at the lowest dose compared to the middle and highest 
dose, possibly suggesting that recAP PK was more affected by liver uptake mechanisms at the 
lowest dose level tested.
Subsequently, a two-compartmental translational population PK model with allometric 
scaling based on body weight was developed that accurately described both the PK of biAP 
and recAP. Due to lack of specificity of the AP enzyme activity assay, biAP data required correc-
tion for baseline endogenous AP circulating in the plasma. The inability to separate endog-
enous enzyme activity from exogenously added biAP may be causative to the increased 
uncertainty (%RSE) of biAP PK parameters compared to recAP parameters. After non-com-
partmental analyses, we observed a slight under-estimation at the highest dose levels versus 
population prediction, which indicates that first-order elimination might not be valid at that 
dose range. However, it might be attributed to random effects due to the small number of 
subjects in the highest dose group. Because inclusion of nonlinear kinetics did not improve 
the prediction at these dose levels, we did not include nonlinear elimination in the model. 
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Furthermore, biAP was rapidly eliminated from dosed volunteers, presumably by the asialo-
glycoprotein receptor on liver cells.27 The high degree of sialylation of recAP could increase 
the terminal half-life of recAP, which is in agreement with the approximately 7.8-fold increase 
of apparent terminal half-life comparing recAP to biAP. The remaining PK parameters were in 
the same order of magnitude compared to biAP, confirming that the difference in PK profile 
between recAP and biAP should be attributed mainly to a difference in clearance rate.
Conclusion 
The results presented in this study indicate that the tissue distribution of recAP is not crit-
ically affected by endotoxemia. In addition, we generated a translational two-compart-
mental model with allometric scaling based on body weight that can be used to simulate 
the predicted human plasma PK profile for different recAP dosing regimens. This model is 
expected to provide valuable insights into the choice of dosing scheme and dose levels for 
the first-in-man trial of recAP, essentially contributing to the clinical development of recAP as 
a potential new treatment option for sepsis-associated AKI.
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Supplemental Figure
Supplemental Figure 1.
 Tissue distribution of 125I-recAP in rats. 
 Rats were pretreated for 2 h with LPS (closed circles) or placebo (open circles), followed by the administration of an IV 
bolus injection of 125I-recAP. Animals were sacrificed at several time-points post 125I-recAP injection and radioactivity, 
expressed as percentage of injected dose per g of tissue, was determined. Data is expressed as mean with standard 
deviation. N = 3 per time-point, except for adrenal gland at t = 30 min (n = 2; LPS) and for all organs at t = 2 (LPS); n 
= 4 for t = 24 h (LPS). * P < 0.05, ** P < 0.01, *** P < 0.001 compared to placebo, determined by two–way ANOVA.  
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Supplemental Figure 1.
 Continued
Supplemental Tables 
Supplemental Table 1. Design 125I-recAP biodistribution study in rats 
GROUP ANIMAL NUMBER PER GROUP BLOOD SAMPLING SACRIFICED
G1 and G8 3 10 min 10 min
G2 and G9 3 30 min 30 min
G3 and G10 3 2 min, 1 hr 1 hr
G4 and G11 3/2a 2 h 2 h
G5 and G12 3 15 min, 4 h 4 h
G6 and G13 3 3 h, 6 h 6 h
G7 and G14 3/4b 12 h, 24 h 24 h
 At t = 0 h, male Sprague-Dawley rats received an IV bolus injection of 111 µg 125I-recAP (444 kBq, ~200 U/kg; n 
= 43). Two h preceding this injection, an IV bolus of 10 mg/kg LPS (n = 22) was administered to rats from group 
G1-G7 to induce endotoxemia. Rats from group G8-G14 received placebo (saline, n = 21). Blood samples were 
collected and animals were sacrificed at several time-points post 125I-recAP injection as depicted in the schedule. 
Organs were harvested, weighed and radioactivity, expressed as percentage of injected dose per g of tissue 
(%ID/g), was measured. aOne rat was excluded from group G11 do to failed 125I-recAP injection. bAnimal number 
in group G14 (LPS + 125I-recAP): n = 4.
Large Intestine  
0.1  1  10  100  
0.0 
0.5 
1.0 
1.5 
2.0 
 
 
Thyroid 
0.1  1  10  100  
0 
10 
20 
30 
40 
50 
 
 *** 
 
%
ID
/g
 
Time (h)
214  |  CHAPTER 8  |  Biodistribution and pharmacokinetics 
 Supplemental Table 2. Tissue distribution of 125I-recAP in rats
 
PLACEBO GROUP 10 MIN 30 MIN 1 HR 2 H 4 H 6 H 24 H
Blood 0.943 (0.35) 0.687 (0.07) 0.630 (0.03) 0.667 (0.09) 0.583 (0.05) 0.473 (0.03) 0.110 (0)
Liver 5.163 (2.00) 5.940 (0.67) 5.850 (0.56) 2.987 (0.32) 0.717 (0.06) 0.337 (0.07) 5.543 (0.58)
Spleen 1.330 (0.61) 1.440 (0.38) 1.110 (0.04) 0.807 (0.09) 0.457 (0.03) 0.300 (0.04) 0.863 (0.30)
Adrenal gland 0.350 (0.10) 0.257 (0.01) 0.317 (0.10) 0.243 (0.06) 0.163 (0.03) 0.120 (0.02) 0.653 (0.22)
Heart 0.233 (0.08) 0.233 (0.02) 0.213 (0.03) 0.253 (0.03) 0.210 (0.02) 0.157 (0.02) 0.490 (0.11)
Lung 0.377 (0.21) 0.330 (0.04) 0.363 (0.09) 0.310 (0) 0.343 (0.02) 0.263 (0.03) 0.513 (0.07)
Kidney 0.340 (0.12) 0.333 (0.02) 0.297 (0.01) 0.367 (0.02) 0.367 (0.02) 0.273 (0.02) 0.450 (0.04)
Stomach 0.060 (0) 0.130 (0) 0.297 (0.03) 0.633 (0.46) 1.387 (0.47) 1.233 (0.25) 0.070 (0.02)
Small Intestine 0.077 (0.04) 0.143 (0.02) 0.183 (0.02) 0.390 (0.11) 0.430 (0.05) 0.413 (0.02) 0.083 (0.01)
Large Intestine 0.063 (0.03) 0.127 (0.02) 0.190 (0.05) 0.467 (0.03) 0.510 (0.27) 0.490 (0.07) 0.063 (0.01)
Thyroid 0.143 (0.07) 0.377 (0.10) 0.890 (0.15) 3.850 (0.82) 17.350 (1.50) 22.940 (5.01) 0.187 (0.09)
Muscle 0.030 (0.02) 0.023 (0.01) 0.040 (0.01) 0.073 (0.01) 0.070 (0) 0.060 (0.01) 0.040 (0.02)
Fat 0.033 (0.01) 0.033 (0.01) 0.040 (0.01) 0.043 (0.01) 0.040 (0) 0.040 (0.01) 0.077 (0.04)
LPS GROUP 10 MIN 30 MIN 1 HR 2 H 4 H 6 H 24 H
Blood 1.717 (0.29)*** 0.743 (0.06) 0.667 (0.01) 0.770 (0.01) 0.773 (0.10) 0.680 (0.02) 0.273 (0.14)
Liver 5.543 (0.58) 6.220 (0.87) 6.070 (0.28) 3.460 (0.17) 1.587 (0.47) 0.717 (0.18) 0.150 (0.06)
Spleen 0.863 (0.30) 1.057 (0.13) 0.977 (0.18) 0.845 (0.06) 0.673 (0.09) 0.493 (0.06) 0.130 (0.05)
Adrenal gland 0.653 (0.22)** 0.475 (0.02) 0.567 (0.17)* 0.515 (0.06)* 0.420 (0.03)* 0.337 (0.02)* 0.108 (0.05)
Heart 0.490 (0.11)*** 0.250 (0.04) 0.240 (0.01) 0.290 (0.01) 0.240 (0.05) 0.217 (0.01) 0.118 (0.04)
Lung 0.513 (0.07) 0.240 (0.02) 0.267 (0.04) 0.395 (0.01) 0.407 (0.07) 0.377 (0.02) 0.193 (0.08)
Kidney 0.450 (0.04) 0.323 (0.04) 0.310 (0.03) 0.445 (0.01) 0.443 (0.06) 0.370 (0.01) 0.195 (0.07)*
Stomach 0.070 (0.02) 0.113 (0.01) 0.153 (0.04) 0.590 (0.40) 1.243 (0.29) 1.430 (0.49) 0.838 (0.27)*
Small Intestine 0.083 (0.01) 0.077 (0.01) 0.147 (0.01) 0.385 (0.08) 0.567 (0.22) 0.643 (0.18)* 0.265 (0.14)
Large Intestine 0.063 (0.01) 0.087 (0.02) 0.103 (0.02) 0.445 (0.15) 1.040 (0.32)*** 0.713 (0.26) 0.290 (0.10)
Thyroid 0.187 (0.09) 0.247 (0.03) 0.617 (0.16) 1.670 (0.51) 8.160 (4.33) 15.710 (3.22) 28.770 (11.70)
Muscle 0.040 (0.02) 0.023 (0.01) 0.037 (0.01) 0.080 (0.01) 0.093 (0.03) 0.073 (0.01) 0.037 (0.01)
Fat   0.077 (0.04) 0.040 (0.02) 0.040 (0.01) 0.070 (0) 0.070 (0.01)* 0.067 (0.03) 0.045 (0.02)
 Data expressed as mean (SD) percentage of injected dose per g of tissue. N = 3 per time-point; n = 2 for adrenal 
gland at t = 30 min (LPS), fat at t = 4 h (LPS) and for all organs at t = 2 h (LPS); n = 4 for t = 24 h (LPS) except for 
muscle (n = 3). * P < 0.05, ** P < 0.01, *** P < 0.001 compared to placebo, determined by two–way ANOVA.
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PLACEBO GROUP 10 MIN 30 MIN 1 HR 2 H 4 H 6 H 24 H
Blood 0.943 (0.35) 0.687 (0.07) 0.630 (0.03) 0.667 (0.09) 0.583 (0.05) 0.473 (0.03) 0.110 (0)
Liver 5.163 (2.00) 5.940 (0.67) 5.850 (0.56) 2.987 (0.32) 0.717 (0.06) 0.337 (0.07) 5.543 (0.58)
Spleen 1.330 (0.61) 1.440 (0.38) 1.110 (0.04) 0.807 (0.09) 0.457 (0.03) 0.300 (0.04) 0.863 (0.30)
Adrenal gland 0.350 (0.10) 0.257 (0.01) 0.317 (0.10) 0.243 (0.06) 0.163 (0.03) 0.120 (0.02) 0.653 (0.22)
Heart 0.233 (0.08) 0.233 (0.02) 0.213 (0.03) 0.253 (0.03) 0.210 (0.02) 0.157 (0.02) 0.490 (0.11)
Lung 0.377 (0.21) 0.330 (0.04) 0.363 (0.09) 0.310 (0) 0.343 (0.02) 0.263 (0.03) 0.513 (0.07)
Kidney 0.340 (0.12) 0.333 (0.02) 0.297 (0.01) 0.367 (0.02) 0.367 (0.02) 0.273 (0.02) 0.450 (0.04)
Stomach 0.060 (0) 0.130 (0) 0.297 (0.03) 0.633 (0.46) 1.387 (0.47) 1.233 (0.25) 0.070 (0.02)
Small Intestine 0.077 (0.04) 0.143 (0.02) 0.183 (0.02) 0.390 (0.11) 0.430 (0.05) 0.413 (0.02) 0.083 (0.01)
Large Intestine 0.063 (0.03) 0.127 (0.02) 0.190 (0.05) 0.467 (0.03) 0.510 (0.27) 0.490 (0.07) 0.063 (0.01)
Thyroid 0.143 (0.07) 0.377 (0.10) 0.890 (0.15) 3.850 (0.82) 17.350 (1.50) 22.940 (5.01) 0.187 (0.09)
Muscle 0.030 (0.02) 0.023 (0.01) 0.040 (0.01) 0.073 (0.01) 0.070 (0) 0.060 (0.01) 0.040 (0.02)
Fat 0.033 (0.01) 0.033 (0.01) 0.040 (0.01) 0.043 (0.01) 0.040 (0) 0.040 (0.01) 0.077 (0.04)
LPS GROUP 10 MIN 30 MIN 1 HR 2 H 4 H 6 H 24 H
Blood 1.717 (0.29)*** 0.743 (0.06) 0.667 (0.01) 0.770 (0.01) 0.773 (0.10) 0.680 (0.02) 0.273 (0.14)
Liver 5.543 (0.58) 6.220 (0.87) 6.070 (0.28) 3.460 (0.17) 1.587 (0.47) 0.717 (0.18) 0.150 (0.06)
Spleen 0.863 (0.30) 1.057 (0.13) 0.977 (0.18) 0.845 (0.06) 0.673 (0.09) 0.493 (0.06) 0.130 (0.05)
Adrenal gland 0.653 (0.22)** 0.475 (0.02) 0.567 (0.17)* 0.515 (0.06)* 0.420 (0.03)* 0.337 (0.02)* 0.108 (0.05)
Heart 0.490 (0.11)*** 0.250 (0.04) 0.240 (0.01) 0.290 (0.01) 0.240 (0.05) 0.217 (0.01) 0.118 (0.04)
Lung 0.513 (0.07) 0.240 (0.02) 0.267 (0.04) 0.395 (0.01) 0.407 (0.07) 0.377 (0.02) 0.193 (0.08)
Kidney 0.450 (0.04) 0.323 (0.04) 0.310 (0.03) 0.445 (0.01) 0.443 (0.06) 0.370 (0.01) 0.195 (0.07)*
Stomach 0.070 (0.02) 0.113 (0.01) 0.153 (0.04) 0.590 (0.40) 1.243 (0.29) 1.430 (0.49) 0.838 (0.27)*
Small Intestine 0.083 (0.01) 0.077 (0.01) 0.147 (0.01) 0.385 (0.08) 0.567 (0.22) 0.643 (0.18)* 0.265 (0.14)
Large Intestine 0.063 (0.01) 0.087 (0.02) 0.103 (0.02) 0.445 (0.15) 1.040 (0.32)*** 0.713 (0.26) 0.290 (0.10)
Thyroid 0.187 (0.09) 0.247 (0.03) 0.617 (0.16) 1.670 (0.51) 8.160 (4.33) 15.710 (3.22) 28.770 (11.70)
Muscle 0.040 (0.02) 0.023 (0.01) 0.037 (0.01) 0.080 (0.01) 0.093 (0.03) 0.073 (0.01) 0.037 (0.01)
Fat   0.077 (0.04) 0.040 (0.02) 0.040 (0.01) 0.070 (0) 0.070 (0.01)* 0.067 (0.03) 0.045 (0.02)
 Data expressed as mean (SD) percentage of injected dose per g of tissue. N = 3 per time-point; n = 2 for adrenal 
gland at t = 30 min (LPS), fat at t = 4 h (LPS) and for all organs at t = 2 h (LPS); n = 4 for t = 24 h (LPS) except for 
muscle (n = 3). * P < 0.05, ** P < 0.01, *** P < 0.001 compared to placebo, determined by two–way ANOVA.
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Abstract
P  
revious clinical trials have suggested that bovine intestinal alkaline phosphatase 
has renal protective effects in patients with sepsis-associated acute kidney injury. 
We conducted a first-in-human study to investigate the pharmacokinetics, safety
and tolerability of a novel human recombinant alkaline phosphatase (recAP), and we developed 
a population pharmacokinetic model to support dose selection for future patient studies.  
Methods
In a randomized, double-blind, placebo-controlled, phase I trial, healthy volunteers received a 
single dose of recAP (200, 500, 1000 or 2000 U/kg; n = 33; 3:1 ratio) or multiple doses of recAP 
(500 or 1000 U/kg; n = 18; 2:1 ratio) via a 1-h intravenous infusion on three consecutive days. 
Serum recAP concentrations, alkaline phosphatase (AP) activity levels and anti-drug antibodies 
were measured, and safety parameters were monitored. A population pharmacokinetic model 
was developed, and simulations were performed to guide dose selection for a phase IIa/b trial.
 
Results
Peak concentrations of recAP and peak AP activity were reached at the end of the 1-h infusion 
and showed a rapid decline, with about 10% of the maximum concentration remaining at 4 
h and less than 5% remaining 24 h post-start. RecAP treatment was generally well tolerated, 
and anti-drug antibodies could not be detected in the serum up to 2 weeks post-injection 
after a single dose, or up to 3 weeks post-injection after multiple doses. A four-compartment 
model best described the pharmacokinetics of recAP administration, with moderate inter-in-
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dividual variability on the central volume of distribution and elimination rate constant. Simu-
lations showed that 1-h intravenous infusions of 250, 500 and 1000 U/kg recAP once every 
24 h for three consecutive days constituted the dosing regimen that best met the criteria for 
dose selection in patient studies. 
Conclusion
RecAP did not raise any safety concerns when administered to healthy volunteers. A popu-
lation pharmacokinetic model was developed to support dose selection for patient studies. 
Trial Registration 2013-002694-21 (EudraCT).
Introduction 
Acute kidney injury (AKI) is a serious complication in critically ill patients, with an incidence of 
20–50 % and a mortality of >50%.1 While AKI may develop after trauma, cardiovascular surgery 
or administration of nephrotoxic drugs, sepsis represents the most common cause.1 Sepsis-as-
sociated AKI increases mortality to 70%, and survivors have an increased risk of developing 
chronic kidney disease.2,3 As yet, no pharmacological interventions have been approved, and 
treatment is limited to renal replacement therapy (RRT). Currently, alkaline phosphatase (AP) 
is one of the limited number of candidate drugs in clinical development to prevent or treat 
sepsis-associated AKI. This endogenous, membrane-bound enzyme is present in many cells 
and organs, including the placenta, liver, bone, kidney, germ cells and granulocytes.4 AP exerts 
detoxifying effects through dephosphorylation of pro-inflammatory molecules, including 
endotoxins (lipopolysaccharide [LPS]) involved in sepsis pathogenesis, and adenosine triphos-
phate (ATP) released from cells during stressful events.5,6 The potency of AP in attenuating the 
innate immune response has been illustrated in several animal models of sepsis, in which 
exogenous AP reduced inflammatory injury and mortality.7,8 Considering the immune-modu-
lating effects of AP, the potential of bovine intestinal AP (biAP) was investigated in critically ill 
patients with sepsis, with or without AKI, in which biAP treatment significantly improved renal 
function and prevented further kidney damage.9,10 An effect on mortality was not demon-
strated in these relatively small studies (n = 36 each). Administration of bovine-derived mate-
rial in humans is less than ideal. Repeated administration of animal-sourced AP could provoke 
immune reactions, and bovine spongiform encephalopathy (BSE)-free sources of bovine-de-
rived enzyme are difficult to obtain. Therefore, a human recombinant AP (recAP) has been 
developed as a pharmaceutically acceptable alternative by replacing the crown domain of 
a human intestinal AP with the crown domain of human placental AP.11 As the renal protec-
tive effects of recAP have been confirmed in vitro in renal proximal tubular epithelial cells, and 
in vivo during LPS-induced AKI in rats12, therapeutic application of recAP could have potent 
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anti-inflammatory and tissue protective effects in patients suffering from sepsis-associated 
AKI. Prior to investigating the potential of recAP in this patient population, it is vital to evaluate 
the pharmacokinetic characteristics of this enzyme. A translational population pharmacoki-
netic model has previously been developed, based on preclinical data on recAP and preclin-
ical and clinical data on biAP13, followed by simulations of several dosing regimens, aiding in 
dose selection for the first-in-human clinical trial, as reported in this article. Here, we evaluate 
the tolerability, safety and pharmacokinetics of recAP in healthy volunteers in a two-part, 
randomized, double-blind, placebo-controlled clinical trial. Using data from this study, the 
population pharmacokinetic model was further developed, and simulations were performed 
to support the design and dose selection for patient studies.
Methods
Phase I Clinical Trial
This two-part, randomized, double-blind, placebo-controlled study was conducted in 51 
healthy volunteers (part A: n = 33; part B: n = 18) at a medical screening facility in Zuidlaren, 
the Netherlands. The local ethics committee approved all protocols, and the study, including 
amendments, was conducted in accordance with the principles of the Declaration of Helsinki 
and in compliance with the International Conference on Harmonisation E6 Guideline for Good 
Clinical Practice (CPMP/ICH/135/95) and the European Union Clinical Trial Directive (2001/20/
EC). This study is reported in accordance with the Consolidated Standards of Reporting Trials 
(CONSORT) guidelines.14 The trial was registered with the European Clinical Trials Register 
(EudraCT number 2013-002694-21) and the Dutch Central Committee on Research Involving 
Human Subjects (CCMO) [reference number NL45925.056.13].
Subjects
All participating healthy volunteers provided written informed consent prior to the start of any 
study-related procedures. Subjects were eligible for the study if they were aged 18–55 years 
and considered healthy on the basis of medical screening, including their medical history, a 
physical examination, routine laboratory testing and a 12-lead electrocardiogram (ECG). The 
exclusion criteria were pregnancy or lactation, a body mass index (BMI) of <18 or >30 kg/m2, 
smoking (more than five cigarettes, one cigar or one pipe daily), a history of alcohol abuse or 
drug addiction, and use of medication (except for acetaminophen). A 4-h fasting period was 
required prior to screening, admission to the medical screening facility, all visits with clinical 
laboratory assessments and the follow-up visit. The use of methylxanthine-containing bever-
ages or food (coffee, tea, cola, chocolate, power drinks), grapefruit (juice) and alcohol was not 
allowed from 48 h prior to entry to the clinical research center and during the stay in the clinic.
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Dosing Regimen
To support the dosing rationale for this trial, human pharmacokinetic profiles of recAP were 
simulated, based on a previously reported translational population pharmacokinetic model 
for recAP, using various dosing regimens.13 The simulations, performed in R version 2.12.0 soft-
ware15 using the lsoda (deSolve Package 1.8.1) and mvrnorm functions (MASS Package version 
7.3-8), were conducted considering the reported population parameters, as well as the full 
covariance matrix describing inter-individual variability (IIV), for 1000 individuals with a typical 
weight of 70 kg. Graphical representation of summary statistics of the simulations (medians 
and 95% prediction intervals of the simulated IIVs) aided in the selection of optimal dosing 
regimens. The dosing regimens that were simulated are presented in Supplemental.
Study Design
Part A was a single-ascending-dose study to assess the safety, tolerability and pharmacoki-
netics of single intravenous doses of recAP in four sequential groups of eight healthy male 
or female subjects per group (groups 1–4). In each group, subjects were randomly assigned 
to receive a single dose of recAP (n = 6) or placebo (n = 2) via a 1-h intravenous infusion on 
day 1. The doses of recAP administered to subjects in groups 1, 2, 3 and 4 were 200, 500, 
1000 and 2000 U/kg, respectively (Table 1). Blood samples were drawn pre-dose and at 0.25, 
Table 1. Human recombinant alkaline phosphatase (recAP) dosing schedule in healthy 
   volunteers      
GROUP SUBJECTS DOSE [U/KG]
All, n = 51 Placebo, n = 14 recAP, n = 37 Day 1 Day 2 Day 3
Part A – SAD 33 8 25
Group 1 8 2 6a 200 - -
Group 2 9 2 7 500 - -
Group 3 8 2 6 1000 - -
Group 4 8 2 6 2000 - -
Part B – MAD 18 6 12
Group 5 9 3 6 500 500 500
Group 6 9 3 6 1000 1000 1000
 The treatment was administered as a 1-h intravenous infusion in healthy volunteers of sexes. aOne subject in 
Group 1 received less than the planned recAP dose of 200 U/kg (because of leakage of the infusion set during the 
study) and was replaced. The safety data, but not the pharmacokinetic data, from this subject were considered 
evaluable for analysis. SAD, single ascending dose; MAD, multiple ascending doses.
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0.5, 0.92, 1.25, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 36, 48, 72, 120 and 192 h after the start of the infusion. 
Part B was a multiple-ascending-dose study to assess the safety, tolerability and pharmacoki-
netics of multiple intravenous doses of recAP in two groups of nine healthy male and female 
subjects per group (groups 5 and 6). Subjects were randomly assigned to receive recAP (n = 
6) or placebo (n = 3) via a 1-h intravenous infusion on days 1, 2 and 3. The doses of recAP or 
placebo administered to subjects in groups 5 and 6 were 500 and 1000 U/kg, respectively 
(Table 1). The selection of the dose and dosing regimen administered in part B was based on 
an interim pharmacokinetic analysis. Blood samples were drawn pre-dose and at 0.5, 0.92, 1.5, 
3, 6 and 12 h after the start of the infusion on day 1; pre-dose just before the start of the infu-
sion on day 2; and pre-dose and 0.25, 0.5, 0.92, 1.25, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 36, 48, 72, 120, 168 
and 240 h after the start of the infusion on day 3.
Randomization, Blinding and Sample Size
A randomization scheme, assigning the study treatments to subject numbers at random, was 
generated by an independent biostatistician team, using SAS PROC PLAN (SAS software version 
9.1.3) per treatment group. The randomization scheme was then transferred in a sealed enve-
lope to the pharmacist for dispensing purposes and kept in the pharmacy. Subjects who met 
all eligibility criteria were given a subject number just prior to dosing according to the rand-
omization scheme, and received the treatment assigned by the scheme. The products that 
were administered were a placebo and the active medication (recAP 7036 U/mL; AM-Pharma, 
Bunnik, the Netherlands). RecAP was diluted with the placebo solution to stock solutions 
containing 600, 1500, 3000 or 6000 U/mL in order to give each subject an equal amount of the 
drug product per kilogram of actual body weight. The placebo consisted of 20 mM citrate, 250 
mM sorbitol, 2 mM MgCl2 and 50 lM ZnCl2 (pH 7.0). To ensure blinding, the recAP and placebo 
were indistinguishable in appearance, AP activity results were not communicated to blinded 
persons during the duration of the study, and the randomization list was accessible only to 
the pharmacist and the pharmacy assistant. A subject’s treatment assignment was not broken 
until the end of the study, unless knowledge of the treatment assigned to the subject was 
necessary to guide medical treatment of the subject. Considering the exploratory nature of 
this study, the sample size (with a minimum of six subjects per group) was selected to provide 
information on safety, tolerability and pharmacokinetics following single and multiple doses of 
recAP. No prospective calculations of sample statistical power were performed.
Bioanalysis and Safety Assessments
All bioanalytical procedures were performed at the Bioanalytical Laboratory of PRA Early 
Development Services (EDS, Assen, The Netherlands). Serum recAP concentrations were 
determined using a validated electrochemiluminescent ligand-binding procedure (ECL) 
[Meso Scale Discovery, Rockville, MD, USA]. The lower limit of quantitation was 3.91 ng/mL 
and the upper limit of quantitation was 500 ng/mL, with overall mean accuracy and preci-
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sion values of ±20.0% at each concentration of the quality-control samples (10, 66 and 400 
ng/mL). Duplicates were not allowed to exceed the coefficient of variation (CV) of 10.0%. Anti-
drug antibodies were determined by an ECL ligand-binding assay, for which a confirmatory 
cut point of 18.9% was established during method validation. Any study sample signal reduc-
tion equal to or higher than the specificity cut point was confirmed as positive, and any signal 
reduction lower than the specificity cut point was scored as negative. Duplicates were not 
allowed to exceed the CV of 20.0%. The activity of AP was determined by routine laboratory 
testing, using the Advia 1800 (ALPAMP; Siemens AG Healthcare Sector, Erlangen, Germany). 
All adverse events that were reported during the course of the study were recorded. Adverse 
events were coded using the Medical Dictionary for Regulatory Activities (MedDRA; Version 
16.116) and evaluated by the principal investigator. The intensity of the adverse events was rated 
as mild, moderate, severe, life threatening or fatal, and the relationship between the adverse 
events and the study medication was indicated as non-existent, unlikely, possible, likely or defi-
nite. Additional safety and tolerability assessments consisted of the results of vital sign assess-
ments, 12-lead ECGs, continuous cardiac monitoring (telemetry), laboratory tests, physical 
examinations and detection of anti-drug antibodies. All subjects who received at least one 
dose of the study medication were included in the analysis. Blood sampling for anti-drug anti-
bodies was performed at screening and at days 9 and 15 (part A) or at days 10 and 19 (part B). 
The data, represented as mean values and standard deviations or as numbers and percentages, 
were summarized in tabular or graphical form, and descriptive statistics are given.
Population Pharmacokinetic Model Development
Population-approach nonlinear mixed-effects modelling was performed with the NONMEM 
software package (version 7.2.0; Icon Development Solutions, Ellicott City, MD, USA). The loca-
tion (the typical value or fixed effect) and the spread between individuals (the variability or 
random effect) were estimated for the model parameters by fitting the model to the data by 
minimizing the objective function based on the log likelihood (-2×LL). Additive, proportional 
or combined residual error structures were investigated, while log-normal distribution for 
the IIV was assumed. Various types of variance–covariance matrices were tested for the IIV. 
In order to find the simplest model that adequately described the pharmacokinetic obser-
vations, different models were compared with increasing complexity in the structural model 
and the number of random effects. The likelihood ratio test was used, which compared the 
difference between -2 log likelihoods of the models (difference in objective function value 
[∆OFV]) with a Chi squared distribution with degrees of freedom corresponding to the differ-
ence in the number of parameters between the two models. Hence, with a difference of 
at least 6.63 points (P < 0.01), the model with one additional parameter was preferable to 
its parent model. Graphical analysis was another tool used to help assessing differences 
between models. These goodness-of-fit plots included (1) population-predicted (PRED) and 
individual-predicted (IPRED) versus observed concentrations (DV); (2) conditional weighted 
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residuals with interaction (CWRESI) versus predicted concentrations and versus time, where 
most observations should be normally distributed around zero and should be within the 
acceptance criterion of -2 to 2; (3) frequency distributions of CWRESI; (4) frequency distribu-
tions of post hoc individual estimates of IIV; and (5) correlation plots with their Pearson’s corre-
lation coefficients for all parameters with IIV.17 The uncertainty of the parameter estimates was 
determined by the relative standard error (RSE) [standard error/parameter estimate × 100%] 
and was considered acceptable when the RSE was <50%. The parameter estimates of the IIV 
were reported as %CV (                          ) and shrinkage was considered acceptable when 
below 35%.18 A covariate analysis was performed on age, actual body weight, sex, height, lean 
body mass and BMI. The covariate in a variable cluster that showed the highest correlation 
with the empirical Bayes’ estimates of the parameters, which was also clinically relevant, was 
implemented in the model. Continuous covariates were centered on their median values. 
Power functions, exponentials and linear functions were explored for the covariate relation-
ships. Covariate analysis was performed by forward inclusion (∆OFV > 3.84), followed by back-
ward elimination (∆OFV > 6.63). The first-order method with conditional estimation and inter-
action (FOCEI) was used for the maximum likelihood parameter estimation. Additionally, R 
version 2.12.0 software was used for the graphical presentation, evaluation of goodness of 
fit, covariate selection and model evaluation. The analyses closely followed the US Food and 
Drug Administration (FDA) and European Medicines Agency (EMA) guidelines for performing 
and reporting population pharmacokinetic analyses.19,20 
Simulations for Phase IIa/b Dose Selection
All simulations for the patient study were performed in R software, using the lsoda (deSolve 
Package 1.8.1) and mvrnorm functions (MASS Package version 7.3-8). The target used for the 
simulations was a serum recAP concentration of >290 U/L (170 ng/mL), maintained for at least 
48 h and preferably for 5–7 days. The dosing rationale for the patient studies was primarily 
based on trough concentration (Cmin) values and on exposure values shown to be associated 
with objective clinical benefit in sepsis-associated AKI patients treated with biAP in previous 
clinical studies.9,21 The simulations were performed considering the estimated population 
parameters, as well as the full covariance matrix describing IIV, in 1000 individuals. To simu-
late the dose in units per kilogram, individual weights were drawn from a normal distribution 
(with resampling) based on the mean and standard deviation of the population of included 
subjects. Graphical representation of the summary statistics of the simulations (the median 
and 95% prediction interval values for the simulated IIV) aided in the selection of optimal 
dosing regimens. The dosing regimens that were simulated are presented in Supplemental 
Table 2.
exp ω2 1 100( ) − × %
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Results
Phase I Clinical Trial
Subjects
Fifty-one subjects were included in the study: 33 subjects (16 female) were assigned to part 
A, the single-ascending-dose part of the study; 18 subjects (8 female) were assigned to part B, 
the multiple-ascending-dose part of the study. All subjects complied with the inclusion and 
exclusion criteria. The dosing schedules and baseline characteristics are presented in Tables 1 
and 2, respectively. There were no clinically significant findings with regard to medical history 
or previous medication. No subjects withdrew or dropped out during the course of the 
study. A total of 50 subjects completed the study per protocol in the period of September–
December 2013. One subject in group 1 (Table 1) received less than the planned recAP dose 
of 200 U/kg because of leakage of the infusion set during administration, and that subject was 
replaced. The safety data for that subject, but not the pharmacokinetic data, were considered 
evaluable for analysis. All other subjects received the study medication as planned and had 
measurable serum recAP concentrations. 
Pharmacokinetic Single-Ascending-Dose Study
The pharmacokinetics were evaluated in healthy volunteers during a 1-h intravenous infusion 
of single-ascending-doses recAP (200, 500, 1000 or 2000 U/kg) in groups of eight subjects 
(six active, two placebo) [Table 1]. The maximum serum concentration values for recAP were 
typically reached at the end of the infusion (Figure 1A). The mean recAP serum concentration 
profiles displayed an increase in serum concentrations following administration of increasing 
doses of recAP and ranged from 1715 to 26,253 ng/mL. At the end of the infusion, the recAP 
serum concentrations decreased rapidly in a multiphasic manner, with 10% of the maximum 
concentration remaining at 4 h and <5% remaining at 24 h after the start of the infusion. RecAP 
concentrations were detectable for up to 120 h post-dose in the 200 U/kg treatment group 
and for up to 192 h post-dose (the last pharmacokinetic sampling time point, on day 9) in the 
other three treatment groups. The serum AP activity levels in recAP-treated subjects followed 
a pattern similar to that of the serum recAP concentrations; after reaching a maximum, at the 
end of the infusion, the AP activity decreased rapidly, followed by a slower decline (Figure 1A), 
and the mean AP activity–time profiles displayed an increase in AP activity following admin-
istration of increasing doses of recAP. In comparison with baseline levels (49–53 U/L), serum 
AP levels dose-dependently increased approximately 35- to 500-fold at the end of the infu-
sion and were still 2.5–20 times higher after 24 h. At 192 h post-dose, the AP activity in most 
subjects had returned to values near those observed at baseline. In each placebo-treated 
subject, the endogenous AP activity varied only minimally over time (not shown).
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Table 2.  Entry demographic characteristics  
SAD MAD
Placebo, 
n = 8
recAP 
200 
U/kg,
n = 7
recAP 
500 
U/kg,
n = 6
recAP 
1000 
U/kg,
n = 6
recAP 
2000
U/kg,
n = 6
Placebo, 
n = 6
recAP 
500 
U/kg,
n = 6
recAP 
1000
U/kg,
n = 6
Age
[years (SD)]
26 (10) 23 (3) 25 (8) 27 (11) 21 (2) 29 (13) 33 (16) 24 (2)
Weight 
[kg (SD)]
73.6 (17.9) 69.4 (10.6) 72.9 (9.0) 69.9 (16.3) 69.4 (8.2) 75.7 (13.1) 73.8 (13.0) 69.8 (14.8)
Height 
[cm (SD)]
174 (12) 175 (11) 175 (8) 175 (15) 177 (10) 179 (9) 178 (12) 171 (11)
Body mass 
index
[kg/m2  (SD)]
24.0 (3.4) 22.6 (2.1) 23.7 (1.8) 22.5 (1.6) 22.3 (2.5) 23.5 (2.1) 23.2 (1.8) 23.7 (3.2)
Sex: female 
[n (%)]
4 (50) 3 (42.9) 3 (50) 3 (50) 3 (50) 2 (33.3) 3 (50) 3 (50)
Race: white 
[n (%)]
7 (87.5) 7 (100) 6 (100) 6 (100) 6 (100) 6 (100) 5 (83.3) 5 (83.3)
Ethnicitya 
[n (%)]
8 (100) 7 (100) 6 (100) 6 (100) 6 (100) 6 (100) 4 (66.7) 5 (83.3)
 a Not hispanic or latino; SAD, single ascending dose; MAD, multiple ascending doses.
Pharmacokinetic Multiple-Ascending-Dose Study
Next, the pharmacokinetics were evaluated in a multiple-ascending-dose study. Healthy 
volunteers received multiple doses of recAP (500 and 1000 U/kg, n = 6 per group) or placebo 
via a 1-h intravenous infusion on days 1, 2 and 3 (Table 1). On days 1 and 3, the maximal serum 
concentrations of recAP were typically reached at the end of the infusion (Figure 1B, C). In just 
one subject (in group 6) on day 1, the maximal serum concentration was reached 0.5 h after 
the end of the infusion. For both multiple-dose levels, the maximum concentrations of recAP 
were similar between days 1 and 3. RecAP was detectable up to 240 h (the last pharmacoki-
netic sampling time point) post-dose in both groups. Like serum recAP concentrations, serum 
AP activity increased to a maximum at the end of the recAP infusion on both days, and the 
mean values were similar between days 1 and 3 for both multiple-dose levels (Figure 1B, C). 
Directly after the infusion, 200- and 460-fold increases in AP activity levels were observed in 
the lower-dose and higher-dose groups, respectively, in comparison with baseline (58 U/L in 
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Figure 1. 
 Serum human recombinant alkaline phosphatase (recAP) concentrations and alkaline phosphatase 
(AP) enzyme activity in healthy volunteers. 
 Subjects received a 1-h intravenous infusion of single ascending doses of recAP (200, 500, 1000 and 2000 U/kg; 
panel A) or multiple ascending doses of recAP (500 and 1000 U/kg) on days 1, 2 and 3 (panel B en C). Serum 
recAP concentrations (upper graphs) and AP enzyme activity levels (lower graphs) were determined at several 
time points after the infusion. The data are expressed as geometric means and standard deviations (n = 6 per 
group). 
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both groups). Serum AP levels were still 5- to 12-fold higher than baseline levels 24 h after the 
start of the first infusion, and they further increased 8- to 20-fold 24 h after the third infusion. 
After an initial rapid decline in serum AP activity during the first 4 h post-infusion, a slower 
decline ensued, which was similar to what was observed after single-dose administration. At 
the last pharmacokinetic measurement (240 h post-dose), AP activity had returned to values 
near to those observed at baseline in most subjects. AP activity in placebo-treated subjects 
varied only minimally over time (not shown). When the serum recAP concentrations and AP 
activity in all subjects at all dose levels and time points evaluated in the study were compared, 
AP activity increased with increasing concentrations of recAP in a linear relationship.
Safety Assessments
Single intravenous infusions of recAP in the range of 200–2000 U/kg, as well as daily intrave-
nous infusions of 500 and 1000 U/kg recAP for three consecutive days, were well tolerated 
by healthy male and female subjects and did not lead to any safety concerns. No serious 
adverse events were reported, and there were no discontinuations due to adverse events in 
any parts of the study. All drug-relatedtreatment-emergent adverse events are presented in 
Supplemental Table 3. The most common events were headache (3/33) and postural dizzi-
ness (2/33) after the single infusion, and infusion-site reactions (3/18) and local swelling (2/18) 
after multiple infusions. None of the subjects demonstrated evidence of the presence of 
serum antibodies against recAP up to 2 weeks after single-dose administration or up to 3 
weeks after multiple-dose administration. There were no significant clinical laboratory find-
ings, 12-lead ECG findings, continuous cardiac monitoring findings or physical examination 
findings during the study. With respect to vital signs, one subject (in group 4) showed a 
postural drop in blood pressure (from 113/66 mmHg in the supine position to 82/49 mmHg in 
the standing position) 3 h post-dose.
Pharmacokinetic Modeling
One-, two- and three-compartment models proved inferior to a four-compartment model 
as the structural model. Introducing a fifth compartment did not significantly improve the 
model. For the four-compartment model, a proportional error structure was preferred over 
an additive error structure or a combined proportional and additive error structure. After 
investigation of IIV (represented as η in the model) on different parameters, the best model 
included an η on the central volume of distribution (V1) and elimination rate constant (K10), 
with a parameter describing the covariance between the η values. Finally, a covariate analysis 
was performed, based on the available covariates. On the basis of the correlation plots, the 
best candidates for covariates on either V1 or K10 were selected and tested in the models, but 
none improved the model fit and they were therefore not taken forward in the model devel-
opment. The parameter estimates are listed in Table 3. The relatively low RSE values (<21%) 
indicate accurate parameter estimation. The IIV, represented as %CV, is within the acceptance 
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criterion, and the shrinkage was well below 35%. The goodness-of-fit plots and individual 
pharmacokinetic profiles are represented in Figure 2. The observed versus population-pre-
dicted values indicate that the model is structurally sound, and inclusion of IIV improves the 
fit, as seen in the observations versus individual predictions. A bias was observed in the plot 
representing CWRESI as a function of time and PRED. The model slightly overpredicts the 
concentrations at 1.5 and 2 h. Most observations, however, lie within the acceptance criterion 
(-2 to 2), indicating that the model describes the data accurately. The visual predictive check 
shows that 95% of the data lie within the 95% prediction interval, indicating that the model 
describes the variability accurately (Figure 3).
Table 3.  Parameter estimates for the model
PARAMETER UNITS ESTIMATE RSE [%] IIV [%CV] SHRINKAGE [%]
K10 /h 0.666 4.97 16.51 4.46
V1 L 3.71 5.23 28.65 0.963
K12 /h 0.311 11.6 NE
K21 /h 0.0143 7.64 NE
K13 /h 0.545 14.1 NE
K31 /h 0.571 20.7 NE
K14 /h 0.564 9 NE
K41 /h 0.0795 11.3 NE
V2 L 80.5 3.85 28.65
V3 L 3.54 16.6 28.65
V4 L 26.3 10.3 28.65
CL L/h 2.47 2.93 18.48
ω2 0.02 4.35
 ω2 residual error, CL clearance, CV coefficient of variation, IIV inter-individual variability, K10 elimination rate 
constant, Kxy rate constant between compartments x and y, NE not estimated, Vx volume of distribution in 
compartment x (1 being the central compartment)
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Figure 2.
 Goodness-of-fit plots for human recombinant alkaline phosphatase concentrations. 
 Left graphs observed (DV) versus population-predicted (PRED) and individual-predicted (IPRED) concentrations, 
showing the lines of unity (black lines) and regression lines (green lines). Right graphs conditional weighted 
residuals with interaction (CWRESI) versus IPRED and time after dose (TAD), showing the Loess fit through the 
data (green lines). 
5 50 500 5000
5
10
50
50
0
50
00
O
bs
er
ve
d 
Co
nc
en
tr
at
io
n 
(n
g/
m
L)
Population Predicted 
Concentration (ng/mL)
Individual Predicted 
Concentration (ng/mL)
5 50 500 5000
5
10
50
50
0
50
00
O
bs
er
ve
d 
Co
nc
en
tr
at
io
n 
(n
g/
m
L)
5 50 500 5000
-5
0
5
10
15
CW
RE
SI
0.2 1.0 5.0 20.0 100.0
-5
0
5
10
15
CW
RE
SI
Individual Predicted 
Concentration (ng/mL)
Time after Dose (h)
DV VS PRED DV VS IPRED CWRESI VS IPRED CWRESI VS TAD
Figure 3. 
 Visual predictive checks of the  pharmacokinetic model after 500 U/kg human recombinant alka-
line phosphatase (recAP) administered once or administered once daily on three consecutive days 
(normalized to the same dosing regimen if needed). 
 The black lines are the median predicted recAP concentrations over time, with the 95% prediction intervals 
shown in gray. The dots are the observations after single dose of 200 U/kg (yellow), 500 U/kg (light green), 1000 
U/kg (blue) or 2000 U/kg (dark green) [left panel], or after multiple doses of 500 U/kg (dark green) or 1000 U/
kg (yellow) [right panel].
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Simulations for Phase IIa/b Dose Selection
Simulations were performed for a wide range of dosing regimens. These included multiple 
doses and continuous infusions, as shown in Supplemental Table 2, and were selected on 
the basis of the knowledge from the current study, taking into account that no dose-limiting 
toxicity was observed in healthy volunteers after single-dose administration of up to 2000 U/
kg and after multiple-dose administration of up to three daily doses of 1000 U/kg. The dosing 
rationale for the patient studies was primarily based on Cmin values and exposure shown to be 
associated with objective clinical benefit in sepsis-associated AKI patients treated with biAP in 
previous clinical studies 9,21, which indicated that clinical benefit occurred above serum recAP 
concentrations of 290 U/L (170 ng/mL). Therefore, the lowest predicted (trough) concentra-
tions should stay above this level for at least 48 h and preferably for 5–7 days. On the basis of 
predictive simulations, three recAP dose levels—all 1-h intravenous infusions administered 
once every 24 h for three consecutive days—were selected, such that a low-dose group (250 
U/kg) achieves borderline exposure and Cmin values, while the medium-dose and high-dose 
groups (500 and 1000 U/kg, respectively) should achieve substantially higher exposure and 
Cmin values. The simulation of the high dose is presented in Figure 4. The three dosing regi-
mens were also selected because the simulated serum recAP concentration–time profiles per 
dose group were sufficiently differentiated, which allows attribution of a potential observed 
treatment effect to a specific dose cohort.
Figure 4. 
 Prediction of human recombinant alkaline phosphatase (recAP) concentrations over time after intra-
venous infusion of the high dose (1000 U/kg, administered once every 24 h for three consecutive 
days) selected for patient studies.
  The solid line is the median predicted recAP concentration over time, with the 95% prediction interval shown in 
gray. The dashed line is the target through concentration of 170 ng/mL.  
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Discussion
Sepsis-associated AKI is a common complication observed in the intensive care unit and is 
accompanied by high mortality rates, while survivors have an increased risk of developing 
end-stage renal disease.22 Two previous clinical trials suggested that biAP had renal protec-
tive effects in critically ill patients with sepsis-associated AKI.9,10 On the basis of these results, 
recAP was developed to replace the bovine-derived enzyme.11 This randomized, double-
blind, placebo-controlled, first-in-human trial demonstrated that single ascending recAP 
doses of up to 2000 U/kg and multiple recAP doses of up to 1000 U/kg per day for 3 days were 
well tolerated by healthy volunteers and that recAP displays a good safety profile. Following 
recAP infusion, no anti-drug antibodies were detectable, no serious adverse events occurred 
and recAP could be administered sequentially without an increase in either the frequency 
or the severity of any treatment-emergent adverse events, in comparison with single recAP 
infusions. The results from the biAP trial showed that a loading dose was required to signif-
icantly raise serum AP activity levels, followed by a continuous infusion over 24 h, to main-
tain relatively stable serum AP levels.21 In order to improve the treatment regimen, recAP was 
developed by replacing the crown domain of a human intestinal AP with the crown domain 
of human placental AP11, which has a half-life of approximately 6–7 days in humans.23 This 
is expected to improve enzyme stability while preserving or enhancing catalytic function. 
Indeed, our results demonstrated that a 1-h recAP infusion resulted in an apparent terminal 
half-life of 48 h, and that 24 h after a single administration of 2000 U/kg recAP, or after 3 days 
of recAP dosing of 1000 U/kg, serum AP activity levels were still up to 20-fold higher than at 
baseline. The improved bioavailability of recAP could be an important feature of a potential 
new treatment option for sepsis-associated AKI, a disease with a complex pathogenesis in 
which multiple pathological processes—including inflammation, hemodynamic instability, 
microvascular dysfunction and unbalanced renal bioenergetics24—should be targeted for a 
longer period of time. On the basis of the pharmacokinetic observations, a four-compart-
ment population pharmacokinetic model was developed with IIV on V1 and K10. The apparent 
terminal half-life (48 h) and volume of distribution (3.5 L) are comparable to those in the previ-
ously developed translational two-compartment pharmacokinetic model (41 h and 4.2 L, 
respectively) used to support the design of this trial.13 The discrepancy in the model struc-
ture could be explained by the experimental design of this trial, as the sampling was more 
intensive, with a longer follow-up period. Nevertheless, our model accurately described 
the data and was used to support the selection of optimal dosing regimens to investigate 
the potential of recAP in patients. The simulations aimed to reach trough recAP concentra-
tions above 290 U/L (170 ng/mL), maintained for at least 48 h and preferably for 5–7 days. 
This resulted in selection of three recAP doses, ranging from 250 to 1000 U/kg, administered 
once every 24 h for three consecutive days. The dosing rationale was primarily based on 
the results of previous clinical studies conducted with biAP.9,21 As could be expected from 
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the enhanced stability by design of the chimeric enzyme, the data from this trial showed 
that AP activity increased with increasing concentrations of recAP in a linear relationship. 
Once the optimal dose of recAP is determined, therapeutic drug monitoring allows exposure 
to be monitored, as AP activity can be quantified by routine laboratory chemistry. Patients 
suffering from sepsis-associated AKI not only have impaired renal function, but also have crit-
ical illness related symptoms such as hypotension, edema and increased vascular permea-
bility, all of which might influence recAP pharmacokinetics. In addition, impaired liver func-
tion could affect recAP clearance, as circulating AP is normally cleared through uptake by the 
hepatic asialoglycoprotein receptor.13 Previously, we demonstrated in vivo that recAP radio-
activity and AP enzyme activity levels were increased during endotoxemia-induced AKI in 
rats, in comparison with placebo, whereas the organ distribution of recAP was not critically 
affected.13 Currently, the safety and efficacy of recAP are being investigated in patients with 
sepsis-associated AKI (ClinicalTrials.gov study ID: NCT02182440). In that trial, recAP pharma-
cokinetics will also be assessed in patients receiving one of three doses of recAP (250, 500 
or 1000 U/kg). Even if pharmacokinetic derangements affect the recAP dosing requirement, 
the highest dose selected for that patient study significantly exceeds the target Cmin of 290 
U/L. Whether recAP administration will result in sufficient exposure in the target organs of 
the heterogeneous patient population, and will thereby exert renal protective effects, will be 
revealed by that large, multicenter trial.
Conclusion
In this study, we investigated the pharmacokinetics, safety and tolerability of recAP, a potential 
new biological treatment option for critically ill patients with sepsis-associated AKI. In healthy 
volunteers, peak concentrations of recAP and AP activity levels were reached at the end of the 
1-h infusion and decreased rapidly in a multiphasic manner. Single ascending recAP doses of 
up to 2000 U/kg and multiple doses of up to 1000 U/kg three times daily did not cause serious 
adverse events. A population pharmacokinetic model was developed and was used to simu-
late different dosing regimens. From these simulations, a more informed dose was selected 
for the patient studies. These results pave the way to investigation of the potential of recAP as 
a new treatment option for sepsis-associated AKI in patient studies.
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Supplemental Tables
Supplemental Table 1. Simulations of recAP doses selected for first-in-human study 
PK PARAMETER UNIT 200 U/KG 500 U/KG 1000 U/KG 2000 U/KG
AUC0-24 ng·h/mL 18323 45807 91613 183227
AUC0-∞ ng·h/mL 51039 127598 255195 510390
Tmax h 1.0 1.0 1.0 1.0
Cmax ng/mL 2927 7318 14636 29273
C 24h ng/mL 552 1381 2762 5524
 1-h intravenous infusion. PK, pharmacokinetic; AUC, area under curve; AUC0-24, AUC from time 0 to time 24 h; 
AUC0-∞, AUC from time 0 to infinity, Cmax, maximum concentration, C24h, concentration at 24 h; tmax, time to reach 
Cmax.
Supplemental Table 2.  Simulations for dose selection patient studies 
IV LOADING DOSE (U/KG) FOR 1 Ha IV INFUSION
Day 1 Day 2 Day 3 Dose (U/kg/48h) Duration (h)
1 250 250 - - -
2 250 250 250 - -
3 500 500 - - -
4 500 500 500 - -
5 1000 1000 - - -
6 1000 1000 1000 - -
7 67.5b - - 32.5c 48
8 67.5b - - 132.5c 72
9 250 - - 250 48
10 500 - - 500 48
11 1000 - - 1000 48
12 500 - - 500 96
 aConsecutive doses administered every 24 h. bIV loading dose (U/kg) for 10 min. cIV infusion (U/kg) per 24 h. 
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Supplemental Table 3. Drug-related treatment-emergent adverse events 
SAD MAD
Placebo
n = 8
recAP
200 U/kg
n = 7
recAP
500 U/kg
n = 6
recAP
1000 U/kg
n = 6
recAP
2000 U/kg
n = 6
Total
n = 33
Placebo
n = 6
recAP
500 U/kg
n = 6
recAP
1000 U/kg
n = 6
Total
n = 18
Total 3a (25%) 3a  (33%) 2a (17%) 3 (50%) 11a (24%) 3a  (33%) 4a  (50%) 1 (17%) 8a (33%)
Abdominal pain 1 (13%) 1 (3%)
Rhinitis 1 (13%) 1 (3%)
Dizziness 1 (17%) 1 (3%)
Dizziness postural 2a (17%) 1 (17%) 3a (6%)
Headache 1 (13%) 2 (33%) 3 (9%)
Presyncope 2 (33%) 2 (6%)
Fatigue 1 (17%) 1 (6%)
Infusion site reactions 2a (17%) 2a (17%) 1 (17%) 5a (17%)
Infusion site swelling 1 (17%) 1 (17%) 2 (11%)
 Data represents the number of times the adverse event occurred. The percentage represents the number of 
subjects as a % of the total number of subjects per treatment. a Includes multiple events in one patients. SAD, 
single ascending dose; MAD, multiple ascending doses.
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Abstract
A 
cute kidney injury (AKI) occurs in 55–60% of critically ill patients, and sepsis is 
the most common underlying cause. No pharmacological treatment options 
are licensed to treat sepsis-associated AKI (SA-AKI); only supportive renal 
replacement therapy (RRT) is available. One of the limited number of candidate compounds 
in clinical development to treat SA-AKI is alkaline phosphatase (AP). The renal protective effect 
of purified bovine intestinal AP has been demonstrated in critically ill sepsis patients. To build 
on these observations, a human recombinant AP (recAP) was developed, of which safety and 
efficacy in patients with SA-AKI will be investigated in this trial.
Methods 
This is a randomised, double-blind, placebo-controlled, four-arm, proof-of-concept, dose-
finding adaptive phase IIa/IIb study, conducted in critically ill patients with SA-AKI. A minimum 
of 290 patients will be enrolled at approximately 50 sites in the European Union and North 
America. The study involves 2 parts. Patients enrolled during Part 1 will be randomly assigned 
to receive either placebo (n=30) or one of three different doses of recAP (n=30 per group) 
once daily for 3 days (0.4, 0.8 or 1.6 mg/kg). In Part 2, patients will be randomly assigned 
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to receive the most efficacious dose of recAP (n=85), selected during an interim analysis, or 
placebo (n=85). Treatment must be administered within 24 hours after SA-AKI is first diag-
nosed and within 96 hours from first diagnosis of sepsis. The primary end point is the area 
under the time-corrected endogenous creatinine clearance curve from days 1 to 7. The key 
secondary end point is RRT incidence during days 1–28.
Ethics and dissemination
This study is approved by the relevant institutional review boards/independent ethics 
committees and is conducted in accordance with the ethical principles of the Declaration of 
Helsinki, guidelines of Good Clinical Practice, Code of Federal Regulations and all other appli-
cable regulations. Results of this study will reveal the efficacy of recAP for the improvement 
of renal function in critically ill patients with SA-AKI and will be published in a peer-reviewed 
scientific journal.
Funding AM-Pharma.
Trial registration number NCT02182440; Pre-results.
Introduction
Acute kidney injury (AKI) is common in critically ill patients and associated with significant 
morbidity and mortality. The intensive care unit (ICU) incidence of AKI is 55-60% with an asso-
ciated mortality of more than 27%.1 Patients surviving an AKI episode have an increased risk to 
develop chronic kidney failure, resulting in a tremendous burden for the patient and society.2 
AKI may occur after cardiovascular surgery, administration of nephrotoxic drugs, trauma, 
burns and sepsis, with the latter being the most frequent cause of AKI.3 Sepsis presents with 
clinical manifestations of systemic inflammation combined with suspicion or evidence of an 
infection and is a major cause of multiple organ dysfunction and death in the ICU.4 The patho-
genesis of sepsis-associated AKI (SA-AKI) is believed to be an interplay of systemic and renal 
inflammation, hypoxia and dysregulated renal bioenergetics.5 There are no pharmacological 
interventions approved for the treatment of SA-AKI. Currently, the only supportive treatment 
option available is renal replacement therapy (RRT). A potent new candidate drug in clinical 
development to treat or prevent SA-AKI is alkaline phosphatase (AP). AP is a dephosphor-
ylating, membrane-bound, endogenously occurring enzyme, exerting detoxifying effects 
through dephosphorylation of endotoxins, involved in sepsis pathogenesis6,7 and other 
pro-inflammatory compounds, including extracellular ATP.8 Several isoenzymes exist, namely 
intestinal, placental, germ-cell and tissue non-specific (liver/kidney/bone) AP, illustrating 
the broad expression throughout the body.9 Previously, clinical trials in healthy volunteers 
and patients with sepsis, with or without AKI, have established the tolerability and potential 
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efficacy of purified bovine intestinal AP (biAP).10-12 In patients with SA-AKI, biAP significantly 
improved renal function according to the combined end point of endogenous creatinine 
clearance, requirement for RRT and duration of RRT. Moreover, a range of markers of systemic 
inflammation, renal function and renal damage in blood and urine demonstrated improve-
ment, suggesting that a systemic anti-inflammatory effect induced by biAP prevented further 
renal injury. Following these encouraging results, a human recombinant AP (recAP) has been 
developed as a pharmaceutically acceptable replacement for bovine-derived AP. In order 
to improve enzyme stability, while maintaining catalytic function, the crown domain of a 
human intestinal AP is replaced with the crown domain of human placental AP.13 In line with 
pre-clinical and clinical studies using purified biAP, animal studies with recAP revealed potent 
anti-inflammatory activity preserving function14 and histological integrity of the affected 
kidneys (unpublished data) and administration to healthy volunteers did not raise any safety 
concerns.15 Therefore, therapeutic application of recAP is predicted to exert potent tissue 
protective and anti-inflammatory effects in patients with SA-AKI. In order to investigate this 
hypothesis, a randomised placebo-controlled phase II trial is being conducted with recAP in 
critically ill patients suffering from SA-AKI.  
Methods and analysis
Design and setting 
A randomised, double-blind, placebo-controlled, four-arm, parallel-group, proof-of-concept, 
dose-finding adaptive phase IIa/IIb study is being conducted in critically ill patients with 
SA-AKI. It is expected that the patients will be recruited by ~50 sites across the European Union 
and North America. Participating institutions will be required to adhere to the Surviving Sepsis 
Campaign 201216 and 2012 KDIGO (Kidney Disease: Improving Global Outcomes) Clinical Prac-
tice Guideline for AKI recommendations.17 The study involves two parts with an interim anal-
ysis between the parts (Figure 1), with continued recruitment during this interim analysis. 
Patients enrolled during Part 1 and during the interim analysis will be randomly assigned 
to receive either placebo or one of three different doses of recAP once daily for 3 days. The 
interim analysis on safety and the primary end point will be performed after the 120th patient 
of Part 1 has completed the day 7 visit of the study to select the dose to be administered in 
Part 2. The dose chosen will be the most efficacious dose of recAP on the primary end point 
in Part 1, provided there are no safety issues with that dose as judged by the data monitoring 
committee (DMC). In Part 2, patients will be randomly assigned to receive either placebo or 
the dose of recAP selected during the interim analysis. Patients recruited during the interim 
analysis period to the dose selected in Part 2 will form part of the Part 2 population, but 
those recruited to the doses that are not selected will be included in the Part 1 population. 
The duration of the study is defined for each patient as the date signed written informed 
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Figure 1. 
 Trial flow. 
 ICF, informed consent; SA-AKI, sepsis-associated acute kidney injury; RRT, renal replacement therapy
Figure 2. 
 Timeline. 
 SA-AKI, sepsis-associated acute kidney injury.
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consent is provided through the last follow-up visit on day 90 (Figure 2). This study is reported 
in accordance with the Standard Protocol Items: Recommendations for Interventional Trial 
(SPIRIT) guidelines.18 
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Study objectives
Primary objectives
The primary objectives are to investigate the optimal therapeutic dose and effect of recAP on 
renal function and related clinical parameters in patients with SA-AKI.
Secondary objectives
The secondary objectives are to investigate the safety and tolerability, pharmacokinetics (in 
the first 120 patients from Part 1 only), immunogenic potential and the effect on quality of life 
of recAP in patients with SA-AKI. 
Other objectives
The other objectives are to determine whether specific patient groups benefit most from 
recAP treatment and whether patient groups that are non-responders can be identified. 
The identification of such groups will be based on several baseline characteristics, including 
kidney function markers and biomarkers for tubular injury and systemic inflammation. 
Patient selection
A minimum of 290 patients will be enrolled, at least 120 patients in Part 1 and at least 170 
patients in Part 2. Potential patients who have been admitted to the ICU will undergo a 
prescreening and, once informed consent is obtained, will undergo screening assessments 
to determine their eligibility. As soon as possible when all of the inclusion criteria and none 
of the exclusion criteria are met (Table 1), and after confirmation of continuing AKI by either 
a fluid-corrected serum creatinine assessment or persistence of attenuated urine output, 
patients will be randomly assigned to a treatment group, undergo baseline determinations 
and start treatment with study drug (day 1). Treatment must be administered within 24 hours, 
at the latest, after SA-AKI is first diagnosed and within 96 hours from fulfilling sepsis criteria. 
Coincident with the interim analysis, but independent from it, some eligibility criteria (eg, age, 
weight, time-window of sepsis diagnosis, time-window of AKI diagnosis) were slightly modi-
fied to facilitate patient inclusion in the second part of the trial (Supplemental Table 1). These 
adjustments were considered to be unlikely to materially influence the characteristics of the 
subject population or to impact the potential risk-benefit of recAP. In addition, to achieve 
adequate participant enrolment, best practices will be shared via national coordinator meet-
ings and if necessary, additional sites will be recruited and dormant sites will be closed.
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Table 1. Patient entry selection 
INCLUSION CRITERIA
• Has informed consent form signed by patient or legal representatives or independent investigator, 
according to local rules and regulations
• Is aged 18-85 years, inclusive
• Is admitted to the intensive care unit or intermediate care unit
• Has diagnosis of sepsis (<96 hours prior to first study drug administration or <72-hour prior to acute kidney 
injury (AKI) diagnosis), according to criteria defined by the American College of Chest Physicians/Society of 
Critical Care Medicine19, based on:    
• A proven or strongly suspected bacterial infection
• At least two of the following four SIRS criteria within a timeframe of 72 hours at the time of AKI diagnosis. 
Note: it is not required that symptoms are present simultaneously at study randomization:
- Core temperature > 38 °C or < 36 °C
- Heart rate > 90 bpm (unless the patient has a medical condition known to increase heart rate or is 
receiving treatment to prevent tachycardia
- Respiratory rate > 20 breaths/minute, PaCO2 < 32 mmHg or the use of mechanical  ventilation for an 
acute respiratory process
- White cell count > 12,000/mm3 or < 4,000/mm3 or a differential count showing > 10% immature 
neutrophils   
• Has first diagnosis of AKI, defined as AKI Stage 1 or greater, according to the following AKIN criteria 
 (Note: adjusted in regards to time-window):
- Urinary output < 0.5 mL/kg/h for > 6 hours following adequate fluid resuscitation when appli-
cable, in the absence of underlying primary renal disease, or 
- Increase (absolute) in serum creatinine > 26.2 µmol/L (0.30 mg/dL) compared with a serum creat-
inine value within the previous 48 hours, or presumed to have occurred in the previous 48 hours 
when compared with a reference creatinine value (see below), or
- Increase (relative) in serum creatinine to > 150% (> 1.5-fold) compared with a serum creatinine  
value in the previous 48 hours or presumed to have occurred in the previous 48 hours, when 
compared with a reference creatinine value (in the absence of primary underlying renal disease). 
- The reference creatinine value is a serum creatinine value in the following order of preference:
1. Lowest value within 3 months of the hospital admission. If not available:
2.  At hospital admission. If not available:
3.  At ICU admission. If not available:
4.  Lowest value between 3 and 12 months prior to hospital admission
- When the diagnosis of AKI is made according to one of the AKIN serum creatinine criteria, 
continuing AKI needs to be confirmed by a confirmative fluid-corrected serum creatinine 
measure, defined as no decrease in serum creatinine ≥ 26.2 µmol/L (≥ 0.30 mg/dL). The result 
must be available prior to randomisation. Administration of study treatment must be started 
within 24 hours after first AKI diagnosis
- When the AKI diagnosis was made according to the AKIN urine output criteria, the oliguria or 
anuria should still meet the AKIN urine output criteria prior to randomisation. Administration of 
study treatment must be started within 24 hours after first AKI diagnosis
 *As urogenital obstruction, frequently observed during urosepsis, may also account for an increase in serum 
creatinine levels, it is not possible to define which proportion might be due to SA-AKI. Therefore, urosepsis patients 
are excluded. † CKD is a disease with a distinct pathophysiology compared with AKI. Also, if eGFR is impaired, 
the chances of an intervention to prevent further deterioration are limited. To increase homogeneity >> 
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EXCLUSION CRITERIA
• Woman of childbearing potential with a positive pregnancy test (blood or urine), pregnant, or breastfeeding
• Weighs more than 115 kg (253 lb)   
• Has life support limitations (eg, do not intubate, do not dialyse, do not resuscitate)
• Is known to be HIV-positive
• Has urosepsis*
• Is already on renal replacement therapy (RRT) or a decision has been made to initiate RRT within 24 hours 
after planned start of study drug administration
• Is receiving immunosuppressant treatment or is on chronic high doses (high-dose therapy exceeding 2 
weeks of treatment) of steroids equivalent to prednisone/prednisolone 0.5 mg/kg/day, including solid 
organ transplant patients. Patients with septic shock
• treated with hydrocortisone (eg, 3×100 mg) can be included
• Is expected to have rapidly fatal outcome (within 24 hours)
• Has known, confirmed fungal sepsis
• Has advanced chronic liver disease, confirmed by a Child-Pugh score of 10-15 (Class C)
• Has acute pancreatitis with no established source of infection
• Has participated in another investigational study within 30 days prior to enrollment into the study
• Is not expected to survive for 28 days due to medical conditions other than SA-AKI, including cancer 
(previous haematological malignancies that are not actively treated allowable), end-stage cardiac disease, 
cardiac arrest requiring cardiopulmonary resuscitation or with pulseless electrical activity or asystole within 
the past 30 days, end-stage lung disease, and end-stage liver disease
• Has known prior history of CKD with a documented eGFR < 60 mL/min by a commonly used formula 
such as MDRD or CKD-EPI, known GFR < 60 mL/min, or a known history of persistent creatinine level ≥150 
μmol/L (1.70 mg/dL) prior to entry for reasons other than the current sepsis condition†
• Has diagnosis of malaria or other parasite infections
• Has burns on > 20% of body surface
• Has had AKI diagnosis according to the AKI inclusion criteria for a period longer than 24 hours prior to study 
drug administration
• Is anticipated to be treated with non-continuous RRT from day 1 to day 7
• During day 1 to day 7 continuous RRT is anticipated to be started or stopped not according to per protocol 
criteria
• The AKI is most likely attributable to other causes than sepsis, such as nephrotoxic drugs (NSAIDs, contrast, 
aminoglycosides) and renal perfusion-related (acute abdominal aortic aneurysm, dissection, renal artery 
stenosis)
• Improvement in serum creatinine of at least 26.2 µmol/L (0.30 mg/dL) prior to administration of the study drug
• Patients who use nephrotoxic medication and who fulfill the SA-AKI inclusion criteria at screening are not 
eligible if the use of this nephrotoxic medication is planned to continue (eg, NSAIDs, ACE inhibitors, genta-
mycin, tobramycin)
• Has a history of known intravenous drug abuse
• Is an employee or family member of the investigator or study site personnel
• Has active haematological malignancy
<< of the study population, these patients are therefore excluded. AKIN, acute kidney injury network; CDK, 
chronic kidney disease; CKD-EPI, Chronic Kidney Disease Epidemiology Collaboration; eGFR, estimated glomer-
ular filtration rate; MDRD, Modification of Diet in Renal Disease; NSAIDs, non-steroidal anti-inflammatory drugs; 
RRT, renal replacement therapy; SIRS, systemic inflammatory response syndrome.
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Randomisation 
Patients will be randomly assigned to receive either placebo or one of three doses of recAP 
using a 1:1:1:1 allocation ratio. The randomisation schedule will be stratified by site. An inde-
pendent statistician will generate a permuted block randomisation schedule for an interac-
tive voice/web response system (IVRS/IWRS), which will link sequential patient randomisa-
tion numbers to treatment codes. After informed consent has been obtained, the IVRS/IWRS 
provides a patient number at screening and retains a unique randomization number for all 
patients. Once the screening assessments are performed, data have been reviewed by an 
investigator and the patient is considered to be eligible, the investigator will contact the IVRS/
IWRS to randomly assign the patient a treatment number through IVRS/IWRS. Once it has 
been decided which is the most efficacious dose of recAP on the primary endvpoint to be 
administered in Part 2, the codes for the treatment groups corresponding to the two dropped 
doses will be discontinued, and 1:1 treatment allocation will continue using the codes for the 
remaining treatments (1 active, 1 placebo).
Informed consent 
Informed consent will be obtained before any study-specific procedures are performed. 
Country-specific regulations regarding the use and collection of personal data and biological 
specimens, ancillary care, and financial care to those who suffer from harm will be followed 
at each site. It is anticipated by the very nature of the study that many patients who will be 
eligible for this protocol due to their severe underlying condition will not be able to provide 
informed consent themselves for various reasons. In a situation where a patient is unable to 
provide consent, the patient’s legally authorised representative may provide written consent 
as approved by the institutional-specific guidelines. Informed consent may be obtained from 
an independent consulting physician in countries where regulation and institution guide-
lines permit. This form of consent can only be used when the patient and legally authorised 
representative are unable to provide consent. In cases where the initial informed consent is 
obtained from a legal representative or an independent consulting physician, the patient 
also must consent as soon as they are able. The investigator shall retain the signed original 
Informed Consent Form (ICF) and give a copy of the signed original form to the patient or 
legal representative.
Blinding
All people involved in the study will be blinded to treatment assignment. The randomis-
ation schedule will be held by an independent, non-blinded statistics team at a different 
regional location and will not be revealed until all patients have completed the study and 
the database has been finalised for the end of the study. The non-blinded interim analysis 
will be conducted and delivered to the independent data monitoring committee by the 
non-blinded biostatistics team, located at a different site to the blinded team. A patient’s 
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treatment assignment will not be broken until the end of the study, unless knowledge of the 
treatment assigned to the patient is necessary to guide medical treatment of the patient. 
The determination of AP activity in plasma, often part of the routine clinical chemistry panel, 
could lead to non-blinding and to erroneous interpretation of liver function, as the recAP 
administered will increase the AP activity, exceeding many times the reference range AP 
levels. Therefore, AP activity levels from samples taken during the first 14 days of the study 
are not allowed to be determined/reported to the study team members or to any other study 
staff member involved in the conduct of the study.
Study intervention
Patients randomly assigned to receive recAP in Part 1 will receive one of the following three 
doses of recAP: 0.4 mg/kg (250 U/kg), 0.8 mg/kg (500 U/kg) or 1.6 mg/kg (1000 U/kg). Study 
drug will be administered by 1-hour intravenous infusion as soon as possible, but within 24 
hours after SA-AKI is first diagnosed, on day 1, and 24±1 hours later on days 2 and 3. A total 
volume of 50 mL will be infused at a constant rate of 50 mL/hour. The preferred route for 
study drug administration is through a central venous line; if this is not possible, a peripheral 
line is acceptable. Study drug is being administered separately from any concomitant drugs 
using a dedicated lumen of the catheter. At the start of each drug administration, the exact 
volume of recAP or placebo to be administered to each patient will be calculated on the basis 
of the patient’s hospital admission weight. Patients weighing between 95 and 115 kg will 
receive the same dose as that for patients weighing 100 kg. The volume of the placebo and 
the volume of the active doses of recAP are identical. RecAP is supplied as a clear, colourless, 
pyrogen-free solution for intravenous infusion with a content of 40 mg per phial at 8.0 mg/
mL in an aqueous buffer. Matching placebo is supplied in an identical manner as the same 
aqueous buffer. RecAP and matching placebo will be prepared in randomised treatment 
packs comprising three daily doses and shipped to the clinical site. Each pack will contain 
a (randomised) dosage for one patient and will contain a sufficient quantity for dispensing 
during the 3-day double-blind treatment period. The content of the vials will be used to fill 
an intravenous dosing syringe and will be dose adjusted to an appropriate volume corre-
sponding to the body weight of the patient, followed by the addition of physiological saline 
solution to a total of 50 mL. All study drug is to be stored in a lockable storage facility under 
appropriate and monitored pharmacy conditions. 
Concomitant medications
After randomisation, the administration of nephrotoxic drugs, such as contrast agents, 
non-steroidal anti-inflammatory drugs (NSAIDs), ACE inhibitors, angiotensin receptor blockers, 
gentamycin or tobramycin should be avoided where possible, as recommended in the KDIGO 
Clinical Practice Guideline for AKI recommendations.17
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Outcome measures
Primary end point
The primary end point is the area under the time-corrected endogenous creatinine clear-
ance curve from day 1 (first measurement after treatment) to day 7, inclusive (AUC1-7), with 
the creatinine clearance curve being the mean creatinine clearance on each day. Time-cor-
rected endogenous creatinine clearance is assessed on each day during a 6±1 hour period 
with serum creatinine measurements before and after the urine collection period to calculate 
in mL/min as the mean creatinine clearance over the period. Although 24-hour urine collec-
tion periods are the most accurate to reliably determine creatinine clearance, a 6-hour period 
is expected to be representative of the full 24 hours for that day.20,21 If there is no diuresis, the 
clearance will be reported as 0 mL/min. 
AUC1-7 is calculated as the average of the time-corrected endogenous creatinine clearance 
values over the 7 days. Specifically, denoting Ci as the mean time-corrected endogenous 
creatinine clearance on day i, AUC1-7 is defined as:
  
Any missing Ci values will be handled by linear interpolation where possible, otherwise they 
will be imputed by last observation carried forward. When there are no preceding postbase-
line measurements to use, the baseline measurement from day 0 (prior to treatment) will be 
carried forward. 
Key secondary end point
The key secondary end point is RRT incidence during the period day 1 (after first treatment) to 
day 28, inclusive. Should a patient die or withdraw from the study during this period without 
recording RRT incidence, he or she will be counted as having not required RRT. From day 1 
to day 7 only continuous modalities of RRT are allowed. From day 8 onward intermittent/
non-continuous modalities such as intermittent haemodialysis are allowed. Criteria for the 
initiation and timing of stopping of RRT are described in Table 2. Although these criteria are 
strongly preferred within the protocol setting, based on clinical judgement, investigators may 
deviate from these criteria. 
Other secondary endpoints
Other secondary renal endpoints include the duration of RRT over 28 days and renal function 
at day 28 (creatinine clearance if available, or estimated GFR (eGFR) according to the chronic 
kidney disease epidemiology collaboration (CKD-EPI) formula) and at days 60 and 90 (eGFR). 
Clinical end points include liver enzymes (aspartate aminotransferase, alanine aminotrans-
ferase, γ-glutamyl transpeptidase, lactate dehydrogenase, bilirubin), lung function (PaO2/FiO2 
ratio, positive end-expiratory pressure and tidal volume), mechanical ventilation over 28 days, 
AUC Ci
i
1 7
1
71
7− =
= ∑ �
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Table 2. Start and stop criteria RRT
INITIATION OF RRT22 *
• Anuria (negligible urine output for 6 hours)
• Severe oligura (urine output <200 mL over 12 hours)
• Hyperkalaemia (potassium concentrations >6.5 mmol/L)
• Severe metabolic acidosis (pH <7.2 despite normal or low partial pressure of carbon dioxide in arte-
rial blood)
• Volume overload (especially pulmonary oedema unresponsive to diuretics)
• Pronounced azotaemia (urea concentrations >30 mml/L or creatinine concentrations >300 μmol/L) 
• Clinical complications of uraemia (eg, encephalopathy, pericarditis, neuropathy)
TIMING OF STOPPING RRT23 *
• If (on continuous RRT or between intermittent haemodialysis sessions) diuresis >30 mL/hour and  
there are no other indications for RRT, then endogenous creatinine clearance should be calculated 
using a 6-hour urine collection period:
• If endogenous creatinine clearance ≥20 mL/min, RRT should be discontinued
• If endogenous creatinine clearance ≤12 mL/min, RRT should be continued
• If endogenous creatinine clearance >12 mL/min and <20 mL/min, continuation or termination will 
be the decision of the treating physician
 * Meeting one criterion makes the patient eligible for initiation of RRT. RRT, renal replacement therapy.
shock over 28 days, SOFA scores and mortality over 90 days. Biomarker end points include 
kidney function markers (urine and serum creatinine, blood urea nitrogen, sodium, proteinuria, 
fractional excretion of sodium and urea and urine volume), biomarkers for tubular injury 
(kidney injury molecule-1, interleukin (IL)-18 and α-glutathione s-transferase) and systemic 
inflammation (IL-6, C reactive protein and lipopolysaccharide (LPS)-binding protein), and 
recAP pharmacokinetic properties.
Additional end points include composite end points (combinations of need for RRT, mortality, 
eGFR and hospitalisation for new AKI episode), serology, assessed by IgG, IgE and total immuno-
globulin, quality of life, assessed by the EuroQol-5D questionnaire and ICU and hospital length 
of stay over 90 days. The safety analyses include (serious) adverse events (SAEs), laboratory 
assessments (eg, antidrug antibodies), haematology, vital signs and electrocardiography data. 
Statistical and analytical plan
Sample size calculations
A sample size of n1 = 30 patients per treatment group in Part 1 with an additional n2 = 85 
patients recruited to the optimal recAP dose and placebo treatment groups in Part 2 (for 
a total sample size of n = 290 patients) is planned. Custom-programmed simulations were 
performed using SAS software Version 9.2 to determine power and type I error rate of the 
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chosen sample size and design under a number of different dose-response scenarios. Each 
scenario assumed an SD of 49 mL/min for the primary end point with an assumed response of 
60 mL/min for the placebo group, and between 60 mL/min (no treatment effect) and 79 mL/
min (strong treatment effect) for the recAP dose groups.
Fifty thousand simulations were performed to show that the one-sided type I error rate is 
2.4% (and hence is well controlled at the one-sided 2.5% significance level). The power was 
defined as the probability of rejecting the null hypothesis (of no difference between treatment 
groups) when one or more recAP dose groups have an effective treatment effect, defined 
as a response of 69.5 mL/min. This was investigated across 7 scenarios with 10 000 simula-
tions performed for each. The chosen design achieved power of between 79% and 86% for 
scenarios with strong treatment effects for the medium and high recAP dose groups and a 
varying response for the low-dose group, and between 66% and 67% when only the high-
dose group had a strong treatment effect. As the sample size determination is based on the 
number of patients required for the intention-to-treat (ITT) analysis, patients who are randomly 
assigned and subsequently withdraw prior to completion of the study will not be replaced.
Interim analysis
A non-blinded interim analysis will be conducted on the Part 1 data to determine the optimal 
recAP dose for Part 2. This analysis will compare the three recAP doses and placebo from 
Part 1 on the primary efficacy end point and the safety data. The optimal dose is defined as 
the dose with the best safe improvement on creatinine clearance compared with placebo. 
Unless the DMC have safety concerns pertaining to specific dose level(s) of recAP and/or the 
dose-response modelling of the primary end point (Emax model) highlights unusual trend(s), 
the optimal dose will be, preferably, the highest dose of recAP. If there are safety concerns 
and/or concerns with regard to the dose-response curve, the optimal dose level will be 
selected among the dose levels where there are no safety or/and dose-response modelling 
concerns. In that case, the effectiveness of a dose level will be determined based on the 
one-sided unadjusted p value for comparison with placebo on the primary end point, that is, 
the dose with the smallest p value will be considered the most effective dose. Should more 
than one dose appear to be the most effective with the same effect, the safety data as well 
as the dose-response modelling should be closely examined for selecting the optimal dose.
Safety data being analysed includes the use of concomitant medications, adverse events 
(AEs), treatment emergent AEs (TEAEs) and SAEs, laboratory assessments and vital signs. 
The results will only be reviewed by an independent non-blinded DMC, who will make the 
dose selection decision. The selected dose will be reported to the sponsor in a blinded 
fashion. The study will not be prematurely terminated in case a statistically significant benefit 
is found during the interim analysis. 
The study may be terminated for futility if none of the three recAP doses in Part 1 show 
evidence of efficacy for the primary end point. Each recAP dose will only be deemed futile if the 
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one-sided, unadjusted p value for its comparison with placebo is <0.8. If all of the doses in Part 
1 fulfil the futility criterion, then the DMC will recommend further discussion with the sponsor 
and Steering Committee to determine whether the trial should be terminated for futility. 
Statistical analyses
Statistical analyses will be performed using SAS software Version 9.2 or later. Continuous variables 
will be summarised using descriptive statistics, and categorical variables will be summarised 
using frequency counts and percentages. All statistical tests, primarily performed on the ITT set, 
will be two-sided and performed using a 5% significance level, leading to 95% (two-sided) CIs. 
The analysis of the primary efficacy end point will be performed separately for Parts 1 and 2: 
for Part 1, AUC1-7 will be compared between the three recAP doses and placebo by an anal-
ysis of variance (ANOVA) of the AUC1-7 with treatment and site as explanatory variables, or 
corresponding non-parametric analyses if appropriate. For Part 2, the optimal recAP dose 
will be compared with placebo using the same ANOVA model or corresponding non-para-
metric analyses if appropriate. To address multiplicity, the type 1 error rate will be controlled 
by combining the results for the primary efficacy end point from the interim analysis (Part 1) 
and the final analysis (Part 2), using the inverse normal method.24
A hierarchical method will be employed to address any multiplicity arising from the analysis of 
the key secondary end point, indicating that the optimal recAP dose will be formally compared 
with placebo, using a logistic regression model with treatment group and site as explanatory 
variables, only if a statistically significant result is obtained from the combination test analysis 
of the primary end point. Otherwise, the results will be reported as exploratory analysis only.
All analyses performed on the other secondary end points are for exploratory purposes only. 
Therefore, no further multiplicity adjustment is required. 
Data quality assurance 
The sites will maintain source documentation and enter patient data into the electronic case 
report form (eCRF) as accurately as possible. eCRFs are accessed through Medidata Rave 
(Medidata Solutions Inc, New York, New York, USA). This electronic data capture system is vali-
dated and compliant with US Title 21 Code of Federal Regulations (CFR) Part 11. Each person 
involved with the study will have an individual user name and password that allows for record 
traceability. A quality review of the data will be performed by the site with additional reviews 
by the clinical monitor through 100% source data verification. Each eCRF is presented as an 
electronic copy, allowing data entry by study site staff, who can add and edit data, iden-
tify and resolve discrepancies, and view records. This system provides immediate direct data 
transfer to the database, as well as immediate detection of discrepancies, enabling site coor-
dinators to resolve and manage discrepancies in a timely manner. After all data reviews and 
query resolutions are complete, the statistical analysis plan approved and signed, and any 
summary/analysis populations approved, the database will be locked.
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Safety assessment
Medication errors 
Since the study drug will be prepared, double-checked and administered by trained hospital 
staff, and since the dose levels under study have not caused any SAEs in healthy volunteers15, 
the risks for potential hazardous or life-threatening events due to medication errors are 
considered to be minimal. 
Overdose
In healthy volunteers, the maximum administered single dose was 3.2 mg/kg (2000 U/kg) and 
this dose did not result in any SAEs.15 As an example of a possible dose error (eg, administra-
tion of the highest study dose for a 100 kg person to a 50 kg person), 1-day administration of 
study drug still would not exceed the tested maximum dose in healthy volunteers.
AEs report
All patients will be monitored closely for signs of adverse reactions. AEs will be reported in 
the eCRF from the time the patient signs the ICF until day 28 visit for all AEs (including SAEs) 
regardless of its relationship to study drug. Any AE that occurs during or after the first dose 
of study drug is considered treatment emergent. The intensity of the AE will be rated as mild, 
moderate or severe. In addition to patient observations, TEAEs will be documented from any 
data collected on the AE page of the eCRF (eg, laboratory values, physical examination find-
ings) or identified from review of other documents (eg, patient diaries) that are relevant to 
patient safety. When patients have left the hospital, they will be instructed to contact the 
investigator at any time if any symptoms develop. In the event of an SAE, the investigator may 
immediately stop treatment if it is considered in the best interest of the patient. In case study 
drug is discontinued early, the patient will continue follow-up in the study as per protocol. 
The assessment of the relationship of an AE to the administration of study drug (unrelated, 
possible, probable, definite) is a clinical decision based on all available information at the time 
of completion of the eCRF.
External data monitoring committee
An independent DMC will review safety and efficacy data during Part 1 and Part 2 of the 
study at predefined milestones. The DMC consist of three members with experience in inde-
pendent clinical review boards: two clinical experts and one biostatistical expert. The DMC is 
supported by two clinical pharmacology advisors.
Withdrawal 
Patients have the right to withdraw from the study at any time and for any reason. Investiga-
tors should attempt to determine the cause of withdrawal and, if agreed by the patient, let 
the patient return for the day 90 visit. The extent of a patient’s withdrawal from the study (ie, 
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withdrawal from further study treatment, withdrawal from active participation in the study, 
withdrawal from any further contact) should be documented. Treatment with study drug 
will be stopped when continued treatment with study drug is not in the best interest of the 
patient, if the patient withdraws consent, when investigator or sponsor decides to discon-
tinue the patient’s participation in the study or when AM-Pharma terminated the study. Addi-
tionally, treatment with study drug may be stopped in case of protocol non-compliance or 
deviations. In case study drug is discontinued early, the patient will continue follow-up in the 
study as per protocol to allow for ITT analysis. 
Study period
Preparations of the study are completed. The study started enrolling patients in December 
2014. Part 1 is completed and the most efficacious dose of recAP has been selected during 
the interim analysis in April 2016. The estimated study enrolment completion date of Part 2 is 
February 2017. Of note, this manuscript was completed prior to the interim analysis.
Ethics and dissemination
Ethics 
Before study onset, the protocol, amendments, informed consent and any other written infor-
mation regarding this study to be provided to the patient or the patient’s legal guardian were 
approved by the relevant institutional review boards (IRBs)/independent ethics committees 
(IECs). Amendments will be communicated to all relevant parties  via mail, investigator meet-
ings and site trainings. The study is being performed in accordance with the ethical princi-
ples that have their origin in the Declaration of Helsinki, ICH E6(R1), Code of Federal Regula-
tions and all other applicable regulations. Fully informed consent will be obtained before any 
study-specific procedures are performed. Country-specific regulations regarding the collec-
tion of personal data will be followed at each site. 
Potential conflicts of interest
During this trial, AM-Pharma, the manufacturer of recAP, has no involvement in the randomisa-
tion, interim analyses and dose selection, and analyses and interpretation of data. AM-Pharma 
is involved in drafting of the manuscript.
Confidentionality
All laboratory specimens, evaluation forms, reports and other records will be identified in 
a manner designed to maintain patient confidentiality. All records will be kept in a secure 
storage area with limited access. Clinical information will not be released without the written 
permission of the patient (or the patient’s legal guardian), except as necessary for monitoring 
and auditing by the sponsor, its designee, the Food and Drug Administration, the European 
Medicines Agency, other regulatory national authorities or the IRB/IEC. The investigator and 
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all employees and coworkers involved with this study may not disclose or use for any purpose 
other than performance of the study any data, record or other unpublished, confidential infor-
mation disclosed to those individuals for the purpose of the study. Prior written agreement 
from the sponsor or its designee must be obtained for the disclosure of any said confidential 
information to other parties.
Monitoring of the study
The clinical monitor, as a representative of the sponsor, has the obligation to follow the study 
closely. In doing so, the monitor will visit the investigator and study site at periodic intervals, in 
addition to maintaining necessary phone and letter contact. The monitor will maintain current 
personal knowledge of the study through observation, review of study records and source 
documentation, and discussion of the conduct of the study with the investigator and personnel.
Dissemination policy 
After completion of the study, the data will be reported at scientific meetings and published 
in a peer-reviewed scientific journal, regardless of the outcome. Authorship will be based 
on the criteria of the International committee of medical journal editors (ICMJE). There is no 
intention to use a professional writer. 
Discussion
RecAP is one of the limited pharmaceutical treatment options for SA-AKI currently being 
tested in a clinical trial setting. Despite several attempts, many promising new treatment 
strategies for AKI have failed when tested in patients.25-27 Potential explanations include the 
heterogeneity of the study population and the complex pathogenesis of this disease.5 Of 
interest, bovine-derived intestinal AP has shown to improve renal function when administered 
to critically ill patients with SA-AKI.11,12 To further improve the renal-protective potential of AP 
in the treatment of SA-AKI, recAP was developed by replacing the crown domain of a human 
intestinal AP with the crown domain of human placental AP.13 This results in a more enzymat-
ically stable, yet catalytically active enzyme, as confirmed by the phase I trial in healthy volun-
teers.15 To investigate the efficacy of recAP in the treatment of critically ill patients with SA-AKI, 
we are conducting a large multicentre phase II clinical trial. 
It is thought that recAP exerts a dual mechanism of action, targeting this multifactorial patho-
genic response. First, recAP dephosphorylates and thereby detoxifies LPS6,7, a part of Gram-neg-
ative bacteria involved in the development of sepsis, which can elicit an inflammatory response 
systemically and locally within the kidney on binding to toll-like receptor 4.28,29 Second, recAP 
dephosphorylates extracellular ATP into the cytoprotective and anti-inflammatory signalling 
molecule adenosine.14 Since recAP mimics the activity of an endogenous enzyme and consid-
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ering the dual mechanism of action, recAP might be superior to other agents tested in the past 
as already suggested by the previous clinical trials performed with biAP.11,12
In this study, sepsis is defined based on a proven or strongly suspected bacterial infection, 
and the presence of at least two of the four SIRS criteria (see Table 1). However, the validity of 
SIRS criteria to define sepsis and the previously recognised key role of immune-modulating 
mechanisms in sepsis pathogenesis are currently under debate. As such, new definitions of 
sepsis and septic shock have been recently proposed, which states that sepsis is a life-threat-
ening organ dysfunction caused by a dysregulated host response, and defines sepsis as a 
suspected or documented infection and the presence of organ dysfunction, defined as 
an acute increase of  ≥2 SOFA points for one organ system.30 As our study was designed 
preceding publication of these new criteria, implementation of these criteria was not feasible. 
However, we expect that we overcome the drawbacks of the original criteria, as this study 
only includes patients with sepsis combined with a failing organ system, namely the kidney. 
As there are no guidelines for the development of drugs for SA-AKI, the study was designed 
by a group of leading global experts in AKI and sepsis, with input from the US Food and Drug 
Administration and the European Medicines Agency and several local European country 
authorities. The resulting design was a dose-finding adaptive trial. The heterogeneity of the 
study population, strict inclusion criteria and narrow time-windows may limit generalisation 
to the entire population of critically ill patients with SA-AKI. On the other hand, the occurrence 
of non-responders, or specific patient groups benefitting the most of recAP treatment will be 
investigated, which may also provide information about the potential of recAP treatment for 
other nephropathies as well.
Results of this randomised controlled phase II study will be of importance for critically ill 
patients with SA-AKI, as they will allow us to draw conclusions on the efficacy of recAP in the 
improvement of renal function and related clinical parameters.
Acknowledgements 
We are grateful to all national coordinators for their contribution. This includes Martin Mate-
jovic (Czech Republic), Jacques Creteur (Belgium), Ville Pettilä (Finland), Didier Payen de la 
Garanderie (Fance), Antonio Artigas (Spain) and Mervyn Singer (United Kingdom).
258  |  CHAPTER 10  |  Study protocol STOP-AKI trial 
Supplemental Table
Supplemental Table 1.  Adjusted eligibility criteria   
 
FIRST PROTOCOL AMENDED PROTOCOL
Age 18-80 yrs 18-85 yrs
Weight ≤ 100 kg (220 lb) ≤ 115 kg (253 lb)
Time-window of sepsis diagnosis < 72 h < 96 h
Time-window of AKI diagnosis < 24 h < 48 h
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Summary, general discussion 
and future perspectives
 
 
A 
cute kidney injury (AKI) is a serious complication in critically ill patients and is 
independently associated with poorer outcomes, with a tremendous burden 
for both patient and society.1,2 While AKI can be caused by a variety of factors3, 
sepsis represents the most important etiology in the critically ill.4 Sepsis-associated AKI is a 
complex and multifactorial disease and increases the mortality rate to two out of three patients.5,6 
Currently, no pharmacological therapeutic interventions are licensed to prevent or to treat AKI 
and the medical need to investigate novel interventions to treat or prevent AKI is urgent.
Previously, two small Phase II studies demonstrated that administration of the bovine-de-
rived dephosphorylating enzyme alkaline phosphatase (AP) to critically ill patients with sepsis 
and associated AKI improved kidney function and biomarker read-outs of inflammation and 
kidney injury.7,8 To build further on these findings, a human recombinant AP (recAP) has been 
developed as a pharmaceutically attractive alternative, of which safety, pharmacokinetics and 
efficacy remain to be confirmed. In addition, the underlying molecular mechanisms of AP 
improving kidney function remains to be unraveled. 
In this thesis, we aimed to further investigate the potential of AP as a treatment for sepsis-as-
sociated AKI. To do so, we provided insight in the global burden of the disease and investi-
gated the possible protective potential of endogenous AP in critically ill patients (part one), we 
conducted preclinical in vitro, ex vivo, and animal studies to assess the molecular mechanisms of 
action of recAP (part two), and we focused on the clinical development of recAP (part three). In 
this chapter, we will summarize and discuss the knowledge obtained in this thesis. 
Part one 
Sepsis, acute kidney injury and alkaline phosphatase in the critically ill
Sepsis is the most important cause of AKI in critically ill patients and is distinct from non-septic 
causes of AKI, with differences in pathogenesis, patient characteristics and clinical outcomes.4,9 
Global epidemiological data comparing the clinical course and outcomes in septic and 
non-septic AKI are sparse. Further, while the impact of development of de novo AKI on short- 
and long-term outcomes is well elucidated, the influence of improvement or further deteri-
oration of renal function on clinical outcomes remains unclear, even though this is of impor-
tance for clinical decision making and future research. In chapter 2 we provided an overview 
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of AKI incidence and clinical outcomes in critically ill adult patients with and without sepsis 
using a large global registry of approximately 8 000 patients, the Intensive Care Over Nations 
(ICON) audit.10 We showed that AKI in sepsis patients is more frequent, more severe and asso-
ciated with higher mortality compared to non-septic AKI. Nevertheless, also the incidence 
and mortality of non-septic AKI should not be underestimated, as in this population nearly 
60% suffered from AKI at admission, with an in-hospital mortality of one out of three patients. 
In addition, we studied the evolution of AKI during the first week of ICU admission and 
demonstrated that almost 40% of patients admitted with milder forms of AKI at admission 
improved during the first week after admission, whereas in a similar percentage of patients, 
AKI deteriorated further. Recovery of renal function was associated with improved survival. 
However, in-hospital mortality was still twice as high in patients recovering from severe AKI, 
compared to patients recovering from milder forms of AKI. A recently published retrospective 
cohort study demonstrated that five distinct patterns of AKI recovery can be recognized: early 
sustained reversal, late sustained reversal, relapse with recovery, relapse without recovery and 
never reversed.11 
Considering these results, it would be of great value to be able to predict who will recover 
and who will not, as this might facilitate clinical decision making. After all, it might be wise to 
delay renal replacement therapy (RRT), as recovery of renal function observed in patients with 
milder forms of AKI could actually be delayed by the expensive and invasive RRT12, thereby 
mitigating the risk of side effects of RRT as well. Moreover, this information suggests that risk 
stratification of AKI could be of benefit for the design of clinical therapeutic trials. For instance, 
although patients with severe AKI were the least likely to improve, recovery of renal function 
did occur in 20 to 30% of this group, indicating that these patients might remain treatable. As 
heterogeneity of the study populations complicates the outcome of clinical therapeutic trials, 
it would be of interest to be able to identify, and subsequently include those patients who are 
most likely to show renal recovery and will benefit most from the therapy. 
As of yet, most methods available to detect kidney function fail to rapidly and accurately 
predict the clinical course of AKI. In daily clinical practice, plasma creatinine levels are used 
to estimate glomerular filtration rate (GFR), a measure that describes the flow rate of filtered 
fluid through the kidney, and is an indicator of renal function. This is fairly reliable in steady 
state situations, but notoriously unreliable during acute changes in renal function, as there 
is an important lag-time in the changes in blood creatinine levels. Also, creatinine levels are 
influenced by muscular content, body weight and fluid therapy.13 To overcome these draw-
backs, up to 24 h urine collection and determination of urinary creatinine excretion can be 
used to accurately determine the clearance. Measuring the endogenous creatinine clearance 
is more reliable and precise than simply measuring plasma creatinine, but also has its limita-
tions as the compound is to some extent excreted and reabsorbed in the kidneys, and errors 
in urine collection may affect the result. Alternatively, blood cystatine C could be measured, 
which is believed to be affected by muscle mass to a lesser extent and is a better estimate of 
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GFR, especially in the elderly. However, as the measurement of cystatin C is costly, its blood 
levels are influenced by positive fluid balance as well, and as there might be nonrenal clear-
ance of cystatin C, this marker failed to substitute creatinine.14 Moreover, commonly known 
urinary and blood biomarkers of kidney damage (e.g. NGAL, KIM-1 or IL-18) are not inflamma-
tion-independent and/or kidney-unspecific, and therefore unreliable in predicting AKI.15 As 
such, there is a clear need for new methods to reliably monitor kidney function. New tools are 
currently being investigated, like the MediBeacon, allowing real-time monitoring of GFR16, the 
bedside measurement of urinary cell-cycle arrest markers17 and the measurement of plasma 
pro-enkephalin, a surrogate marker for the release of small endogenous opioid ligands, which 
have a strong influence on renal function.18 Whether these markers can be used to accurately 
predict the course of AKI in critically ill patients, and even may facilitate earlier AKI diagnosis, 
has to be established in future studies. 
In view of the protective effects of exogenous AP during sepsis and associated AKI7,8, elevated 
endogenous levels of AP theoretically could potentially be associated with anti-inflammatory 
and beneficial clinical effects. For example, inhibition of endogenous AP levels by adminis-
tration of levamisole significantly decreased the survival rates in rats exposed to a sublethal 
dose of gram-negative E. coli.19 On the other hand, in clinical practice, endogenous AP is a 
well-established marker used to evaluate liver function. In chapter 3, we investigated the 
interplay between endogenously circulating AP levels, inflammation and clinical outcomes 
in critically ill sepsis patients. In two cohorts of septic shock (n=147) and septic ICU patients 
(n=3 276) we demonstrated that inflammatory plasma cytokines on the first day of septic 
shock correlated with predominantly liver-, but also bone-derived AP levels during follow-up. 
In sepsis patients, the highest AP level during the ICU stay was independently associated 
with ICU length of stay, the occurrence of severe AKI and the need for RRT, which was most 
pronounced in the two highest AP quintiles. In this study, we found no evidence that endog-
enous AP levels were associated with anti-inflammatory or beneficial clinical effects during 
sepsis. This may seem to contrast the results of the previously conducted clinical trials in crit-
ically ill sepsis patients.7,8 However, as we demonstrated in chapter 9, clinical benefit may 
occur above serum recAP concentrations of at least 290 U/L, maintained for at least 48 hours 
and preferably for 5-7 days. Possibly, the threshold level and/or duration above this threshold 
is not reached in these cohorts, which demonstrate median AP baseline levels of 89 [60-130] 
U/L and 91 [65-141] U/L. 
The association between AP levels and kidney function has been demonstrated previously in 
non-infectious populations.20,21 In chapter 3, we added that AP is also associated with kidney 
function in sepsis patients. Sepsis is often complicated by direct organ failure9,22 and the asso-
ciation between higher AP levels (as a marker of liver dysfunction) and AKI, may merely be 
an epiphenomenon, although we corrected for disease severity. After all, there is crosstalk 
between the kidneys and several other organs, including the liver, that may further deterio-
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rate organ function.23,24 In addition, we found that the bone-derived iso-enzyme accounted 
for a significant part of the increased AP-levels. Of interest, another feature of critical illness 
is hyperresorptive bone failure, an often unrecognized component of the systemic inflam-
matory response syndrome.25 As bone resorption and bone formation are closely coupled 
26,27, hyperresorptive bone failure is expected to be accompanied by increased osteoblastic 
activity, reflected by bone-derived AP. Therefore, these associations most likely reflect an 
epiphenomenon of inflammation-induced organ dysfunction as well, and, although we 
cannot draw conclusions on the causality of our findings, the predictive capacity of AP to 
detect kidney dysfunction seems to be limited.
Part two
Protective effect of human recombinant alkaline phosphatase  
In the second part of this thesis, we investigated the molecular mechanism of action of the 
protective effect of recAP using in vitro, ex vivo and animal models mimicking different aspects 
of the pathogenesis of sepsis and associated AKI.9 In chapter 4, we confirmed the renal 
protective effect of recAP during endotoxemia-induced AKI and investigated the mechanism 
of action behind these effects using a human proximal tubule cell model. Subsequently, this 
cell model was used in chapter 5 to investigate further the effects of recAP during hypoxia-in-
duced mitochondrial inhibition. Chapter 6 explored the modulatory effects of recAP on renal 
hemodynamics, oxygenation and inflammation in two rat models of AKI, and in chapter 7, we 
characterized the platelet-inhibiting effects of recAP in healthy volunteers and septic shock 
patients by ex vivo blood stimulations. 
Inflammatory response
First, the renal protective effect of the newly developed recAP was confirmed in chapter 4 
in a model of LPS-induced AKI in rats. LPS is part of the outer membrane of Gram-negative 
bacteria and plays an important role in the inflammatory cascade observed during sepsis. 
In this study, renal function was assessed via measurement of the FITC-labelled sinistrin 
kinetics. This compound is cleared by the kidneys through filtration solely and its disappear-
ance from the plasma compartment can be measured transcutaneously in real-time.28,29 This 
allowed investigating the progression of AKI in a more accurate manner as compared to the 
commonly used endogenous creatinine clearance.30 Treatment with recAP or placebo, two 
hours following LPS administration, demonstrated that recAP prevented the LPS-induced 
prolonged FITC-sinistrin half-life, measured immediately following treatment. Renal function 
was completely recovered within 24 hours after LPS treatment, which could explain why the 
endogenous creatinine clearance, measured over a 16-hour urine collection period, was not 
affected by endotoxemia. In addition, recAP treatment prevented the LPS-induced increase in 
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proximal tubule injury marker KIM-1 expression and protein content as well its urinary excre-
tion. Subsequently, these renal-protective effects were confirmed in chapter 6, where renal 
immunohistochemistry data in rats showed that recAP treatment, 1.5 hours after initiating 
shock, attenuated the LPS-induced immunoreactivity of renal injury biomarkers. Interestingly, 
a subgroup analysis of the phase II trial demonstrated in 15 patients that bovine-derived 
AP treatment reduced the urinary expression of proximal tubule injury marker glutathione 
S-transferase A1 and attenuated the expression of nitrosative stress marker iNOS in cells 
isolated from urine, predominantly derived from the proximal tubular segment.7 Together, 
these studies indicate that AP can provide proximal tubule protection.  
LPS triggers the inflammatory cascade through binding upon TLR4, localized on cells of the 
innate immune system. Also in the kidney, LPS can interact with TLR4.31 Animal data showed 
that during Gram-negative sepsis, LPS binds to TLR4 localized at the brush border membrane 
of the first part of the proximal tubule.32 This results in downstream oxidative stress in lower 
segments of these tubules33 and activates the immune system, resulting in a local inflamma-
tory response.34,35 In addition, tubular epithelium in the outer medullary region responds to 
LPS directly by producing pro-inflammatory and chemotactic cytokines, such as TNF-α, IL-6 
and IL-8, which will further accelerate the inflammatory cascade.4,36 Considering the role of the 
proximal tubule during LPS-mediated inflammation, the molecular mechanism of action of 
recAP was investigated further in chapter 4 using a human conditionally immortalized prox-
imal tubule epithelial cell model (ciPTEC).37 Indeed, LPS stimulation induced the production of 
cytokines TNF-α, IL-6 and IL-8. This response was mediated via TLR4 signaling as the cytokine 
production was inhibited upon co-incubation with LPS from R. Sphaeroides, a TLR4 antago-
nist. Treatment with recAP attenuated the LPS-induced cytokine production, an effect medi-
ated through the dephosphorylating nature of the enzyme, as inactive recAP, lacking hydro-
lyzing properties, did not attenuate the LPS-induced inflammatory response. Subsequently, 
the renal protective mechanism of recAP was investigated further by incubating ciPTEC with 
the pro-inflammatory cytokine TNF-α, which cannot be dephosphorylated by AP38, or with 
supernatant of LPS-stimulated human peripheral blood mononuclear cells (PBMCs), to mimic 
renal inflammation induced by circulating inflammatory mediators.39 In both models, recAP 
attenuated the inflammatory response, whereas inactive recAP had no effect. The absence of 
LPS this experimental set-up suggested the presence of another mediator targeted by recAP. 
In chapter 4, extracellular ATP and ADP were identified as these potential targets. Intracel-
lular ATP is a vital source of energy essential for several functions and levels within the cell are 
tightly regulated. Transport to the extracellular compartment is low, but may occur through 
e.g. ion channels, exocytosis and gap junction hemichannels.40 Under pathophysiological 
conditions, extracellular ATP release is enhanced and binding to the purinergic P2X and P2Y 
receptors can accelerate inflammation and tissue injury through NLRP3 inflammasome acti-
vation and the attraction of phagocytes and inflammatory cells.41 In addition, ADP is known 
to be released during cellular distress and enhances inflammation through platelet activa-
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tion via P2 receptor signaling.41 As inflammation is of major importance in the pathogenesis 
of septic AKI and enhances ADP and ATP release41,42, dephosphorylation of ATP and ADP in 
addition to LPS may potentially be a therapeutic effective approach. The capacity of recAP to 
dephosphorylate both molecules was demonstrated previously in vitro.43 Here, we provided 
additional evidence using the ciPTEC model and demonstrated the LPS-induced cellular 
release of both ATP and ADP, which were rapidly converted by recAP into the cytoprotective 
adenosine within 20 min after LPS stimulation. As ATP and ADP release upon LPS incubation 
peaks within this short time frame, and recAP still provided protection when administered 
two hrs after LPS administration, dephosphorylation of both compounds is likely to essen-
tially contribute to the renal protective effect of the enzyme. 
Another hallmark of sepsis is platelet activation,44 leading to increased platelet aggregation, 
platelet-endothelium binding and platelet-leukocyte complex formation, which contrib-
utes to renal microvascular thrombosis, thereby compromising kidney function.45 In chapter 
7, we investigated the effects of recAP on platelet activation and showed that recAP treat-
ment reduced platelet reactivity and platelet-monocyte complex formation towards different 
agonists by using blood from healthy volunteers. Moreover, similar results were obtained 
using platelet-rich plasma, indicating that recAP exerted its effect directly on platelets and 
also in sepsis patients, ex vivo recAP treatment reversed platelet hyperreactivity. The mech-
anism behind these effects is mediated via increased adenosine formation, which can exert 
both anti-inflammatory and tissue-protective effects, and signals by binding with 1 of its 4 
receptors: A1, A2A, A2B or A3. On platelets, the A2A receptor is present in high density.46 In 
chapter 7, we showed that platelet activation is accompanied by ADP release, which was, 
together with ATP, completely turned over into adenosine upon recAP pre-treatment. Subse-
quently, blocking the A2A receptor by the selective A2A antagonist ZM-241385 partially 
reversed the platelet inhibiting effects by recAP, suggesting that not only the dephosphoryla-
tion of ADP inhibits platelet activation and reactivity, but the concomitant formation of aden-
osine may also augment the inhibitory effect of recAP on platelet function.
The role of adenosine signalling may explain the notion that recAP pretreatment could not 
attenuate the LPS-induced inflammatory response in PBMCs (chapter 4). Adenosine recep-
tors agonists can suppress TNF-α production by LPS-challenged monocytes.47 Although ATP 
is released by monocytes upon LPS stimulation48 and could have been converted into aden-
osine by recAP treatment, the majority of PBMCs consist of lymphocytes which take-up aden-
osine49 thereby limiting free adenosine levels in the in vitro setting.  
In addition, the platelet data contrasts the results observed in the ciPTEC, in which we 
demonstrated that neither antagonizing the A2A receptor by ZM-241385 (chapter 4) nor 
inhibiting functional expression of the A2A receptor (chapter 5) could prevent the anti-in-
flammatory effect of recAP. Yet, based on these results, we cannot exclude that adenosine 
A2A receptor signalling is key in the renal protective effect of recAP. While platelets express 
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the A2A receptor, as well as the A2B receptor which is only up-regulated and activated when 
pathophysiological adenosine concentrations are present50, proximal tubule cells express all 
four adenosine receptor sub-types. As animal studies show that all receptors play an impor-
tant role in providing renal protection51, adenosine may exert protective effects via signal-
ling through one of the other three adenosine receptors, possibly combined with adenosine 
A2A receptor signalling. Moreover, we have to acknowledge the limitations of a conditionally 
immortalized cell line. Although these cells are fully characterized and demonstrate func-
tional characteristics37, we were not able to demonstrate LPS-induced gene expression levels 
of KIM-1 or iNOS, hallmarks of the pathogenesis of sepsis-AKI. As we could not confirm the 
expression of the A2A receptor on a protein level or demonstrate functionality of the protein, 
this model might not be suitable to completely unravel the involvement of adenosine signal-
ling pathways in the renal protective effect of recAP. 
Renal microcirculation
The kidney is highly susceptible to hypoxic injury, as the organ is borderline ischemic and 
has to meet high energy demands under baseline conditions.52 As such, tissue oxygenation 
within the kidney is strictly regulated. Under normal conditions, there is a delicate balance 
between oxygen delivery, mainly determined by renal blood flow (RBF), local tissue perfusion 
and blood oxygen content; and oxygen consumption, influenced by GFR, sodium reabsorp-
tion, mitochondrial function and tubular integrity.53
During sepsis, renal vascular endothelium is directly exposed to pathogens and danger-as-
sociated molecular patterns, inducing a local inflammatory response, which together with 
endothelial swelling leads to a compromised renal microcirculation and renal hypoxia.54 
The role of renal vasoconstriction and reduced RBF in this process is still under debate since 
animal and human data suggest that in daily clinical practice, AKI may develop in the setting 
of sustained or even increased RBF.55,56 This is in contrast to renal ischemia/reperfusion (I/R) 
injury, during which RBF is reduced, causing hypoperfusion in the ischemic phase, followed by 
a decreased renal oxygen delivery and oxygen consumption and increased intrarenal oxygen 
shunting during the reperfusion phase.57 Due to this discrepancy, the modulatory effects of 
recAP on renal microcirculatory dysfunction and hemodynamic changes were investigated 
following I/R- or endotoxin-induced AKI (chapter 6). In both models, recAP treatment had 
no effect on systemic hemodynamics, as it could not affect the reduced mean arterial pres-
sure. In the I/R model, RBF was impaired during the post-reperfusion period. After recAP treat-
ment, RBF was not longer significantly affected immediately following reperfusion and neither 
were renal oxygen delivery and consumption at this time-point. Although these microcircu-
latory improvements were modest and were not maintained until the end of reperfusion, the 
anti-inflammatory effect of recAP may have reduced arterial to venous shunting, resulting in 
an improved cortical microvascular oxygen pressure during the 2.5 hour reperfusion period. In 
contrast, recAP was found not to improve renal oxygenation during endotoxemia, differences 
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which could possibly be explained by the timing of the intervention (recAP was administrated 
15 min following ischemia and 60 min following LPS administration). RBF was not significantly 
affected in this model by LPS administration. 
Although recAP modulated renal hemodynamics and oxygenation during I/R-induced AKI, 
these effects were modest and considering the limited time-frame of the experimental 
setup, the clinical relevance on the onset or development of AKI might be limited. More-
over, whether recAP can modulate these parameters during sepsis-associated AKI cannot be 
concluded from these experiments. Although we did not observe an effect on oxygenation, 
the method used in this study reflected large tissues areas and were not sensitive enough to 
differentiate between different parts of the microenvironment (e.g. capillary luminal space, 
interstitium and parenchymal cells). To elucidate whether or not recAP could modulate renal 
oxygenation and hemodynamics during sepsis-associated AKI would be of interest to assess 
in a clinically more relevant model, for example during continuous infusion of endotoxin in a 
larger animal species. 
Renal bioenergetics
Despite a marked decline in renal function and the occurrence of tubular dysfunction, histo-
logical signs of apoptosis or necrosis are barely present in patients with sepsis-associated AKI.58 
Considering the severity of injury, cells are likely to have a mechanism to limit activation of cell 
death pathways, which might be arranged by mitochondria.9 Mitochondria are most abun-
dantly expressed in the heart, followed by the renal proximal tubule cells, where there is a 
high need for ATP in order to facilitate solute exchange.59 During stress, mitochondria reduce 
the metabolic activity of cells by reducing energy requirements. To this end, mitochondria 
remove and digest dysfunctional organelles and initiate cell cycle arrest to prevent further 
damage.9 During this state, akin to hibernation, mitochondria do not function normally, but do 
produce enough ATP to prevent activation of cell death pathways.60 Exactly how mitochon-
drial dysfunction contributes to the development of AKI is poorly understood, but during over-
whelming cellular stress, the protective capacity of mitochondria might be exhausted.59
In chapter 5, we investigated the effects of recAP upon impaired mitochondrial function in 
ciPTEC. Mitochondrial dysfunction was effectively induced by inhibition of the mitochondrial 
oxidative phosphorylation (OXPHOS) system, the major mitochondrial energy generating 
system.61 We achieved such a block of the respiratory chain using antimycin A, an inhibitor 
of the third OXPHOS complex, thereby completely inhibiting cellular oxygen consumption 
without affecting cell viability. While recAP did not affect the antimycin A-induced decreased 
oxygen consumption and increased hypoxia-dependent genes expression levels of hypox-
ia-inducible factor-1α or adrenomedullin gene expression levels, the antimycin A-induced 
increase of pro-inflammatory cytokines IL-6 and IL-8 was attenuated. As observed in chapter 4, 
recAP dephosphorylates detrimental purines ATP and ADP into adenosine. Also antimycin 
A tended to induce the release of ATP and ADP, which reached statistical significance when 
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antimycin A was co-incubated with lipopolysaccharide, resulting in a complete conversion 
into adenosine by recAP.
Whether or not recAP may improve oxygen consumption in patients with sepsis-associated 
AKI is difficult to extrapolate from our in vitro model. Here, mitochondrial function is inhib-
ited in all cells simultaneously, whereas in the in vivo situation, AKI presents as patchy areas of 
injured cells, with some cells being affected whereas others are not.58 Therefore, it would be 
of interest to explore the effect of recAP on mitochondrial function during LPS- or hypoxia-in-
duced renal injury in vivo, for example by performing real-time in vivo imaging multiphoton 
imaging62, or by using mice deficient in genes essential for tubular energy metabolism.63    
Together, these results indicate that recAP exerts renal-protective and anti-inflammatory 
effects in vitro and in vivo, effects mediated via dephosphorylation of LPS, and extracellular 
ATP and ADP into the cytoprotective adenosine. RecAP could not promote renal oxygenation 
and mitochondrial dysfunction in vitro and in vivo, which could indicate that the protective 
nature of recAP may be primarily explained by the anti-inflammatory effects of the enzyme. 
In addition, the notion that recAP reduced ex vivo platelet reactivity indicates that the effects 
of recAP may not exclusively be related to the kidney. This could explain attenuated systemic 
levels of CRP, IL-6 and LBP observed upon bovine intestinal AP treatment in the clinical trial.8 
However, these effects cannot be contributed to the platelet-mediated effects of recAP solely. 
After all, sepsis and associated AKI is a complex syndrome and the potential of recAP on other 
inflammatory components, such as complement and coagulation pathways, other pathogen- 
or danger-associated molecular patterns and activated leukocytes has not been investigated.
Part three
Clinical development of human recombinant alkaline phosphatase  
To follow-up on the results of the clinical trials demonstrating renal protective effects of 
bovine intestinal AP in critically ill patients with sepsis-associated AKI7,8, a human recombinant 
AP (recAP) has been developed as a pharmaceutically attractive alternative to the bovine 
sourced variant. Preceding the conduct of confirmatory phase II trial with recAP, of which the 
study protocol is presented in chapter 10, we studied the biodistribution and pharmacoki-
netics (PK) of recAP in animal models (chapter 8) and we evaluated the PK, safety and tolera-
bility of recAP in healthy volunteers (chapter 9). 
In chapter 8, we first investigated the biodistribution of iodine-125 (125I)-labeled recAP in vivo. 
Rats received LPS to induce systemic inflammation and, subsequently, endotoxemia-induced 
AKI. After two hours, when systemic inflammation reached its peak64, 125I-labeled recAP was 
injected, and at several time-points radioactivity levels in diverse tissues were determined and 
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compared to values from animals treated with placebo. As circulating AP is normally cleared 
through uptake by the hepatic asialoglycoprotein receptor65,66, the liver was the major site of 
accumulation and removal of 125I-recAP; indeed most 125I-recAP radioactivity was captured by 
this organ within 10 min after injection and disappeared after two to four hours. In addition, 
spleen, adrenal gland, heart, lung and kidney showed uptake shortly after 125I-recAP infusion, 
followed by the gastro-intestinal tract and thyroid gland. Endotoxemia did not critically affect 
the 125I-recAP tissue distribution and enzymatic terminal half-life.
Although we demonstrate that 125I-recAP is present within the kidney already 10 min after 
injection, we did not identify the exact location of the enzyme. Under normal physiolog-
ical circumstances, AP is expressed at the proximal tubule apical (brush-border) membrane, 
whereas during systemic inflammation and renal ischemia-reperfusion injury, a loss of brush 
border membranes is observed accompanied by increased urinary AP levels.67-69 Consid-
ering the protective effects observed in the ciPTEC model, it is tempting to speculate that 
recAP supplementation during sepsis-associated AKI restores the local enzyme levels, thereby 
preventing further renal injury. The question remains whether or not AP can reach the brush 
border of tubular cells. The molecular mass of the recAP monomer is approximately 70 kDa.43 
However, APs occur as a dimeric enzyme, resulting in an expected size of recAP of approxi-
mately 140 kDa.70 Although the molecular weight cut-off for the glomerulus is about 70 kDa, 
mice studies demonstrated that carbon nanotubes, novel components that could be used 
as cellular drug delivery vehicle71, are renally cleared even though the molecular weight is 
350-500 kDa.72 Likewise, recAP could potentially be filtered by the glomeruli during health, 
but also during diseases like sepsis, which alters the glomerular filtration barrier thereby 
inducing albuminuria.73
Subsequently, safety, tolerability and pharmacokinetics of recAP were explored. Chapter 8 
described the single and multiple dose administration of recAP (50, 200 or 1000 U/kg) to rats 
and minipigs. Repeated dosing was well tolerated, without discernible effects on morbidity, 
mortality and clinical observations, indicating that in these species repeated dosing of recAP 
could be done without any safety concerns. Subsequently, a two-compartmental transla-
tional population PK model with allometric scaling based on body weight was developed 
that accurately described both the PK of biAP74 and recAP. This model was used to simu-
late the predicted human plasma PK profile for different recAP dosing regimens in order 
to provide valuable insights into the choice of dosing scheme and dose levels for the first-
in-man trial of recAP, which is described in chapter 9. This randomized, double-blind, place-
bo-controlled trial demonstrated that single ascending doses up to 2000 U/kg recAP, and 
multiple doses of up to 1000 U/kg recAP per day for three days were well tolerated by healthy 
volunteers and that recAP displays a good safety profile. Peak concentrations of recAP and 
AP activity levels were reached at the end of the one-hour infusion and decreased rapidly 
in a multiphasic manner. Based on the PK observations, a four-compartment population PK 
273
model was developed with inter-individual variability on the central volume of distribution 
and elimination rate constant. The discrepancy in model structure could be explained by the 
experimental design of this trial, as sampling was more intensive and with a longer follow-up 
period. The model was used to support the selection of optimal dosing regimens to investi-
gate the therapeutic potential of recAP in patients. Simulations aimed to reach trough levels 
above 290 U/L (0.17 mg/L) recAP, maintained for at least 48 hours, but preferably 5 to 7 days. 
This resulted in the selection of three doses, ranging from 250 to 1000 U/kg recAP adminis-
tered once every 24 hours for three consecutive days. 
Currently, the safety, kinetics and efficacy of recAP for the improvement of renal function in 
critically ill patients with sepsis-associated AKI is being investigated in a randomised, double-
blind, placebo-controlled, four-arm, proof-of-concept, dose-finding adaptive phase IIa/IIb 
study, of which the study protocol is described in chapter 10. A minimum of 290 patients will 
be enrolled at approximately 50 sites in the European Union and North America. The first part 
of the study is finalized (n=120) and the optimal recAP dose has been selected following an 
interim analysis. During part 2, patients will be randomly assigned to receive the most effica-
cious dose of recAP (n=85), or placebo (n=85). The primary end point is the area under the 
time-corrected endogenous creatinine clearance curve from days 1 to 7. The key secondary 
end point is RRT incidence during days 1–28. The anticipated study enrolment completion 
date of Part 2 is early 2017 and results are expected to follow in the end of 2017. 
The work performed up to date indicates that recAP could be effective to treat sepsis-associ-
ated AKI, as recAP exerts a dual mechanism of action, potentially able to target the multifac-
torial pathogenic response. Importantly, detoxification of endotoxin or purines as a potential 
critical function of AP in AKI is not only relevant for sepsis-associated AKI, but may as well be 
important to prevent occurrence of AKI in patients at risk due to other causes. For instance it is 
known that prolonged ischemic conditions in cardiac surgery patients may lead to increased 
permeability of the gut, predisposing these patients to secondary endotoxemia.75 Indeed, 
patients undergoing coronary artery bypass grafting demonstrated a significant TNF-α 
response, which was not observed in patients treated with bovine intestinal AP.76 Also, animal 
studies demonstrated that recAP tends to also exert renal protective effects during cisplatin- 
or gentamicin-induced nephropathies as well.77 
Moreover, considering the crosstalk between kidneys and other organs that may deteriorate 
their function as well,23,24 it is of interest to assess whether AP can also promote non-renal 
organ function or recovery. Interestingly, treatment of sepsis-associated AKI patients by 
bovine intestinal AP significantly reduced the duration of mechanical ventilation8,78, an 
interesting phenomenon as AP is known to be present in the lung79 and lung epithelium is 
directly exposed to LPS and local inflammation can cause extravasation of neutrophils and 
other inflammatory cells.80 Pre-treatment of mice exposed to experimental autoimmune 
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encephalomyelitis with bovine intestinal AP reduced the neurological signs present during 
this neuro-inflammatory condition.81 Furthermore, animal models of necrotizing enteroco-
litis demonstrated that bovine intestinal AP treatment decreased intestinal injury, nitrosative 
stress and the associated systemic inflammatory response resulting from this gastrointes-
tinal disease.82-84 These effects were confirmed in patients with moderate to severe ulcer-
ative colitis.85 Likely, this therapeutic effect of AP on gut-associated inflammation could be 
promoted by detoxification of other pathogen- or danger-associated molecular patterns 
such as bacterial CpG DNA and flagellin, bacterially derived inflammation-related products 
that have been demonstrated to be detoxified by bovine intestinal AP.38 Thereby, mice studies 
showed that administration of recAP could be effective to treat skeletal and dental manifes-
tations of hypophosphatasia, a mineralization disorder induced by a deficiency of tissue-non-
specific AP.86 Clearly, these findings support a broader application of AP and could possibly be 
used to treat or prevent failure of other organ dysfunction. 
Conclusion
This thesis demonstrates that recAP holds a therapeutic promise and distinguishes itself from 
other therapies, because treatment with the dephosphorylation enzyme restores an intrinsic 
protective mechanism of the human body. Whether recAP will truly be effective in the treat-
ment of sepsis-associated AKI will be revealed by the results of the currently ongoing random-
ized controlled phase II study of which the results will be available in the second half of 2017. 
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Inleiding
A 
cute nierschade (acute kidney injury, AKI) is een veelvoorkomend probleem 
bij patiënten op de intensive care (IC) en wordt gekenmerkt door een plot-
selinge verslechtering van de nierfunctie. Hierdoor zijn de nieren niet meer 
goed in staat om afvalstoffen uit het bloed te filteren en om de vloeistof- en elektrolytenba-
lans in het lichaam te handhaven. Ongeveer één- tot tweederde van de patiënten op de IC 
ontwikkelt AKI, en van deze patiënten overlijdt circa de helft. Patiënten die overleven hebben 
een verhoogd risico op blijvende nierschade, hetgeen gepaard gaat met een enorme ziekte-
last voor de patiënt, en ziektekosten voor de maatschappij. AKI kan zich onder andere ontwik-
kelen na bijvoorbeeld een openhartoperatie of door toediening van medicijnen die nier-
schade als bijwerking hebben. De belangrijkste oorzaak van AKI is echter bloedvergiftiging, 
ook wel sepsis genoemd. 
Sepsis is de opnamediagnose van ongeveer 30% van de patiënten die op de IC worden 
opgenomen. Sepsis wordt veroorzaakt door een ontregelende ontstekingsreactie van 
het lichaam op een infectie. In de ergste gevallen kan dit leiden tot daling van de bloed-
druk, er wordt dan gesproken over septische shock, een levensbedreigend syndroom 
waarvan circa één op de drie patiënten overlijdt. Wanneer patiënten AKI ontwikkelen als 
gevolg van de sepsis (‘sepsis-geassocieerde AKI’), wordt de kans op overlijden nog groter. 
Op dit moment is er geen enkel medicijn beschikbaar om sepsis-geassocieerde AKI te voor-
komen of te behandelen. De huidige behandeling bestaat uit het aanbieden van ondersteu-
nende maatregelen, zoals nierfunctievervangende therapie (dialyse). Gezien het aantal pati-
enten dat sepsis-geassocieerde AKI ontwikkelt, en de daarbijhorende ziektelast en sterfte, is 
er dringend medische behoefte aan een effectieve behandeling. 
Een nieuw medicijn dat mogelijk sepsis-geassocieerde AKI zou kunnen verminderen is alkali-
sche fosfatase (AP). AP is een ontgiftigingsenzym doordat het fosfaatgroepen van moleculen 
kan verwijderen. Het is een membraan-gebonden eiwit en komt voor in verschillende weef-
sels in het lichaam, waaronder de lever, darmen, nier, placenta en bot. AP dat in de bloedbaan 
aanwezig is, komt voornamelijk van de lever en het bot. AP kan ook de fosfaatgroepen van een 
bestanddeel van bacteriën afknippen, en hiermee de immuunreactie op de bacterie minder 
heftig laten verlopen. Gebaseerd op deze eigenschap zou AP mogelijk als nieuw medicijn 
tegen sepsis ingezet kunnen worden. Een belangrijk bestanddeel van bacteriën is een deel 
van de celwand: endotoxine, of ook wel lipopolysaccharide (LPS) genoemd. LPS speelt een 
belangrijke rol bij het ontstaan van sepsis, doordat LPS het afweersysteem kan activeren. 
Laboratoriumonderzoek met cellen heeft aangetoond dat AP een fosfaatgroep van lipopoly-
282  |  APPENDIX  |  Nederlandse samenvatting
saccharide (LPS) kan afknippen (defosforyleren), waardoor LPS onschadelijk wordt gemaakt. 
Dierexperimenteel onderzoek heeft inderdaad aangetoond dat AP de sterfte verminderd 
wanneer ontsteking wordt veroorzaakt door de toediening van LPS. Gezien deze resultaten 
werd het effect van AP-toediening onderzocht bij 36 IC patiënten met sepsis. Het was per 
toeval dat in het Radboudumc te Nijmegen werd ontdekt dat toediening van AP met name 
was geassocieerd met nierbeschermende effecten bij deze patiënten. De behandeling met AP 
verminderde de uitscheiding van nierschademarkers en verbeterde de nierfunctie bij sepsis 
patiënten. Gezien deze ontdekking werd het effect van AP opnieuw onderzocht bij 36 IC pati-
enten met sepsis, maar ditmaal specifiek bij patiënten met sepsis-geassocieerde AKI. Opnieuw 
was AP geassocieerd met nierbeschermende effecten: toediening van AP leidde tot een snel-
lere verbetering van de nierfunctie en minder patiënten hadden dialyse nodig. Daarnaast was 
de uitscheiding van nierschademarkers in urine verlaagd bij patiënten behandeld met AP. 
Doel van dit proefschrift  
Uit bovenstaande studies werd geconcludeerd dat toediening van AP mogelijk bescher-
ming kan bieden bij patiënten met sepsis-geassocieerde AKI. Bij de twee uitgevoerde studies 
werden de patiënten behandeld met AP opgezuiverd uit de darmen van runderen. Omdat 
herhaaldelijk toedienen van dierlijk materiaal zou kunnen leiden tot een ongewenste allergi-
sche reactie, is er een nieuwe variant van het medicijn ontwikkeld, het humane recombinant 
AP (recAP). Dit medicijn toont grote overeenkomst met de menselijke vorm van AP en is een 
combinatie van de variant die in de darm voorkomt, en erg biologisch actief is, en het van 
de placenta-afkomstige AP, wat een lange verblijftijd in het lichaam kent. Het recAP is daar-
door zowel een actief als stabiel eiwit. Echter, de veiligheid, farmacokinetiek en de werkzaam-
heid van dit nieuw ontwikkelde medicijn moet nog worden aangetoond. Daarnaast is het 
werkingsmechanisme hoe het AP ervoor zorgt dat de nierfunctie verbetert nog niet duidelijk. 
Het doel van dit proefschrift is om inzicht te verkrijgen in het werkingsmechanisme van AP 
en om verder te onderzoeken of AP geschikt is om sepsis-geassocieerde AKI te behandelen. 
In deel 1 van dit proefschrift stellen we eerst de wereldwijde ziekte-ernst van AKI vast en 
onderzoeken we of lichaamseigen AP bescherming biedt in IC patiënten. Vervolgens wordt in 
deel 2 het nierbeschermende werkingsmechanisme van recAP op niercelniveau onderzocht, 
en richten we ons op de veiligheid en farmacokinetiek van recAP in dieren en gezonde vrij-
willigers in deel 3, waar afgesloten wordt met de beschrijving van het studieprotocol van de 
grote klinische trial die thans wordt uitgevoerd met recAP.   
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Deel 1 
Sepsis, acute nierschade en alkalische fosfatase op de intensive care 
Sepsis is de belangrijkste oorzaak van AKI bij patiënten op de IC en verschilt van niet-septische AKI 
op het gebied van patiëntkarakteristieken, hoe de ziekte ontstaat en de ziekte-ernst. Wereldwijde 
studies die het voorkomen en de gevolgen van septische en niet-septische AKI vergelijken zijn 
er nauwelijks. Ook is het nog niet duidelijk wat het effect is op de overleving van patiënten als de 
nierfunctie verbetert of juist verder verslechtert tijdens de IC opname. Deze kennis is van belang 
omdat dit de arts kan ondersteunen in het vaststellen van het beleid voor de patiënt, en omdat 
dit de opzet van toekomstig wetenschappelijk onderzoek kan sturen. In hoofdstuk 2 geven we 
een overzicht van het aantal patiënten dat AKI ontwikkelt en de gevolgen hiervan bij IC-pati-
enten met en zonder sepsis. Dit hebben we onderzocht in een internationale database van ruim 
10.000 IC-patiënten, de Intensive Care Over Nations (ICON) audit. AKI, gediagnosticeerd binnen de 
eerste twee dagen na opname op de IC, komt bij sepsis patiënten vaker voor en is ernstiger verge-
leken met patiënten met niet-septische AKI. Bijna 40% van patiënten met sepsis-geassocieerde 
AKI komt te overlijden in het ziekenhuis; voor niet-septische AKI patiënten is dit ongeveer 20%. 
Daarnaast hebben we het beloop van AKI onderzocht gedurende de eerste week na opname. 
Bijna 40% van de patiënten opgenomen met een milde vorm van AKI verbetert in deze periode, 
terwijl hetzelfde percentage verslechtert. Verbetering van nierfunctie gaat gepaard met een 
hogere overlevingskans. Echter, de ziekenhuissterfte blijft tweemaal zo hoog in patiënten die 
volledig herstellen van ernstige AKI vergeleken met patiënten die herstellen van een milde AKI 
of überhaupt geen AKI hebben ontwikkeld. Deze resultaten tonen aan dat zowel septische als 
niet-septische AKI een groot probleem is op de IC en gepaard gaat met hoge sterfte. Dit onder-
schrijft de noodzaak tot het ontwikkelen van nieuwe medicijnen.   
Gezien de eerder gevonden beschermende werking van de toediening van AP tijdens 
sepsis-geassocieerde AKI, zou de verhoogde aanwezigheid van lichaamseigen AP in het 
bloed mogelijk ook bescherming kunnen bieden. Uit dierexperimenteel onderzoek is name-
lijk gebleken dat een verlaging van AP in de bloedbaan tijdens een systemische ontstekingsre-
actie gepaard gaat met hogere sterfte. Anderzijds wordt AP gebruikt in de kliniek om de lever-
functie te beoordelen, waarbij lage waarden juist beter zijn dan hoge waarden. In hoofdstuk 3 
onderzoeken we de relatie tussen ontsteking, lichaamseigen AP en klinische uitkomsten bij 
IC-patiënten met sepsis. In twee groepen van 147 patiënten met septische shock en ruim 3200 
patiënten met sepsis tonen we aan dat hoe hoger de ontstekingseiwitten (cytokines) in het 
bloed op de eerste dag van septische shock zijn, des ter hoger is AP in het bloed op de vijfde 
en zevende dag van de IC-opname. Dit AP is vooral afkomstig uit lever en bot. Bij sepsispati-
enten laten we zien dat de hoogste waarde van AP tijdens de IC opname in relatie staat tot een 
langere IC opnameduur, de ernst van AKI en de dialyse-noodzaak, maar onafhankelijk is van de 
ziekte-ernst of de leeftijd van de patiënt. Daarnaast tonen we aan dat er geen relatie is tussen 
het lichaamseigen AP en een ontstekingsremmend of gunstig effect tijdens sepsis. 
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Deel 2 
Beschermende effecten van humaan recombinant alkalische fosfatase
In het tweede deel van dit proefschrift onderzoeken we het werkingsmechanisme achter de 
beschermende effecten van recAP. Omdat sepsis-geassocieerde AKI een complexe ziekte is, 
gebruiken we verschillende modellen die ieder een ander aspect van de ziekte nabootsen. In 
hoofdstuk 4 onderzoeken we of recAP nierbeschermend werkt tijdens ontstekings-geïndu-
ceerde AKI in ratten en onderzoeken we het werkingsmechanisme hierachter met menselijke 
niercellen. In hoofdstuk 5 gebruiken we deze cellen om de effecten van recAP te bestuderen 
tijdens een verstoorde energiehuishouding. In hoofdstuk 6 gebruiken we twee diermodellen 
van AKI om het effect van recAP te bestuderen op de bloedstroom, zuurstofvoorziening en 
ontstekingsrespons in de nier, en in hoofdstuk 7 hebben we het effect van recAP op bloed-
plaatjes bestudeerd in bloed afkomstig van gezonde vrijwilligers en sepsispatiënten. 
De ontstekingsreactie
In hoofdstuk 4 beschrijven we de nierbeschermende werking van het nieuw ontwikkelde 
recAP tijdens LPS-geïnduceerde AKI. LPS speelt een belangrijke rol bij het ontstaan van sepsis 
doordat LPS het afweersysteem kan activeren na binding aan Toll-like receptor 4 (TLR4). Deze 
LPS-receptor is aanwezig op cellen van het afweersysteem, maar ook op niercellen. Binding 
van LPS aan TLR4 brengt de ontstekingsreactie op gang, zowel systemisch, als lokaal in de 
nier. In deze studie hebben we de nierfunctie bij ratten gemeten door het injecteren van fluo-
rescent-gelabeld sinistrin. Dit suikermolecuul wordt niet in het lichaam afgebroken en wordt 
alleen uitgescheiden via de nier. De daling van de concentratie sinistrin in het bloed (gemeten 
door de huid van de rat) is daarom een maat voor de nierfunctie. Deze methode om de nier-
functie vast te stellen blijkt nauwkeuriger te zijn dan het meten van de stof kreatinine in het 
bloed, wat de gangbare methode voor nierfunctiebepaling is. 
In hoofdstuk 4 tonen we aan dat LPS zorgt voor een verslechtering van de nierfunctie bij ratten, 
aangezien de hoeveelheid sinistrin langer verhoogd blijft in het bloed vergeleken met ratten die 
geen LPS kregen. Het medicijn recAP, toegediend twee uur na de toediening van LPS, voorkomt 
deze verslechtering van de nierfunctie. Daarnaast voorkomt recAP de stijging van de nierscha-
demarker KIM-1 in de nier en in de urine, die was veroorzaakt door LPS. Uit deze studie conclu-
deren we dat recAP een nierbeschermend effect heeft tijdens LPS-geïnduceerde AKI in ratten. 
Vervolgens hebben we het werkingsmechanisme onderzocht van recAP in een celmodel 
van menselijke proximale niertubuluscellen. Op deze cellen, die afkomstig zijn van het eerste 
gedeelte van het niersegment, is TLR4 aanwezig. We laten zien dat de cellen reageren op 
blootstelling aan LPS door ontstekingseiwtten (cytokines) aan te maken, hetgeen geremd kan 
worden door gelijktijdige blootstelling aan recAP. Hiervoor is de defosforylerende werking van 
het recAP essentieel, aangezien inactief recAP, een eiwit dat geen fosfaatgroepen kan knippen, 
geen effect had op de LPS-geinduceerde cytokinerespons. Vervolgens hebben we het 
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werkingsmechanisme verder onderzocht door de cellen bloot te stellen aan het ontsteking-
seiwit TNF-α, een cytokine die niet kan worden gedefosforyleerd door AP. Ook hebben we de 
cellen blootgesteld aan een mix van allerlei cytokines, gemaakt door met LPS-gestimuleerde 
menselijke witte bloedcellen. In beide modellen verlaagt recAP de geïnduceerde cytokine-
productie, terwijl inactief recAP geen effect heeft. Aangezien LPS niet aanwezig is tijdens deze 
stimulaties, moet defosforylering van een ander schadelijk molecuul door recAP ten grond-
slag liggen aan het beschermende effect. Dit zijn hoogstwaarschijnlijk het adenosine trifosfaat 
(ATP) en adenosine difosfaat (ADP). ATP is aanwezig in iedere cel en is een essentiële bron van 
energie. De concentraties van ATP in de cel zijn strikt gereguleerd, en het transport van ATP de 
cel uit is beperkt. Echter tijdens ziekte wordt het transport uit de cel verhoogd, hetgeen scha-
delijke gevolgen heeft doordat ATP de ontstekingsreactie kan versterken wat uiteindelijk kan 
leiden tot weefselschade. Daarnaast komt ADP vrij uit de cel bij ziekte, wat ook de ontstekings-
reactie kan versnellen. Defosforylering van ATP en ADP door recAP zou, naast het effect op LPS, 
de effectiviteit van recAP kunnen verklaren. Dat recAP in staat is om het ATP en ADP te defos-
foryleren is al eerder aangetoond. Wij laten nu in ons celmodel van menselijke niercellen zien 
dat LPS de afgifte van ATP en ADP verhoogt en dat recAP dit wegvangt door het direct om te 
zetten in adenosine. Adenosine ontstaat doordat er drie keer een fosfaatgroep van ATP wordt 
geknipt, en adenosine heeft nierbeschermende en ontstekingsremmende eigenschappen. 
ATP en ADP komt al binnen 20 minuten vrij na toediening van LPS en wordt direct omgezet 
door recAP in adenosine. Omdat recAP nog steeds een ontstekingsremmende werking heeft 
wanneer recAP twee uur na toediening van LPS wordt gegeven, concluderen wij dat defosfo-
rylering van zowel ATP en ADP als LPS een cruciale bijdrage levert aan het nierbeschermende 
effect van recAP.   
 
In hoofdstuk 7 hebben we gekeken naar het effect van recAP op de bloedplaatjes. Bloed 
bestaat uit bloedplasma, rode bloedcellen, witte bloedcellen en bloedplaatjes. Deze bloed-
plaatjes spelen een rol bij de bloedstolling. Tijdens sepsis worden bloedplaatjes geactiveerd, 
wat ervoor zorgt dat deze aan elkaar gaan plakken, aan de celwand van de bloedbaan en 
aan witte bloedcellen. Dit kan leiden tot bloedstolsels in de bloedvaten naar de nier, waar-
door het bloed minder goed naar de nier kan stromen en er een zuurstoftekort ontstaat. 
Dit kan uiteindelijk leiden tot een verminderde nierfunctie. Wij hebben onderzocht of recAP 
de activatie van de bloedplaatjes kan beïnvloeden. In bloed van gezonde vrijwilligers tonen 
we aan dat wanneer we plaatjes kunstmatig activeren, recAP ervoor zorgt dat de plaatjes 
minder geactiveerd worden, en dat de binding van de bloedplaatjes aan monocyten, een 
bepaald type witte bloedcellen, wordt geremd. Ook wanneer we dit experiment herhalen 
met bloedplasma zonder rode en witte bloedcellen, zien we dat recAP de plaatjesactivatie 
remt. Hieruit concluderen we dat recAP een rechtstreeks effect heeft op bloedplaatjes. Daar-
naast hebben we aangetoond dat in bloed afgenomen van sepsispatiënten de bloedpla-
tjes verhoogd actief zijn, hetgeen weer geremd kon worden door toevoeging van recAP. 
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Deze effecten kunnen worden verklaard doordat er meer adenosine wordt gevormd na 
toediening van recAP. Adenosine biedt bescherming doordat het kan binden aan adenosine-
receptoren. In hoofdstuk 7 laten we zien dat de activatie van plaatjes gepaard gaat met een 
verhoogde afgifte van ADP, wat samen met ATP door recAP direct en volledig wordt omgezet 
in adenosine. Wanneer we de binding van adenosine aan de adenosinereceptor blokkeren, 
dan zien we dat recAP minder goed werkt. Hieruit concluderen we dat niet alleen de defos-
forylering van ADP en ATP de plaatjesactivatie remt, maar dat ook de vorming van adenosine 
bijdraagt aan de remmende werking van recAP. 
Doorbloeding van de nier
Wanneer er in de nier een tekort is aan zuurstof, kan er schade ontstaan. Daarom is 
de zuurstofvoorziening van dit orgaan strikt gereguleerd. Onder normale omstandig-
heden is er een delicate balans tussen het aanbod van zuurstof door de bloedstroom 
naar de nier, de druk waarmee bloed door de nier wordt gepompt en de hoeveelheid 
zuurstof in het bloed aan de ene kant, en het verbruik van zuurstof aan de andere kant. 
In hoofdstuk 6 hebben we in twee verschillende modellen van AKI bij ratten het effect van 
recAP onderzocht op de bloedstroom en zuurstofvoorziening in de nier. In het eerste model 
hebben we de bloedstroom naar de nieren volledig onderbroken door een bloedvat naar de 
nier gedurende 30 minuten af te klemmen. In de herstelperiode, wanneer de klem weer wordt 
verwijderd, zien we vervolgens dat de bloedstroom naar de nier nog steeds verminderd blijft. 
Wanneer recAP wordt toegediend, zien we dat deze initiële afname van de bloedstroom niet 
optreedt. Hetzelfde geldt voor de vermindering van het zuurstofaanbod en zuurstofverbruik 
dat ontstaat door het afklemmen. Ook dit wordt voorkomen door toediening van recAP. In 
het tweede model hebben we LPS toegediend aan ratten. In dit model zien we geen veran-
dering in de bloedstroom naar de nier. Wel zien we een vermindering van het zuurstofaanbod 
en het zuurstofverbruik na toediening van LPS, maar recAP had hier geen positief effect op. 
Tot slot tonen we in beide modellen aan dat recAP de hoeveelheid ontstekingseiwitten 
en schademarkers in de nier vermindert, wat de bevindingen uit hoofdstuk 4 bevestigt. 
Uit deze studie concluderen we dat recAP een gunstig effect heeft op de bloedstroom en 
de zuurstofvoorziening in de nier na het afklemmen van de bloedstroom. Echter, het model 
is kortdurend en de effecten die we vinden zijn klein, waardoor de klinische relevantie van 
deze bevindingen beperkt zou kunnen zijn. Daarnaast concluderen we dat recAP geen effect 
heeft op de verminderde zuurstofvoorziening die wordt veroorzaakt door toediening van 
LPS, maar dat recAP desondanks in beide modellen wel de ontstekingsreactie en daarop 
volgende schade in de nier vermindert. 
Energiehuishouding 
Sepsis-geassocieerde AKI gaat gepaard met nierschade en nierfunctieverlies. Wanneer cellen in 
het lichaam te ernstig beschadigd zijn, gaan de cellen kapot. Ook kan het lichaam de bescha-
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digde cellen opruimen voordat ze kapot gaan, om zo verdere schade te voorkomen. Bij pati-
enten met sepsis-geassocieerde AKI zijn er ondanks de ernstige nierschade, bijna geen kapotte 
of opgeruimde cellen terug te vinden in de nier. Dit is opmerkelijk en zou kunnen betekenen dat 
niercellen in staat zijn om deze ‘opruimactie’ te voorkomen. De mitochondriën in de cel zouden 
hierbij een belangrijke rol kunnen spelen. Mitochondriën zijn de energiefabriekjes van de cellen 
en zorgen ervoor dat zuurstof wordt omgezet in energie. Wanneer niercellen opmerken dat er 
schade is, kan het zo zijn dat de mitochondriën minder zuurstof in energie gaan omzetten, om 
te voorkomen dat verdere schade ontstaat. Hoewel hierdoor de nierfunctie van de cel achteruit 
kan gaan, blijft de cel wel in leven. Ondanks dat de cellen blijven leven, is het denkbaar dat het 
optredende energietekort schadelijke gevolgen heeft. In hoofdstuk 5 hebben we deze moge-
lijke schadelijke gevolgen onderzocht en het effect van recAP hierop bestudeerd. We hebben 
wederom gebruik gemaakt van menselijke proximale niertubuluscellen. In deze cellen hebben 
we de omzetting van zuurstof in energie geremd door de cellen bloot te stellen aan Antimycine 
A. We tonen aan dat het remmen van de mitochondriële functie met deze stof inderdaad ervoor 
zorgt dat de cellen wel in leven blijven, maar geen zuurstof meer kunnen verbruiken. We laten 
zien dat toediening van recAP dit niet kan voorkomen. Als reactie op het energietekort maken 
de cellen ontstekingseiwitten aan. De aanmaak van deze eiwitten kan wel worden geremd door 
het recAP. Daarnaast lijkt het energietekort de afgifte van ATP en ADP te verhogen, hetgeen 
direct en volledig door recAP wordt omgezet in adenosine. Ook tijdens sepsis-geassocieerde AKI 
is er een ontstekingsreactie aanwezig in het lichaam. Daarom hebben we vervolgens het ener-
gietekort in de niercellen gecombineerd met blootstelling aan LPS. Dit zorgt voor een hogere 
afgifte van ontstekingseiwitten, wat opnieuw kan worden geremd door recAP. Ook de afgifte 
van ATP en ADP is verhoogd, wat door recAP direct en volledig wordt omgezet in adenosine. 
Uit deze studie concluderen we dat recAP geen invloed heeft op het zuurstofgebruik van nier-
cellen tijdens mitochondriële functieremming, maar dat recAP wel de ontstekingsreactie kan 
remmen die hiervan het gevolg is, mogelijk door omzetting van ATP en ADP in adenosine. 
 
De resultaten uit dit deel van het proefschrift tonen aan dat recAP een ontstekingsremmende 
en nierbeschermende werking heeft in niercellen en proefdieren. Deze effecten kunnen 
worden verklaard door defosforylering van LPS, en van ATP en ADP, en door vorming van 
het beschermende molecuul adenosine. RecAP is niet in staat om de zuurstofvoorziening en 
het zuurstofgebruik in de nier te bevorderen. De bevinding dat recAP plaatjesactivatie kan 
remmen in het bloed wijst erop dat de beschermende werking mogelijk niet gelimiteerd is 
tot een lokaal effect in de nier.
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Deel 3 
Klinische ontwikkeling van humaan recombinant alkalische fosfatase
Zoals eerder beschreven is op basis van de nierbeschermende resultaten van runder-AP bij 
sepsispatiënten een menselijke variant van het medicijn ontwikkeld; humaan recombinant 
AP (recAP). Alvorens de werkzaamheid van recAP kan worden onderzocht bij patiënten met 
sepsis-geassocieerde AKI, hebben we de veiligheid en farmacokinetiek van recAP onderzocht 
in dieren (hoofdstuk 8) en in gezonde vrijwilligers (hoofdstuk 9). Tenslotte wordt de opzet 
van de internationale multicenter studie die thans met recAP wordt uitgevoerd beschreven 
in hoofdstuk 10.
In hoofdstuk 8 hebben we eerst in een diermodel onderzocht hoe recAP zich verspreidt 
over alle weefsels in het lichaam. Immers, om een nierbeschermend effect te bewerkstel-
ligen, is het van belang om te weten of recAP daadwerkelijk in de nier terecht komt, én of dat 
een ontstekingsreactie, zoals aanwezig bij patiënten met sepsis-geassocieerde AKI, de verde-
ling van recAP kan beïnvloeden. Om een ontstekingsreactie te induceren hebben we LPS 
(of een placebo) toegediend aan ratten. Vervolgens hebben alle ratten radioactief-gelabeld 
recAP (125I-recAP) toegediend gekregen en is de hoeveelheid radioactiviteit in verschillende 
weefsels bepaald. In deze studie laten we zien dat 125I-recAP binnen 10 minuten na toedie-
ning sterk aanwezig is in de lever, wat is als verwacht aangezien AP in dit orgaan wordt afge-
broken. Daarnaast is 125I-recAP ook aanwezig in de milt, bijnier, hart, longen en nieren. Twee 
tot vier uur na toediening verdwijnt 125I-recAP uit deze organen, en zien we een verhoging van 
125I-recAP in het maag-darm stelsel en de schildklier. Toediening van LPS had geen effect op 
de weefselverdeling van 125I-recAP. 
 
Vervolgens hebben we de veiligheid en farmacokinetiek van recAP bij dieren bestudeerd. 
Hoofdstuk 8 beschrijft de toediening van oplopende doseringen van recAP (50, 200 of 1000 
units per kilogram lichaamsgewicht) in de bloedbaan in ratten en minivarkens, eenmalig of 
eenmaal daags toegediend gedurende zeven achtereenvolgende dagen. Herhaalde dose-
ringen van recAP worden goed getolereerd, zonder aantoonbare nadelige effecten op de 
gezondheid van de dieren. Hieruit concluderen we dat er geen veiligheids-issues zijn na 
herhaalde toediening van recAP aan deze diersoorten. Bij deze dierproeven werden de 
concentraties van recAP in de bloedbaan gemeten. In combinatie met eerder onderzoek met 
runder-AP bij mensen is er een computermodel ontwikkeld waarmee we kunnen voorspellen 
welke dosering van recAP het meest geschikt is om toe te dienen aan mensen. In hoofdstuk 
9 beschrijven we deze studie, waarin recAP voor het eerst aan mensen is toegediend. Deze 
gerandomiseerde, dubbelblinde, placebo-controleerde fase 1 studie toont aan dat eenmalige 
doseringen tot 2000 units per kilogram lichaamsgewicht, en eenmaal daagse doseringen tot 
1000 units per kilogram lichaamsgewicht gedurende drie achtereenvolgende dagen, goed 
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worden getolereerd door gezonde vrijwilligers en dat recAP een goed veiligheidsprofiel heeft. 
De hoogste concentratie recAP in de bloedbaan wordt bereikt direct aan het einde van de 
één-uur durende toediening in de bloedbaan. Met deze gegevens kan het computermodel 
verder worden aangepast, zodat het meest optimale doseringsschema van recAP voor pati-
enten met sepsis-geassocieerde AKI kan worden voorspeld. Computersimulaties laten zien dat 
de hoeveelheid recAP in het bloed minimaal 48 uur boven de 290 units/liter dient te blijven, 
en dat een dergelijke concentratie gedurende vijf tot zeven dagen het meest effectief is. Op 
basis van deze gegevens zijn drie verschillende doseringen voor de klinische studie bij sepsis- 
patiënten met AKI geselecteerd, namelijk 250, 500 en 1000 units per kilogram lichaamsgewicht, 
die eenmaal daags gedurende drie achtereenvolgende dagen kan worden toegediend. 
 
Op dit moment wordt de veiligheidheid, farmacokinetiek en werkzaamheid van recAP om de 
nierfunctie te verbeteren bij IC patiënten met sepsis-geassocieerde AKI onderzocht. De opzet 
van deze gerandomiseerde, dubbelblinde, placebo-gecontroleerde fase 2a/b studie wordt 
beschreven in hoofdstuk 10. Circa 300 patiënten zullen in deze studie worden geïncludeerd, 
en uitvoering vindt bij ongeveer 50 verschillende centra in Europa en Noord-Amerika plaats. 
De studie bestaat uit twee delen; in deel 1 krijgen 120 patiënten ofwel placebo toegediend, 
ofwel één van de drie doseringen recAP zoals gemeld in hoofdstuk 9. Vervolgens wordt vast-
gesteld wat de meest optimale dosering van recAP is gedurende een tussentijdse analyse. 
Tijdens deel 2 krijgen patiënten ofwel placebo (85 patiënten) ofwel de meest optimale dose-
ring recAP (85 patiënten) toegediend. De belangrijkste uitkomstmaat van deze studie zal het 
effect van recAP op de nierfunctie gedurende de eerste 7 dagen na inclusie zijn, en deze 
wordt bepaald door het meten van de endogene kreatinineklaring. Daarnaast zal het effect 
van recAP op de noodzaak tot dialyseren gedurende de eerste 28 dagen na inclusie worden 
vastgesteld. Op dit moment is deel 1 van de studie afgerond en wordt verwacht dat in de 
eerste helft van 2017 deel 2 wordt afgerond. De resultaten van de studie worden eind 2017 
verwacht. 
Conclusie
Onze analyse van de Intensive Care Over Nations database bevestigt dat sepsis-geassocieerde 
AKI wereldwijd een groot probleem is op de IC en gepaard gaat met hoge sterfte. Humaan 
recombinant AP zou mogelijk geschikt kunnen zijn om sepsis-geassocieerde AKI te behan-
delen, doordat het schadelijke lichaamsvreemde én lichaamseigen stoffen kan defosforyleren 
en daarmee onschadelijk maakt. Of recAP daadwerkelijk een effectieve behandeling is voor 
IC patiënten met sepsis-geassocieerde AKI zal de lopende patiëntenstudie moeten uitwijzen.
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